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Abstract 
This thesis is concerned with the synthesis, characterisation and evaluation of novel 
metal complexes for their application as anti-cancer agents. It contains the in vitro 
cell results, along with a range of other techniques to determine their biological 
relevance and their potential as anti-cancer agents. 
Chapter 1 contains an introduction to the project including a literature search, previously 
synthesised complexes and project aims 
Chapter 2 presents the synthesis and characterisation of novel -diketonate and -
ketoiminate ligands. X-ray crystallographic data are analysed for some of the ligands. 
Chapter 3 discusses the synthesis and characterisation of novel -ketoiminate ruthenium 
chloride complexes. X-ray crystallographic data are analysed for all of the complexes. 
Chapter 4 introduces the MTT technique for assessing cytotoxicity, and presents in vitro 
activities for the library of complexes synthesised in Chapter 3.  
Chapter 5 looks at modifications of the previous ruthenium (II) complexes, introducing 
new ligands and iridum metal centres. X-ray crystallographic data for all of these 
complexes has been discussed, along with in vitro activity against a range of cell lines. 
Chapter 6 introduces hypoxia and states the cytotoxicities of a range of complexes under 
1.0% and 0.1% oxygen concentrations. 
Chapter 7 discusses mechanistic studies on the complexes, including hydrolysis, 
hydrophobicity, Comet assay, apoptosis and thioredoxin reductase inhibition. 
Chapter 8 introduces the previous group IV work within the group and an extension of 
the library by synthesis of -ketoiminate titanium complexes. X-ray crystallographic 
analysis is discussed where applicable. 
Chapter 9 contains experimental details and characterisation data for all compounds 
described in Chapters 2, 3, 5 and 8. Also protocols for all the biological studies. 
Appendix presents a summary of X-ray crystallographic structure analysis for any 
crystals obtained within this work 
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2 
1 Introduction 
This thesis describes the synthesis and evaluation of novel ruthenium complexes as 
potential anticancer agents, with some further work on titanium complexes. The 
complexes feature substituted -ketoiminate ligands with differing electronic and 
steric properties and adaptations of these complexes. This chapter will present a 
review of previous research in the area of metal based anticancer agents, with 
particular emphasis on ruthenium, titanium and iridium based complexes. 
 
1.1 Cancer 
Since the mid 1970s, incidence rates for cancer in Great Britain in the UK have 
increased by 22% in men and 42% in women. However, over the last ten years, 
these incidence rates have increased by just 2% in men and 6% in women. Cancer 
occurs predominantly in older people, with the chance of developing cancer 
increasing rapidly from 50 years of age. More than three in five cancers (63%) 
were diagnosed in people aged 65 and over, and more than a third (36%) were 
diagnosed in the elderly (aged 75 and over). The most common cancer found in 
men is prostate cancer, which accounts for a quarter (25%) of all male cancer 
cases. In females, the most common is breast cancer and accounts for nearly a third 
(31%) of all cancers in women. In both males and females the second and third 
most common cancers are lung cancer and bowel cancer respectively.
1
 The 
majority of deaths occur in older generations, with the rates increasing at the age of 
60. More than three quarters (77%) of deaths occur in patients 65 and over, whilst 
over half of these (52%) occur in patients over 75 years of age.
1
 Recent statistics 
show that in 2010, 324,579 people in the UK were diagnosed with cancer
2
 costing 
£9.4 billion across the NHS, private and voluntary sectors.
3
 In 2011, 159,178 
people died from cancer in the UK.
4
 
Cancer is the term given to a group of diseases resulting from mutations in our cells 
which can cause them to undergo uncontrollable cell division.
5
 The cells divide 
through a process known as mitosis, which is controlled by two ‘cancer genes’ 
know as oncogenes and tumour gene suppressor genes. However, if one or more of 
these genes has a mutation the cell uncontrollably divides causing a lump of tissue 
known as a tumour. Normal cells frequently undergo a process known as 
programmed cell death. However, these activated oncogenes can cause a cell that 
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ought to die to survive and enter cell proliferation.
6
 This can cause one of two types 
of tumour, known as benign or malignant. A benign tumour does not invade other 
tissues, is usually not life-threatening and is easily treated. Whereas malignant 
tumours can undergo metastasis, in which the initial tumour can migrate to a 
secondary site producing a secondary tumour. These are usually hard to treat and 
can be life threatening.
7
 The risk of developing cancer can be increased by 
exposure to carcinogens, a high fat diet or genetic susceptibility.
8
 Cancers are 
different depending on what cells are affected and therefore different types of 
cancer treatment are used to maximise treatability, these include surgery, 
radiotherapy, immunotherapy, chemotherapy and gene therapy.
9
 Often several 
types of treatment are used simultaneously to give maximum effects.
10
 
 
1.2 Metal-Based Drugs 
Transition metal complexes are well known in biological processes and play a vital 
role in the human anatomy. The use of metal-based complexes has been understood 
since as early as 1910, when Salvarsan (Arsphenamine), an arsenic containing 
therapeutic agent, was used in the treatment of syphilis, and was the first known 
chemotherapeutic agent.
11
 The structure of this complex was thought to contain an 
As=As double bond. However, in 2005 work by Nicholson et al. provided evidence 
that Salvarsan in fact exists as cyclic trimers and pentamers (Figure 1.1).
12
 
 
Figure 1.1 Cyclic Salvarsan structures 
 
Since the discovery of Salvarsan, therapeutic agents have been established across 
the periodic table, including a gold containing complex Auranofin (Ridura) which 
is used to treat rheumatoid arthritis, by reducing tender joints and morning stiffness 
commonly caused by arthritis (Figure 1.2).
13
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Figure 1.2 Auranofin (Ridura) 
 
Another modern example is Tetrofosmin (Figure 1.3), a 99mTc based cardiac 
imaging agent better known as Myoview™, which is used to enable the diagnosis 
and localisation of regions of reversible myocardial ischemia.
14
 
 
Figure 1.3 Tetrofosmin 
 
1.3 Cisplatin 
Cisplatin [cis-dichlorodiammine platinum(II)] was first discovered by Peyrone in 
1845 and was known as Peyrone’s salt.15 Its structure (Figure 1.4) was later 
elucidated in 1893 by Werner, when he proposed the theory of coordination 
chemistry, showing that ammonia can in fact bind to the Pt(II) by donating its lone 
pair in a dative or coordination bond.
16, 17
 However, the anti-cancer properties of 
cisplatin were not discovered until over a century after its initial discovery, by 
Rosenberg et al. in 1965.
18
 The discovery was made whilst researching electric 
field effects on cell growth in E. coli using an aqueous solution of NH4Cl and 
platinum electrodes. Since then it entered clinical phase trials in 1971 and was 
approved for pharmaceutical use in 1978.
19
 It has since become the world’s leading 
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anti-cancer drug in treating neck, bladder, ovarian and testicular cancers.
20
 
 
Figure 1.4 Structure of cisplatin 
 
Once cisplatin enters the body and reaches the desired organs, it diffuses through 
the cell membrane by passive transport. This is due to a chloride ion concentration 
deficiency in the cytoplasm of the cells, which enables the labile chloride ligands 
of cisplatin to dissociate and be replaced by water molecules (Scheme 1.1).
21
 
 
Scheme 1.1 Hydrolysis of Cisplatin 
 
The water ligand is easily displaced by the basic nitrogen atoms on DNA, 
specifically the N7 position on guanine residues. Once it is bound to the DNA, the 
second chloride ligand is replaced by another nitrogen atom from either the same 
DNA strand (intrastrand) or an adjacent DNA strand (interstrand) (Figure 1.5). 
Incorporation of this platinum centre causes irreversible dehydration and induces 
structural changes to the DNA strand preventing replication. The cross-linking 
prevents cell division and stops tumour growth. This DNA damage in tumour cells 
causes the strands to ‘kink’; this is not recognised and results in programmed cell 
death (apoptosis). It is crucial that the cis isomer is used as it has the correct 
geometry for cross-linking; whereas transplatin is thought to be deactivated before 
it reaches the DNA.
16
 However, this is a non-specific process and affects healthy 
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cells as well as cancerous cells, causing severe physiological side effects such as 
nausea, and nephrotoxicity. Current research has now led to second-generation 
derivatives of cisplatin, in the hope to achieve higher activity with reduced 
toxicity.
22
  
 
Figure 1.5 Representation of a. intrastrand and b. interstrand cross-linking 
 
1.4 Second Generation of Platinum Complexes 
The most successful cisplatin analogue is cis-diammine (1,1-
cyclobutanedicarboxylato)platinum(II) (carboplatin) (Figure 1.6). It has shown 
similar activity to cisplatin against lung and ovarian tumours but with lower 
cytotoxic behaviour.
21
 
 
Figure 1.6 Carboplatin 
 
Its activity is due to the cyclobutanedicarboxylate ligand being more stable than the 
chloride ligands of cisplatin, causing slower in vivo hydrolysis and allowing more 
time for the complex to reach target cells before the ligand is displaced.
23
 A 
significant advantage is that carboplatin has much lower toxic side effects, 
allowing the drug to be administrated in much higher dosages when compared to 
cisplatin. However, the main disadvantage of this drug is that it induces greater 
bone marrow toxicity.
24
 Other platinum complexes have been synthesised with 
either platinum(II) or platinum(IV) centres (Figure 1.7), many of which have 
entered into clinical trials. 
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Figure 1.7 Molecular structures of a nedaplatin, b oxaliplatin, c ZN0473, d JM216 
and e Lobaplatin. 
 
Nedaplatin (a) was found to have the highest anti-cancer activity of this second 
generation, possessing lower nephrotoxicity in comparison to cisplatin, and has 
been approved for clinical use in Japan.
25
 Oxaliplatin (b) was found to be effective 
in cisplatin-resistant cells for a range of different cancers and has since been 
approved for clinical use in France.
26-28
 ZN0473 (c) is sterically hindered and 
hydrolyses around 4 times slower than cisplatin and this is thought to be a factor 
contributing to its high activity against cisplatin-resistant cell lines.
29
 JM216 (d) 
was the first orally administrated platinum complex and was found to form at least 
six metabolites, with no parent compound being detected after 20 minutes of 
administration.
30
 Finally, Lobaplatin (e) was introduced in 1992 and is currently in 
phase II clinical trials for cisplatin-resistant ovarian cancer, head and neck cancers 
and small-cell lung cancer.
31-33
 
 
Research groups are still investigating the group 10 metals for their use in anti-
cancer treatment. However, in more recent years researchers have begun to 
investigate a larger range of transition metals. Therefore this chapter discusses 
some key complexes currently being investigated, with a closer look into current 
titanium, ruthenium and iridium complexes. 
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1.5 Titanocene Dichloride 
The anti-cancer properties of dichlorobis(5-cyclopentadienyl)titanium(IV) 
(titanocene dichloride) were discovered in 1979 by Köpf and Köpf-Maier (Figure 
1.8).
34
 Its cytotoxic potential was investigated due to the similarities in structure 
between titanocene dichloride and cisplatin; both contain cis-dichloro ligands in the 
neutral complex. Titanocene dichloride was tested on a group of CF1 mice 
implanted with Ehrlich ascites tumour cells, and was found to give a cure rate of 
over 80%. It was both the first metallocene and the first titanium-based compound 
to exhibit cytotoxic properties. 
 
Figure 1.8 Structure of Titanocene Dichloride 
 
Titanocene dichloride has been shown to be effective against several carcinomas 
and does not exhibit the same toxological profile as cisplatin, but it does exhibit 
liver damage (hepatotoxicity).
35
 It entered phase I clinical trials in 1991 but was 
rejected during phase II clinical trials as it produced responses too small to justify 
its use in single-agent therapy against both renal and breast cancer.
36, 37
 The in vivo 
aqueous chemistry is thought to be similar to that of cisplatin involving hydrolysis 
of the chloride ligands (Scheme 1.2), with mechanistic findings by Marks et al. 
showing the substitution of the chloride ligands occurred faster than in the case of 
cisplatin.
38
 Titanocene dichloride can also be taken up by transferrin at blood 
plasma pH (7.35-7.45) and proton-induced loss of the Cp rings occurs. This is 
thought to be a key step in the mechanism, with the rate at which the Cp is lost 
controlling the activity of the complexes.
39
 Once inside the cell, the complex is 
transported to the nucleus via interaction with ATP, where it is then free to interact 
with the DNA.
40-42
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Scheme 1.2 Hydrolysis of Titanocene Dichloride 
 
1.5.1 Variations of the Chloride Ligands 
Köpf-Maier et al. investigated modifications of titanocene dichloride, including 
substituting the chloride ligands for different halides and pseudo halides i.e. X = F, 
Br, I, NCS and N3. These complexes showed similar activities to both titanocene 
dichloride and cisplatin, with the pseudo halide being displaced during hydrolysis 
in all cases.
43
 The introduction of the hydrophilic trichloroacetate or 
pentafluorophenoxy (Figure 1.9a and b respectively) saw a significant decrease in 
toxicity (LD50 = 440 mg/kg and 480 mg/kg respectively) compared to titanocene 
dichloride (LD50 = 100 mg/kg). 
 
Figure 1.9 Variations of titanocene dichloride containing; a trichloroacetate and b 
pentafluorophenoxy 
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Other modifications have included neutral and charged moieties in addition to both 
monodentate and bidentate ligands. These included a range of ionic, salt like 
derivatives (Figure 1.10), which have showed good water solubility. This has led 
to further research aimed towards increasing both the solubility and hydrophilic 
character, as both have proven to be beneficial in the design of active titanium anti-
cancer drugs.
44, 45
 
 
Figure 1.10 Ionic derivatives of titanocene dichloride 
 
1.5.2 Cyclopentadienyl Derivatives of Titanocene Dichloride 
As well as alterations to the chloride ligands, research has since moved onto 
modification of the Cp ligand by addition of either a small group or larger pendant 
arms. Köpf and Köpf-Maier proved that addition of electron donating groups to the 
Cp ring did not lead to an increase in cytotoxic properties.
46
 Baird et al. conversely 
added electron withdrawing groups to the Cp ring in an attempt to increase 
cytoxicity.
47
 It was hoped that a more stable Ti-Cp bond would form, which under 
physiological pH would give an electrophilic titanium centre. This would increase 
the Lewis acidity of the titanium centre and effectively increase the binding to 
DNA, which is a Lewis base. When pendant arms were added on to the Cp ring, 
lower IC50 values were observed in comparison to titanocene dichloride. These 
were extensively researched by Tacke et al. with bis-[(4-
methoxybenzyl)cyclopentadienyl]titanium dichloride (Titanocene Y) (Figure 1.11) 
showing an IC50 value of 21 M when tested on LLC-PK, in comparison to an IC50 
value of 2 mM for titanocene dichloride.
48
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Figure 1.11 Structure of Titanocene Y 
 
Tacke et al. have also synthesised a range of Titanocene Y analogues with the 
corresponding difluoride derivatives, some showing higher activity than the 
dichloride complexes.
5
 Substituting the chloride ligands for a bidentate oxalate 
ligand (Oxali-Titanocene Y) showed around a 13-fold increase in activity against 
LLC-PK, giving an IC50 value of 1.6M (Figure 1.12).
49
 Due to the success of 
these complexes, it was necessary to conduct research into a library of carboxylate 
anion-substituted derivatives of Titanocene Y. Some improvements were seen in 
cytotoxicity when compared to titanocene dichloride, but Titanocene Y still 
remains the leading drug candidate of this library.
48
  
 
Figure 1.12 Oxali-Titanocene Y 
 
McGowan et al. have studied the addition of amino functionalised pendant arms, 
and have synthesised the following classes of substituted titanocenes (Figure 1.13). 
In the case of the monocationic complexes (Figure 1.13a), additional methyl and 
silyl groups have been added to the non-pendant cyclopentadienyl ring to improve 
lipophilicity and hence the ability to cross the cell membrane. In vitro testing on 
cell lines MCF7, LoVo, LS 174T, A2780 and A2780cis showed the mono- and 
dicationic species to be potent cytotoxic agents, with the most active complexes 
outperforming titanocene dichloride by 10-fold. Upon addition of one silyl group 
onto the non-pendant cyclopentadienyl ligand showed little effect on the IC50, 
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whereas the addition of two silyl groups led to a marked decrease in IC50. It was 
seen that these complexes were sensitive to cisplatin-resistance cell lines, 
supporting the theories of these complexes acting via a different mechanism to 
cisplatin, although in the case of these ionic complexes there is evidence of 
significant DNA cross-linking.
50-54
 
 
Figure 1.13 a. Mono- b and c bifunctionalised pendant-arm titanocene dichlorides 
 
The lead complex of this type is [C5H4(CH2)2N(CH2)5]2TiCl2.2HCl, which was 
shown to have increased activity in comparison to Cp2TiCl2 (Figure 1.14). 
50, 51, 54
 
 
Figure 1.14 Ionic piperidine functionalised titanocene dichloride 
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1.6 Budotitane 
Along with titanocene dichloride, another library of complexes known as the bis 
(-diketonate) titanium complexes has undergone extensive research as potential 
anti-cancer drugs. The first to enter phase trials was Ti(bzac)2(OEt)2 (Budotitane) 
(Figure 1.15). The complex and its anti-cancer potential have been studied by 
Keppler et al. and has been shown to be effective against sarcoma 180 ascitic 
tumours, Walker 256 carcinosarcoma ascitic tumours, and induced colorectal 
tumours in mice.
55-59
 
 
Figure 1.15 Budotitane 
 
Budotitane entered phase I clinical trials stating a maximum tolerated dosage of 
230 mg/m
2
 with the dose-limiting toxicity being cardiac arrhythmia, and a 
biweekly dose of 180 mg/m
2
 was recommended for further treatment.
60
 However, 
phase II and III clinical trials were postponed due to problems with formulation.
61, 
62
 The issues associated with this complex included poor solubility and stability in 
water, which is a significant limiting factor. Attempts were made to encapsulate the 
active species within a micelle containing glycerine polyethylene-
glycolericinoleate and 1,2-propylene glycol in water-free ethanol; this protective 
micelle is formed when dissolved in water.
63
 However, this formulation provided 
hydrolytic stability for only a few hours, and has proved problematic to 
characterise.
64
 It has been proposed that budotitane loses the ethoxide ligands 
initially, followed by the acac ligands, to form titanium dioxide (Scheme 1.3). 
However, to date the mechanism is poorly understood.
57, 60, 65
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Scheme 1.3 Proposed pathway for the hydrolysis of budotitane 
 
A major issue with budotitane is that it can exist as five different isomers (Figure 
1.16) and this makes it difficult to determine which isomer is key for the observed 
activity. Dubler et al. showed crystallographically evidence that budotitane adopted 
a cis-cis-trans (b) geometry in the solid state, in comparison to the titanium 
chloride derivative which adopted a cis-trans-cis (a) configuration.
66
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Figure 1.16 Five possible isomers of budotitane 
 
Solution studies have shown broad 
1
H NMR signals for the presence of multiple 
isomers, which were thought to be the cis geometries, with the cis-cis-cis (c) being 
the most abundant at 60%, the cis-trans-cis (a) at 21% and then the cis-cis-trans 
(b) at 19%. A further issue is that (a) and (b) are found as enantiomeric pairs, 
further complicating the purification and separation. The presence of the phenyl 
rings is thought to be the key to the activity of these complexes, as replacement 
with methyl groups destroyed the activity, but this has not yet been proven and 
recent studies have shown no DNA damage during both in vivo or in vitro 
studies.
67
 
Aside from titanium, research has continued in the group IV metals, where Keppler 
et al. were amongst the first to show their potential as anti-cancer complexes. 
Analogues of budotitane were made, incorporating either zirconium or hafnium 
with -diketonate ligands, showing that the titanium gave the most promising 
results in vivo.
68
 These libraries have been extended within the McGowan et al. 
showing the in vitro testing of these metal complexes actually have a reversed 
activity where compared to in vivo studies by Keppler. Whereby we show that the 
hafnium analogues are the most active complexes (discussed in Chapter 8).
69
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1.7 Ruthenium 
The use of ruthenium as potential anti-cancer complexes has emerged due to the 
following three properties; 
1. Ligand Exchange 
When considering both ruthenium(II) and (III) complexes, it has been shown that 
the ligand exchange in aqueous conditions is relatively slow and is similar to that 
seen for the platinium(II) complexes.
70
 It is thought that ligand exchange is a key 
process in the drug’s activity and that most complexes in fact alter their structure 
before interaction with the biological targets.
71, 72
 
2. Oxidation State 
Ruthenium has variable oxidation states that are easily accessible under 
physiological conditions, meaning that it can be easily reduced by one electon 
transfer proteins and thus have potential under hypoxic or anoxic conditions. Due 
to the increased metabolic rates of cancer cells there is an increase in lactic acid 
being produced, which decreases the pH within the cancer cells and lowers the 
concentration of O2 at the cell, leading to a preference of ruthenium(II) species 
over ruthenium (III).
72, 73
 
According to the “activation by reduction” hypothesis, ruthenium (II) complexes 
are more available for binding to cellular components than ruthenium (III).
63
 The 
relatively inert and non-toxic ruthenium(III) complexes, which have no effect on 
healthy cells, may be administered, and are then biologically activated by reduction 
to the more active ruthenium(II) complexes. As a result, the ruthenium complexes 
are more selective for cancer cells and decrease the toxicity.
70, 72 
3. Iron Mimicking 
Another advantage is ruthenium’s capacity to mimic iron in binding in vivo to 
different biomolecules, including protein albumin and transferrin. It is known that 
cancer cells have more transferrin receptors on the surface of the cell membrane 
and therefore more ruthenium complexes are able to enter the cell. Radio-labelling 
studies have shown this increase ranges from 2-12 fold, depending on the cell type, 
therefore reducing the toxicity.
63, 72, 74
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1.7.1 Ruthenium Red 
One of the most common forms of ruthenium complex is “ruthenium red” 
[(NH3)5Ru(III)ORu(IV)(NH3)4ORu(III)(NH3)5]
6+
 (Figure 1.17), a polycationic red 
dye used to selectively stain mitochondria by binding to the calcium channels and 
inhibiting calcium ion uptake.
73
 The use of ruthenium red as an anti-cancer agent is 
also known, although its high toxicity has prevented further research.
75, 76
 
 
Figure 1.17 Ruthenium Red 
 
In 1976, Durig et al. discovered that fac-[Cl3(NH3)3Ru] worked in a similar way to 
cisplatin and in fact inhibited E. coli growth, however its low water solubility 
prevented clinical use.
77, 78
 In order to increase solubility, the use of labile ligands 
were suggested and the complex [cis-RuCl2(DMSO)4] was synthesised and was the 
earliest ruthenium complex to exhibit anti-cancer properties.
79
 Not only was it 
active against several metastatic tumours, it also forms covalent bonds to the N7 
position on the guanine residue.
80, 81
 
 
1.7.2 NAMI-A 
Imidazolium [trans-imidazoledimethylsulfoxidetetrachlororuthenate(III)] (NAMI-
A) was discovered by Sava et al. and is the most successful ruthenium anti-cancer 
drug to date and the first to enter phase I clinical trials (Figure 1.18).
82
 
 
Figure 1.18 NAMI-A 
 
Introduction  Chapter 1 
18 
The complex NAMI contains a sodium counterion and replacement of this with an 
imidazolium cation gives NAMI-A. NAMI-A is easier to reproduce synthetically 
then NAMI and is air stable. Both of these complexes have shown activity against 
reducing lung metastasis formation on mice and the anti-metastatic activity of both 
complexes has been shown to have no relation to their cytotoxicity against 
cancerous cells.
82
 It has been suggested they have a different mode of activity in 
comparison to cisplatin and other ruthenium complexes, where their action 
involves extracellular activity which is unique to both agents.
82-84
 It was shown that 
they are able to treat metastatic tumours at doses which are not toxic for the liver, 
lung or kidney,
82, 85
 and have the advantage of being administrated orally. The 
reduction of NAMI-A by ascorbic acid prior to administration led to NAMI-AR. It 
was found that this complex improves the efficiency against the metastasis growth, 
according to the “activation by reduction” hypothesis.85 
 
1.7.3 KP418 and KP1019 
Imidazolium [trans-tetrachlorobis(imidazole)-ruthenate(III)] (KP418) (Figure 
1.19), has shown to be much less toxic than its indazole analogue, however it still 
shows high activity against colorectal carcinoma models in mice.
87
 
 
Figure 1.19 Imidazolium [trans-tetrachlorobis(imidazole)-ruthenate(III)] (KP418) 
 
Indazolium [trans-tetrachlorobis(indazole)-ruthenate(III)] (KP1019) (Figure 1.20) 
was discovered by Keppler et al. and has shown high activity against a range of 
cell lines. Unlike NAMI-A, which exhibited activity against metastasis processes, 
KP1019 is active against colon carcinomas and primary human tumours.
 
Inhibiting 
approximately one third of tumours, the only side-effect of KP1019 is the increased 
production of red blood cells (erythropoiesis), with clinical reports suggesting no 
severe side effects.
89
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Figure 1.20 Indazolium [trans-tetrachlorobis(indazole)-ruthenate(III)] (KP1019) 
 
Although KP1019 has poor water solubility, the substitution of the indazolium 
cation with sodium increases its water solubility, improving its potential for clinical 
use.
88
 The active species of both these complexes have been shown to be the 
hydrolysed species of the chloride precursor, with KP418 hydrolysing at a rate 
comparable to cisplatin. However, KP1019 hydrolyses more slowly and via a 
different pathway and is dependent upon both temperature and pH. Following 
hydrolysis both complexes interact with the nucleophilic sites on DNA. They are 
also active against cisplatin-resistant cell lines and therefore it is thought that 
binding of ruthenium complexes will have different cytotoxic effects in comparison 
to cisplatin.
75,89, 90
 
 
It has been shown that colorectal tumour uptake for KP418 was 10-fold lower than 
KP1019, leading to lower anti-cancer activity. KP1019 has been shown to be active 
against cisplatin-resistant tumours and this could be due to a different mechanism 
of action. It is thought that ruthenium complexes target the N7 position of guanine 
or adenine and shows that KP1019 has less interstrand cross-linking in comparison 
to cisplatin.
89
 
 
1.7.4 Organometallic Ruthenium Arenes 
Organometallic complexes were once restricted to ruthenocene, until Sheldrick et 
al. reported the biological use of organometallic 6–arene ruthenium complexes. 
This organometallic work was based on his previous coordination work and the 
reported activity of cis-[RuCl2(DMSO)4].
91
 Sheldrick made a range of 6-
ruthenium organometallic complexes, with the most promising ones taking the 
form [(6-arene)Ru(II)(en)X]+ (X = halide, en = ethylenediamine) (Figure 1.21). It 
was shown that differing the arene substituents lead to differences in activity both 
in vitro and in vivo against a range of cancer cell lines, including cisplatin-resistant 
cell lines.
92-94
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Figure 1.21 Examples of [(6-arene)Ru(II)(en)X]+ complexes 
 
These types of complex have also been studied by Sadler et al. (Figure 1.22) and 
the 2-phenoxy derivatives showed the highest cytotoxicity amongst the polar 
substituents, but further results showed the non polar substituents had higher 
activity than polar groups.
94
 They also showed that polycyclic arenes on average 
had higher activity than monocyclic arenes. It is thought that increasing the number 
of arenes increases hydrophobicity, allowing easier passive transport into the 
cell.
92-94
 To achieve better DNA binding the neutral ethylenediamine ligand was 
replaced with an anionic -diketonate ligand, which exhibited high activity due to 
rapid hydrolysis in water and a change in binding specificity. They show selective 
binding to adenosine, with very little binding to other residues.
95
 
 
Figure 1.22 [(6-arene)Ru(II)(en)X].PF6 complexes 
 
It is thought that these types of ruthenium complexes hydrolyse at a faster rate than 
cisplatin, resulting in [(η6–arene)Ru(en)(H2O)]
2+
 which reacts rapidly with 
guanosine monophosphate (5′-GMP).96 The interaction of these complexes with 
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guanine derivatives in vitro were studied by Sadler et al.
97
 A crystal structure was 
determined and shows π-π arene-nucleobase stacking of [(η6–dha)Ru(en)9EtG-
N7]
2+ 
and [(η6–tha)Ru(en)9EtG-N7]2+ (9EtG-N7 = N7 bound 9-ethyl guanine). It 
was also shown that there is intermolecular π-π stacking between the pendant 
phenyl ring and the guanine base, and a hydrogen bond interaction between the 
ligand NH and guanine O6.
97
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Figure 1.23 Interactions between [6-dhaRu(en)]2+ and 9EtG 
 
McGowan et al. have carried out extensive work on arene ruthenium complexes to 
try and produce higher activity against cancerous cells and cisplatin-resistant cell 
lines. These include a range of picolinamide and quinaldamide complexes (Figure 
1.24), that have been synthesised by reactions with the p-cymene ruthenium(II) 
chloride dimer.
98
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Figure 1.24 Ruthenium picolinamides and quinaldamides 
 
The lead drug within this type of complex is the charged ruthenium (II) chloride 
2,5-dichloropicolinamide complex, which is made by filtering the uncharged 
complex onto NH4PF6 (Figure 1.25). These types of (N,N) chelating ligands are of 
high interest due to previous results discussed within the work of Sheldrick et al. 
and they also have the advantage of coordinating as (N,O) chelating ligands, giving 
them potential to target different organelles within the cancerous cells. 
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Figure 1.25 McGowan et al. lead compound 
 
NMR studies have shown that equilibrium between the (N,O) and (N,N) 
coordination can be altered by changes in temperature and pH.
99
 The ruthenium 
complexes with 3-nitro, 4-nitro and 4-fluoro picolinamide have shown IC50 values 
against a range of tumour cells in the same order of magnitude as cisplatin and 
carboplatin, with the added advantage of being active against a cisplatin resistant 
cell line. It was shown that the binding mode of these complexes is essential to its 
cytotoxic behaviour. Studies showed that the more cytotoxic (N,N) complexes have 
rapid hydrolysis and bind preferentially to guanine, whereas switching the binding 
mode to (N,O) slows the rate of hydrolysis and switches off the activity.
99-101
 
Work has since continued on ruthenium and iridium arene complexes incorporating 
either a picolinamide (N,N), ketoiminate (N,O) or a napthoquinone (O,O) ligand, 
where the IC50 values against both HT-29 and MCF-7 show the difference in 
binding mode is key for the cytotoxic values seen.
102
 The most significant result 
was seen for the ketoiminate (N,O) complexes for both ruthenium and iridium and 
activity followed the general trend (N,O) > (O,O) > (N,N). Part of the work in this 
thesis helps to explore further structural activity relationships. 
Since the start of this project, Dyson et al. have also started working on ruthenium 
-ketoiminate complexes (Figure 1.26). They show that altering the Ru-arene 
substituent can tune the activity of the complexes, whereby the p-cymene ligand 
gave the highest activities. Upon minor alterations of the -ketominate ligand, large 
differences were noted in the cytotoxicities observed. It was also noted that all 
ruthenium -ketominate complexes were less active than cisplatin against A2780, 
but they were more active than cisplatin against A2780cis, suggesting these 
complexes are activated via a different mechanism to cisplatin.
103
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Figure 1.26 Ruthenium -ketoiminate complexes reported by Dyson et al.103 
 
1.8 Research Aims 
The aims of the project were to synthesise a range of -ketominate ruthenium 
chloride complexes, altering both the electronics and sterics of the -ketominate 
ligand in order to gain structural activity relationships and assess their potential as 
anti-cancer compounds. 
 Firstly, the -diketonate ligands104 and -keiminate ligands105 will be 
synthesised according to Scheme 1.4 and Scheme 1.5 respectively. 
 
Scheme 1.4 Synthetic route for -diketonate ligands104 
 
Scheme 1.5 Synthetic route for -ketoiminate ligands105 
 The complexes will be synthesised according to Scheme 1.6. 
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Scheme 1.6 Synthetic route of -ketominate ruthenium chloride complexes 
 
Complexes synthesised will include the following components which have been 
shown to be important: 
 
Figure 1.27 Target ruthenium complexes 
I. The p-cymene moiety may stabilise the ruthenium centre towards 
hydrolysis and increase the hydrophobic character of the complex, allowing 
the complex to remain intact in vivo and facilitating passive transport across 
cell membranes. 
II. Varying the substituents R and R1 may increase the water solubility of the 
complex as well as increasing the anti-cancer activity of the complex. 
III. Planar aromatic groups may provide a potential site for -stacking with 
nucleobases within the DNA chain (intercalation). 
IV. The presence of a labile halide ligand could allow rapid hydrolysis of the 
complex at the low intracellular chloride levels, forming the more reactive 
species which can then form covalent bonds with nucleophilic sites on the 
DNA chain. 
The complexes will be assessed for their anti-cancer potential by determining their 
cytotoxicities using several biological assays and gaining structure activity 
relationships (SARs). 
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2 Preparation of (O,O) and (N,O) Ligands 
2.1 Preparation of -Diketonate (O,O) Ligands 
This section extends the previous library of 4-hydroxy-4-phenyl-3-buten-2-one (-
diketonate) ligands which have previously been reported within the research 
group.
1, 2
 The library was first extended by the synthesis of novel mono-aryl -
diketonate ligands (L1-L4) and also novel bi-aryl -diketonate ligands (L5-L10) 
(Figure 2.1). All compounds have been synthesised and fully characterised by the 
author using 
1
H NMR, 
1
H-
1
H COSY, 
13
C{
1
H} NMR, 
1
H-
13
C{
1
H} HMQC 
spectroscopy, mass spectrometry and micro-analysis. 
R
OH O
R1
 
R = Me, R1 = 4’-
t
butyl L1 R = Py, R1 = H L5 
 2’-OEt, 4’-F L2  4’-Br L6 
 2’, 5’-diF L3  4’-OMe L7 
 4’-imidazole L4  4’-Me L8 
    3’-naphthyl L9 
    2’,3’,4’-triCl L10 
Figure 2.1 Novel -diketonate ligands synthesised within this chapter 
 
2.2 Synthesis of Mono-Aryl -Diketonate Ligands 
There are several different synthetic routes for the preparation of these mono-aryl 
ligands. In this work, a Claisen condensation reaction was carried out by reacting a 
substituted acetophenone with ethyl acetate in the presence of sodium ethoxide 
(Scheme 2.1).
3
 
OH O
R1
O
R1
i) NaOEt
   EtOAc
   reflux
ii) H2SO4  
Scheme 2.1 Synthetic route for mono-aryl -diketonate ligands 
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2.2.1 Characterisation of Mono-Aryl -Diketonate Ligands 
The
 1
H NMR spectra of these mono-aryl ligands (Figure 2.2) are all very similar 
with the aromatic hydrogens (f-h) having the highest chemical shifts (an example 
for L4 is seen in Figure 2.3), all appearing in the region 6.6-8.1 ppm. The methine 
hydrogen (c) is the most characteristic peak and appears as a one proton singlet in 
the region 6.1-6.5 ppm. The methyl hydrogens (a) appear as a three proton singlet 
in the region 2.1-2.3 ppm. In some ligands a peak for the OH can be seen at 
approximately 16 ppm. 
e
f
g
h
d
c
b
a
OH O
R1
 
Figure 2.2 General structure of mono-aryl -diketonate 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
8.0 7.9 7.8 7.7 7.6 7.5 7.4 7.3 7.2
Chemical Shift (ppm)
c, 1H
a, 3H
f, 2H
imidazole, 1H
imidazole, 1H
imidazole, 1H
g, 2H
 
Figure 2.3 
1
H NMR spectrum for ligand L4 (CDCl3, 500 MHz, 300K) 
 
The
 13
C{
1
H} NMR spectra show the highest chemical shifts for the quaternary 
carbonyl/enol carbons (b and d), these appear in the range 175-195 ppm. All 
aromatic quaternary carbons are in the region 130-160 ppm and aromatic CH seen 
between 100-130 ppm and these values differ depending on the substituent R. The 
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methine carbon (c) is in the region 95-105 ppm and finally the methyl carbon (a) is 
usually seen between 25-27 ppm. 
 
2.3 Synthesis of Biaryl -Diketonate Ligands 
The biaryl -diketonate ligands were also prepared via a Claisen condensation 
reaction of a substituted aromatic ketone with a substituted pyridine ester in the 
presence of sodium ethoxide, acetic acid and water (Scheme 2.2). This is a 
modification of a previously published literature route by Levine et al. and goes via 
a similar mechanistic pathway to the mono-aryl ligands.
4
 
OH O
R
O
R
i) NaOEt
    Et2O
ii) acetic acid
H2O
NN
OEt
O
Scheme 2.2 Synthetic route for biaryl -diketonate ligands 
 
2.3.1 Characterisation of Biaryl -Diketonate Ligands 
The 
1
H NMR spectra for these biaryl ligands (Figure 2.4) are very similar, but 
show significant differences when compared to the mono-aryl ligands. The protons 
a-d appear slightly higher in at a chemical region of 7.4-8.8 ppm. The aromatic 
protons j-l are within the region 6-8 ppm. The methine hydrogen (g) is seen at a 
much higher chemical shift when compared to the mono-aryl ligands and appears 
as a one hydrogen singlet between 7.2-7.7 ppm (example for L5 seen in Figure 
2.5) 
i
j
k
l
h
g
f
e
OH O
N
a
b
c
d
R1
 
Figure 2.4 General structure of a biaryl -diketonate 
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8.5 8.0 7.5 7.0
Chemical Shift (ppm)
a, 1H
d, 1H
j, 2H
c, 1H
g, 1H
b, 
1H
k , 2H
l, 1H
 
Figure 2.5 
1
H NMR spectra example of the biaryl ligand L5 (CDCl3, 500 MHz, 
300K) 
 
The 
13
C{
1
H} NMR spectra are similar to the mono-aryl -diketonate ligands, with 
the highest shifts seen between 180-190 ppm for the quaternary carbons f and h. 
All the pyridine and aromatic CH signals appear between 120-150 ppm and were 
assigned using a 2D 
1
H-
13
C{
1
H} COSY spectra. The quaternary pyridine carbon e 
is typically seen between 150-160 ppm and the aromatic quaternary carbon i 
between 127-135 ppm. Finally, the methane carbon g has the lowest chemical shift 
and can be found between 90-95 ppm. 
 
2.4 Preparation of -Ketoiminate (N,O) Ligands 
This section expands on previously synthesised phenyl-3(phenylamino)-2-buten-1-
one (-ketoiminate) ligands.5 The novel ligands shown in Figure 2.6 have been 
synthesised and characterised by the author using 
1
H NMR, 
1
H-
1
H COSY, 
13
C{
1
H} 
NMR, 
1
H-
13
C{
1
H} COSY spectroscopy, mass spectrometry, microanalysis. In 
addition single X-ray crystallography data has been obtained for ligands L11, L12, 
L14-16, L19, L21, L22, L24 and L25. 
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NH O
R
R1
 
R = H, R1 = 4’-Me L11 R = H, R1 = 4’-OMe L20 
 3’-F L12  3’,4’-diOMe L21 
 4’-F L13  2’-OEt, 4’-F L22 
 2’,5’-diCl L14  4’-OEt L23 
 3’,4’-diCl L15  3’,4’-methylene L24 
 2’,3’,4’-triCl L16  4’-imidazole L25 
 3’-Br L17  3’-naphthyl L26 
 4’-I L18 R = 2’,5’-diF, R1 = 4’-F L27 
 4’-Et L19 R1 = 2’-F, R1 = 4’-F L28 
Figure 2.6 Novel -ketoiminate ligands synthesised within this chapter 
 
2.5 Synthesis of -Ketoiminate Ligands 
The -ketoiminate ligands were synthesised using an adaptation of a previously 
established method by Tang et al.
6
 The corresponding functionalised -diketonate 
ligand was reacted with the relevant aniline in the presence of toluene and HCl 
(Scheme 2.3). 
OH O
R1
Toluene
HCl
NH2
R
NH O
R
R1
 
Scheme 2.3 General synthetic route for the -ketoiminate ligands 
 
2.5.1 NMR Characterisations for -Ketoiminate Ligands 
The
 1
H NMR spectra for the -ketoiminate ligands (Figure 2.7) show a 
characteristic broad singlet between 12.7-13.2 ppm corresponding to the NH. In 
general, the aniline aromatic protons are usually within the range 7.1-7.5 ppm, with 
the meta hydrogens (c) usually appearing as a broad triplet and the para hydrogens 
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(d) as a multiplet. These are at higher ppm values and generally more deshielded 
than the ortho hydrogens (b) which often appear as broad doublets. The methyl 
hydrogens (e) appear as a three proton singlet between 2.1-2.2 ppm and the 
methine hydrogen (g) is a one proton singlet in the region of 5.4-6.1 ppm and is 
shifted upfield approximately 0.5 ppm from the corresponding -diketonate ligand. 
The protons from the aromatic ring (j-l) all differ depending on the substituent 
R1and can be seen within the region 6-8 ppm (example for L11 seen in Figure 2.8). 
i
j
k
l
h
g
f
e
NH O
a
d
c
b
R1
R
 
Figure 2.7 General structure of the -ketoiminate ligand 
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)
13.2 13.1 13.0 12.9
Chemical Shift (ppm)
NH, 1H
j, 2H
e, 3H
g, 1H
b, 2H
c, d, j, k, 7H
R group, Methyl, 3H
 
Figure 2.8 
1
H NMR spectra example for ligand L11 (CDCl3, 300 MHz, 300K) 
 
The 
13
C{
1
H} spectrum for ligands are all similar, with the highest peaks for the 
quaternary carbonyl carbon (h) and quaternary carbon ipso to NH (f), these are 
usually seen in the region of 160-188 ppm. All aromatic carbons are in the range 
100-135 ppm and the order differs depending on the substituent R. The methine 
carbon (g) appears in the region 93-100 ppm and the methyl carbon (e) is seen in 
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the region 19-21 ppm. 
 
2.5.2 X-ray Crystallography for -Ketoiminate  
Single crystals suitable for X-ray crystallography were obtained by slow 
evaporation from hot ethanol. Structural solutions were performed in a monoclinic 
(L11, L12, L14, L16, L19, L24 and L25), orthorhombic (L15) or triclinic (L21 
and L22) space group. All angles around the central atoms are between 118-125°, 
showing this section of the ligand is planar, with the atoms held together by an 
intramolecular hydrogen bonding interaction between N-H…O, this interaction is 
seen in all crystal structures. Most of the ligands have intermolecular interactions 
holding pairs of molecules together and have a distinctive herringbone arrangement 
when viewed along an axis.  
 
2.6 Characterisation of Novel -Ketoiminate Compounds 
2.6.1 X-ray Characterisation of C17H17NO (L11) 
L11 has been previously synthesised,
5
 however, colourless crystals suitable for X-
ray crystallographic analysis were obtained by slow evaporation in hot ethanol over 
a period of 3 days. The molecular structure is given in Figure 2.9, and selected 
bond lengths and angles are stated in Table 2.1. Ligand L11 was solved in a 
monoclinic cell and structural solution was performed in the space group P21/n, 
with two molecules in the asymmetric unit. 
 
Figure 2.9 Molecular structure of L11, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
 
-Diketonate and -Ketoiminate Ligands  Chapter 2 
39 
Table 2.1 Selected bond lengths and angles for both molecules of L11 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.4104(13) C(1)-N(1)-C(8) 133.39(9) 
N(1)-C(8) 1.3543(13) N(1)-C(8)-C(9) 119.60(9) 
C(7)-C(8) 1.4996(14) C(8)-C(9)-C(10) 124.15(10) 
C(8)-C(9) 1.3805(15) O(1)-C(10)-C(9) 122.67(10) 
C(9)-C(10) 1.4298(14) O(1)-C(10)-C(11) 117.81(9) 
O(1)-C(10) 1.2552(12)   
C(10)-C(11) 1.4988(14)   
C(14)-C(17) 1.5092(15)   
Bond Distance (Å) Bond Angle (˚) 
C(1’)-N(1’) 1.4147(13) C(1’)-N(1’)-C(8’) 130.88(8) 
N(1’)-C(8’) 1.3499(13) N(1’)-C(8’)-C(9’) 119.79(9) 
C(7’)-C(8’) 1.5018(14) C(8’)-C(9’)-C(10’) 123.66(9) 
C(8’)-C(9’) 1.3797(14) O(1’)-C(10’)-C(9’) 122.56(10) 
C(9’)-C(10’) 1.4265(14) O(1’)-C(10’)-C(11’) 117.67(9) 
O(1’)-C(10’) 1.2610(12)   
C(10’)-C(11’) 1.4967(14)   
C(14’)-C(17’) 1.5114(15)   
 
The packing diagram for L11 shows the molecules pack in pairs of alternating 
molecules with a head-tail-tail-head arrangement when viewed along the c axis 
there is a slight herringbone structure. Intramolecular hydrogen bonding can be 
seen between N-H...O of both molecules and an intermolecular hydrogen bond 
between C(3)-H(3)...O(1’) which is contributing to the packing of this molecule. 
The packing diagram and intermolecular interactions are presented in Figure 2.10, 
with D…A distances and torsion angles are stated in Table 2.2. 
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Packing along the c axis C(3)-H(3)…O(1’) 
Figure 2.10 Packing diagrams and intermolecular interaction of L11, and hydrogen 
atoms are omitted for clarity. 
Table 2.2 Bond lengths and torsion angles of ligand L11 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1)...O(1) 2.6286(12) Å 
 N(1’)-H(1’)...O(1’) 2.6107(12) Å 
Intermolecular C(3)-H(3)...O(1’) 3.3190(14) Å 
Torsion Cg(1)-Centre 15.49° 
 Centre-Cg(2) 15.00° 
 
2.6.2 X-ray Characterisation of C16H14FNO (L12) 
Yellow plates of L12 suitable for X-ray crystallographic analysis were obtained by 
slow evaporation in hot ethanol over a period of several days. The molecular 
structure is given in Figure 2.11, and selected bond lengths and angles are stated in 
Table 2.2. Ligand L12 was solved in a monoclinic cell and structural solution was 
performed in the space group P21/c, with one molecule in the asymmetric unit. 
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Figure 2.11 Molecular structure of L12, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 2.3 Selected bond lengths and angles of L12 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.4235(14) C(1)-N(1)-C(8) 130.54(9) 
N(1)-C(8) 1.3457(14) N(1)-C(8)-C(9) 120.17(9) 
C(7)-C(8) 1.5049(14) C(8)-C(9)-C(10) 123.34(10) 
C(8)-C(9) 1.3963(15) O(1)-C(10)-C(9) 123.39(10) 
C(9)-C(10) 1.4286(15) O(1)-C(10)-C(11) 118.88(9) 
O(1)-C(10) 1.2583(13)   
C(10)-C(11) 1.5105(14)   
C(13)-F(1) 1.3622(13)   
 
The packing diagrams for L12 show that when viewed along the a axis there is a 
herringbone arrangement with intermolecular interactions holding rows of 
molecules together. Intramolecular hydrogen bonding can be seen between N(1)-
H(1N)...O(1) and an intermolecular T-stacking interaction is seen between C(16)-
H(16)…Cg(1). The interactions and packing diagrams are presented in Figure 
2.12, with D…A distances and torsion angles stated in Table 2.4. 
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C(16)-H(16)...Cg(1) Packing showing intermolecular interaction 
 
 
C(7)-H(7B)…O(1) along the c axis Packing along the a axis 
Figure 2.12 Intermolecular interactions and packing diagram of L12  
Table 2.4 Bond lengths and torsion angles of L12 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)...O(1) 2.6434(14) Å 
Intermolecular C(16)-H(16)...Cg(1) 3.5834 Å 
 N(1)-H(1N)…O(1) 3.1450(13) Å 
 C(7)-H(7B)…O(1) 3.3968(14) Å 
Torsion Cg(1)-Centre 34.83° 
 Centre-Cg(2) 24.74° 
 
2.6.3 X-ray Characterisation of C16H13Cl2NO (L14) 
Yellow plates of L14 suitable for X-ray crystallographic analysis were obtained by 
slow evaporation in hot ethanol over a period of several days. The molecular 
structure is given in Figure 2.13, and selected bond lengths and angles are stated in 
Table 2.5. Ligand L15 was solved in a monoclinic cell and structural solution was 
performed in the space group P21/n, with one molecule in the asymmetric unit. 
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Figure 2.13 Molecular structure of L14, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 2.5 Selected bond lengths and angles of L14 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.4232(15) C(1)-N(1)-C(8) 128.29(11) 
N(1)-C(8) 1.3460(16) N(1)-C(8)-C(9) 119.87(11) 
C(7)-C(8) 1.4987(17) C(8)-C(9)-C(10) 123.80(11) 
C(8)-C(9) 1.3883(16) O(1)-C(10)-C(9) 125.41(11) 
C(9)-C(10) 1.4158(18) O(1)-C(10)-C(11) 118.14(11) 
O(1)-C(10) 1.2480(16)   
C(10)-C(11) 1.5146(16)   
C(12)-Cl(1) 1.7412(12)   
C(15)-Cl(2) 1.7380(12)   
 
The packing diagrams show the molecules pack in a head-tail arrangement and 
when viewed along both the a and c axes there is a herringbone structure, with 
intermolecular T-stacking interactions holding rows of molecules together. 
Intramolecular hydrogen bonding can be seen between N(1)-H(1N)...O(1), and two 
intermolecular T-stacking interactions are seen between C(3)-H(3)…Cg(2) and 
C(13)-H(13)…Cg(2). The packing diagrams and T-stacking interactions and are 
presented in Figure 2.14, with D…A distances and torsion angles stated in Table 
2.6. 
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Packing along the a axis Packing along the c axis 
 
T-stacking between C(3)-H(3)…Cg(2)…H(13)-C(13) 
Figure 2.14 Packing diagrams and T-stacking interactions of L14  
Table 2.6 Bond lengths and torsion angles of L14 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)...O(1) 2.6788(14) Å 
Intermolecular C(3)-H(3)...Cg(2) 3.5000 Å 
 C(13)-H(13)…Cg(2) 3.5220 Å 
Torsion Cg(1)-Centre 45.61° 
 Centre-Cg(2) 81.99° 
 
2.6.4 X-ray Characterisation of C16H13Cl2NO (L15) 
Yellow fragments of L15 suitable for X-ray crystallographic analysis were 
obtained by slow evaporation in hot ethanol over a period of several days. The 
molecular structure is given in Figure 2.15, and selected bond lengths and angles 
are stated in Table 2.7. Ligand L15 was solved in an orthorhombic cell and 
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structural solution was performed in the space group Pbca, with one molecule in 
the asymmetric unit. 
 
Figure 2.15 Molecular structure of L15, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 2.7 Selected bond lengths and angles of L15 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.4107(3) C(1)-N(1)-C(8) 129.75(22) 
N(1)-C(8) 1.3528(3) N(1)-C(8)-C(9) 120.22(23) 
C(7)-C(8) 1.4997(4) C(8)-C(9)-C(10) 123.29(24) 
C(8)-C(9) 1.3759(4) O(1)-C(10)-C(9) 122.67(23) 
C(9)-C(10) 1.4236(4) O(1)-C(10)-C(11) 117.26(22) 
O(1)-C(10) 1.2564(3)   
C(10)-C(11) 1.5003(3)   
C(13)-Cl(1) 1.7391(3)   
C(14)-Cl(2) 1.7353(3)   
 
The packing diagrams for L15 show the molecules pack in a head-tail-tail-head 
herringbone arrangement when viewed along the a axis, with intermolecular T-
stacking interactions holding rows of molecules together. Intramolecular hydrogen 
bonding interactions can be seen between N(1)-H(1N)...O(1) and C(12)-
H(12)…O(1). There are intermolecular T-stacking interaction between C(13)-
Cl(1)…Cg(2) and C(10)-O(1)…Cg(2). These interactions and the packing diagram 
are presented in Figure 2.16, with D…A distances and torsion angles stated in 
Table 2.8. 
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Intramolecular interactions 
Intermolecular interactions along the 
a axis 
Figure 2.16 Intra-/Intermolecular interactions and packing diagram of L15  
Table 2.8 Bond lengths and torsion angles of L15 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)...O(1) 2.607(3) Å 
 C(12)-H(12)…O(1) 2.733(3) 
Intermolecular C(13)-C(1)...Cg(2) 3.911 Å 
 C(10)-O(1)…Cg(2) 3.478 Å 
 C(15)-H(15)…O(1) 3.175(3) Å 
Torsion Cg(1)-Centre 45.61° 
 Centre-Cg(2) 81.99° 
 
2.6.5 X-ray Characterisation of C16H12Cl3NO (L16) 
Brown fragments of L17 suitable for X-ray crystallographic analysis were obtained 
by slow evaporation in hot ethanol over a period of several days. The molecular 
structure is given in Figure 2.17, and selected bond lengths and angles are stated in 
Table 2.9. Ligand L17 was solved in a monoclinic cell and structural solution was 
performed in the space group P21/c, with one molecule in the asymmetric unit. 
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Figure 2.17 Molecular structure of L16, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 2.9 Selected bond lengths and angles for L16 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.411(3) C(1)-N(1)-C(8) 128.72(15) 
N(1)-C(8) 1.346(2) N(1)-C(8)-C(9) 120.35(16) 
C(7)-C(8) 1.494(2) C(8)-C(9)-C(10) 123.85(16) 
C(8)-C(9) 1.380(2) O(1)-C(10)-C(9) 125.19(15) 
C(9)-C(10) 1.418(2) O(1)-C(10)-C(11) 118.99(15) 
O(1)-C(10) 1.245(2)   
C(10)-C(11) 1.510(2)   
C(12)-Cl(1) 1.7326(17)   
C(13)-Cl(2) 1.7153(17)   
C(14)-Cl(3) 1.7304(17)   
 
The packing diagrams for L16 show that when viewed along the c axis they have a 
slight herringbone arrangement. An intramolecular hydrogen bonding interaction 
can be seen between N(1)-H(1N)...O(1) and an intermolecular interaction between 
C(13)-Cl(1)…Cg(2) and C(5)-H(5)…O(1). These interactions and the packing 
diagram are presented in Figure 2.18, with D…A distances and torsion angles 
stated in Table 2.10. 
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Packing along the b axis Packing along the c axis 
Figure 2.18 Intra-/Intermolecular interactions and packing diagram for L16 
Table 2.10 Bond lengths and torions angles for L16 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)...O(1) 2.6792(19) Å 
Intermolecular C(13)-Cl(2)...Cg(2) 4.8661 Å 
 C(5)-H(5)...O(1) 3.473(2) Å 
Torsion Cg(1)-Centre 45.42° 
 Centre-Cg(2) 59.40° 
 
2.6.6 X-ray Characterisation of C18H18NO (L19) 
Brown crystals of L19 suitable for X-ray crystallographic analysis were obtained 
by slow evaporation from hot ethanol over a period of 2-3 weeks. The molecular 
structure is given in Figure 2.19, and selected bond lengths and angles are stated in 
Table 2.11. Ligand L19 was solved in a monoclinic cell and structural solution 
was performed in the space group P21/n, with a two molecules in the asymmetric 
unit. 
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Figure 2.19 Molecular structure of L19, displacement ellipsoids are at the 50% 
probability level, hydrogen atoms and the second molecule are omitted for clarity. 
Table 2.11 Selected bond lengths and angles for both molecules of L19 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.4148(2) C(1)-N(1)-C(8) 129.79(16) 
N(1)-C(8) 1.3461(2) N(1)-C(8)-C(9) 119.78(18) 
C(7)-C(8) 1.4958(3) C(8)-C(9)-C(10) 123.71(17) 
C(8)-C(9) 1.3809(3) O(1)-C(10)-C(9) 122.80(17) 
C(9)-C(10) 1.4220(3) O(1)-C(10)-C(11) 117.6(17) 
O(1)-C(10) 1.2581(2)   
C(10)-C(11) 1.4970(3)   
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.4104(2) C(1)-N(1)-C(8) 131.97(16) 
N(1)-C(8) 1.3505(2) N(1)-C(8)-C(9) 119.83(17) 
C(7)-C(8) 1.4941(3) C(8)-C(9)-C(10) 124.36(17) 
C(8)-C(9) 1.3729(3) O(1)-C(10)-C(9) 122.58(16) 
C(9)-C(10) 1.4288(3) O(1)-C(10)-C(11) 118.11(17) 
O(1)-C(10) 1.2503(2)   
C(10)-C(11) 1.4970(3)   
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The packing diagram when viewed along both the b axis shows the molecules 
packing in a head-tail-tail-head arrangement within each plane of molecules. When 
viewed along the c axis the molecules pack in pairs and give a herringbone 
arrangement. Intramolecular interactions are seen between the N-H…O of both 
molecules, along with several intermolecular T-stacking interactions. The packing 
diagrams are presented in Figure 2.20, with D…A distances and torsion angles 
stated in Table 2.12. 
 
 
Packing along the b axis Packing along the c axis 
Figure 2.20 Packing diagrams of L19 when viewed along the b and c axis 
Table 2.12 Bond lengths and torsion angles for L19 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)...O(1) 2.614(2) Å 
 N(1’)-H(1’N)...O(1’) 2.6346(19) Å 
Intermolecular C(2')-H(2')...Cg(2) 3.6518 Å 
 C(6)-H(6)...Cg(2) 3.7445 Å 
 C(12)-H(12)...Cg(1) 3.6236 Å 
 C(12')-H(12')...Cg(1) 3.6315 Å 
 C(15)-H(15)...Cg3 3.6671 Å 
 C(17')-H(17C)...Cg(3) 3.5166 Å 
 C(18')-H(18A)...O(1) 3.386(2) Å 
Torsion Cg(1)-Centre 35.75° 
 Centre-Cg(2) 23.36° 
 Cg(3)-Centre’ 25.37° 
 Centre’-Cg(4) 24.43° 
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2.6.7 X-ray characterisation for C18H18NO3 (L21) 
Yellow fragments of L21 suitable for X-ray crystallographic analysis were 
obtained by slow evaporation in hot ethanol over a period of several days. The 
molecular structure is given in Figure 2.21, and selected bond lengths and angles 
are stated in Table 2.13. Ligand L21 was solved in a triclinic cell and structural 
solution was performed in the space group P1, with two molecules in the 
asymmetric unit. 
 
Figure 2.21 Molecular structure of L21, displacement ellipsoids are at the 50% 
probability level, the hydrogen atoms and second molecule are omitted for clarity. 
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Table 2.13 Selected bond lengths and angles for both molecules of L21 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.431(3) N(1)-C(8)-C(9) 120.1(2) 
N(1)-C(8) 1.362(3) C(8)-C(9)-C(10) 123.3(2) 
C(7)-C(8) 1.511(4) O(1)-C(10)-C(9) 122.7(2) 
C(8)-C(9) 1.403(3) O(1)-C(10)-C(11) 117.8(2) 
C(9)-C(10) 1.439(4)   
O(1)-C(10) 1.271(3)   
C(10)-C(11) 1.515(3)   
Bond Distance (Å) Bond Angle (˚) 
C(1’)-N(1’) 1.430(3) N(1’)-C(8’)-C(9’) 120.8(2) 
N(1’)-C(8’) 1.361(3) C(8’)-C(9’)-C(10’) 123.0(2) 
C(7’)-C(8’) 1.526(4) O(1’)-C(10’)-C(9’) 122.2(3) 
C(8’)-C(9’) 1.270(3) O(1’)-C(10’)-C(11’) 118.4(2) 
C(9’)-C(10’) 1.449(4)   
O(1’)-C(10’) 1.390(4)   
C(10’)-C(11’) 1.503(4)   
 
The packing diagrams when viewed along the both the a and b axis show there is a 
herringbone arrangement. Intramolecular hydrogen bonding interactions can be 
seen between N(1)-H(1)...O(1), the packing also has a large number of 
intermolecular interactions, all contributing to the packing of these molecules. The 
packing diagrams are presented in Figure 2.22, with D…A distances and torsion 
angles stated in Table 2.14. 
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Packing diagram along the a axis Packing along the b axis 
Figure 2.22 Packing diagrams of L21 when viewed along the a and b axes 
Table 2.14 Bond lengths and torsion angles for both molecules of L21 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)…O(1) 2.642(3) Å 
 N(1’)-H(1N’)…O(1’) 2.633(3) Å 
Intermolecular C(2)-H(2)…Cg(2) 3.639 Å 
 C(2’)-H(2’)…Cg(4) 3.635 Å 
 C(12)-H(12)…Cg(1) 3.605 Å 
 C(12’)-H(12’)…Cg(3) 3.614 Å 
 C(17)-H(17A)…Cg(3) 3.585 Å 
 C(17)-H(17D)…Cg(1) 3.573 Å 
 C(7)-H(7B)...O(1) 3.310(4) Å 
 C(7’)-H(7’B)...O(1’) 3.300(4) Å 
 C(6)-H(6)...O(2’) 3.324(4) Å 
 C(6’)-H(6’)...O(2) 3.319(4) Å 
 C(6)-H(6)...O(3’) 3.407(4) Å 
 C(6’)-H(6’)...O(3) 3.411(4) Å 
 C(17)-H(17C)...O(1) 3.332(4) Å 
 C(17’)-H(17’C)...O(1’) 3.346(4) Å 
Torsion Cg(1)-Centre 48.92° 
 Centre-Cg(2) 27.30° 
 Cg(3) Centre’ 49.14° 
 Centre’-Cg(4) 27.23° 
 
-Diketonate and -Ketoiminate Ligands  Chapter 2 
54 
2.6.8 X-ray Characterisation of C18H18FNO2 (L22) 
Yellow crystals of compound L22 suitable for X-ray crystallographic analysis were 
obtained by slow evaporation in hot ethanol over a period of 2-3 weeks.  The 
molecular structure is given in Figure 2.23, and selected bond lengths and angles 
are stated in Table 2.15. Ligand L22 was solved in a triclinic cell and structural 
solution was performed in the space group P1, with two molecules in the 
asymmetric unit. 
 
Figure 2.23 Molecular structure of L22, displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms omitted for clarity. 
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Table 2.15 Selected bond lengths and angles for both molecules of L22 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.431(3) N(1)-C(8)-C(9) 121.1(2) 
N(1)-C(8) 1.346(4) C(8)-C(9)-C(10) 123.5(3) 
C(7)-C(8) 1.501(4) O(1)-C(10)-C(9) 123.4(2) 
C(8)-C(9) 1.394(4) O(1)-C(10)-C(11) 117.1(2) 
C(9)-C(10) 1.427(4)   
O(1)-C(10) 1.258(3)   
C(10)-C(11) 1.509(4)   
Bond Distance (Å) Bond Angle (˚) 
C(1’)-N(1’) 1.430(4) N(1’)-C(8’)-C(9’) 120.9(3) 
N(1’)-C(8’) 1.350(4) C(8’)-C(9’)-C(10’) 123.2(3) 
C(7’)-C(8’) 1.514(5) O(1’)-C(10’)-C(9’) 122.8(3) 
C(8’)-C(9’) 1.388(4) O(1’)-C(10’)-C(11’) 116.4(3) 
C(9’)-C(10’) 1.425(5)   
O(1’)-C(10’) 1.264(4)   
C(10’)-C(11’) 1.513(4)   
 
When viewed along the a axis the molecules pack in pairs with a tail-head-head-tail 
arrangement and alternate in each row. Intramolecular hydrogen bonding is seen 
between N(1)-H(1N)...O(1) and C(9)-H(9)…O(2) of both molecules. There are 
observable intermolecular T-stacking interactions between C(2’)-H(2’)...Cg(2), 
C(17)-H(17B)...Cg(2) and C(14’)-F(1’)...Cg(1). The interactions and packing 
diagrams are presented in Figure 2.24, with D…A distance and torsion angles 
stated in Table 2.16. 
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Intramolecular interactions N(1)-H(1N)…O(2) and C(9)-H(9)…O(2) 
 
 
Intermolecular interactions along the c 
axis 
Intermolecular interactions along the c 
axis 
Figure 2.24 Intra-/Intermolecular packing along the a and c axes for L22 
Table 2.16 Bond lengths and torsion angles for L22 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)…O(1) 2.667(3) Å 
 N(1’)-H(1N’)…O(1’) 2.632(5) Å 
 C(9)-H(9)...O(2) 2.852(3) Å 
 C(9’)-H(9’)...O(2’) 2.867(4) Å 
Intermolecular C(2’)-H(2’)...Cg(2) 3.758 Å 
 C(17)-H(17B)...Cg(2) 3.618 Å 
 C(14’)-F(1’)...Cg(1) 4.423 Å 
Torsion Cg(1)-Centre 54.31° 
 Centre-Cg(2) 28.91° 
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2.6.9 X-ray Characterisation for C17H15NO3 (L24) 
Green crystals of L24 suitable for X-ray crystallographic analysis were obtained by 
slow evaporation from hot ethanol over a period of 2 weeks and further washing 
with diethyl ether. The molecular structure is given in Figure 2.25, selected bond 
lengths and angles are stated in Table 2.17. Ligand L24 was solved in a 
monoclinic cell and structural solution was performed in the space group P21, with 
a single molecule in the asymmetric unit. 
 
Figure 2.25 Molecular structure of L24, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms omitted for clarity. 
Table 2.17 Selected bond lengths and angles of L24 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.433(2) C(6)-C(1)-N(1) 118.17(17) 
N(1)-C(8) 1.361(3) C(2)-C(1)-N(1) 121.7(2) 
C(7)-C(8) 1.515(3) N(1)-C(8)-C(9) 121.60(18) 
C(8)-C(9) 1.389(3) C(8)-C(9)-C(10) 124.02(19) 
C(9)-C(10) 1.452(3) O(1)-C(10)-C(9) 122.34(19) 
O(1)-C(10) 1.259(2) O(1)-C(10)-C(11) 119.02(17) 
C(10)-C(11) 1.509(3) C(10)-C(11)-C(12) 118.34(17) 
  C(10)-C(11)-C(17) 122.14(17) 
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The packing diagram shows that when viewed along both the a and c axes the 
molecules pack in a herringbone arrangement. Intramolecular hydrogen bonding 
can be seen between N(1)-H(1N)...O(1) and C(16)-H(16)...O(1). Intermolecular 
hydrogen bonding interaction are seen between the molecules within the same 
plane and also between different planes of molecules. The interactions and packing 
diagrams are presented in Figure 2.26, with a D…A distances and torsion angles 
stated in Table 2.18. 
 
 
Packing diagram along the c axis Packing diagram along the a axis 
 
Intramolecular interactions 
Figure 2.26 Interactions and packing diagrams of L24 
Table 2.18 Bond lengths and torsion angles of L24 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)…O(1) 2.693(2) Å 
 C(16)-H(16)…O(1) 2.798(3) Å 
Intermolecular C(2)-H(2)...O(2) 3.486(3) Å 
 C(6)-H(6)...O(3) 3.491(3) Å 
Torsion Cg(1)-Centre 44.39° 
 Centre-Cg(2) 10.00° 
 
-Diketonate and -Ketoiminate Ligands  Chapter 2 
59 
2.6.10 X-ray Characterisation of C19H17N3O (L25) 
Green crystals of ligand L25 suitable for X-ray crystallographic analysis were 
obtained by slow evaporation from hot ethanol over a period of 2-3 weeks and 
further washing with diethyl ether. Molecular structure is given in Figure 2.27, 
selected bond lengths and angles are stated in Table 2.19. Ligand L25 was solved 
in a monoclinic cell and structural solution was performed in the space group P21, 
with a single molecule in the asymmetric unit. 
 
Figure 2.27 Molecular structure of L25, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms omitted for clarity. 
Table 2.19 Selected bond lengths and angles of L25 
Bond Distance (Å) Bond Angle (˚) 
C(1)-N(1) 1.4420(13) N(1)-C(8)-C(9) 121.36(10) 
N(1)-C(8) 1.3567(14) C(8)-C(9)-C(10) 124.18(10) 
C(7)-C(8) 1.5179(16) O(1)-C(10)-C(9) 123.27(10) 
C(8)-C(9) 1.4048(15) O(1)-C(10)-C(11) 118.39(9) 
C(9)-C(10) 1.4401(15)   
O(1)-C(10) 1.2772(13)   
C(10)-C(11) 1.5178(14)   
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The packing diagrams show the molecules pack in pairs with intermolecule 
interactions between each plane of molecules. Also when viewed along the c axis 
the molecules pack in a herringbone arrangement. An intramolecular hydrogen 
bonding interaction is observed between N(1)-H(1N)...O(1) and an intermolecular 
hydrogen bonding interaction between C(17)-H(17)...O(1). The packing diagrams 
are present in Figure 2.28, with D…A distances and torsion angles are stated in 
Table 2.20. 
 
 
 
Packing along the a axis Packing along the c axis 
Figure 2.28 Interactions and packing diagram of L25 
Table 2.20 Bond lengths and torsion angles of L25 
Interaction Atoms Bond Lengths and Angles 
Intramolecular N(1)-H(1N)…O(1) 2.7179(11) Å 
Intermolecular C(17)-H(17)...O(1) 3.2994(14) Å 
Torsion Cg(1)-Centre 44.95° 
 Centre-Cg(2) 23.24° 
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2.7 Conclusions 
A range of novel mono-aryl and biaryl -diketonate and -ketoiminate ligands 
have been synthesised and fully characterised, including X-ray crystallography data 
for several of the -ketoiminate ligands. All ligands show similar 1H and 13C{1H} 
NMR spectra with a distinctive methine proton that is characteristic of ligand 
formation. The ligands were obtained as single crystals, with structural solutions 
performed in a monoclinic (L11, L12, L14, L16, L19, L24 and L25), 
orthorhombic (L15) or triclinic (L21 and L22) space groups. All ligands show an 
intramolecular hydrogen bonding interaction between N-H…O which holds the 
centre of the molecule in a planar orientation. The tables of torsion angles show 
that both the aniline and aromatic rings are bent out of this plane, with the size of 
the torsion angle depending on the nature and electronics of the aromatic 
substituents. A range of compounds were synthesised to include different electronic 
and steric properties in order to gain structure activity relationships upon 
complexations; these complexes are presented in Chapters 3, 5 and 8. 
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Synthesis and Characterisation of Functionalised -
Ketoiminate Ruthenium (II) Chloride Complexes 
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3 Ruthenium Arene Complexes 
The work within this chapter builds on the libraries of ruthenium compounds with 
(N,N), (N,O) and (O,O) chelating ligands. This area has been extensively studied by 
the Sadler, Keppler and Dyson research groups. Sadler et al. first reported the 
cationic ruthenium arene complexes (Figure 3.1) incorporating neutral 
ethylenediamine (N,N) chelating ligands, along with a range of derivatives 
containing different Ru-halides and different arene substituents (A-C).
1
 Cytotoxic 
values were all comparable to cisplatin against A2780 (human ovarian 
carcinomas), with the most hydrophobic arene substituent (C) giving the most 
promising results. It was observed that rates of hydrolysis were independent of 
ionic strength but proportional to the size of the arene substituent.
1
 Sadler has also 
investigated the interactions with DNA models and found that these ruthenium 
ethylenediamine compounds preferentially bind to the N7 position of guanine; this 
has been studied by solid state X-ray crystallography and in solution by 2D NMR, 
with all studies confirming this preferential binding.
2
 A range of ruthenium (N,O) 
and (O,O) chelating compounds (D-F), all showing moderate cytotoxicity and 
again preferential binding to the N7 position of guanine (Figure 3.1).
3
 
 
Figure 3.1 Compounds previously synthesised by Sadler et al. 
 
Dyson et al. have carried out extensive work in this area, with particular interest in 
multinuclear ruthenium arene clusters and their ability to form host-guest type 
structures. The water-soluble metallaprism cages were shown to deliver the 
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hydrophobic dendrimer guest to the cells, with noticeably increased cytotoxicity for 
the host-guest molecules against A2780 (human ovarian carcinomas) and A2780cis 
(cisplatin resistant human ovarian carcinomas), when compared to the empty host 
molecule.
4, 5
 They have also carried out studies using hexaosmium cages (Figure 
3.2) and their delivery systems compare favourably with the ruthenium arene 
analogues.
6
 
 
Figure 3.2 Ruthenium and osmium host-guest molecules synthesised by Dyson et 
al. 
 
Keppler et al. have coupled known enzyme inhibitors (G),
7, 8
 pain relief molecules 
(H)
9
 and antibacterial agents (I)
10, 11
 (Figure 3.3) to ruthenium/osmium arenes and 
carried out extensive research into their antiproliferative activities, apoptosis, cell 
cycling kinetics and measured DNA shrinkage using AFM measurements. 
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Figure 3.3 Ruthenium and osmium compounds synthesised by Keppler et al. 
 
The McGowan research group has since carried out work on ruthenium arenes 
incorporating picolinamide and quinaldamide ligands (Figure 3.4), which show 
high cytotoxicity and significant binding to 9-EtG. Results showed a reversible 
inter-conversion in the binding of these ligands, either (N,N) or (N,O); the 
differences in cytotoxicity showed potential in tuning the ligands for biological 
application
12, 13
  
RuCl
N
N
O R
RuCl
N
N
O
R
 
Figure 3.4 Picolinamide and quinaldamide compounds by McGowan et al. 
 
Since these results, the group started work into incorporating -ketoiminate (N,O) 
ligands and has since produced a library of compounds stated within this chapter. 
Cell line testing against a range of human carcinomas has been completed and 
biological evaluations into the modes of action will be discussed in chapters 4-6. In 
addition work was published on an iridium(III) Cp* analogue incorporating a -
ketoiminate ligand that has also been synthesised, along with a small library of 
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(N,N), (N,O) and (O,O) iridium compounds, with cell line data being compared to 
that of complex 1 (see synthesis within this Chapter). These showed a trend in 
binding mode, whereby the activity followed the trend N,O > O,O > N,N (Figure 
3.5).
14,15
 
M
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O
R
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M = Ru, arene = p-cym
R = 2,4-diF or 2,5-diF
 
Figure 3.5 List of complexes previously synthesised by McGowan et al. 
 
3.1 Ruthenium (II) Chloride Complexes  
All -ketoiminate ruthenium complexes were prepared according to Scheme 3.1, 
by reacting two equivalents of a functionalised -ketoiminate ligand, two 
equivalents of triethylamine and [p-cymRuCl2]2 in dichloromethane overnight at 
room temperature, followed by recrystallisation by slow evaporation from a 
methanolic solution. 
Ru
Cl
Ru
ClCl
Cl
NH O
R1
2
Ru
Cl
N
O
R1
Et3N 
(2 equiv.)
DCM
RT
R
R
 
Scheme 3.1 General synthetic pathway for ruthenium(II) arene compounds 
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Figure 3.6 List of complexes synthesised within this Chapter 
 
Complexes 1-13 (Figure 3.6) were synthesised and characterised by the author, 
with full experimental data described in Chapter 9. All of the compounds were 
obtained as analytically pure solids and have been characterised by 
1
H NMR, 
1
H-
1
H COSY, 
13
C{
1
H}NMR, 
1
H-
13
C{
1
H} HMQC spectroscopy, mass spectrometry 
and micro-analysis. In addition X-ray crystallographic data has been obtained for 
all complexes. 
 
3.2 NMR Data for Ruthenium(II) Chloride Complexes 
The 
1
H NMR spectra for [p-cymRuCl2]2 shows the aromatic p-cymene protons (c, 
d, f and g, Figure 3.7) as two doublets at 5.35 and 5.48 ppm for two protons each. 
Upon complexation to a -ketoiminate ligand they separate into four broad 
doublets ranging from 3.68-5.35 ppm, each peak one proton each (shown for 
compound 7 in Figure 3.8). The chemical shifts for l-n and t-v remain within the 
same range as the starting ligand but are frequently seen in a different order, their 
chemical shift ranges depending on the substituent R. The characteristic shift for 
complexation is seen when monitoring proton q, which is shifted upfield upon 
complexation. In the case of compound C7, proton q is a singlet at 5.84 ppm in the 
free ligand and it shifts upfield to 5.36 ppm upon complexation. Also the p-cymene 
proton h, which appears as a broad septet, usually shows a significant upfield 
chemical shift from 2.93 ppm to 2.67 ppm upon complexation. The broad singlet at 
around 13 ppm seen for the NH in the free ligand disappears indicating the reaction 
has gone to completion. 
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Figure 3.7 General ruthenium(II) -ketoiminate structure 
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Figure 3.8 
1
H NMR for [p-cymRuCl2]2 (black), free ligand (blue) and complex 7 
(red) (CDCl3, 300 MHz, 300K) 
 
When analysing the 
13
C{
1
H} NMR spectra for the -ketoiminate complexes, they 
have similar trends with the highest shifts seen for the quaternary carbons p and r 
which are typically in the range 170-190 ppm. All CH peaks for the -ketoiminate 
ligand are in the range 100-150 ppm. The aromatic p-cymene quaternary carbons 
(b and e) have higher chemical shifts of 96-102 ppm, whilst the CH carbons (c, d, f 
and g) are between 78-90 ppm. The methine CH (q) from the -ketoiminate ligand 
is also within this range and typically seen at 93-95 ppm. The remaining carbon 
atoms have low chemical shifts between 18-31 ppm. 
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3.3 X-ray Crystallography for Ruthenium (II) Chloride Complexes 
X-ray crystallographic data was analysed for complexes 1-13 and all crystals were 
obtained using slow evaporation from a methanolic solution, appearing as orange/ 
red single crystals. Solutions were performed in either a monoclinic Cc (4 and 7) or 
triclinic P1 (1-3, 5, 6 and 8-13) space groups. All of the angles around the metal 
centre show the geometry expected for pseudo octahedral compounds which is 
common for half-sandwich “piano-stool” structures. The angles between the N-Ru-
O, N-Ru-Cl and O-Ru-Cl are expected to be 90° and complexes here show angles 
ranging between 83-90°. The smaller angles can be explained due to the 
restrictions caused by the bidentate ligand. The remaining three coordination sites 
are occupied by the bulky p-cymene ligand and when considering the restriction 
from the -ketoiminate ligand the angles observed for Cg-Ru-Cl, Cg-Ru-N and Cg-
Ru-O are within the range 124-133°. 
When comparing the ruthenium -ketoiminate complexes, intramolecular 
interactions are typically seen between a p-cymene C-H and either the centroid of 
the aniline ring or the Ru-Cl bond. This is thought to correspond to the upfield shift 
seen for one of the p-cymene C-H protons upon analysis of the 
1
H NMR spectra. 
The intramolecular T-stacking interactions can be seen in compounds 1, 2, 4-7, 10, 
12 and 13, with D...A distances ranging between 3.4-3.6 Å. However, complexes 3, 
8 and 11 have the p-cymene ligand rotated away from the aniline ring and D...A 
distances are too large to be considered as a T-stacking interaction. This is due to 
an additional intramolecular hydrogen interaction between the methyl group of the 
p-cymene and the chloride of the Ru-Cl bond, causing restricted rotation of the p-
cymene ligand.  
 
3.3.1 X-ray Characterisation for C26H27ClFNORu (1) 
Red fragments of 1 suitable for X-ray crystallographic analysis were obtained using 
slow evaporation from a methanolic solution over a period of several days. The 
molecular structure is shown in Figure 3.9 and selected bond lengths and angles 
are stated in Table 3.1. Complex 1 crystallised in a triclinic cell and structural 
solution was performed in the space group P1, with a single molecule in the 
asymmetric unit. 
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Figure 3.9 Molecular structure of 1, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 3.1 Selected bond lengths and angles for 1 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.0870(17) N(1)-Ru(1)-O(1) 88.40(6) 
Ru(1)-O(1) 2.0683(13) N(1)-Ru(1)-Cl(1) 83.65(5) 
Ru(1)-Cl(1) 2.4384(6) O(1)-Ru(1)-Cl(1) 87.14(4) 
Ru(1)-Cg(3) 1.6673(8) Cg(1)-Ru(1)-O(1) 124.22(5) 
C(23)-F(1) 1.340(3) Cg(1)-Ru(1)-N(1) 131.97(5) 
  Cg(1)-Ru(1)-Cl(1) 127.07(3) 
 
The packing diagram for complex 1 shows the molecules pack in pairs about a 
centre of inversion, in alternating rows, with evidence of intermolecular hydrogen 
bonding between these pairs of molcules. There is also a suggested intramolecular 
T-stacking interaction between the p-cymene H(3) and aniline centroid Cg(3). 
These interactions and packing diagram are presented in Figure 3.10, with D...A 
distance and torsion angles stated in Table 3.2. 
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Intramolecular 
C(3)-H(3)...Cg(1) 
Intermolecular 
C(6)-H(6)...Cl(1) 
 
Packing diagram when viewed along the a axis 
Figure 3.10 Interactions and packing diagram for 1 
Table 3.2 Bond lengths and torsion angles for 1 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(3)-H(3)...Cg(2) 3.458 Å 
Intermolecular C(6)-H(6)...Cl(1) 3.622(2) Å 
Torsion Cg(2)-Centre 77.28° 
 Centre-Cg(3) 29.31° 
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3.3.2 X-ray Characterisation for C26H27ClFNORu (2) 
Red fragments of 2 suitable for X-ray crystallographic analysis were obtained using 
slow evaporation from a methanolic solution over a period of several days. The 
molecular structure is shown in Figure 3.11 and selected bond lengths and angles 
are stated in Table 3.3. Complex 2 crystallised in a triclinic cell and structural 
solution was performed in the space group P1, with a single molecule in the 
asymmetric unit. 
 
Figure 3.11 Molecular strucutre of 2, displacement displacement ellipsoids are at 
the 50% probability level and hydrogen atoms are omitted for clarity. 
Table 3.3 Selected bond lengths and angles for 2 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.088(3) N(1)-Ru(1)-O(1) 89.08(12) 
Ru(1)-O(1) 2.059(3) N(1)-Ru(1)-Cl(1) 83.86(11) 
Ru(1)-Cl(1) 2.4362(13) O(1)-Ru(1)-Cl(1) 85.01(9) 
Ru(1)-Cg(1) 1.6680(19) Cg(1)-Ru(1)-O(1) 124.71(11) 
C(24)-F(1)  Cg(1)-Ru(1)-N(1) 130.90(12) 
  Cg(1)-Ru(1)-Cl(1) 128.44(8) 
 
The packing diagram for complex 2 shows the molecules pack in pairs about a 
centre of inversion, in alternating rows, with evidence of intermolecular hydrogen 
bonding between these pairs of molcules. There is also a suggested intramolecular 
T-stacking interaction between the p-cymene H(3) and aniline centroid Cg(2) and 
also between H(1A) and Cl(1). These interactions and packing diagram are 
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presented in Figure 3.12, with D...A distance and torsion angles stated in Table 
3.4. 
 
 
C(3)-H(3)…Cg(2) 
C(1)-H(1A)…Cl(1) 
Packing along the b axis – showing 
intermolecular interaction, C(17)-
H(17A)…Cg(3) 
Figure 3.12 Interactions and packing diagram for 2  
Table 3.4 Bond lengths and torsion angles for 2 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(3)-H(3)...Cg(2) 3.571 Å 
 C(1)-H(1A)…Cl(1) 3.437(5) Å 
Intermolecular C(17)-H(17A)...Cg(3) 3.590 Å 
 Ru(1)-Cl(1)…Cg(1) 3.711 Å 
 C(4)-H(4)…Cl(1) 3.505(5) Å 
 C(8)-H(8)…F(1) 3.229(5) Å 
Torsion Cg(1)-centre 78.34° 
 centre-Cg(2) 17.11° 
 
3.3.3 X-ray Characterisation for C26H27Cl2NORu (3) 
Red fragments of 3 suitable for X-ray crystallographic analysis were obtained using 
slow evaporation from a methanolic solution over a period of three days. The 
molecular structure is shown in Figure 3.13, selected bond lengths and angles are 
stated in Table 3.5. Complex 3 crystallised in a triclinic cell and structural solution 
was performed in the space group P1, with a single molecule in the asymmetric 
unit. 
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Figure 3.13 Molecular structure of 3, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 3.5 Selected bond lengths and bond angles for 3 
Bond Distance (Å) Bond Angle (˚) 
Ru(1)-N(1) 2.099(4) N(1)-Ru(1)-O(1) 89.45(15) 
Ru(1)-O(1) 2.068(3) N(1)-Ru(1)-Cl(1) 84.03(12) 
Ru(1)-Cl(1) 2.4513(13) O(1)-Ru(1)-Cl(1) 84.90(11) 
Ru(1)-Cg(1) 1.677(2) Cg(1)-Ru(1)-O(1) 124.02(13) 
C(24)-Cl(2) 1.755(4) Cg(1)-Ru(1)-N(1) 130.73(14) 
  Cg(1)-Ru(1)-Cl(1) 129.02(9) 
 
The packing diagram for complex 3 shows the molecules pack in alternating rows, 
with no evidence of intermolecular interactions suggesting the packing of 
molecules is due to crystal packing interactions only. There is an intramolecular 
hydrogen bond between H(1B) and Cl(1), however, no T-stacking interaction is 
observed between the p-cymene and aniline ring. The intramolecular interaction 
and packing are presented in Figure 3.14, with the D...A distance and torsion 
angles stated in Table 3.6. 
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Intramolecular C(1)-H(1B)...Cl(1) Packing along the b axis 
Figure 3.14 Intramolecular interaction and packing diagram for 3 
Table 3.6 Bond lengths and torsion angles for 3 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(1)-H(1B)...Cl(1) 3.393(7) Å 
Torsion Cg(2)-Centre 76.49° 
 Centre-Cg(3) 24.36° 
 
3.3.4 X-ray Characterisation for C26H26Cl3NORu (4) 
Red fragments of 4 suitable for X-ray crystallographic analysis were obtained by 
slow evaporation in methanol over a period of several days. The molecular 
structure is shown in Figure 3.15 with selected bond lengths and angles stated in 
Table 3.7. Complex 4 crystallised in a monoclinic cell and structural solution was 
performed in the space group Cc, with a single molecule in the asymmetric unit. 
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Figure 3.15 Molecular strcuture of 4, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 3.7 Selected bond lengths and bond angles for 4 
Bond Distance (Å) Bond Angle (˚) 
Ru(1)-N(1) 2.095(5) N(1)-Ru(1)-O(1) 89.61(15) 
Ru(1)-O(1) 2.077(3) N(1)-Ru(1)-Cl(1) 85.74(12) 
Ru(1)-Cl(1) 2.4314(12) O(1)-Ru(1)-Cl(1) 82.74(9) 
Ru(1)-Cg(1) 1.670(2) Cg(1)-Ru(1)-O(1) 125.63(12) 
C(22)-Cl(2) 1.745(5) Cg(1)-Ru(1)-N(1) 129.19(14) 
C(24)-Cl(3) 1.736(5) Cg(1)-Ru(1)-Cl(1) 129.07(8) 
 
The packing diagram for complex 4 shows the molecules pack in head-to-tail pairs, 
with intermolecular interactions between each pair and also holding together 
alternate rows of molecules. There are intramolecular hydrogen bonds between 
H(8)-Cl(2), and also an intramolecular T-stacking interaction is observed between 
the p-cymene H(3) and the aniline ring Cg(2). The intramolecular interactions and 
packing diagram are presented in Figure 3.16, with the D...A distance and torsion 
angles stated in Table 3.8. 
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Intramolecular interactions Intermolecular interactions 
Figure 3.16 Intramolecular interactions and packing diagram for 4  
Table 3.8 Bond lengths and torsion angles for 4 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(3)-H(3)...Cg(2) 3.445 Å 
 C(8)-H(8)…Cl(2) 3.695(6) Å 
Intermolecular Ru(1)-Cl(1)…Cg(1) 1.670 Å 
 C(10)-H(10C)…Cl(3) 3.672(6) Å 
 C(17)-H(17B)…Cl(3) 3.539(6) Å 
 C(17)-H(17C)…Cl(1) 3.649(6) Å 
 C(25)-H(25)…Cl(2) 3.670(5) Å 
Torsion Cg(2)-Centre 78.85° 
 Centre-Cg(3) 41.28° 
 
3.3.5 X-ray Characterisation for C26H26Cl3NORu (5) 
Red fragments of 5 suitable for X-ray crystallographic analysis were obtained using 
slow evaporation from a methanolic solution over a period of several days. The 
molecular structure is shown in Figure 3.17 with selected bond lengths and angles 
stated in Table 3.9. Complex 5 crystallised in a triclinic cell and structural solution 
was performed in the space group P1, with two molecules in the asymmetric unit. 
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Figure 3.17 Molecular structure of 5, displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms and the second molecule are omitted for clarity 
Table 3.9 Selected bond lengths and angles for both molecules of 5 
Bond Distance (Å) Bond Angle (˚) 
Ru(1)-N(1) 2.1223(15) N(1)-Ru(1)-O(1) 88.06(5) 
Ru(1)-O(1) 2.0762(12) N(1)-Ru(1)-Cl(1) 84.56(4) 
Ru(1)-Cl(1) 2.4587(5) O(1)-Ru(1)-Cl(1) 85.35(4) 
Ru(1)-Cg(1) 1.6836(8) Cg(1)-Ru(1)-O(1) 124.74(4) 
C(22)-Cl(2) 1.7580(19) Cg(1)-Ru(1)-N(1) 132.30(5) 
C(25)-Cl(3) 1.756(2) Cg(1)-Ru(1)-Cl(1) 126.88(3) 
Bond Distance (Å) Bond Angle (˚) 
Ru(1’)-N(1’) 2.1198(14) N(1’)-Ru(1’)-O(1’) 88.25(5) 
Ru(1’)-O(1’) 2.0874(12) N(1’)-Ru(1’)-Cl(1’) 88.09(4) 
Ru(1’)-Cl(1’) 2.4477(5) O(1’)-Ru(1’)-Cl(1’) 84.91(4) 
Ru(1’)-Cg(4) 1.6790(7) Cg(4)-Ru(1’)-O(1’) 125.49(4) 
C(22’)-Cl(2’) 1.754(2) Cg(4)-Ru(1’)-N(1’) 130.12(5) 
C(25’)-Cl(3’) 1.759(2) Cg(4)-Ru(1’)-Cl(1’) 126.02(3) 
 
The packing diagram for complex 5 shows the molecules pack in a head-tail-tail-
head arrangment, within alternating rows. There are several intermolecular 
interactions contributing to the packing of the molecules. There is evidence of a T-
stacking interaction between the p-cymene H(3) and the centroid of the aniline ring 
Cg(1). Interactions and the packing diagram are present in Figure 3.18, with D…A 
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distances and torsion angles stated in Table 3.10. 
 
 
Packing along the b axis 
Intermolecular C(27)-H(27)...Cl(1) 
C(27’)-H(27-)...Cl(1) 
 
Intramolecular C(3)-H(3)...Cg(1) 
Figure 3.18 Interactions and packing diagram for 5 
Table 3.10 Bond lengths and torsion angles for both molecules of 5 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(3)-H(3)...Cg(2) 3.620 Å 
Intermolecular C(25)-Cl(3)...Cg(1) 4.180 Å 
 C(25’)-Cl(3’)...Cg(4) 4.148 Å 
 C(17’)-H(17’B)...Cl(1’) 3.570(2) Å 
 C(7)-H(7)...O(1) 3.312(2) Å 
 C(7’)-H(7’)...O(1’) 3.198(2) Å 
Torsion Cg(2)-Centre 87.58° 
 Centre-Cg(3) 75.01° 
 Cg(5)-Centre 75.88° 
 Centre-Cg(6) 59.41° 
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3.3.6 X-ray Characterisation for C26H25Cl4NORu (6) 
Red fragments of 6 suitable for X-ray crystallographic analysis were obtained by 
slow evaporation in methanol over a period of three days. The molecular structure 
is shown in Figure 3.19, selected bond lengths and angles are stated in Table 3.11. 
Complex 6 crystallised in a triclinic cell and structural solution was performed in 
the space group P1, with two complex molecules and two molecules of methanol 
in the asymmetric unit. 
 
Figure 3.19 Molecular structure of 6, displacement ellipsoids are at the 50% 
probability level. Hydrogen atoms, disorder, the second molecule and solvent 
molecules are omitted for clarity. 
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Table 3.11 Selected bond lengths and angles for both molecules of 6 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.128(3) N(1)-Ru(1)-O(1) 88.66(10) 
Ru(1)-O(1) 2.086(3) N(1)-Ru(1)-Cl(1) 84.23(8) 
Ru(1)-Cl(1) 2.4622(10) O(1)-Ru(1)-Cl(1) 84.54(7) 
Ru(1)-Cg(1) 1.6839(16) Cg(1)-Ru(1)-O(1) 124.50(9) 
  Cg(1)-Ru(1)-N(1) 131.23(10) 
  Cg(1)-Ru(1)-Cl(1) 128.64(6) 
Bond Distance (Å) Bond Angle (°) 
Ru(1’)-N(1’) 2.125(3) N(1’)-Ru(1’)-O(1’) 88.48(11) 
Ru(1’)-O(1’) 2.102(3) N(1’)-Ru(1’)-Cl(1’) 84.56(9) 
Ru(1’)-Cl(1’) 2.4700(11) O(1’)-Ru(1’)-Cl(1’) 85.59(9) 
Ru(1’)-Cg(4) 1.6914(15) Cg(4)-Ru(1’)-O(1’) 124.54(11) 
  Cg(4)-Ru(1’)-N(1’) 131.55(9) 
  Cg(4)-Ru(1’)-Cl(1’) 127.45(9) 
 
The packing diagram for complex 6 shows the molecules pack in a head-tail-tail-
head pairs, alternating in each row. There are several intermolecular interactions 
contributing to the packing of the molecules. There is also evidence of a T-stacking 
interaction between the p-cymene and the centroid of the aniline ring. In one of the 
molecules, the substituted phenyl ring is disordered and the molecule was solved 
with each atom set at half the occupancy. These interactions and packing diagram 
are presented in Figure 3.20, with D…A distances and torsion angles are stated in 
Table 3.12. 
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Intramolecular C(3)-H(3)...Cg(2) 
Intermolecular C(6’)-H(6’)...Cl(1’) 
C(7’)-H(7’)...O(1’) 
 
 
Packing diagram along the a axis Disorder around Cg(3) 
Figure 3.20 Interactions and packing diagram for 6  
Table 3.12 Bond lengths and torsion angles for both molecules of 6 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(3)-H(3)...Cg(2) 3.552(5) Ǻ 
Intermolecular C(3)-H(3)...Cl(4) 3.370(5) Ǻ 
 C(14’)-H(14’)...Cg(2) 3.809 Ǻ 
 C(6)-H(6)...O(1) 3.269(2) Ǻ 
 C(6’)-H(6’)...Cl(1’) 3.632(5) Ǻ 
 C(7’)-H(7’)...O(1’) 3.257(5) Ǻ 
Torsion Cg(2)-Centre 83.11° 
 Centre-Cg(3) 76.29° 
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3.3.7 X-ray Characterisation for C26H27BrClNORu (7) 
Red fragments of 7 suitable for X-ray crystallographic analysis were obtained using 
slow evaporation from a methanolic solution over a period of several days. The 
molecular structure is shown in Figure 3.21, selected bond lengths and angles are 
stated in Table 3.13. Complex 7 crystallised in a monoclinic cell and structural 
solution was performed in the space group Cc, with one molecule in the 
asymmetric unit. 
 
Figure 3.21 Molecular structure of 7, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity 
Table 3.13 Selected bond lengths and angles for 7 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.101(2) N(1)-Ru(1)-O(1) 89.10(8) 
Ru(1)-O(1) 2.0516(19) N(1)-Ru(1)-Cl(1) 85.01(7) 
Ru(1)-Cl(1) 2.4281(7) O(1)-Ru(1)-Cl(1) 83.27(6) 
Ru(1)-Cg(1) 1.6661(12) Cg(1)-Ru(1)-O(1) 125.24(7) 
C(23)-Br(1) 1.902(3) Cg(1)-Ru(1)-N(1) 129.73(8) 
  Cg(1)-Ru(1)-Cl(1) 129.44(4) 
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The packing diagram for complex 7 shows the molecules pack in head-to-tail 
arrangement with the molecules alternating in each row. There are several 
intermolecular interactions contributing to the packing of the molecules. There is 
also evidence of a T-stacking interaction between the p-cymene H(3) and the 
centroid of the aniline ring Cg(2). These interactions and packing diagrams are 
presented in Figure 3.22, with D…A distances and torsion angles are stated in 
Table 3.16. 
  
Intermolecular interactions along the c 
axis 
Intermolecular interactions along the a 
axis 
 
Intramolecular C(3)-H(3)…Cg(2) 
Figure 3.22 Intra/intermolecular interactions and packing diagrams for 7 
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Table 3.14 Bond lengths and torsion angles for 7 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(3)-H(3)...Cg(2) 3.471(3) Ǻ 
Intermolecular C(3)-H(3)...Cg(3) 3.484 Ǻ 
 C(23)-Br(1)...Cg(1) 3.932 Ǻ 
 Ru(1)-Cl(1)...Cg(1) 1.6661 Ǻ 
 C(17)-H(17B)...Cl(1) 3.588(3) Ǻ 
Torsion Cg(2)-Centre 74.99° 
 Centre-Cg(3) 31.76° 
 
3.3.8 X-ray Characterisation for C26H27BrClNORu (8) 
Red fragments of 8 suitable for X-ray crystallographic analysis were obtained using 
slow evaporation from a methanolic solution over a period of several days. The 
molecular structure is shown in Figure 3.23, selected bond lengths and angles are 
stated in Table 3.15. Complex 8 crystallised in a triclinic cell and structural 
solution was performed in the space group P1, with one molecule in the 
asymmetric unit. 
 
Figure 3.23 Molecular structure of 8, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity 
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Table 3.15 Selected bond lengths and angles for 8 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.086(2) N(1)-Ru(1)-O(1) 89.42(8) 
Ru(1)-O(1) 2.0518(17) N(1)-Ru(1)-Cl(1) 83.68(7) 
Ru(1)-Cl(1) 2.4377(8) O(1)-Ru(1)-Cl(1) 84.85(5) 
Ru(1)-Cg(1) 1.6661(11) Cg(1)-Ru(1)-O(1) 124.54(7) 
C(24)-Br(1) 1.906(3) Cg(1)-Ru(1)-N(1) 130.71(8) 
  Cg(1)-Ru(1)-Cl(1) 128.82(5) 
 
The packing diagram for complex 8 shows the molecules pack in head-to-tail 
arrangement with the molecules alternating in each rows around a centre of 
inversion. There is evidence of a intramolecular interaction between the p-cymene 
H(1C)-Cl(1). The interactions and packing diagram are presented in Figure 3.22, 
with D…A distances and torsion angles are stated in Table 3.14. 
  
Intramolecular C(1)-H(1C)…Cl(1) Packing along the b axis 
Figure 3.24 Intra/intermolecular interactions and packing diagrams for 8 
Table 3.16 Bond lengths and torsion angles for 8 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(1)-H(1C)…Cl(1) 3.374(3) Å 
Torsion Cg(2)-centre 46.49° 
 Centre-Cg(3) 63.43° 
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3.3.9 X-ray Characterisation for C26H27ClINORu (9) 
Orange needles of 9 suitable for X-ray crystallographic analysis were obtained 
using slow evaporation from a methanolic solution over a period of several days. 
The molecular structure is shown in Figure 3.25, selected bond lengths and angles 
are stated in Table 3.17. Complex 9 crystallised in a triclinic cell and structural 
solution was performed in the space group P1, with one molecule in the 
asymmetric unit. 
 
Figure 3.25 Molecular structure of 9, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity 
Table 3.17 Selected bond lengths and angles for 9 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.088(3) N(1)-Ru(1)-O(1) 89.44(13) 
Ru(1)-O(1) 2.063(3) N(1)-Ru(1)-Cl(1) 84.07(11) 
Ru(1)-Cl(1) 2.4422(13) O(1)-Ru(1)-Cl(1) 84.75(10) 
Ru(1)-Cg(1) 1.6663(19) Cg(1)-Ru(1)-O(1) 124.54(11) 
C(24)-I(1) 2.109(4) Cg(1)-Ru(1)-N(1) 130.49(13) 
  Cg(1)-Ru(1)-Cl(1) 128.81(8) 
 
The packing diagram for complex 9 shows the molecules pack in rows, with each 
pair of molecules around a centre of inversion. Packing along the a axis shows the 
pairs of moleucles around the centre of inversion, whilst the packing along the b 
axis shows they pack in a herringbone arrangement. There is no evidence of either 
intramolecular or intermolecular interactions contributing to the packing of the 
molecules and therefore they pack by crystal packing interactions only. The 
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packing diagram are presented in Figure 3.26, and torsion angles are stated in 
Table 3.18. 
 
 
Packing along the a axis Packing along the b axis 
Figure 3.26 Packing diagrams for complex 9 when viewed along both the a and b 
axis 
Table 3.18 Torsion angles for 9 
Interaction Atoms Bond Lengths and Angles 
Torsion Cg(2)-centre 76.87° 
 Centre-Cg(3) 23.63° 
 
3.3.10 X-ray Characterisation for C28H32ClNO2Ru (10) 
Orange needles of 10 suitable for X-ray crystallographic analysis were obtained 
using slow evaporation from a methanolic solution over a period of several days. 
The molecular structure is shown in Figure 3.27, selected bond lengths and angles 
are stated in Table 3.19. Complex 10 crystallised in a triclinic cell and structural 
solution was performed in the space group P1, with one molecule in the 
asymmetric unit. 
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Figure 3.27 Molecular structure of 10, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity 
Table 3.19 Selected bond lengths and angles for 10 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.0891(19) N(1)-Ru(1)-O(1) 88.30(6) 
Ru(1)-O(1) 2.0676(14) N(1)-Ru(1)-Cl(1) 83.62(5) 
Ru(1)-Cl(1) 2.4268(6) O(1)-Ru(1)-Cl(1) 86.95(5) 
Ru(1)-Cg(1) 1.6654(9) Cg(1)-Ru(1)-O(1) 124.64(5) 
C(24)-O(2) 1.370(2) Cg(1)-Ru(1)-N(1) 132.54(5) 
  Cg(1)-Ru(1)-Cl(1) 126.20(3) 
 
The packing diagram for complex 10 shows the molecules pack in rows, with each 
pair of molecules around a centre of inversion. There is evidence an intramolecular 
T-stacking interaction between H(3) and the centroid of the aniline ring Cg(2). 
There are also several intermolecular interactions contributing to the packing of 
these molecules. The packing diagram are presented in Figure 3.28, and torsion 
angles are stated in Table 3.20. 
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Packing along the b axis All intermolecular interactions 
 
Intramolecular C(3)-H(3)…Cg(2) 
Figure 3.28 Intra-/Intermolecular interactions and packing diagrams for 10 
Table 3.20 Bond lengths and torsion angles for 10 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(3)-H(3)…Cg(2) 3.498 Å 
Intermolecular C(17)-H(17B)…Cl(1) 3.620(2) Å 
 C(6)-H(6)…Cl(1) 3.481(2) Å 
 C(9)-H(9B)…Cl(1) 3.681(3) Å 
Torsion Cg(2)-centre 78.18° 
 Centre-Cg(3) 31.57 
 
3.3.11 X-ray Characterisation for C27H30ClNORu (11) 
Red fragments of 11 suitable for X-ray crystallographic analysis were obtained by 
slow evaporation in methanol over a period of one day. The molecular structure is 
shown in Figure 3.29, selected bond lengths and angles are stated in Table 3.21. 
Complex 11 crystallised in a triclinic cell and structural solution was performed in 
the space group P1, with a single molecule in the asymmetric unit. 
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Figure 3.29 Molecular strucutre of 11. Displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity 
Table 3.21 Selected bond lengths and angles for 11 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.1064(14) N(1)-Ru(1)-O(1) 89.41(5) 
Ru(1)-O(1) 2.0711(13) N(1)-Ru(1)-Cl(1) 83.90(4) 
Ru(1)-Cl(1) 2.4623(5) O(1)-Ru(1)-Cl(1) 84.84(4) 
Ru(1)-Cg(1) 1.6830(7) Cg(1)-Ru(1)-O(1) 124.31(5) 
C(24)-C(27) 1.528(3) Cg(1)-Ru(1)-N(1) 130.72(5) 
  Cg(1)-Ru(1)-Cl(1) 128.90(3) 
 
The packing diagram for complex 11 shows the molecules pack in head-tail-tail-
head pairs, alternating in each row, with evidence of an intramolecular interaction 
between C(1)-H(1B)...Cl(1). The intramolecular interaction and packing diagram 
are presented in Figure 3.30, with D...A distances and torsion angles stated in 
Table 3.22. 
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Intramolecular C(1)-H(1B)...Cl(1) Packing diagram along the b axis 
Figure 3.30 Intramolecular interaction and packing along the b axis for 11 
Table 3.22 Bond lengths and torsion angles for 11 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(1)-H(1B)...Cl(1) 3.399(2) Ǻ 
Torsion Cg(2)-Centre 75.05° 
 Centre-Cg(3) 23.41° 
 
3.3.12 X-ray Characterisation for C30H30ClNORu (12) 
Red fragments of 12 suitable for X-ray crystallographic analysis were obtained 
using slow evaporation from a methanolic solution over a period of one day. The 
molecular structure is shown in Figure 3.31, selected bond lengths and angles are 
stated in Table 3.23. Complex 12 crystallised in a triclinic cell and structural 
solution was performed in the space group P1, with two molecules in the 
asymmetric unit. 
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Figure 3.31 Molecular strucutre of 12. Displacement ellipsoids are at the 50% 
probability level and hydrogen atoms and the second molecule are omitted for 
clarity. 
Table 3.23 Selected bond lengths and angles for both molecules of 12 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.094(6) N(1)-Ru(1)-O(1) 88.4(2) 
Ru(1)-O(1) 2.069(4) N(1)-Ru(1)-Cl(1) 85.71(16) 
Ru(1)-Cl(1) 2.4340(18) O(1)-Ru(1)-Cl(1) 83.33(12) 
Ru(1)-Cg(1) 1.675(3) Cg(1)-Ru(1)-O(1) 126.30(16) 
  Cg(1)-Ru(1)-N(1) 129.91(19) 
  Cg(1)-Ru(1)-Cl(1) 128.09(13) 
Bond Distance (Å) Bond Angle (°) 
Ru(1’)-N(1’) 2.101(5) N(1’)-Ru(1’)-O(1’) 88.8(2) 
Ru(1’)-O(1’) 2.070(5) N(1’)-Ru(1’)-Cl(1’) 85.79(16) 
Ru(1’)-Cl(1’) 2.4365(19) O(1’)-Ru(1’)-Cl(1’) 84.25(13) 
Ru(1’)-Cg(5) 1.674(3) Cg(5)-Ru(1’)-O(1’) 125.07(15) 
  Cg(5)-Ru(1’)-N(1’) 129.78(17) 
  Cg(5)-Ru(1’)-Cl(1’) 128.57(13) 
 
The packing diagram for complex 12 shows the molecules pack in pairs about a 
centre of inversion. There is evidence of intramolecular interactions in both 
molecules of 12 and evidence of several intermolecular interactions between these 
molecules. The p-cymene is rotated and a T-stacking interactions is now seen 
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between the p-cymene H(7) and aniline ring Cg(2). The interaction and packing 
diagram are presented in Figure 3.32, with D...A distances and torsion angles 
stated in Table 3.24. 
  
Intramolecular interactions 
 
Packing diagrama along the b axis 
Figure 3.32 Intramolecular interaction and packing along the b axis for 12 
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Table 3.24 Bond lengths and torsion angles for 12 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(9B)-H(9BC)…O(1) 3.336(13) Å 
 C(29)-H(29)…O(1) 3.041(8) Å 
 C(29’)-H(29’)…O(1’) 3.077(8) Å 
 C(7)-H(7)…Cg(2) 3.547(9) Å 
Intermolcular C(24)-H(24)…Cg(7) 3.526(8) Å 
 Ru(1’)-Cl(1’)…Cg(5) 1.674(3) Å 
 C(3)-H(3)…O(1) 3.256(10) Å 
 C(7’)-H(7’)…O(1’) 3.144(9) Å 
Torsion Cg(2)-Centre 83.88(22)° 
 Centre-Cg(3) 56.95(19)° 
 Cg(6)-Centre 80.49(19)° 
 Centre-Cg(7) 64.07(2)° 
 
3.3.13 X-ray Characterisation for C26H25ClF3NORu (13) 
Red fragments of 13 suitable for X-ray crystallographic analysis were obtained 
using slow evaporation from a methanolic solution over a period of two days. The 
molecular structure is shown in Figure 3.33, selected bond lengths and angles are 
stated in Table 3.25. Complex 13 crystallised in a monoclinic cell and structural 
solution was performed in the space group Cc, with a single molecule in the 
asymmetric unit. 
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Figure 3.33 Molecular structure of 13, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 3.25 Selected bond lengths and bond angles for 13 
Bond Distance (Å) Bond Angle (˚) 
Ru(1)-N(1) 2.131(2) N(1)-Ru(1)-O(1) 89.32(8) 
Ru(1)-O(1) 2.0930(18) N(1)-Ru(1)-Cl(1) 86.24(6) 
Ru(1)-Cl(1) 2.4661(7) O(1)-Ru(1)-Cl(1) 83.86(5) 
Ru(1)-Cg(1) 1.6861(10) Cg(1)-Ru(1)-O(1) 124.53(6) 
C(12)-F(1) 1.370(3) Cg(1)-Ru(1)-N(1) 129.46(7) 
C(15)-F(2) 1.370(3) Cg(1)-Ru(1)-Cl(1) 128.98(4) 
C(24)-F(3) 1.381(3)   
 
The packing diagram for compound 13 shows the molecules pack in alternating 
rows with T-stacking between one row and a hydrogen bond linking the two rows 
together. There is evidence of several intermolecular interactions contributing to 
the packing of the molecule and a possible intramolecular T-stacking interaction 
seen between the p-cymene hydrogen H(3) and the centroid of the aniline ring 
Cg(2). These interactions are presented in Figure 3.34, with D...A distances and 
torsion angles stated in Table 3.26. 
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Packing diagram along the a axis 
Intermolecular C(12)-F(1)...Cg(3) 
C(10)-H(10C)...F(3) 
 
Intramolecular C(3)-H(3)...Cg(2) 
Figure 3.34 Interactions and packing diagram for 13 
Table 3.26 Bond lengths and torsion angles for 13 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(3)-H(3)...Cg(2) 3.576 Å 
Intermolecular Ru(1)-Cl(1)...Cg(1) 1.6861 Å 
 C(12)-F(1)...Cg(3) 4.021 Å 
 C(10)-H(10C)...F(3) 3.405(4) Å 
Torsion Cg(1)-Cg(2) 76.38° 
 Cg(2)-Cg(3) 33.47° 
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3.4 Conclusions 
A range of novel functionalised -ketoiminate ruthenium(II) chloride pseudo 
octahedral “piano-stool” complexes has been synthesised and fully characterised, 
with X-ray crystallographic analysis obtained for all complexes. All of these 
complexes crystallised as orange/red single crystals and structural solutions were 
performed in either a monoclinic Cc (4 and 7) or a triclinic P1 (1-3, 5, 6 and 8-13) 
space groups. The complexes all show similar 
1
H and 
13
C{
1
H} NMR spectra, with 
a distinctive upfield shift for one of the p-cymene hydrogens seen when analysing 
the 
1
H NMR spectra. Apart from 9, which shows no intramolecular interactions, X-
ray crystallographic analysis shows all compounds have an intramolecular 
interaction with the p-cymene ring. Complexes 1, 2, 4-7, 10, 12 and 13 all show an 
intramolecular T-stacking interaction between a p-cymene C-H and the centroid of 
the aniline ring. Complexes 3, 8 and 11 all have the p-cymene twisted and instead 
have an intramolecular interaction between the p-cymene C-H and the Ru-Cl. Both 
of these types of interaction are thought to be the cause of the upfield shift seen in 
the 
1
H NMR spectra. The -ketoiminate ligands were functionalised to include 
electron withdrawing groups, electron donating groups and increased steric bulk, 
these were to allow conclusive structure activity relationships to be determined and 
to allow relationships in IC50 to be determined (see Chapter 4). 
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4 Cytotoxicity Evaluation 
Biological assays require a technique to measure the amount of cell survival or 
proliferation of mammalian cells. This can be carried out by either counting cells 
using a dye, measuring the release of 
51
Cr-labelled proteins after cell lysis or 
incorporation of radioactive nucleotides during profileration.
1
 Tetrazolium salts are 
good candidates as they are used to measure the activity of various dehydrogenase 
enzymes.
2
 Current research requires assays which are quantitative and rapid and 
which are able to handle large amounts of data on a daily basis.  
 
4.1 MTT Assay 
The MTT assay was developed by Mosmann in 1983 and is a method of measuring 
the survival of mammalian cells, in which the yellow 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) is reduced to the purple formazan in 
living cells (Scheme 4.1)
3, 4
 
 
Scheme 4.1 Reduction of MTT to Formazan 
 
The cancer cells are incubated with the potential drug for a period of 3-5 days at 
37°C. A solution of MTT in distilled water (5 mg/ mL) is added and the cells 
incubated for a further 3-4 hours to allow for the reduction to the purple formazan. 
The reduction occurs due to the transfer of electrons to the MTT (E0’ = -0.11 V) 
from oxidising substrates such as NADH and NADPH (E0’ = -0.317 V).
5
 The 
primary source for the reduction is thought to start within the mitochondria, 
however there is no evidence indicating it is confined here.
6, 7
 The purple formazan 
crystals can be separated by removing the MTT/medium via pipette and dissolving 
the crystals in DMSO. The absorbance is then measured at a wavelength of 540 nm 
using a multi-well scanning spectrophotometer. 
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4.2 XTT Assay 
A variation of the MTT assay known as XTT was developed by Paull et al. in 
1988. The sodium 3’-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-
6-nitro)benzene-sulfonic acid hydrate (XTT) undergoes a bioreduction in the 
presence of ascorbic acid, in which the charged sulfonic acid groups are key for its 
water solubility (Scheme 4.2).
8
 The XTT in pre-warmed medium (1 mg/ mL), 
without serum, is mixed with PMS in phosphate buffered saline (PBS) (1.53 mg/ 
mL). Once added to the plate and incubated for a period of time, a mechanical 
shaker is used to mix the solutions and the readings taken at 450 nm. The assay 
time is reduced due to the elimination of the solubilising step, shortening the 
culture assay procedure. 
NH N N
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Scheme 4.2 Reduction of XTT to a water-soluble formazan 
 
In the late 1980’s the US National Cancer Institue (NCI) noted problems with both 
MTT and XTT assays which made them unsuitable for use on large scale drug 
screening.
9
 MTT reduction varied depending on both the specific cell line and the 
age of the cell culture. Vistica et al. noticed a correlation with the amount of D-
glucose within the cell medium and that cells with increased metabolic rates for 
sugar demonstrated lower reduction of MTT.
6
 XTT also had problems with either 
the absence/ inhibition of reduction without the presence of an electron-coupling 
agent such as phenazine methosulfate.
9
 This was thought to be due to the presence 
of a disulfonate which has shown to have difficulty permeating the cell 
membrane.
10, 11
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4.3 SRB Assay 
This assay was developed by Skehan et al. in 1990 after investigating the 
suitability of a series of different dyes for providing cell density measurements.
12
 It 
utilises an aminoxanthene dye, Sulforhodamide B (SRB) (Figure 4.1), which under 
mildly acidic conditions binds electrostatically to amino acids through the charged 
sulfonic acid group. Cultures fixed with trichloroacetic acid are stained and 
incubated for 30 minutes with SRB (0.4%, w/v) and dissolved in acetic acid (1%). 
The unbound dye is removed by four washes with acetic acid (1%) and the bound 
dye extracted with an unbuffered base (10 mM). The absorbance is measured at a 
wavelength between 490-530 nm using a microtiter plate reader. The SRB assay 
has shorter incubation times than the previous assays and gives more consistent 
results over a greater number of cell lines. At present this is the only assay used for 
large scale measurements, where several million culture wells are run per year. 
 
Figure 4.1 Sulforhodamide B (SRB) Dye 
 
4.4 5-Day MTT Assay 
The complexes to be tested are firstly dissolved in DMSO, control assays have 
previously been carried out using only DMSO to investigate the effect on 
cytotoxicity with differing concentrations.
13
 Using HT-29 cells, the rate of cell 
survival remained high for all concentrations of DMSO, falling to only 73% at a 
concentration of 2.0% DMSO. For the MCF-7 cell line, the cytotoxic effect of 
DMSO was more significant, with a 52% cell survival at the same concentration of 
DMSO. The A2780 cell line exhibited the highest sensitivity to DMSO, with 
significant cell death observed with 63% cell survival at 2.0% DMSO and 76% cell 
survival at 1.0% DMSO.
13
 The complexes stated within this chapter had IC50 
values under the thresholds stated and it was decided that the DMSO-related 
toxicity would not interfere significantly with the assay. 
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4.4.1 Conducting MTT Under Normoxic Conditions (21% O2) 
A series of complexes were incubated with the cancer cells at ten different 
concentrations, each one a double dilution of the previous one. To obtain these 
concentrations the drugs were diluted in DMSO to give an initial concentration of 
25 mM, followed by dilutions in cell media to give a range of concentrations 
between 250-0.48 M. Firstly, the cell plates are incubated for 24-hours, followed 
by addition of the drug dilutions on day two and then a 5-day incubation period. 
After the 5-day incubation, MTT solution (5 mg/ mL) was added to the plates, 
incubated for a further 3 hours and then absorbance measured at 540 nm, using a 
Thermo Scientific Multiskan EX microplate photometer. All IC50 values were 
taken from an average of three different assays with good repeatability; any 
measurements not correlating were repeated until they were within a 10% error. 
The full protocol for this procedure is stated within Chapter 9. 
 
4.5 Results and Discussion 
4.5.1 -Ketoiminate Ruthenium(II) Complexes 
The series of novel ruthenium(II) -ketominate chloride complexes previously 
reported in Chapter 3 (Figure 4.2) and cisplatin as a control, were tested against a 
range of cell lines including; HT-29 (human colon adenocarinoma), MCF-7 
(human breast carcinoma), A2780 (human ovarian adenocarcinoma) and A2780cis 
(cisplatin resistant human ovarian adenocarcinoma). Assays were carried out using 
a 5-day drug exposure and during this period were incubated at 37 °C with a 5.0% 
CO2 concentration. 
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Figure 4.2 Ruthenium (II) chloride complexes tested in vitro using the MTT assay 
 
Once the incubated cells had been treated with the MTT solution (5mg/ mL), the 
amount of living cells could be determine due to the change in MTT colour. The 
living cells are able to reduce the MTT to the purple formazan and so the amount 
of purple coloration seen is proportional to cell survival. To calculate the IC50 
values of the complexes, graphs were plotted of % cell survival versus drug 
concentration (M) and the concentration found at 50% cell survival. The graph in 
Figure 4.3 shows the % cell survival versus drug concentration (M) for cisplatin, 
1 and 12 against HT-29 cell line. The values were calculated by plotting two 
points, one above and one below the 50% cell survival value, then plotting a line of 
best fit and rearrangement of the equation to find the concentration (M). 
 
Figure 4.3 % Cell survival versus concentration (M) for cisplatin, 1 and 12 
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The values are stated in Table 4.1 and have also been summarised as a bar-chart in 
Figure 4.4. It can be seen that all the complexes tested have moderate to high 
activities against all cell lines. Complexes 1, 3 and 4 have the most consistent IC50 
values over all four cell lines, with significantly higher cytotoxic values against the 
cisplatin resistant ovarian cell line A2780cis then the other cell lines. Against HT-
29 and A2780cis there are differences in IC50 when comparing the different 
electronic properties of the complex, where increasing the withdrawing nature 
decreased the cytotoxicity of the complex. Whereas, against MCF-7 and A2780 
cell lines all of the complexes have high cytotoxicity and no clear trend can be seen 
between electronic or steric properties versus cytotoxic behaviour.  
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Table 4.1 Summary of IC50 values for cisplatin and ruthenium complexes using a 5-day exposure 
Complex 
HT-29 MCF 7 A2780 A2780cis 
IC50 (M) ± SD (M) IC50 (M) ± SD (M) IC50 (M) ± SD (M) IC50 (M) ± SD (M) 
Cisplatin 2.4 0.1 1.07 0.10 0.94 0.04 10.5 0.2 
[p-cymRuCl2]2 197.09 4.5 183.6 2.9 195.4 4.5 216.6 9.2 
1 3.5 0.3 1.9 0.1 2.60 0.08 3.13 0.09 
2 10.5 0.4 5.07 0.09 2.8 0.1 3.37 0.07 
3 5.40 0.09 3.0 0.2 1.6 0.1 3.8 0.1 
4 4.3 0.5 3.22 0.09 2.35 0.04 5.59 0.05 
5 11.4 0.6 3.5 0.2 2.5 0.1 6.4 0.1 
6 12.6 0.2 3.27 0.08 2.84 0.04 11.5 0.3 
7 6.1 0.3 3.55 0.09 2.5 0.2 3.69 0.09 
8 10.3 0.6 6.2 0.2 2.3 0.2 7.00 0.04 
9 11.8 0.8 - - -  - - 
10 12.8 0.5 - - -  - - 
11 10.21 0.09 2.9 0.1 2.87 0.05 9.1 0.1 
12 22 2 13.0 0.2 -  - - 
13 6.3 0.3 7.2 0.2 1.9 0.1 3.80 0.09 
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Figure 4.4 Barchart of IC50 values for cisplatin and complexes 1-13 
 
Previously within the McGowan group it was found that para substituted -
diketonate titanium complexes gave the greatest cytotoxic behaviour, with the 4-
fluoro--diketonate titanium complex giving the highest cytotoxicity values.13, 14 
Therefore the following bar-chart (Figure 4.5) shows the difference in cytotoxic 
behaviour of the para -ketoiminate ruthenium chloride complexes (C2=4F, 
C3=4Cl, C8=4Br and C9=4I).  
 
Figure 4.5 Bar-chart showing comparisons with the para ruthenium complexes 
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There is no overall trend seen with most cell lines but it appears the para chloro--
ketoiminate complex (3) has the most potential against all four cell lines. When 
considering the cytotoxicities against the cisplatin resistant ovarian A2780cis it can 
be seen there is a slight trend, with the most electron withdrawing fluoro complex 
(2) having the highest activity and this activity decreases down the periodic table, 
with all complexes showing higher activity than cisplatin The para methyl 
complex (11) was synthesised and tested to see if substituting an electron donating 
group had any effects on the cytotoxicity. In most cases this complex had similar 
activity to the electron withdrawing substituents, except against MCF-7, where 
complex 11 gave the highest cytotoxicity. A larger library of compounds must be 
synthesised to gain more conclusive structure activity relationships, but so far this 
data suggests there is a limited relationship between the electronics of the complex 
and its cytotoxic behaviour. 
 
4.6 Conclusion 
The library of ruthenium chloride complexes characterised in Chapter 3 has been 
tested under normoxic (21% O2) conditions using the well know MTT assay. This 
enables measurements of cytotoxic behaviour and gives an indication of the 
complexes potential as an anti-cancer compound. The assays, data manipulation 
and evaluation of results have been completed by the author at the Institute of 
Cancer Therapeutics, Bradford. The library tested shows that these (N,O) -
ketoiminate ruthenium (II) chloride complexes have moderate to high cytotoxicity 
behaviour, with some of the complexes showing great potential for future 
biological studies, which will be discussed in Chapters 6 and 7. These easily 
tuneable complexes allow for a wider library to be synthesised and future work 
would require a larger library to be tested in order to gain more extensive structure 
activity relationships and to optimise the potential of these complexes. 
  
Evaluation of in vitro Cytotoxicity  Chapter 4 
107 
4.7 References 
1. T. Mosmann, J. Immunol. Meth,, 1983, 65, 55-63. 
2. T. F. Slater, B. Sawyer and U. D. Strauli, Biochim. Biophys. Acta, 1963, 77, 
383-393. 
3. T. Mosmann, J. Immunol. Meth., 1983, 65, 55. 
4. R. D. Lillie, H. J. Conn's Biological Stains, Willians and Wilkins, 
Baltimore, 1977. 
5. D. T. Vistica, P. Skehan, D. Scudiero, A. Monks, A. Pittman and M. R. 
Boyd, Cancer Res., 1991, 51, 2515-2520. 
6. D. T. Vistica, P. Skehan, D. Scudiero, A. Monks, A. Pittman and M. R. 
Boyd, Cancer Res., 1991, 51, 2515. 
7. A. G. E. Pearse, Histochemistry, Theoretical and Applied, Churchill 
Livingstone, Edinburgh, 1972. 
8. K. D. Paull, R. H. Shoemaker, M. R. Boyd, J. L. Parsons, P. A. Risbood, 
W. A. Barbera, M. N. Sharma, D. C. Baker, E. Hand, D. A. Scudiero, A. 
Monks, M. C. Alley and M. Grote, J. Heterocycl. Chem., 1988, 25, 911-
914. 
9. D. A. Scudiero, R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. 
Nofziger, M. J. Currens, D. Seniff and M. R. Boyd, Cancer Res., 1988, 48, 
4827-4833. 
10. P. A. Knauf and A. Rothstein, J. Gen. Physiol., 1971, 58, 211. 
11. P. A. Knauf and A. Rothstein, J. Gen. Physiol., 1971, 58, 190. 
12. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. 
T. Warren, H. Bokesch, S. Kenney and M. R. Boyd, J. Natl. Cancer Inst., 
1990, 82, 1107-1112. 
13. B. D. Crossley, Ph. D Thesis, University of Leeds, 2011. 
14. J. J. Mannion, Ph. D Thesis, University of Leeds, 2008. 
 
 
 
 
 108 
Chapter 5 
Synthesis, Characterisation and Cytotoxic Evaluation of 
Modified Ruthenium Complexes 
 
  
Modified Complexes  Chapter 5 
109 
5 Modified Complexes 
Previously in Chapters 3 and 4, a range of -ketoiminate ruthenium(II) chloride 
complexes were synthesised and showed very promising cytotoxic behaviour, with 
many values comparable or higher than cisplatin against A2780cis. Due to the 
success of these complexes, an effort has been made to tune the structure of the 
complexes by either; 
 
i) eliminating part of the ligand 
ii) altering the sterics of the arene ring 
iii) changing the metal centre, or  
iv) changing the binding mode of the ligand.  
This chapter discusses the synthesis, characterisation and cytotoxic behaviour of 
these complexes, with comparisons made to the previous complexes, discussed in 
Chapter 4. 
 
5.1 Synthesis of Aniline Ruthenium (II) Dichloride (14) 
It was postulated that the T-stacking interactions commonly seen with the aniline 
ring may be key for the compounds activity. Complex 14 was synthesised to 
eliminate the -ketoiminate ligand. The synthesis of this complex was reported in 
2006 by Govindaswamy et al. but for the purpose of cytotoxic comparisons has been 
resynthesised by the author.
1
 This complex was synthesised according to Scheme 
5.1, where [p-cymRuCl2]2 was added to aniline and Et3N in dichloromethane. 
 
Scheme 5.1 Synthetic route to complex 14 
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5.1.1 X-ray Characterisation of C16H21Cl2NRu (14) 
Red fragments of 14 suitable for X-ray crystallographic analysis were obtained 
using slow evaporation from a methanolic solution over a period of several days. 
The molecular structure is shown in Figure 5.1 and selected bond lengths and angles 
are stated in Table 5.1. Complex 14 crystallised in a triclinic cell and structural 
solution was performed in the space group P1, with a single molecule in the 
asymmetric unit. 
 
Figure 5.1 Molecular structure of 14, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 5.1 Selected bond lengths and angles for 14 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.1932(13) Cl(1)-Ru(1)-Cl(2) 87.70(1) 
Ru(1)-Cl(1) 2.4407(5) N(1)-Ru(1)-Cl(1) 80.23(4) 
Ru(1)-Cl(2) 2.4250(5) N(1)-Ru(1)-Cl(2) 83.80(4) 
Ru(1)-Cg(1) 1.6684(7) Cg(1)-Ru(1)-N(1) 132.29(4) 
  Cg(1)-Ru(1)-Cl(1) 128.55(2) 
  Cg(1)-Ru(1)-Cl(2) 127.62(3) 
 
The packing diagram along the a axis shows the molecules pack head-tail and 
alternate in each plane, with intermolecular N-H…Cl holding the two pairs in the 
head-tail-tail-head arrangement and the C-H…Cg interactions between each plane. 
When viewed along the c axis two hydrogen’s of the NH2 form N-H…Cl interaction 
with adjacent molecules giving a head-tail-tail-head arrangement. There is one 
intramolecular interaction seen between the p-cymene CH3 and the centroid of the 
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aniline ring. The intermolecular interactions and packing diagrams are presented in 
Figure 5.2, with D…A distances stated in Table 5.2. 
 
 
Intramolecular C(8)-H(8)…Cg(2) Intermolecular N(1)-H(2N)…Cl(2) 
 
 
Intermolecular interactions along the c 
axis 
Intermolecular interactions along the a 
axis 
Figure 5.2 Interactions and packing diagrams along the c and a axes for 14 
Table 5.2 Bond lengths for complex 14 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(8)-H(8)...Cg(2) 3.7156 Å 
Intermolecular C(1)-H(1C)...Cg(2) 3.8084 Å 
 Ru(1)-Cl(1)…Cg(1) 1.6684 Å 
 N(1)-H(1N)…Cl(1) 3.2954(17) Å 
 N(1)-H(2N)…Cl(2) 3.3424(16) Å 
 C(7)-H(7)…Cl(1) 3.7261(16) Å 
 C(12)-H(12)…Cl(1) 3.5939(17) Å 
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5.2 Synthesis of Diphenyl -Ketoiminate Ruthenium(II) Chloride (15) 
This complex was designed to move the position of the phenyl ring of the aniline 
group and so comprises of an -ketoiminate ligand with the ligand binding via a 
NH. Complex 15 was synthesised according to Scheme 5.2, where [p-cymRuCl2]2 
was added to the diphenyl -ketoiminate ligand and Et3N in dichloromethane. 
Ru
Cl
Ru
ClCl
Cl NH2 O2
Ru
Cl
N
O
Et3N 
(2 equiv.)
DCM
H
 
Scheme 5.2 Synthetic route to complex 15 
 
5.2.1 X-ray Characterisation of C25H26ClNORu (15) 
Red fragments of 15 suitable for X-ray crystallographic analysis were obtained 
using slow evaporation from a methanolic solution over a period of several days. 
The molecular structure is shown in Figure 5.3 and selected bond lengths and angles 
are stated in Table 5.3. Complex 15 crystallised in a monoclinic cell and structural 
solution was performed in the space group P21/c, with a single molecule in the 
asymmetric unit. 
 
Figure 5.3 Molecular structure of 15, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
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Table 5.3 Selected bond lengths and angles for 15 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-N(1) 2.052(3) N(1)-Ru(1)-O(1) 87.52(11) 
Ru(1)-O(1) 2.058(3) N(1)-Ru(1)-Cl(1) 86.25(8) 
Ru(1)-Cl(1) 2.4413(10) O(1)-Ru(1)-Cl(1) 85.80(8) 
Ru(1)-Cg(1) 1.6481(17) Cg(1)-Ru(1)-O(1) 126.41(10) 
  Cg(1)-Ru(1)-N(1) 129.40(10) 
  Cg(1)-Ru(1)-Cl(1) 127.19(6) 
 
The packing diagrams show the molecules pack in head-tail-tail-head pairs on all 
axes, with intermolecular C-H…Cl interactions holding the molecules together. 
When viewed along the c axis intermolecular T-stacking interactions can be seen 
between the p-cymene and the centroid of the aromatic ring C(10)-H(10B)…Cg(2), 
these interactions hold two planes of molecules together. The intermolecular 
interactions and packing diagrams are presented in Figure 5.4, with D…A distances 
and torsion angles stated in Table 5.4. 
 
 
Packing along the b axis Packing along the c axis 
 
Intermolecular interactions along the b axis  
Figure 5.4 Packing diagrams showing intermolcular interactions along the b and c 
axes for 15 
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Table 5.4 Bond lengths and torsion angles for 15 
Interaction Atoms Bond Lengths and Angles 
Intermolecular C(3)-H(3)...Cg(2) 3.633 Å 
 C(6)-H(6)...Cg(2) 3.553 Å 
 C(10)-H(10C)…Cg(3) 3.628 Å 
 C(1)-H(1B)…Cl(1) 3.629(4) Å 
Torsion Cg(2)-Centre 77.28° 
 Centre-Cg(3) 29.31° 
 
5.3 Synthesis of -Diketonate Ruthenium(II) Chloride (16) 
It was seen during synthesis that the -ketoiminate ligands can sometimes dissociate 
back to the starting -diketonate ligand. Complex 16 was synthesised to incorporate 
the starting ligand. As the previous chapters shows that the meta fluoro -
ketoiminate ruthenium complex (1) was active against all four cell lines, the meta 
fluoro -diketonate ruthenium (II) chloride complex was synthesised. Complex 16 
was synthesised according to Scheme 5.3, where [p-cymRuCl2]2 was added to the 
meta fluoro -diketonate ligand and Et3N in dichloromethane. 
Ru
Cl
Ru
ClCl
Cl OH O2
Ru
Cl
O
O
Et3N 
(2 equiv.)
DCM
F
F
 
Scheme 5.3 Synthetic route to complex 16 
 
5.3.1 X-ray Characterisation of C20H26ClO2Ru (16) 
Orange plates of 16 suitable for X-ray crystallographic analysis were obtained using 
slow evaporation from a methanolic solution over a period of several days. The 
molecular structure is shown in Figure 5.5 and selected bond lengths and angles are 
stated in Table 5.5. Complex 16 crystallised in a monoclinic cell and structural 
solution was performed in the space group P21/c, with a single molecule in the 
asymmetric unit. 
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Figure 5.5 Molecular structure of 16, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 5.5 Selected bond lengths and angles for 16 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-O(1) 2.069(2) O(1)-Ru(1)-O(2) 85.21(9) 
Ru(1)-O(2) 2.217(2) O(1)-Ru(1)-Cl(1) 87.76(7) 
Ru(1)-Cl(1) 2.5340(8) O(2)-Ru(1)-Cl(1) 65.31(7) 
Ru(1)-Cg(1) 1.8681(15) Cg(1)-Ru(1)-O(1) 123.30(8) 
C(16)-F(1A) 1.395(6) Cg(1)-Ru(1)-O(2) 139.34(8) 
  Cg(1)-Ru(1)-Cl(1) 135.39(5) 
 
The packing diagram show the molecules pack in pairs with intermolecular 
interactions holding the molecules together and when viewed along the c axis this 
gives a herringbone arrangement. There are also intermolecular interactions between 
C-H…Cl which holds the molecules between each plane. The intramolecular 
interaction and packing diagrams are presented in Figure 5.6, with D…A distances 
and torsion angles stated in Table 5.6. 
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Intramolecular C(16)-H(16)…O(2) Packing along the c axis 
Figure 5.6 Intramolecular interactations and packing diagrams for 16 
Table 5.6 Bond lengths and torsion angles for 16 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(16)-H(16)...O(2) 2.917(5) Ǻ 
Intermolecular C(18)-H(18)...O(1) 2.951(5) Ǻ 
 C(3)-H(3)...Cl(1) 3.323(3) Ǻ 
 C(10)-H(10A)...O(2) 3.449(7) Ǻ 
 C(7)-H(7)...Cg(1) 3.585 Å 
Torsion Centre-Cg(2) 1.30° 
 
5.4 Synthesis of -Ketoiminate Ruthenium Arene Chloride (17) 
Complex 17 was synthesised to incorporate the meta fluoro -diketonate and the p-
cymene ligand is substituted for an phenyl ring. Complex 17 was synthesised 
according to Scheme 5.3, where [areneRuCl2]2 was added to the meta fluoro -
diketonate ligand and Et3N in dichloromethane. 
Ru
Cl
Ru
ClCl
Cl OH O2
Ru
Cl
O
O
Et3N 
(2 equiv.)
DCM
F
F
 
Scheme 5.4 Synthetic route to complex 17 
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5.4.1 X-ray Characterisation of C16H14ClFO2Ru (17) 
Orange plates of 17 suitable for X-ray crystallographic analysis were obtained using 
slow evaporation from a methanolic solution over a period of several days. The 
molecular structure is shown in Figure 5.7 and selected bond lengths and angles are 
stated in Table 5.7. Complex 17 crystallised in a monoclinic cell and structural 
solution was performed in the space group P21/c, with a single molecule in the 
asymmetric unit. 
 
Figure 5.7 Molecular structure of 17 displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 5.7 Selected bond lengths and angles for 17 
Bond Distance (Å) Bond Angle (°) 
Ru(1)-O(1) 2.0689(18) O(1)-Ru(1)-O(2) 88.62(7) 
Ru(1)-O(2) 2.0622(19) O(1)-Ru(1)-Cl(1) 84.82(5) 
Ru(1)-Cl(1) 2.4148(7) O(2)-Ru(1)-Cl(1) 86.10(5) 
Ru(1)-Cg(1) 1.6403(12) Cg(1)-Ru(1)-O(1) 128.34(7) 
C(17)-F(1A) 1.358(3) Cg(1)-Ru(1)-O(2) 126.51(7) 
  Cg(1)-Ru(1)-Cl(1) 128.22(5) 
 
The packing diagram shows the molecules pack in a head-tail-tail-head arrangement 
along the a axis, with intermolecular C-H…Cl interactions between each plane of 
atoms. The intramolecular interaction and packing diagrams are presented in Figure 
5.8, with D…A distances and torsion angles stated in Table 5.8. 
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Packing along the c axis Packing along the a axis 
 
Intermolecular interactions 
Figure 5.8 Intramolecular interactations and packing diagrams for 17 
Table 5.8 Bond lengths and torsion angles for 17 
Interaction Atoms Bond Lengths and Angles 
Intermolecular C(11)-H(11A)...Cg(2) 3.607 Ǻ 
 C(19)-H(19)...Cl(1) 3.582(3) Ǻ 
 C(20)-H(20)...Cl(1) 3.444(3) Å 
Torsion Centre-Cg(2) 9.81(7)° 
 
5.5 Synthesis of -Ketoiminate Iridium Cp* Chloride (C18) 
Complex 18 was first synthesised within the research group for its catalytic 
potential,
2
 as it is analogous to complex 1 it was tested for its cytotoxic potential. It 
was synthesised according to Scheme 5.5, initial cytotoxic results have since been 
published
3
 and it is stated within this chapter as future cytotoxic and biological 
studies have been assessed using this complex. 
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Ir
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O
Et3N 
(2 equiv.)
DCM
F
F
C18
Scheme 5.5 Synthetic route to 18
3
 
 
5.6 Synthesis of -Diketonate Iridium Cp* Chloride (19) 
Complex 19 was synthesised as it is analogues to complex C16 and allows 
comparisons to be made between binding modes of the ligands and changing the 
metal source. Complex 19 was synthesised according to Scheme 5.6, where 
[Cp*IrCl2]2 is added to the 3-fluoro -diketonate ligand and Et3N in 
dichloromethane. 
Ir
Cl
Ir
ClCl
Cl OH O2
Ir
Cl
O
O
Et3N 
(2 equiv.)
DCM
F
F
 
Scheme 5.6 Synthetic route to complex 19 
 
5.6.1 X-ray Characterisation of C20H26ClNORu (19) 
Yellow fragments of 19 suitable for X-ray crystallographic analysis were obtained 
using slow evaporation from a methanolic solution over a period of several days. 
The molecular structure is shown in Figure 5.9 and selected bond lengths and angles 
are stated in Table 5.9. Compound 19 crystallised in an orthorhombic cell and 
structural solution was performed in the space group P212121, with a single molecule 
in the asymmetric unit. 
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Figure 5.9 Molecular structure of 19, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 5.9 Selected bond lengths and angles for 19 
Bond Distance (Å) Bond Angle (°) 
Ir(1)-O(1) 2.1177(16) O(1)-Ir(1)-O(2) 85.94(5) 
Ir(1)-O(2) 2.1270(12) O(1)-Ir(1)-Cl(1) 86.10(4) 
Ir(1)-Cl(1) 2.4412(6) O(2)-Ir(1)-Cl(1) 87.34(4) 
Ir(1)-Cg(1) 1.7711(10) Cg(1)-Ir(1)-O(1) 125.31(5) 
  Cg(1)-Ir(1)-O(2) 129.07(5) 
  Cg(1)-Ir (1)-Cl(1) 128.69(3) 
 
The packing diagram show the molecules pack in pairs with intermolecular 
interactions holding the molecules together and when viewed along both the a and c 
axes the molecules have a herringbone arrangement, with intermolecular C-H…Cl 
interactions holding pairs of molecules together. The intramolecular interaction and 
packing diagrams are presented in Figure 5.10, with D…A distances and torsion 
angles stated in  Table 5.10. 
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Intramolecular C(20)-H(20)…O(2) 
 
 
Packing along the a axis Packing along the c axis 
Figure 5.10 Intramolecular interactations and packing diagrams for 19 
 Table 5.10 Bond angles and torsion angles for 19 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(20)-H(20)...O(2) 2.729(2) Ǻ 
Intermolecular Ir(1)-Cl(1)…Cg(1) 1.7711 Ǻ 
 C(18)-H(18)...Cl(1) 3.707(2) Ǻ 
Torsion Centre-Cg(2) 4.49° 
 
Modified Complexes  Chapter 5 
122 
5.7 Cytotoxic Evaluation 
After the success of the complexes stated in Chapter 4, this small library of 
complexes has been synthesised and their cytotoxic potential evaluated. The 
complexes were assessed using the MTT assay used previously and were again 
incubated using the same 5-day incubation period at 37°C under a 5.0% CO2 
concentration (see protocol in Chapter 9). The IC50 values are stated in Table 5.11 
and have also been summarised as a bar-chart in Figure 5.11. When considering 
complex 14 it is appears to be essential to have the -ketoiminate ligand bound, as 
this aniline bound complex is completely inactive. The cytotoxic values were 
obtained against HT-29 and A2780 and due to having IC50 values > 100 M, this 
complex was not tested against the other cell lines. Also when considering 15, this 
has a -ketoiminate ligand bound to the ruthenium but the aniline ring has been 
eliminated and instead bound by the N-H. It can be seen from Table 5.11 this 
complex has a two-fold increase in activity when compared to complex 14, however 
it still remains relatively inactive and is not within the same magnitude as the 
previous complexes seen in Chapter 4. 
When changing the ruthenium p-cymene (complex 1) for an iridium Cp* (18), the 
activity of the complex remains high against all four cell lines and like its ruthenium 
analogue, complex 18 shows the highest cytotoxic values against MCF-7. 
Complexes 16 and 19 were synthesised to allow comparisions to made using a 
different mode of binding, and these complexes incorporate a -diketonate (O,O) 
ligands. The ruthenium complex 17 is only moderately active against all four cell 
lines, where the iridium complex 19 is completely inactive. When comparing the 
same metals using the -ketoiminate (N,O) ligands, complex 1 (N,O) is more active 
than complex 16 (O,O), with up to a 9-fold increase in IC50 value against MCF-7 
and 18 (N,O) is more active than complex 19 (O,O), with up to a 18-fold increase in 
IC50 value against HT-29. In addition, complex 17 was synthesised to assess the 
importance of the p-cymene ligand, this complex is analogous to complex 16 but 
contains a phenyl arene ligand instead of the p-cymene. This complex was tested 
against both HT-29 and MCF-7 and it can be seen that the activity decreases further, 
with complex 17 being completely inactive against both lines. 
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Table 5.11 IC50 values for cisplatin and the complexes synthesised within this chapter, against HT-29, MCF-7, A2780 and A2780cis cell lines 
Complex 
HT-29 MCF-7 A2780 A2780cis 
IC50 (M) ± SD IC50 (M) ± SD IC50 (M) ± SD IC50 (M) ± SD 
Cisplatin 2.4 0.1 1.09 0.08 0.94 0.04 10.5 0.2 
14 128 4 - - 147 8 - - 
15 53 1 - - 56 2 - - 
1 3.5 0.3 1.9 0.1 2.60 0.08 3.13 0.09 
16 18 2 18.4 0.8 19.4 0.8 24.3 0.5 
17 68 3 - - 71 2 - - 
18 5.1 0.3 3.4 0.2 5.7 0.1 5.8 0.5 
19 93 7 51 4 35 1 51 1 
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Figure 5.11 Bar-chart of IC50 values against HT-29, MCF-7, A2780 and A2780cis 
 
5.8 Conclusion 
A small library of complexes have been synthesised in an attempted to understand 
the key features of the complex which are needed for high in vitro activity. The 
results show that not only is a -ketoiminate (N,O) ligand essential for high in vitro 
activity, but the ligand must be bound to an aniline substituent. On elimination of 
this ring or changing the binding mode of the ligand the activity of the complex 
decreases. The most noticeable results are seen for the iridium complexes where 
the (N,O) complex 18 has up to a 18-fold increase in activity when compared to the 
(O,O) complex 19. These initial results show the -ketoiminate complexes 1 and 
18 are again the most active against all four cell lines tested, showing that high in 
vitro results can be seen with different metals, therefore suggesting the ligand is 
essential for activity. This library must be extended further to gain more extensive 
and conclusive structure activity relationships and to understand the key features 
required to tune the complexes activity. 
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Chapter 6 
Cytotoxicity Studies under Hypoxic Conditions 
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6 Cytotoxicity under Hypoxic Conditions 
6.1 Hypoxia 
Molecular O2 is essential for aerobic metabolism and to maintain intracellular 
processes. Hypoxia is defined as an environment of reduced O2 concentration and 
occurs in pathological conditions such as strokes, inflammation and growth of solid 
tumours. The ambient air is 21% O2, with most mammalian tissues existing 
between 2-9% O2. However, hypoxia is defined as ≤ 2% O2, where severe hypoxia 
(anoxia) is at ≤ 0.02% O2.
1, 2
 Early demonstrations of tumour hypoxia were 
observed in 1955 by Thomlinson and Gray, in which they studied the histology of 
sections of human tumours and observed that cells grow in cords, having a necrotic 
core surrounded by a region of viable cells, and proposed the necrosis was due to 
an insufficient supply of O2 and nutrients.
3
 The effects and direct measurements of 
O2 in tissues is still poorly understood, due to the lack of methods which are non-
invasive, precise and quantitative.
4
 However, many researchers have attempted to 
study hypoxia by; (i) studying the oxyhaemoglobin of tumours by polarographic 
electrodes, gaining insight into the regional oxygen environment of the tumour,
5
 
(ii) 
31
P NMR spectroscopy studies to monitor metabolism of misonidazole, which 
selectively binds hypoxic cells
6-9
 and (iii) using a DNA-binding stain to label cells 
based on their proximity to the blood supply.
10
 The latter was able to differentiate 
between diffusion-limited (chronic) hypoxia and acute hypoxia, and that cells 
adjacent to the blood supply may become hypoxic during treatment, concluding 
that the two types of hypoxia may have different effects on treatment response. 
 
6.2 Effects of Hypoxia on Cancer 
The decrease in O2 concentration has been confirmed to inhibit tumour growth, and 
even as early as 1909 it was noted that normal cells irradiated under 
hypoxic/anoxic conditions were less sensitive then those irradiated in the presence 
of O2.
11
 The first studies showing a correlation were using vegetable seeds,
12
 but in 
the 1950s this was quantified in mice studies, both in vitro and in vivo. Using 
human embryo liver cells, in vitro studies under anoxic conditions exhibited ~2.5 
fold greater colony growth after irradiation, when compared to those cultured in 
air.
13
 More recently it has been proposed that hypoxic cells can be directly targeted 
using hypoxia-specific cytotoxins. Alongside radiation, this combination has the 
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potential of destroying the entire tumour population.
14
 It was known that exposing 
cancer cells to hypoxic conditions causes a reduced response to radiotherapy 
treatment, however it was shown that exposure to oxygen immediately after 
radiation has no effect on this response.
15
 The mechanism of radio-sensitivity is 
known to be a competition between the oxidation and reduction of the DNA 
following radiation.
16
 A DNA radical is formed, and under normal conditions the 
DNA is oxidised making the damage permanent. Under hypoxic conditions the 
DNA is repaired through reduction by a thiol containing protein, as shown in 
Scheme 6.1. 
 
Scheme 6.1 Mechanism of hypoxia-induced resistance of a tumour cell to radiation 
 
Tumours typically contain irregular networks of leaky micro-vessels with 
heterogeneous blood flow and large inter-vessel distances.
17
 Along with the lack of 
lymphatic drainage and high interstitial pressure, diffusion of nutrients and drugs 
dominates.
18
 The cancer cells are a greater distance from the capillary blood 
supply, meaning poor tissue penetration of drugs is a large limiting factor in cancer 
therapy. It has also been found that cell proliferation decreases further from the 
blood supply, meaning the reduction in division will lead to a decrease in drug 
activity.
19, 20
 
 
6.3 Hypoxia-Inducible Factor (HIF) 
The hypoxia-inducible factor (HIF) is a transcription factor that responds to 
changes in available O2 in cellular environments, in particular decreases in O2 
concentration. HIF-1 is heterodimeric and consists of two subunits; an oxygen-
sensitive HIF-1 and the oxygen-insensitive HIF-1. The  subunit is subject to 
enzymatic modifications by a hydroxylase enzyme and is a target for degradation 
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in the presence of oxygen. Hypoxia inhibits this activity of the enzyme and leads to 
accumulation of the  subunit and formation of the active HIF-1.21 The HIF-
1subunit contains two proline residues, which are hydoxylated under normoxic 
conditions by a family of 4-prolyl hydroxylases. The hydroxylated HIF-1 can be 
recognised by the von Hippel-Lindau (VHL) tumour suppressor gene, which 
further alters the subunit marking it for degradation by the proteasome.
22-26
 Under 
hypoxic conditions the hydroxylation of HIF-1 is inhibited; the subunit is not 
degraded and instead stabilised by dimerisation with the HIF-1 This dimer binds 
to genes and activates the transcription of products which are involved in tumour 
survival and proliferation.
27-30
 An overview of HIF-1 regulation is shown in 
Scheme 6.2. 
 
Scheme 6.2 Mechanism of HIF-1 regulation within the cell31 
 
6.4 Hypoxia Targeting Drugs 
There has been much interest in the design of tumour-activated prodrugs (TAPs), 
which are administrated as prodrugs and converted to their active form under 
hypoxic conditions (Scheme 6.3). These hypoxia-selective cytotoxins are required 
to undergo a one-electron reduction from a relatively non-toxic prodrug to a radical 
which becomes a substrate for re-oxidation by O2 and reforms the original 
compound. These compounds are classified as bioreducible and the ability to 
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bioreduce is an essential feature for a successful hypoxic-selective drugs.
32
 Some 
compounds known as hypoxia-activated prodrugs of diffusible cytotoxins (HPDC) 
have been designed to target the hypoxia region of a tumour and also have the 
ability to diffuse into surrounding normoxic cells, thereby increasing the overall 
efficacy of the compounds.
33
 
 
Scheme 6.3 Mechanism of pro-drug activation by hypoxia
34
 
 
6.4.1 Organic Hypoxia-activated Drugs 
 Quinones 
The bioreductive agent mitomycin C (MMC) (Figure 6.1) was in clinical use but 
only in the 1980s it was recognised that the hypoxic environment could facilitate 
the bioreduction and activate MMC. In vitro results were compared to normoxic 
values and generally a five-fold increase in activity was seen.
35-38
 The one electron 
reduction produces a semi-quinone radical anion that covalently cross-links with 
DNA, then in the presence of oxygen is oxidised back to the quinine.
35, 39, 40
  
Further investigation into these molecules has led to a methylated analogue known 
as porfiromycin
41, 42
 and a series of indolequinones,
43, 44
 which have all shown to be 
superior and when combined with radiotherapy gave promising pre-clinical data in 
tumour models.
45
 
N
O
O
O
O
H2N
O
NH
H2N
 
Figure 6.1 Structure of mitomycin C (MMC) 
 
 Nitroaromatics 
This work initially focused on a hypoxic cell radio-sensitiser misonidazole (Figure 
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6.2) after results showed promising selectivity towards hypoxic cells. These 
nitroaromatics are bioreduced via stepwise addition of up to six electrons. 
Misonidazole was found to have a similar or higher hypoxic cytotoxic ratio (HCR) 
than MMC
46
 and could enhance radiotherapeutic outcome.
47
 A range of compounds 
including, 2-nitroimidazole,
48, 49
 bis-bioreductive agents (two reducible centre)
50
 
and dinitrobenzamide mustards
51
 have shown promising results, however, the lead 
compound PR-104 (Proacta) has been identified and commenced phase I clinical 
trials in solid tumours.
52
 
N
N
OH
O
O2N  
Figure 6.2 Structure of misonidazole 
 
 Aliphatic N-oxides 
The lead compound in this series is a bis N-oxide banoxantrone (AQ4N) (Figure 
6.3) and is reduced under hypoxic conditions to the cytotoxic AQ4. This compound 
has high binding affinity for DNA and acts as a topoisomerase II inhibitor and 
causes cell death.
53
 Hypoxic selectivity was observed when cultured cells were 
incubated with NADPH-supplemented microsomes.
54
 When tested in vivo, AQ4 
had limited effects on tumour growth, however when combined with methods to 
increase hypoxia, a substantial growth delay was observed.
55, 56
 The data were 
supported by human tumour xenograph studies with radio- or chemotherapy, 
showing that the addition of AQ4 gave more persistent damage than with just 
radiation alone.
57
 Along with other promising results, AQ4 has since entered 
clinical trials, where phase I combinational studies with cisplatin and phase II 
studies with radiotherapy are still ongoing in Europe.
58
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Figure 6.3 Structure of AQ4N 
 Heteroaromatic N-oxides 
The current lead compound of the heteroaromatics, is tirapazamine (TPZ), which 
was first understood as a hypoxia-selective cytotoxin in the 1980s.
59
 This 
compound first entered clinical trial in 1994,
60
 and since then there has been nine 
phase I trials and 15 phase II/III trials. TPZ has shown to be an excellent substrate 
for one-electron reductases, cytochrome P450 and P450R
61-65
 and NOS.
66, 67
 In the 
absence of oxygen the nitroxide radical undergoes a rearrangement by the loss of 
water to form an oxidising radical which causes DNA damage through abstraction 
of a hydrogen atom.
68
 TPZ has been shown to become increasingly cytotoxic as 
oxygen levels decrease,
69
 meaning that it can target cells at intermediate oxygen 
tension but is not sufficiently hypoxic for targeting with other bioreductive drugs.
70
 
The most widely used range for TPZ is 260-330 mg/m
2
, with neutropenia reported 
but in a tolerated range. The most frequent non-haematological toxicities reported 
are nausea, vomiting, diarrhoea and skin rashes, with the highest dosages showing 
grade 3-4 toxicities.
60, 71-74
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Scheme 6.4 Mechanism of hypoxia-activation for tirapazamine 
 
6.4.2 Transition Metal Complexes for Hypoxia 
The first TAP compounds based around transition metals utilised DNA-alkylating 
nitrogen mustard ligands attached to Co(III) centres. These were hoped to stabilise 
the Co(III) centre and enable reduction to a labile Co(II) under hypoxic conditions, 
allowing the cytotoxic ligand to dissociate and target the tumour cells (Figure 
6.4).
75-77
 
 
Figure 6.4 Cobalt(III) complex containing bidentate nitrogen mustard ligand 
 
Tetradentate Cu(II) complexes have been synthesised by Parker et al. (Figure 6.5) 
which exhibited much greater selectivity than the previous Co(III) complexes This 
drug is activated by reduction from Cu(II) to Cu(I). In the presence of oxygen, this 
process is reversed, the tetradentate ligand stabilises the complexes to avoid 
dissociation before oxidation back to Cu(II). Under hypoxic conditions the Cu(I) 
complex is hydrolysed to [Cu(H2O)n]
+
 and the free mustard ligand.
78
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Figure 6.5 Copper(II) complex containing tetradentate nitrogen mustard ligand 
 
Cobalt complexes containing a tetraazamacrocycle and 8-hydroxyquinoline have 
been studied by Ahn et al. (Figure 6.6)
79
 and are activated through reduction by 
ionising radiation. This has advantages over enzyme activation, one being the 
ability to control precisely where the pro-drug is activated by specific radiation 
targeting.
80
 Addition of a 8-hydroxyquinoline to the Co(III) reduced the 
compounds activity by >1000-fold. The cytotoxic ligand is released selectively 
under hypoxic conditions, when treated with ionising radiation, demonstrating the 
feasibility of the radiation-activated approach to hypoxia-selective drug design.
81
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Figure 6.6 Cobalt(III) complex containing 8-hydroxyquinoline 
 
6.5 Conducting the MTT Assay Under Hypoxic Conditions (≤ 1% O2) 
This assay was carried out as previously discussed in Chapter 4, with incubation 
periods carried out in a Don Whitley Scientific H35 Hypoxystation. This was kept 
at 37°C with an O2 concentration of either 1.0% or 0.1%. The compounds were 
made up to an initial concentration of 25 mM using DMSO. Ten different dilutions 
were made using cell medium, ranging from 250-0.49 M. The assays uses a 24-
hour incubation of the cells within the well plate, followed by addition of the drug 
dilutions on day two and then a 5-day incubation period. After the 5-day 
incubation, MTT solution (5 mg/ mL) was added to the plates, incubated for a 
further 3 hours and then absorbance measured at 540 nm, using a Thermo 
Scientific Multiskan EX microplate photometer. All IC50 values were taken from 
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an average of three different assays with good repeatability, any measurements not 
correlating we repeated until they were within an approximate 10% error. The 
protocols for this procedure are stated within Chapter 9. 
 
6.6 Results and Discussion 
The ruthenium and iridium complexes 1, 16, 18 and 19 (Figure 6.7) were tested for 
their cytotoxic potential under hypoxic conditions, at either 1.0% or 0.1% O2 
concentration. These were selected as they showed the largest differences in 
activity (Chapter 5). These complexes were tested under both O2 concentrations, as 
they showed the largest differences in their normoxic values. 
 
Figure 6.7 List of meta-fluoro complexes tested under hypoxic conditions 
 
In addition to these, complexes 2, 3, 8, 9 and 11 were chosen as they have a 
functional group in the para position and the modified complexes 14 and 15 were 
also tested (Figure 6.8). As previously discussed, tirapazamine is a well know 
hypoxic sensitive compound and was tested under under hypoxic conditions to act 
as a positive control and cisplatin was also tested for completion. 
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Figure 6.8 List of complexes tested under hypoxic conditions 
 
The results in Table 6.1 (Figure 6.9) show the cytotoxic results for the ruthenium 
complexes incorporating a -ketoiminate ligand (1) and the -diketonate ligand 
(16). The table also shows the results for the iridium analogues 18 and 19. The 
hypoxic sensitive positive control tirapazamine was tested and as expected its 
activity increases on a decrease in O2 concentration. A surprising result was seen 
for the ruthenium (N,O) complex 1, which remains highly active even under very 
low O2 concentrations. Comparing this to the (O,O) complex 16, there is a 5-fold 
decrease in activity on decreasing the O2 concentration from 21% to 0.1%. The 
iridium (N,O) complex 18 still remains moderately active even under very low O2 
concentration, but again the (O,O) complex 19 decreases under low O2 
concentrations and becomes completely inactive.  
The results in Table 6.2 (Figure 6.10) show the activity of the para substituted -
ketoiminate ruthenium complexes synthesised in Chapter 3; their activities all 
increase on a decrease in O2 concentration, with up to a 1.8-fold increase in activity 
seen for complex 2. This is a very promising result as it shows these complexes are 
hypoxic sensitive, which is a key feature that researchers strive to achieve with 
anti-cancer compounds, as the hypoxic environment gives a more realistic idea of 
the cytotoxic potential. The modified complexes 14 and 15 show only minor 
differences in IC50 on changing the O2 concentration and these complexes are still 
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inactive under hypoxic conditions. The results presentated both here and in Chapter 
4 show that the library of ruthenium -ketoiminate complexes synthesised in 
Chapter 3 are not only cytotoxic but activities are further increased under low O2 
concentrations, showing these complexes have the potential for future in vivo 
studies.  
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  Table 6.1 IC50 values for TPZ, cisplatin and complexes 1, 16, 18 and 19 in 21%, 1.0% and 0.1% O2 concentrations 
Complexes 
21.0% O2 1.0% O2 0.1% O2 
IC50 (M) ± SD IC50 (M) ± SD IC50 (M) ± SD 
TPZ 31 3 3.2 0.5 2.4 0.4 
Cisplatin 2.4 0.1 3.5 0.2 2.8 0.4 
1 3.5 0.3 6.4 0.2 5.7 0.2 
16 18 2 62.9 0.3 95 4 
18 5.1 0.3 10.6 0.2 20 2 
19 93 7 109 2 121 3 
Table 6.2 IC50 values for TPZ, cisplatin and complexes 2, 3, 8, 9, 11, 14 and 15 in 21% and 0.1% O2 concentrations 
Complexes 
21% O2 0.1% O2 
IC50 (M) ± SD IC50 (M) ± SD 
TPZ 31 3 2.4 0.4 
Cisplatin 2.4 0.1 2.8 0.4 
2 10.5 0.4 5.7 0.2 
3 5.40 0.09 4.6 0.3 
8 10.3 0.6 5.76 0.09 
9 11.8 0.8 7.0 0.1 
11 10.21 0.09 6.3 0.3 
14 128 4 109 3 
15 53 1 57.3 0.7 
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Figure 6.9 Bar-chart of IC50 at differing O2 concentrations for TPZ, cisplatin, 1, 
16, 18 and 19 
 
Figure 6.10 Bar-chart of IC50 at differing O2 concentrations for TPZ, cisplatin, 2, 
3, 8, 9, 11, 14 and 15 
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6.7 Conclusions 
This chapter presents in vitro cytoxic values under hypoxic conditions for a small 
library of complexes synthesised in Chapters 3 and 5. The results for the 
comparisons between -ketoiminate and -diketonate ruthenium complexes (1 and 
16 respectively), shows that 1 remains active even under very low O2 
concentrations, whereas 16 decreases in activity under lower O2 concentrations. 
Similar results were seen for the iridium -ketoiminate and -diketonate analogues, 
18 and 19 respectively. Complex 18 only decreases slightly in activity and is still 
considered active, whereas 19 becomes completely inactive at 0.1% O2. These 
results confirm that the complexes containing a -ketoiminate ligand are promising 
candidates for further cell investigations. 
Due to the success of 1 and to confirm the results stated above, a second small 
library of ruthenium -ketoiminate complexes were tested under a 0.1% O2 
concentration. These consisted of a para-substituted ligand to allow comparisons to 
be made. It could be seen that all of the complexes increased in activity on 
decreasing the O2 concentration, with the para-fluoro (2) giving the most 
promising result, with up to a 1.8-fold increase in activity. These were tested to 
prove the need for a -ketoiminate ligand and show that the library synthesised 
within Chapter 3 all have the potential for future in vivo work, as they are all 
hypoxia-sensitive, a key feature required for the design of novel anti-cancer drugs.  
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7 Biological Relevance 
7.1 Introduction 
This chapter discuss further biological testing to distinguish the potential of the 
ruthenium and iridium complexes discussed in Chapters 3 and 5 for future in vivo 
testing. Initial results have been obtained for the hydrolysis and hydrophobicity of 
the complexes, as a means to assess the complexes potential to enter a cell 
membrane. These types of organometallic ruthenium(II) arene complexes (Chapter 
1) have shown to interact with DNA
1
 and so using this as a possible target, studies 
have included Comet assays to measure the degree of DNA damage and melting 
curve analysis to determine the specific base interactions with these complexes. 
Apoptosis studies have been measured to assess if the activities seen in Chapters 4 
and 5 are due to cell death or cell inhibition, and as we have previously shown 
these types of complexes cause thioredoxin reductase inhibition, this has been 
analysed for several complexes.
2
 
 
7.2 Hydrolysis 
As stated in Chapter 1, for cisplatin and titanocene dichloride hydrolysis is the 
proposed mechanism of action. Therefore, experiments have been carried out using 
either one equivalent of water or an excess of water. 
1
H NMR spectra were 
recorded over a 5 day period as to mimic the 5-day MTT assay. To date, results 
have been inconclusive and no changes have been observed in the NMR spectra 
after a period of 5-days, suggesting that these complexes do not undergo hydrolysis 
or hydrolysis is too fast to measure. Attempts have been made to increase the 
concentration of water added to the samples, however this causes them to 
precipitate and neither NMR nor UV-vis spectrometry could be conducted. 
 
7.3 Hydrophobicity (Log P) 
This is a test of lipophilicity and can help determine if a drug is capable of entry 
into a cell membrane. One of Lipinski’s rule of five (RO5) states that the octanol-
water partition coefficient (Log P) must not exceed 5 if the drug is to be 
administrated orally.3-5. In an attempted to improve the predictions of drug likeness, 
the rules were extended to the Log P range -0.4 - +5.6
6
 and then later extended to 
the rule of three (RO3), which takes into consideration the molecular weight of the 
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compound. The compound should have a molecular weight of less than 300 dalton 
and a Log P of less than 3.
7
 
 
7.3.1 Conducting Hydrophobicity 
Complexes from Chapters 3 and 5 where tested to determine their effect partition 
coefficient (Log P) on changing the electronics features of the complex. Firstly, 
equal volumes of octanol and water (NaCl saturated) were stirred overnight at 
room temperature and then separated to give octanol-saturated water and water-
saturated octanol. Most experiments use the octanol-saturated water layer to carry 
out the measurements due to cost efficiency; however, all compounds were 
insoluble in octanol-saturated water. Therefore, accurate amounts of the compound 
were dissolved in water-saturated octanol (25 mL), a volume of this was layered 
with an equal volume of octanol-saturated water and placed in a vibrax machine for 
4 hours at 1000 gmin
-1
, a minimum of six repeats were analysed. The layers were 
separated and the water-saturated octanol layer retained for analysis by UV-vis 
spectroscopy. Using the maximum absorbance of each compound, the average of 
the six runs was calculated and rearrangement of individual calibration graph gave 
the [C]org final. Equation 7.1 and Equation 7.2 were used to determine the 
partition coefficient and hence determine if the compound is predominantly 
hydrophilic or hydrophobic.
5, 8-10
 
       
      
     
      Equation 7.1 
       
            
                               
 Equation 7.2 
 
7.3.2 Results and Discussion 
Complexes 1-13 (Figure 7.1) were tested using the previously discussed 
experimental, in order to assess their lipophilicity. The results are summarised in 
Table 7.1 and it can be seen that complexes range from slightly hydrophilic to 
slightly hydrophobic, -0.87-1.5, both cisplatin and [p-cymRuCl2]2 were tested as 
comparisons. 
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Figure 7.1 List of complexes tested for lipophilicity 
Table 7.1 Log P values for cisplatin, [p-cymRuCl2]2 and complexes 1-8, 11-13 
Complex Log p  ± SD 
Cisplatin -2.36 0.01 
[p-cymRuCl2]2 -0.67 0.03 
1 -0.87 0.04 
2 -0.17 0.02 
3 0.12 0.04 
4 1.1 0.2 
5 0.07 0.04 
6 0.27 0.03 
7 0.11 0.05 
8 0.41 0.03 
11 0.53 0.05 
12 1.5 0.2 
13 0.46 0.06 
 
The results show that complexes 1 and 2 are both hydrophilic possibily due to the 
electronegative fluorine atoms within the molecules, which make strong hydrogen 
bonds with the H2O. As cisplatin is also hydrophilic, it was thought that the 
hydrophilic nature is key for the complexes activity; however this contradicts 
Lipinski’s rules. Cisplatin is highly activity and has a Log P value (-2.4) lower than 
the stated threshold for a drug candidate, this can also be seen for 1 which is highly 
active against most cell lines and again is outside the considered threshold. It can 
be seen that [p-cymRuCl2]2 is also hydrophilic and is completely inactive against 
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all cell lines. This shows that the Log P values calculated have no correlation with 
the activities seen. The remaining complexes are all hydrophobic and fall with the 
required range for a likely drug candidate. These results are summarised as a bar-
chart in Figure 7.2. 
 
Figure 7.2 Bar-chart to show the Log P values for cisplatin, [p-cymRuCl2]2, 
complexes 1-8 and 11-13 
 
It was seen in Chapter 5 that on changing the ligands from a -ketoiminate to a -
diketonate produced a large difference in activity (Figure 7.3). Whereby, both of 
the ruthenium -ketoiminate 1 and the iridium -ketoiminate 18 gave IC50 values 
much higher than their -diketonate analogues. Therefore, their Log P values were 
analysed to evaluate if there was a correlation between hydrophobicity and activity. 
The results are shown in Table 7.2 and summarised as a bar-chart in Figure 7.4. It 
can be seen that the more activity complexes are in fact opposite in their lipophilic 
nature, the ruthenium (1) is hydrophilic and the iridium (18) is hydrophobic. When 
assessing the -diketonate analogues the opposite trend is seen and the ruthenium 
(16) is now hydrophobic and the iridium (19) is hydrophilic. These results confirm 
those previously, showing there is no correlation seen between IC50 values obtained 
and lipophilic nature of the complex. This means that passive diffusion into the cell 
is unlikely and these complexes probably enter the cell through a cell-mediated 
response. 
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Figure 7.3 List of complexes from Chapter 5 tested for their Log P 
Table 7.2 Log P values for complexes 1, 16, 18 and 19 
Complex Log p  ± SD 
1 -0.87 0.04 
16 0.11 0.06 
18 0.63 0.06 
19 -0.28 0.09 
 
 
Figure 7.4 Bar-chart to show Log P values for 1, 16, 18 and 19 
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As hydrolysis and hydrophobicity studies are inconclusive to the mode of entry of 
these complexes, it is essential that these are tested for protein and enzyme 
interactions as a means of determining cell uptake. Once inside the cell, a common 
target for these types of half-sandwich “piano-stool” complexes is DNA. 
Researchers have shown that these types of complexes bind selectively to either 
adenosine or guanine residues.
1
 Therefore the next sections discuss DNA as a 
potential target for the activity of these complexes. 
 
7.4 Comet Assay 
Comet assay is a microelectrophoresis study first developed by Ostling and 
Johanson in 1984
11
 and was later modified by Singh et al. in 1988.
12
 It is a method 
used to analyse DNA breakage in single eukaryotic cells by gel electrophoresis. 
The cells are embedded into a layer of low melting point agarose, a lysis buffer 
solution is added to remove the membrane, proteins and histones, which diffuse 
into the agarose. Due to the high molecular weight of DNA, it uncoils and remains 
in the cell cavity within the agarose. Electrophoresis is then carried out at neutral, 
mildly alkaline or strongly alkaline conditions. The DNA is negatively charged and 
therefore when an electric field is applied the relaxed DNA is pulled towards the 
anode. DNA which remains coiled within the nucleoid forms the ‘head’ of the 
comet, whilst the relaxed loops of damaged DNA which are pulled towards the 
anode will form the ‘tail’. These comets can be seen when a SYBR™ Gold 
solution is added to the slides and they are studied using a microscope. DNA 
damaged is scored and the comet tail lengths recorded for 50 different comets. The 
% DNA in the tail is proportional to the amount of DNA damage and therefore the 
comets with the longest tails have the largest amount of DNA damage. This 
technique is a quantitative measurement of DNA damage. 
 
7.4.1 Conducting the Comet Assay 
HT-29 cells were used as they show the largest range of IC50 values (Chapter 4 and 
5), other cell lines showed no significant correlation and gave similar IC50 values 
for most compounds. The HT-29 cells were incubated with the compounds at an 
initial concentration of 20 M and four further concentrations were made each 
ranging from 20-1.25 M. After incubation with the drugs, the cell suspensions 
were diluted in low melting point agarose and added to the previously prepared 
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slides containing an agarose layer. A neutral or alkaline lysis buffer was added to 
the slides and then placed into an electrophoresis tank where an electric field was 
applied for 25 minutes, after washing the slides were left to dry overnight. The 
SYBR™ Gold staining solution was added and the cells scored under a microscope 
and using the Comet assay III software. 
 
Double Strand Breakage (DSB) 
This assay uses a neutral lysis buffer containing 2% sarkosyl, 0.5 M Na2EDTA, 0.5 
mg/ mL proteinase K and adjusted to pH 8.0. The slides are incubated in the lysis 
buffer for one hour at 37°C, then submerged in the electrophoresis buffer for a 
period of thirty minutes and repeated three times. Finally, the slides are submerged 
in the electrophoresis tank with the buffer and a 24 V electric field applied. Once 
washed and dried overnight, the fluorescence dye is applied and comets scored. At 
neutral pH the double helices remain intact and any comet tails seen are 
representative of double strand damage. 
Single Strand Breakage (SSB) 
This assay uses an alkaline lysis buffer containing 2.5 M NaCl, 100 mM EDTA 
and 10 mM Trizma base. The slides are incubated at 4˚C for 1 hour prior to the 
electrophoresis. The electrophoresis tank is then filled with alkaline buffer (pH < 
13) and a 24V electric field applied for 25 minutes. The slides are then washed 
with a neutralisation buffer, and then repeatedly washed with deionised water and 
finally 100% ice cold ethanol. Once the slides are left to dry overnight, the Comet 
assay scoring can be continued when convenient. 
 
7.4.2 Results and Discussion 
Complexes 1, 16, 18, 19 (Figure 7.3) and cisplatin were tested for both DSB and 
SSB, the compounds were incubated with HT-29 cells before harvesting and 
conducting the electrophoresis. It can be seen in Chapter 5 that complex 1 has a 
large difference in cytotoxicity when compared to complex 16 and the same trend 
is seen for the iridium Cp* complexes (18 and 19). The comet assays were 
conducted to distinguish if the IC50 values seen correlated to the extent of DNA 
damaged measured. However, this assay required a positive control and a 
compound such as Camptothecin CAMP (Figure 7.5) which inhibits the DNA 
enzyme topoisomerase I (topo I) inducing apoptosis.
13, 14
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Figure 7.5 Camptothecin (CAMP) 
 
The results are shown as bar-charts in Figure 7.6 and show both DSB and SSB for 
cisplatin and complexes 1, 16, 18 and 19. Results show that like cisplatin, both 
ruthenium complexes show no significant double strand breakage and have tail 
moments comparable to that of cisplatin. When considering the SSB assay, 
cisplatin shows moderate single strand damage and at a concentration of 20 M has 
a tail moment of approximately 20. Complex 1 shows a larger degree of single 
strand damage when compared to cisplatin and at the same concentration it shows a 
tail moment of approximately 65, whereas complex 16 does not show any single 
strand breakage. 
The same assays were conducted for the iridium analogues 18 and 19 and the 
results are shown as bar-charts in Figure 7.7. They do not show the same degree of 
damage as their ruthenium analogues, but still have the same general trend, with 
the complex 18 having preferential single strand breakage and complex 19 showing 
neither double or single strand damage. This preferential single strand breakage for 
the -ketoiminate complexes could be the reason for their increase in IC50 values, 
as a direct trend is seen between cytotoxicity of the complex and the degree of 
DNA damage measured. This assay is quantitative, but only shows that the DNA is 
disrupted but does not quantify any cross-linking that may be present. 
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Cisplatin DSB Complex 1 DSB Complex 16 DSB 
   
Cisplatin SSB Complex 16 SSB Complex 16 SSB 
Figure 7.6 DSB and SSB Comet assay results for cisplatin, 1 and 16 
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Cisplatin DSB Compound 18 DSB Compound 19 DSB 
   
Cisplatin SSB Compound 18 SSB Compound 19 SSB 
Figure 7.7 DSB and SSB Comet assay results for cisplatin, 18 and 19 
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Cross-Linking Comet Assay 
The previous section discusses the results from the double and single strand Comet 
assays, but as stated it does not provide any information for the possibility of cross-
linking within the complexes mode of action. This assay follows the same 
experimental as the single strand breakage assay, but requires 20 minutes exposed 
with hydrogen peroxide after the incubation with the complexes. This is added to 
disrupt the DNA and produce the Comets usually seen; a measurement is then taken 
of percentage tail decrease. If the complexes are forming cross-links there should be 
a decrease in tail moment. 
 
7.4.3 Results and Discussion 
Complexes 1, 16, 18 and 19 (Figure 7.3) were tested using this cross-linking assay 
to distinguish if the preferential single strand breakage seen for complexes 1 and 18 
is due to a cross-linking interaction. Cisplatin was tested as a positive control for this 
assay as it is a well know cross-linking complex.
15, 16
 The results are shown as bar-
charts in Figure 7.8 and show that cisplatin does cross-link with a % tail moment 
decrease of 17% when comparing the control and 20 M. As expected, complexes 
16 and 19, which showed no double or single strand breakage, also show no cross-
linking. When assessing complexes 1 and 18, which do show single strand breakage, 
it can be seen that neither show a significant tail moment decrease. However, these 
values were taken from an average score of 50 comets, and in fact under the 
microscope a large proportion of the comets had significant tail decrease and this 
can account for the large standard deviations seen. This shows that at 20 M there is 
some cross-linking present, however a higher concentration would have to be 
analysed in the hope to maximise the degree of cross-linking. 
 
 
Biological Relevance         Chapter 7 
156 
  
 
Cross-linking for Cisplatin Cross-linking for 1 Cross-linking for 16 
  
Cross-linking for 18 Cross-linking for 19 
Figure 7.8 Cross-linking Comet assay results for cisplatin and complexes 1, 16, 18 and 19 
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7.5 Apoptosis 
In the early stages of apoptosis, changes can occur at the cell membrane
17-19
 and one 
of these alterations is the translocation of the phosphatidylserine (PS). It is a 
phospholipid component that is usually found on the inner-leaflet of the membrane. 
In apoptotic cells, this can move from the inner to the outer part of the membrane, in 
which the PS then becomes exposed on the surface of the cell.
20
 Fadok et al. showed 
that macrophages specifically recognise the exposed PS during the development of 
apoptosis.
18
 This recognition and phagocytosis of apoptotic cells protects the cellular 
compounds leading to inflammation and usually accompanies necrosis. The analysis 
of PS on apoptotic cell membranes is performed using Annexin-V-Fluorescein, and 
also Propidium Iodide (PI) for the differentiation from necrotic cells. 
Annexin V is a Ca
2+
 dependent phospholipid-binding protein with a high affinity for 
PS.
20
 Therefore this protein can be used as a sensitive probe for PS exposure on the 
outer-leaflet of the membrane and is able to detect apoptotic cells.
20-23
 The necrotic 
cells also expose PS due to the loss of membrane integrity, and so to distinguish 
these from apoptotic cells a DNA stain (PI) is used as a necrotic cell would uptake 
both stains and give a positive result for both. 
 
7.5.1 Conducting the Annexin-V assay 
The complexes shown in Figure 7.3 were incubated with either HT-29 or A2780 for 
a period of 48 hours. These were then harvested according to the protocol in Chapter 
9 and flow cytometry was used to analyse a minimum of 10,000 cells. The flow 
cytometer uses a 488 nm excitation and a 515 nm band-pass filter for fluorescein 
detection (Annexin-V) and a filter > 600 nm for PI detection. Electronic 
compensation of the instrument is required to exclude overlapping of the two 
emission spectra. Figure 7.9 shows a general graph seen for the dual parameter FL1 
= Annexin-V-FLUOS versus FL2 = Propidium Iodide.  
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Figure 7.9 General graph seen for the quadrants seen using dual parameters 
R1 = living cells – membranes are intact and therefore are not stained by either of 
the two dyes. 
R2 = apoptotic cells – in which the Annexin-V binds to the negatively charged 
phospholipid surfaces but not the PI dye (excitation = 488 nm, emission = 518 nm) 
R3 = necrotic cells – again this has the PS exposed and binds to the Annexin-V, but 
necrotic cells are ‘leaky’ and the PI stains the exposed DNA (excitation = 518 nm, 
emission = 617 nm) 
 
7.5.2 Results and Discussion 
The results for this assay are stated in Table 7.3 and when considering incubation 
with the HT-29 cells (Figure 7.10), it can be seen that at a drug concentration of 20 
M, the active -ketominate ruthenium complex (1) induces late apoptosis or 
necrosis of up to 72.25%, confirming that the IC50 values obtained are due to cell 
death. Also the active -ketoiminate iridium complex (18) shows induced apoptosis, 
with 31.67% early apoptotic cells and 49.94% late apoptotic or necrotic cells. When 
considering the -diketonate analogues, 17 and 19 respectively, it can be seen that 
even at the highest drug concentration of 20 M, there are still over 84% of the cells 
living. Showing a clear correlation with the IC50 results seen for these complexes, in 
which the more active the complex the higher degree of cell death is induced. 
When considering the incubations with A2780 cells (Figure 7.11), the same trend is 
seen, where at a drug concentration of 20 M, both 1 and 18 have over 60% of the 
cells in the late apoptotic or necrotic stages. However, there is a difference seen in 
the early apoptotic stages in which 1 has a higher degree of living cells, showing it 
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induces later apoptosis only. Again, at the same drug concentration, the inactive 17 
and 19 show over 82% of living cells. These results show that even against two 
different cells lines; these types of -ketoiminate complexes are able to induce a 
high degree of late apoptosis or necrosis in cells. It also suggests that the 
cytotoxicities of these complexes seen in Chapters 4 and 5 are due to cell death and 
not to cell inhibition, therefore it was not necessary to undertake any cell cycling 
experiments. 
 
Figure 7.10 Bar-chart showing late apoptotic/necrotic, early apoptotic and living 
percentage for complexes 1, 16, 18 and 19, against HT-29 
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Figure 7.11 Bar-chart showing late apoptotic/necrotic, early apoptotic and living 
percentage for complexes 1, 16, 18 and 19, against A2780 
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Table 7.3 Apoptosis results for complexes 1, 16, 18 and 19, showing % of living, early apoptotic and late apoptotic/necrotic cells 
  HT-29 A2780 
Complexes 
Concentration 
(M) 
Live (%) 
Early 
Apoptotic (%) 
Late Apoptotic/ 
Necrotic (%) 
Live (%) 
Early 
Apoptotic (%) 
Late 
Apoptotic/ 
Necrotic (%) 
1 0 88.67 5.70 4.07 91.37 2.91 4.95 
 10 9.03 47.19 43.45 49.31 5.76 43.28 
 20 7.86 18.95 72.25 31.52 6.63 60.13 
16 0 90.43 5.94 3.57 92.25 3.45 2.99 
 10 90.54 5.21 2.88 90.54 3.48 5.21 
 20 84.96 10.07 4.62 82.29 5.99 11.38 
18 0 93.68 2.52 2.40 88.52 7.39 1.81 
 10 67.18 27.49 5.01 45.55 10.92 41.83 
 20 18.03 31.67 49.94 3.34 34.57 61.09 
19 0 92.42 3.04 2.65 87.60 6.91 2.01 
 10 88.49 4.73 3.74 86.25 7.60 3.75 
 20 86.26 5.73 5.98 84.52 7.63 5.41 
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7.6 Thioredoxin Reductase 
The thioredoxin (Trx) system is a thiol redox system that plays a key role in the 
cells survival and proliferation.
24, 25
 The thioredoxin reductase (TrxR) has two main 
forms; a cytosolic (TrxR1)
26
 and a mitochondrial one (TrxR2),
27
 it is the only 
known enzyme to catalyse the NADPH-dependent reduction of the active disulfide 
(Csy32 and Cys35) of oxidised Trx.
28
 The electrons which are taken from NADPH 
via TrxR are transferred to the active site of Trx.
29
 The Trx system performs in 
many biological functions,
 
such as;
 23, 24, 29, 30
 
1. Protection of cellular proteins against oxidation by reducing protein 
disulfides. 
2. An antioxidant acting as an electron donor to peroxide scavengers. 
3. Redox control of transcription factors, including the hypoxia-inducible 
factor HIF-1 
4. An electron donor for enzyme ribonucleotide reductase (RNR) which is 
involved in DNA synthesis. 
In cancer, the biological effects of the Trx system have been shown to contribute to 
tumour growth and progression.
30
 However, over-expression of the Trx has been 
reported in several tumour cancers and therefore targeting the inhibition of this has 
been key in current drug research.
31-33
 The increase of Trx expression has since 
been associated with the resistance to docetaxel in primary breast cancer
34
 and 
decreased survival in colorectal cancer patients.
35
 Therefore the TrxR in 
tumorigenesis has been studied in mouse models, in which tumour growth and 
metastasis were largely reduced.
36
 The active site of the Trx is a selenoate group, 
which after reduction allows the site to react with “soft” metal ions, making the 
TrxR a likely target for metallodrugs and is potentially the reasons that gold(I) and 
platinum(II) compounds have been previously reported for their inhibition of 
mammalian TrxR.
37-40
 It was thought that ruthenium compounds, due to their “soft” 
nature, would have the potential of inhibiting TrxR. The first results were published 
on this in 2007 by Mura et al. in which they show that ruthenium(III) compounds in 
fact have selectivity towards the cytosolic TrxR1 and is reminiscent to that seen for 
calcium ions. In which the TrxR1 is also extremely sensitive to Ca
2+
 inhibition and 
exerts only a weak inhibitory action on the mitochondrial TrxR2.
41
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7.6.1 Conducting the Thioredoxin Reductase Assay 
This assay is based on a modified assay by Chew et al.,
42
 in which the substrate 
DTNB also known as Ellman's reagent (5,5'-dithiobis-(2-nitrobenzoic acid)) is used 
to quantify the concentration of thiol groups in a sample, as thiols react with this 
compound and cleave the disulfide bond giving TNB (Scheme 7.1).
43
 
Scheme 7.1 Cleaving of a disulfide bond by DTNB to give TNB 
 
The inhibition of TrxR is measured by addition of DTNB, NADPH and TrxR, and 
then differing concentrations of drug samples to gain the concentration needed to 
inhibit 50% (IC50). The production of TNB is then measured at 412 nm and the IC50 
calculated by plotting graphs of % absorption versus inhibition concentration [I]. 
This assay was carried out using complexes stated in Figure 7.3 at varying 
concentrations, up to a maximum of 10 M. The TrxR in buffer solutions were 
allowed to react with the drug samples for 30 seconds and then UV-vis 
spectroscopy was measured for 1 minute at 412 nm. An initial spectrum was 
recorded for the TrxR only and any decrease in absorbance seen indicated 
inhibition (Scheme 7.2). 
DTNB NADPH H
TrxR
2TNB NADP  
Scheme 7.2 The reaction of DTNB with NADPH with TrxR 
 
7.6.2 Results and Discussion 
The results for this assay are stated in Figure 7.12 and show graphs of % 
absorption versus [I], straight line graphs were plotted for 50% region and from the 
line of best fit, IC50 values were calculated. It can be seen that the active -
ketominate ruthenium complex 1 is also good inhibitors of TrxR with a [I] of 285 
nM and the inactive -diketonate ruthenium complex 16 has a [I] of only 1.42 M. 
A similar trend is seen for the iridium complexes, whereby the inactive -
diketonate iridum 19 only inhibits in the micromolar range and the iridium -
ketoiminate complex 18 has a [I] of 68.5 nM. These results show there is some 
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selectivity towards the complexes, with a trend seen in the IC50 inhibition and the 
cytotoxicity values. These results are similar to those obtained within the 
McGowan group, in which the iridium picolinamide complexes were the more 
active than their ruthenium analogues, with IC50 values in the nanomolar range. The 
results show that the ruthenium complexes were completely inactive and here the 
ruthenium complexes are as high as the nanomolar range, this could mean the -
ketoiminate ligands may play a role in the activity of these complexes.
2
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Complex 1– IC50 = 285 nM Complex 16 – IC50 = 1.42 M 
  
Complex 18 – IC50 = 68.5 nM Complex 19– IC50 = 1.48 M 
Figure 7.12 Graphs showing the % Absorption versus [I] and IC50 values for complexes 1, 16, 18 and 19
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7.7 Conclusion 
This chapter presents a range of biological experiments and assays on complexes 1, 
16, 18 and 19; to determine the activities of these complexes and to assess their 
potential for further in vivo testing. The initial hydrolysis and hydrophobicity 
studies were inconclusive as to the mode of action into the cell and future work 
needs to be carried out on the possible entry into a cell. 
As previous research had stated such compounds to interact with DNA, single cell 
gel electrophoresis was conducted to assess interactions with complexes on double 
strand (DSB), single strand (SSB) and cross-linking samples. It was found that the 
active -ketoiminate complexes 1 and 18 show preferential single strand damage 
but no double strand or cross-linking, whereas the inactive -diketonate complexes 
show no interactions with DNA. 
Assays were carried out to assess the nature of the cytotoxicity values measure in 
Chapters 4 and 5, to determine if these IC50 values were due to cell death or cell 
inhibition. Firstly, apoptosis studies were carried out and showed the same trends 
seen in other assays, in which the -ketoiminate complexes are able to induce cell 
death in both HT-29 and A2780 cells. Therefore, no cell cycling studies were 
required and the cytotoxicity values obtained were considered to be due to cell 
death and not inhibition. 
As thioredoxin reductase is known to be over expressed in cancers, studies were 
carried out to assess the potential of these complexes to inhibit this enzyme. 
Results show that indeed the active -ketoiminate complexes inhibit this enzyme 
well, with IC50 values in the nanomolar range, and the most promising activity seen 
for the iridium complex 18. As thought, the inactive -diketonate complexes do not 
inhibit the TrxR enzyme to the same extent and are only active in the micromolar 
range. 
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8 Synthesis and Characterisation of -Diketonate and -
Ketoiminate Group IV Chloride Complexes  
After the success of budotitane described in Chapter 1, modified analogues have 
been synthesised within the McGowan group.
1-3
 Attempts have been made to 
synthesise novel group IV chloride complexes with incorporation of both the novel 
-diketonate and -ketoiminate ligands described in Chapter 2. 1H and 13C{1H} 
NMR spectroscopy, mass spectrometry and X-ray crystallographic analysis have 
been described where possible. Due to the air sensitive nature of these complexes 
bulk purification has not been possible to date. 
 
8.1 Mechanistic and Cytotoxicity Evaluation for -Diketonate Group 
IV Chloride Complexes 
A range of complexes have previously been reported within the McGowan group, 
where a small range was selected and tested for their cytotoxic potential. The 
titanium, zirconium and hafnium complexes were synthesised according to Scheme 
8.1 (1a). The para-fluoro and para-methyl -diketonate complexes were selected 
for each metal, allowing comparisons to be made between the electronic effects and 
the cytotoxic behaviour down the group. Two symmetrical complexes (e and h), 
were also synthesised in order to limit the possible isomers. In addition a 
symmetrical tris -diketonate hafnium complex (i) was synthesised according to 
Scheme 8.1 (1b), in order to assess the need for the cis-chlorides and to increase 
the sterics of the complex.
4
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Scheme 8.1 Synthetic pathway for Ti, Zr and Hf (IV) -diketonate complexes 
 
Budotitane contains two asymmetric -diketonate ligands and it has been 
postulated that different isomers of budotitane may exhibit different in vitro 
activities.
5, 6
 It has been shown within the McGowan research group that complexes 
which contain asymmetric functionalised -diketonates, show 1H NMR spectra 
comprised of a series of broad peaks at room temperature (Figure 8.1). 
1
H NMR 
spectra were recorded by Dr. James Mannion and upon cooling the samples from 
333 K to 233 K, the broad signals separate into multiple peaks which were assigned 
as the three cis isomers.
1
 This phenomenon is similar to that observed for the 
budotitane series of complexes in which they see the same three cis isomers.
7
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Figure 8.1 Possible cis isomers for the structure L2TiX2 (L = -diketonate, X = 
halide) and the 
1
H NMR spectra from 333 K-233 K (CDCl3, 300 MHz) 
 
In order to restrict the number of isomers, the symmetrical titanium -diketonate 
complexes A and B were synthesised to evaluate the nature of the 
exchange/fluxional process. These were both synthesised and the 
1
H NMR spectra 
recorded by Dr. Andrew Hebden. Approximately equal molar amounts of A and B 
were dissolved in deuterated chloroform and an initial proton spectrum was 
recorded at 300K. This showed two distinct sharp signals at 6.16 ppm and 6.01 
ppm respectively, corresponding to the -diketonate methine protons of both 
species. Another 
1
H NMR spectrum at 300K was recorded after eight hours and 
showed four separate signals in the same region. Two signals can be identified as 
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the original molecules A and B and the additional peaks for the ligand exchange 
product C (Scheme 8.2). The same experiment was carried out with complex B and 
free heptane-3,5-dione ligand, when followed using 
1
H NMR the same exchange 
species was observed. It has been previously reported that zirconium compounds 
with higher coordination numbers of -diketonate ligand also show an exchange 
process.
8 
The hexa coordinate -diketonate complexes have shown fluxionality but 
we report that these group IV complexes show an exchange process.
2
 
 
Scheme 8.2 Ligand exchange for symmetrical -diketonate titanium (IV) 
compounds 
 
The complexes a-i shown in Scheme 8.1 and cisplatin were tested using the MTT 
assay stated in Chapter 4, using a 5-day incubation period at 37°C in a 5.0% CO2 at 
atmosphere. The IC50 (M) ± SD values are shown in Table 8.1 and also 
summarised as a bar-chart in Figure 8.2, complexes were tested against both HT-
29 (human colon adenocarcinoma) and MCF-7 (human breast adenocarcinoma). 
Against HT-29 there is general trend seen in the cytotoxcity of the asymmetric 
complexes, with Hf > Zr > Ti. However, against MCF-7 asymmetric complexes of 
Ti and Zr do not show a particular trend, with the asymmetric Hf compounds all 
showing an increase in cytotoxicity when compared to both Ti and Zr. Symmetrical 
complexes e, h and i are comparable with cisplatin against both cell lines showing 
these symmetrical complexes to have superior cytotoxicity when compared to the 
asymmetric. An interesting result was seen for the symmetrical zirconium complex 
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e which has up to a 35-fold increase in its cytotoxicity when compared to c, against 
MCF-7. The tris diphenyl -diketonate hafnium complex i is the most promising 
drug candidate of this library with high cytotoxicity values against both cell lines, 
with an IC50 value of 4.9 ± 0.9 M (cisplatin, 2.4 ± 0.1 M) against the HT-29 cell 
line and 3.2 ± 0.3 M (cisplatin 1.1± 0.08 M) against MCF-7. These results are in 
contrast to the in vivo results reported for the seven coordinate Hf complexes 
measured previously, which are only active in higher doses compared to the six 
coordinate counterparts.
9 
Our work also shows it is not essential to have two labile 
chloride ancillary ligands to gain high in vitro activity, suggesting these complexes 
may act via a different in vitro pathway to that of cisplatin. 
 
Table 8.1 IC50 values for cisplatin and complexes a-i against HT-29 and MCF-7 
Complexes 
HT-29 MCF-7 
IC50 (M) ±SD IC50 (M) ±SD 
Cisplatin 2.4 0.1 1.09 0.08 
a 58 2 47 3 
b 47 3 35 2 
c 74 4 109 2 
d 84 4 57 2 
e 12.2 0.1 3.1 0.2 
f 30.2 0.8 28.9 0.4 
g 12 2 27 1 
h 7.4 0.5 3.3 0.1 
i 4.9 0.9 3.2 0.3 
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Figure 8.2 IC50 values for cisplatin and complexes a-i against HT-29 and MCF-7 
 
8.2 Attempted Synthesis of -Diketonate Titanium (IV) Halide 
Complexes 
Complexes were attempted to extend the library of complexes synthesised 
previously within the group. Synthesis was carried out according to Scheme 8.3, 
where two equivalents of the substituted -diketonate ligand was added to one 
equivalent of titanium tetrahalide and stirred at room temperature in a relevant 
solvent. 
 
Scheme 8.3 Synthetic Pathway of -Diketonate Titanium(IV) Complexes 
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Complexations have been attempted with the ligands L1-L10, however only crude 
1
H NMR data has been obtained. Several of the NMR spectra show a shift in peaks 
for the methine CH, which suggests complexation. However, further analysis and 
bulk purification has proven unsuccessful for this library and further attempts to 
synthesise would include the use of a base in the hope to drive the reaction to 
completion. 
 
8.3 -Diketonate Titanium(IV) Isopropoxide Complexes 
The synthesis of these complexes were attempted according to Scheme 8.4, where 
two equivalents of the substituted -diketonate was added to one equivalent of 
titanium isoproxide and stirred at room temperature in tetrahydrofuran. 
 
Scheme 8.4 Synthetic pathway for titanium (IV) isopropoxide -diketonate 
complexes 
 
Complexations were attempting using ligands L1-L10, however only one product 
was obtained from this reaction, this complex was quickly oxidised and X-ray data 
shows a solvent bridged dimer. Re-synthesis of this complex and similar 
modifications has since proven unsuccessful. 
 
8.3.1 1H NMR Data for Ti2(C28H20N2O4)(OCH3)6 (20) 
The crude
 1
H NMR data were obtained for complex 20 (Figure 8.3), shows the 
complex with free ligand L5 and clear shifts can be seen in ppm values and notable 
new peaks seen for the bridging methanol groups at approximately 1.0 ppm 
(Figure 8.4). However, the crystals disintegrated upon analyses before bulk 
purification was obtained. 
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Figure 8.3 Structure of complex 20 
9 8 7 6 5 4 3 2 1
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Figure 8.4 
1
H NMR data for complex 20 and unreacted ligand L5 (CDCl3, 300 
MHz, 300K) 
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8.3.2 X-ray Crystallography of Ti2(C28H20N2O4)(OCH3)6 (20) 
Yellow crystals of 20 suitable for X-ray crystallographic analysis were obtained 
from methanol at -20°C, over a period of 2 weeks. The molecular structure is given 
in Figure 8.5, selected bond lengths and angles are stated in Table 8.2. This 
compound crystallised in a monoclinic cell and structural solution was performed 
in the space group P21/c, with half a molecule in the asymmetric unit. 
 
Figure 8.5 Molecular structure of 20. Displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 8.2 Selected bond lengths and angles for 20 
Bond Distance (Å) Bond Angle (˚) 
Ti(1)-O(1) 2.0389(11) O(1)-Ti(1)-O(2) 82.12(5) 
Ti(1)-O(2) 2.0695(12) O(1)-Ti(1)-O(3) 167.65(5) 
Ti(1)-O(3) 1.8077(13) O(1)-Ti(1)-O(4) 87.08(6) 
Ti(1)-O(4) 1.8114(13) O(1)-Ti(1)-O(5) 88.18(5) 
Ti(1)-O(5) 1.9906(11) O(2)-Ti(1)-O(3) 86.01(5) 
O(1)-(C6) 1.2726(19) O(2)-Ti(1)-O(4) 99.42(6) 
C(6)-C(7) 1.411(2) O(2)-Ti(1)-O(5) 90.11(5) 
C(7)-C(8) 1.392(2) O(3)-Ti(1)-O(4) 98.28(6) 
C(8)-O(2) 1.2887(19) O(3)-Ti(1)-O(5) 102.33(5) 
  O(4)-Ti(1)-O(5) 95.13(5) 
  Ti(1)-O(5)-Ti(1)
(a)
 106.31(5) 
  O(5)-Ti(1)-O(5)
(a)
 73.69(5) 
Symmetry related atoms (a) 1-x, -y, 1-z 
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The packing diagrams of 20 when viewed along the c axis shows the molecules 
pack in pairs of molecules with C-H…Cg interactions between each plane. 
Intramolecular interactions and seen between C(7)-H(7)....N(1), C(15)-
C(15B)....O(1) and C(16)-C(16A)....O(2), and two intermolecular interactions 
between C(11)-H(11)....O(4) and C(16)-H(16C)...Cg(2). The packing diagrams are 
shown in Figure 8.6, with D...A distances and torsion angles stated in Table 8.3. A 
similar complex was obtained within the McGowan research group when reacting 
Ti(iOPr)4 with two equivalents of a picolinamide ligand.
10
 These structures are 
similar to those by Johnson et al., which were used for heterogeneous titanium-
centred epoxidation catalysts.
11
 
  
Intramolecular interactions 
Intermolecular interactions along the c 
axis 
Figure 8.6 Packing diagram of 20 when viewed along the c axis 
Table 8.3 Bond lengths and torsion angles for 20 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(7)-H(7)...N(1) 2.871(3) Å 
 C(15)-C(15B)...O(1) 3.155(3) Å 
 C(16)-H(16A)...O(2) 3.104(3) Å 
Intermolecular Cg(2)...Cg(4) 2.9723 Å 
 C(11)-H(11)...O(4) 3.348(3) Å 
 C(16)-H(16C)...Cg(3) 3.683 Å 
Torsion Cg(1)...Cg(2) 10.03˚ 
 Cg(2)...Cg(3) 5.81˚ 
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8.4 -Ketoiminate Titanium(IV) Chloride Complexes 
The-ketoiminate titanium (IV) chloride complexes were synthesised according to 
Scheme 8.5, where two equivalents of the substituted -ketoiminate ligand and two 
equivalents of base were added to one equivalent of titanium tetrachloride and 
stirred at room temperature in a relevant solvent. 
 
Scheme 8.5 Synthetic Route for -Ketoiminate Titanium(IV) Chloride Complexes 
 
Figure 8.7 List of -ketoiminate titanium (IV) complexes synthesised in this 
chapter 
 
Complexes 21-26 (Figure 8.7) were synthesised and characterised by the author, 
with full experimental data is described in Chapter 9. Limited analysis has been 
obtained for these complexes due to their extreme air sensitivity, however where 
possible complexes have been characterised by 
1
H NMR, 
1
H-
1
H COSY, 
13
C{
1
H}NMR, 
1
H-
13
C{
1
H} HMQC spectroscopy and mass spectrometry. In 
addition X-ray crystallographic data have been obtained for complexes 21-25. 
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8.5 NMR Data for Titanium(IV) Chloride Complexes 
The
 1
H NMR has been obtained for complexes 22 and 24-27 using either 
deuterated chloroform or acetonitrile. A general structure is shown in Figure 8.8 
and an example for complex 25 shown in Figure 8.9. All spectra show a shift in 
proton peak for the methine CH g at approximately 6.0 ppm. The aromatic protons 
b-d and j-l all appear in the same region between 6.5-8.0 ppm and the methyl 
protons e between 1.5-2.0 ppm. The NH from the free -ketoiminate is usually 
seen at approximately 12-13 ppm disappears upon complexation. 
 
Figure 8.8 General structure of a -ketoiminate titanium chloride complex 
12 11 10 9 8 7 6 5 4 3 2 1
Chemical Shift (ppm)
Complex C25
Ligand L21
 
Figure 8.9 
1
H NMR spectra for complex 25 and free ligand L21 (CDCl3, 300 
MHz, 300K) 
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When analysing the 
13
C{
1
H} NMR spectra for the -ketoiminate titanium 
complexes, they have similar trends with the highest shifts seen for the quaternary 
carbons f and h which are typically in the range 170-190 ppm. All of the CH peaks 
for the -ketoiminate ligand are in the range 100-150 ppm. The methine CH g from 
the -ketoiminate ligand is typically seen at 93-95 ppm and the lowest chemical 
shifts between 18-31 ppm for the methyl carbon e. 
 
8.6 X-ray Crystallography for Titanium(IV) Chloride Complexes 
Crystals were obtained from either acetonitrile or dichloromethane solutions stored 
at -20°C, appearing as yellow-red single crystals. X-ray crystallographic data was 
analysed for complexes 21-25. Solutions were performed in either a monoclinic 
(21, 22, 24 and 25) or a trigonal (23) space groups. All of the angles around the 
metal centre show the geometry expected for an octahedral compound which is 
common for these bis chelating ligand structures. The angles between the N-Ti-O, 
N-Ti-Cl and O-Ti-Cl are expected to be 90° and complexes here show angles 
ranging between 85-97°. The smaller angles can be explained due to the 
restrictions caused by the bidentate ligand. The other coordination sites are 
occupied by the chloride ligands and have a Cl-Ti-Cl angle of 94-97° and it appears 
that these complexes prefer a cis-trans-cis geometry, with the chlorides in a cis 
arrangement. 
 
8.6.1 X-Ray Characterisation for Ti(C32H26F2N2O2)Cl2 (21) 
Yellow crystals of 21 suitable for X-ray crystallographic analysis were obtained 
from DCM at room temperature, over a period of 3 days. The molecular structure is 
given in Figure 8.10 with selected bond lengths and angles are stated in Table 8.4. 
Complex 20 crystallised in a monoclinic cell and structural solution was performed 
in the space group C2/c, with half a molecule in the asymmetric unit and has a cis-
trans-cis geometry. 
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Figure 8.10 Molecular structure of 21, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity. 
Table 8.4 Selected bond lengths and bond angles for 21 
Bond Distance (Å) Bond Angle (˚) 
Ti(1)-Cl(1) 2.3385(4) Cl(1)-Ti(1)-N(1) 88.67(3) 
Ti(1)-N(1) 2.2090(10) Cl(1)-Ti(1)-O(1) 95.84(3) 
Ti(1)-O(1) 1.8824(8) N(1)-Ti(1)-O(1) 81.54(4) 
C(1)-N(1) 1.4561(14) Cl(1)-Ti(1)-Cl(1)
(a)
 96.01(2) 
N(1)-C(8) 1.3330(15) Ti(1)-N(1)-C(1) 115.55(7) 
C(7)-C(8) 1.5303(18) Ti(1)-N(1)-C(8) 127.47(8) 
C(8)-C(9) 1.4502(16) C(1)-N(1)-C(8) 116.93(10) 
C(9)-C(10) 1.3772(17) N(1)-C(8)-C(9) 122.88(11) 
O(1)-C(10) 1.3259(13) C(8)-C(9)-C(10) 124.37(11) 
C(10)-C(11) 1.4987(15) C(9)-C(10)-O(1) 120.46(10) 
  Ti(1)-O(1)-C(10) 142.06(8) 
  O(1)-C(10)-C(11)  114.10(10) 
Symmetry related atoms (a) -x, +y, 1/2-z 
 
The packing diagrams show that when viewed in the b-c and a-b planes shows the 
molecules packing in pairs with a slight herringbone arrangement. There is an 
intramolecular hydrogen bonding interactions between C(16)-H(16)....O(1), and a 
suggested π-π stacking interaction between Cg(3)-Cg(3) of 3.5412(9) Å. The 
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interactions and packing diagrams are presented in Figure 8.11, with D…A 
distances and torsion angles stated in Table 8.5. 
 
 
π-π stacking between Cg(3)…Cg(3) Packing along the c axis 
 
 
Packing along the b-c plane Packing along the a-b plane 
Figure 8.11 Interactions and packing diagrams for 21 
Table 8.5 Bond lengths and torsion angles for 21 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(16)-H(16)...O(1) 2.7011(16) Å 
Intermolecular Cg(3)...Cg(3) 3.5412 Å 
Torsion Cg(1)...Cg(2) 71.81˚ 
 Cg(2)...Cg(3) 1.83˚ 
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8.6.2 X-Ray Characterisation for Ti(C32H26Cl2N2O2)Cl2 (22) 
Yellow crystals of 22 suitable for X-ray crystallographic analysis were obtained 
from DCM at room temperature, over a period of several days. The molecular 
structure is given in Figure 8.10, selected bond lengths and angles are stated in 
Table 8.4. Complex 22 crystallised in a monoclinic cell and structural solution was 
performed in the space group P21/n, with one molecule in the asymmetric unit and 
two molecules of acetonitrile, and a cis-trans-cis geometry. 
 
Figure 8.12 Molecular structure of 22, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms and solvent molecules are omitted for clarity 
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Table 8.6 Selected bond lengths and angles for 22 
Bond Distance (Å) Bond Angle (˚) 
Ti(1)-Cl(1) 2.3364(8) Cl(1)-Ti(1)-Cl(2) 95.93(3) 
Ti(1)-Cl(2) 2.3161(8) Cl(1)-Ti(1)-N(1) 87.13(6) 
Ti(1)-N(1) 2.153(2) Cl(1)-Ti(1)-O(1) 93.55(6) 
Ti(1)-N(2) 2.149(2) Cl(1)-Ti(1)-N(2) 172.01(6) 
Ti(1)-O(1) 1.8881(17) Cl(1)-Ti(1)-O(2) 92.18(6) 
Ti(1)-O(2) 1.8698(17) Cl(2)-Ti(1)-N(1) 174.39(6) 
N(1)-C(8) 1.317(3) Cl(2)-Ti(1)-O(1) 92.63(6) 
C(8)-C(9) 1.423(4) Cl(2)-Ti(1)-N(2) 90.63(6) 
C(9)-C(10) 1.363(4) Cl(2)-Ti(1)-O(2) 94.54(6) 
C(10)-O(1) 1.316(3) O(1)-Ti(1)-O(2) 170.31(8) 
N(2)-C(28) 1.324(3) O(1)-Ti(1)-N(1) 82.47(8) 
C(28)-C(29) 1.424(4) O(1)-Ti(1)-N(2) 90.68(8) 
C(29)-C(30) 1.362(4) O(2)-Ti(1)-N(1) 90.03(8) 
C(30)-O(2) 1.320(3) O(2)-Ti(1)-O(1) 82.74(8) 
C(14)-Cl(3) 1.732(3) N(1)-Ti(1)-N(2) 86.72(8) 
C(34)-Cl(4) 1.739(3)   
 
When viewed along the c axis the molecules pack in a head-tail...tail-head 
arrangement with a slight herringbone structure. There is one intramolecular 
hydrogen bonding interaction between C(36)-H(36)...O(2) and several 
intermolecular interactions contributing to the packing of these molecules. The 
interactions and packing diagrams are presented in Figure 8.13, with D…A 
distances and torsion angles stated in Table 8.7. 
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Packing along the b axis Packing along the c axis 
Figure 8.13 Packing diagram for 22 
Table 8.7 Bond lengths and torsion angles for 22 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(36)-H(36)...O(2) 3.471(3) Å 
Intermolecular Cg(1)...Cg(5) 3.6996 Å 
 C(7)-H(7A)...Cg(3) 3.463 Å 
 C(27)-H(27C)...Cg(3) 3.573 Å 
 C(14)-Cl(3)...Cg(6) 5.174 Å 
 C(4)-H(4)...Cl(3) 3.471(3) Å 
 C(39)-H(39B)...Cl(1) 3.554(3) Å 
Torsion Cg(1)...Cg(2) 82.97˚ 
 Cg(2)...Cg(3) 27.61˚ 
 Cg(4)...Cg(5) 70.41˚ 
 Cg(5)...Cg(6) 7.15˚ 
 
8.6.3 X-ray Crystallography for Ti(C32H26F2N2O2)Cl2 (23) 
Orange crystals of 23 suitable for X-ray crystallographic analysis were obtained 
from DCM at -20˚C, over a period of several weeks. The molecular structure is 
given in Figure 8.14, selected bond lengths and angles are stated in Table 8.8. This 
compound crystallised in a trigonal cell and structural solution was performed in 
the space group R-3, with a third molecule in the asymmetric unit. This complex 
oxidised on exposure to air and is an oxygen bridged trimer (Figure 8.15), instead 
of the expected cis-chloride monomer. 
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Figure 8.14 Asymmetric unit of 23, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms and other molecules are omitted for clarity 
 
Figure 8.15 Molecular structure of the oxygen bridged trimer, ellipsoids and 
hydrogens omitted for clarity. 
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Table 8.8 Selected bond lengths and angles for 23 
Bond Distance (Å) Bond Angle (˚) 
Ti(1)-O(3) 1.833(2) O(3)-Ti(1)-O(1) 96.18(9) 
Ti(1)-O(3)
(a)
 1.854(3) O(3)-Ti(1)-O(2) 96.70(9) 
Ti(1)-N(1) 2.310(3) O(3)-Ti(1)-N(1) 175.60(10) 
Ti(1)-O(1) 1.949(2) O(3)-Ti(1)-N(2) 89.60(10) 
Ti(1)-N(2) 2.308(3) O(3)-Ti(1)-O(3)
(a)
 96.87(11) 
Ti(1)-O(2) 1.938(2) O(1)-Ti(1)-O(2) 160.34(12) 
N(1)-C(8) 1.322(5) O(1)-Ti(1)-N(1) 80.71(9) 
C(8)-C(9) 1.444(5) O(1)-Ti(1)-N(2) 84.25(10) 
C(9)-C(10) 1.380(6) O(1)-Ti(1)-O(3)
(a)
 96.30(9) 
C(10)-O(1) 1.316(5) O(2)-Ti(1)-N(1) 85.54(9) 
N(2)-C(28) 1.469(4) O(2)-Ti(1)-N(2) 81.04(10) 
C(28)-C(29) 1.443(5) O(2)-Ti(1)-O(3)
(a)
 96.84(9) 
C(29)-C(30) 1.388(6) N(1)-Ti(1)-N(2) 87.00(10) 
C(30)-O(2) 1.315(5) N(1)-Ti(1)-O(3)
(a)
 86.60(11) 
C(14)-F(1) 1.391(4) N(2)-Ti(1)-O(3)
(a)
 173.40(11) 
C(34)-F(2) 1.382(4)   
Symmetry related atoms (a) 1-y, x-y, z 
 
The packing diagram when viewed along the c axis shows the molecules pack in a 
circular arrangement with the symmetry generated oxygen atom forming a cavity in 
the centre. A space filling diagram is shown along this axis and shows that this 
space is not large enough to be a void. Intramolecular interactions are seen between 
C-H…O of both -ketoiminate ligands and several intermolecular π-π and X…Cg 
interactions which contribute to the packing of these molecules. The interactions 
and packing diagrams are presented in Figure 8.16, with D…A distances and 
torsion angles stated in Table 8.9. These types of oxygen bridged complexes have 
been shown within the McGowan group when reacting TiCl4 with two equivalents 
of a picolinamide ligand.
10
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Intramolecular interactions 
  
Packing along the c axis Space filling diagram 
Figure 8.16 Intramolecular interactions and packing diagrams of 23 
Table 8.9 Bond lengths and torsion angles for 23 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(16)-H(16)...O(1) 2.741(4) Ǻ 
 C(36)-H(36)...O(2) 2.728(4) Ǻ 
Intermolecular Cg(2)...Cg(5) 3.3429 Ǻ 
 Cg(3)...Cg(4) 3.936 Ǻ 
 C(15)-H(15)-Cg(3) 3.583 Ǻ 
Torsion Cg(1)...Cg(2) 76.01° 
 Cg(2)...Cg(3) 16.40° 
 Cg(4)...Cg(5) 70.82° 
 Cg(5)...Cg(6) 7.52° 
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8.6.4 X-ray Crystallography for Ti(C34H32N2O2)Cl2 (24) 
Orange crystals of 24 suitable for X-ray crystallographic analysis were obtained 
from acetonitrile at -20˚C, over a period of several weeks. The molecular structure 
is given in Figure 8.17, selected bond lengths and angles are stated in Table 8.10. 
This compound crystallised in a monoclinic cell and structural solution was 
performed in the space group P21/n, with a one molecule and two molecules of 
acetonitrile in the asymmetric unit, and a cis-trans-cis geometry. 
 
Figure 8.17 Molecular structure of 24, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms and other molecules are omitted for clarity. 
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Table 8.10 Selected bond lengths and angles for 24 
Bond Distance (Å) Bond Angle (˚) 
Ti(1)-Cl(1) 2.3447(7) Cl(1)-Ti(1)-Cl(2) 95.28(3) 
Ti(1)-Cl(2) 2.3251(8) Cl(1)-Ti(1)-N(1) 87.20(5) 
Ti(1)-N(1) 2.1450(18) Cl(1)-Ti(1)-O(1) 93.39(5) 
Ti(1)-N(2) 2.1543(18) Cl(1)-Ti(1)-N(2) 172.62(5) 
Ti(1)-O(1) 1.8904(13) Cl(1)-Ti(1)-O(2) 92.52(5) 
Ti(1)-O(2) 1.8695(13) Cl(2)-Ti(1)-N(1) 175.09(5) 
N(1)-C(8) 1.327(3) Cl(2)-Ti(1)-O(1) 92.88(5) 
C(8)-C(9) 1.423(3) Cl(2)-Ti(1)-N(2) 90.72(5) 
C(9)-C(10) 1.355(3) Cl(2)-Ti(1)-O(2) 94.35(5) 
C(10)-O(1) 1.325(3) O(1)-Ti(1)-O(2) 170.20(7) 
N(2)-C(28) 1.325(2) O(1)-Ti(1)-N(1) 82.73(6) 
C(28)-C(29) 1.425(3) O(1)-Ti(1)-N(2) 90.59(6) 
C(29)-C(30) 1.366(3) O(2)-Ti(1)-N(1) 89.76(6) 
C(30)-O(2) 1.323(2) O(2)-Ti(1)-O(1) 82.72(6) 
C(14)-C(17) 1.503(3) N(1)-Ti(1)-N(2) 87.14(7) 
C(34)-Cl(37) 1.505(3)   
 
When viewed along the c axis, the molecules pack in pairs with C-H…Cg 
interactions between each pair. There are also X…C-H interactions seen with the 
acetonitrile solvent molecules. Unlike complex 23, this molecule shows a C-H…O 
hydrogen bonding in just one -ketoiminate ligands as the other ligand has a larger 
torsion angle between the planar centre and the aromatic ring. There are several 
intermolecular interactions contributing to the packing of these molecules. The 
interactions and packing diagrams are presented in Figure 8.18, with D…A 
distances and torsion angles stated in Table 8.11. 
Group IV Complexes  Chapter 8 
193 
 
 
Intramolecular interactions 
Intermolecular interactions along the 
c axis 
Figure 8.18 Intramolecular interaction and packing diagram for 24 
Table 8.11 Bond lengths and torsion angles for 24 
Interaction Atoms Bond Lengths and Angles 
Intramolecular C(36)-H(36)-O(2) 2.749(2) Ǻ 
Intermolecular Cg(1)...Cg(5) 3.7132 Ǻ 
 C(7)-H(7C)-Cg(3) 3.429 Ǻ 
 C(27)-H(27A)-Cg(3) 3.547 Ǻ 
 C(41)-H(41B)-Cl(1) 3.588(3) Ǻ 
Torsion Cg(1)...Cg(2) 84.58˚ 
 Cg(2)...Cg(3) 28.39˚ 
 Cg(4)...Cg(5) 69.26˚ 
 Cg(5)...Cg(6) 7.67˚ 
 
8.6.5 X-ray Crystallography for Ti(C36H36N2O2)Cl2 (25) 
Orange crystals of 25 suitable for X-ray crystallographic analysis were obtained 
from acetonitrile at -20˚C, over a period of several weeks. The molecular structure 
is given in Figure 8.19, selected bond lengths and angles are stated in Table 8.12. 
This compound crystallised in a monoclinic cell and structural solution was 
performed in the space group C2/c, with a half a molecule in the asymmetric unit, 
and a cis-trans-cis geometry. 
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Figure 8.19 Molecular structure of 25, displacement ellipsoids are at the 50% 
probability level and hydrogen atoms are omitted for clarity 
Table 8.12 Selected bond lengths and angles for 25 
Bond Distance (Å) Bond Angle (˚) 
Ti(1)-Cl(1) 2.3238(7) Cl(1)-Ti(1)-Cl(1)
(a)
 96.42(4) 
Ti(1)-N(1) 2.1710(15) Cl(1)-Ti(1)-N(1) 170.63(6) 
Ti(1)-O(1) 1.8673(18) Cl(1)-Ti(1)-O(1) 91.15(5) 
N(1)-C(8) 1.319(3) Cl(1)-Ti(1)-N(1)
(a)
 90.23(5) 
C(8)-C(9) 1.437(3) Cl(1)-Ti(1)-O(1)
(a)
 95.58(5) 
C(9)-C(10) 1.362(2) Cl(1)
(a)
-Ti(1)-N(1) 90.23(5) 
C(10)-O(1) 1.319(3) Cl(1)
(a)
-Ti(1)-O(1)
 
95.58(5) 
C(14)-C(17) 1.512(3) Cl(1)
(a)
-Ti(1)-N(1)
(a)
 170.63(6) 
  Cl(1)
(a)
-Ti(1)-O(1)
(a)
 91.15(5) 
  O(1)-Ti(1)-O(1)
(a)
 169.91(6) 
  O(1)-Ti(1)-N(1) 81.61(7) 
  O(1)-Ti(1)-N(1)
(a)
 90.87(7) 
  O(1)
(a)
-Ti(1)-N(1) 90.87(7) 
  O(1)
(a)
-Ti(1)-N(1)
(a)
 81.61(7) 
  N(1)-Ti(1)-N(1)
(a)
 83.97(6) 
Symmetry related atoms (a) 1-x, y, ½-z 
 
  
Group IV Complexes  Chapter 8 
195 
When viewed along the a axis the molecules pack head-tail and then alternate in 
the next row, giving a herringbone arrangement. When viewed along the c axis the 
molecules pack in pairs, with the two cis-chloride ligands pointing away from the 
metal centre, allowing the aromatic groups to pack in close proximity. However, 
distances between these aromatics are too large to be considered as π-π stacking 
interactions. The packing diagrams are shown in Figure 8.20, with D…A distances 
and torsion angles stated in Table 8.13. 
 
 
Packing diagram along the a axis Packing diagram along the c axis 
Figure 8.20 Packing diagrams along the a and c axes for 25 
Table 8.13 Bond lengths and torsion angles for 25 
Interaction Atoms 
Bond Lengths and 
Angles 
Intermolecular Cg(1)-Cg(3) 3.6228 Ǻ 
Torsion Cg(3)-Cg(1) 81.83° 
 Cg(1)-Cg(4) 19.87° 
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8.7 Conclusions and Future Work 
This chapter presents the mechanistic and cytotoxicity results for a library of group 
IV complexes. These results have been obtained as part of the McGowan research 
group, in which the author obtained the cytotoxicity results.
4
 Secondly, this chapter 
presents the initial synthesis of both -diketonate and -ketoiminate titanium 
complexes, where X-ray crystallographic data have been obtained for complexes 
21-25. Bond angles for these complexes show an octahedral geometry, with a 
preference for the cis-trans-cis geometry. Initial results have been obtained, 
however full analysis has not been possible due to issues with air sensitivity and 
the samples were easily oxidised. 
Future work for this chapter would be work on bulk purification and attempts to 
optimise the reaction by trying a wider range of solvents and bases. These 
complexes would also be tested for their mechanistic and cytotoxic potential in 
order to compare with the previously synthesised -diketonate complexes. It was 
hoped that like the ruthenium complexes stated in Chapter 3, these complexes 
incorporating a -ketoiminate ligand could help to increase the cytotoxic potential 
of the group IV metals. However, these complexes have shown to be extremely air 
sensitive and change oxidation state and structure on contact with air, restricting 
the cytotoxic studies that can be achieved. However, these types of redox active d
0
 
complexes have been used extensively in the literature for olefin polymerisation, 
giving these complexes a potential application for future work. 
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9 Experimental 
9.1 General Experimental Procedures 
All novel titanium complexes were synthesised using standard Schlenk line 
techniques, under an atmosphere of dry dinitrogen with a dual vacuum/dinitrogen 
line to perform the synthesis. All ruthenium complexes were synthesised under 
aerobic conditions. 
 
All chemicals were supplied by Sigma-Aldrich Chemical Co., Acros Organics, 
Strem Chemical Co. and BOC gases. Functionalised -diketonate and -
ketoiminate ligands were prepared by adaptations of literature methods.
1, 2
 
Deuterated NMR solvents were supplied by Sigma-Aldrich Chemical Co. or Acros 
Organics. 
 
9.2 Instrumentation 
All NMR spectra were recorded by either the author or Mr Simon Barrett on a 
Bruker DPX 300 or a Bruker DPX 500 spectrometer. Microanalyses were recorded 
by Mr. Ian Blakeley or Ms Tanya Marinko-Covell at the University of Leeds 
Microanalytical Service. Mass Spectra were recorded by Ms. Tanya Marinko-
Covell or Dr. Stuart Warriner on a Micromass ZMD spectrometer with electrospray 
ionisation and photoiodide array analyser at the University of Leeds Mass 
Spectrometry Service. 
 
9.3 X-Ray Crystallography 
X-ray diffraction data were collected by either the author, Dr. Stephanie Lucas, Dr. 
Andrea Rodríguez Bárzano, Mr. Felix Janeway, Dr. Andrew Hebden or Dr. Helena 
Shephard (University of Leeds, X-ray service). A suitable single crystal was 
selected and immersed in an inert oil. The crystal was then mounted on a glass 
capillary and attached to a goniometer head on a Bruker X8 Apex or an Agilent 
Supernova diffractometer using graphite monochromated Mo-K radiation ( = 
0.71073 Å) using 1.0° -rotation frames. The crystal was cooled to 100 K by an 
Oxford Cryostream low temperature device.
3
 The full data set was recorded and the 
images processed using DENZO and SCALEPACK programs.
4
 The structures 
were solved by either the author or Dr. Helena Shephard. 
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Structure solution by direct methods was achieved through the use of SHELXS86,
5
 
SIR92
6
 or SIR97
7
 programs, and the structural model refined by full matrix least 
squares on F
2
 using SHELX97.
5
 Molecular graphics were plotted using POV-Ray
8
 
via the XSeed program. Editing of CIFs and construction of tables of bond lengths 
and angles were achieved using WC
9
 and PLATON.
10
 Unless otherwise stated, 
hydrogen atoms were placed using idealised geometric positions (with free rotation 
for methyl groups), allowed to move in a “riding model” along with the atoms to 
which they were attached, and refined isotropically. 
 
9.4 Syntheses of Functionalised -Diketonate Ligands 
Ligands L1-L4 have been synthesised according to a literature method
11
 and 
ligands L5-L10 were synthesised using a modified version of the synthetic route 
published by Levine et al.
1
 
9.4.1 Preparation of C14H18O2 (L1) 
Sodium ethoxide (0.60 g, 8.79 mmol) was added to ethyl acetate (40 mL) and 4-tert 
butylacetophenone (1.55 g, 8.79 mmol). The mixture was stirred and heated under 
reflux for 4 hours, then allowed to cool to room temperature. The solvent was 
removed under reduced pressure and washed with petrol (60-80˚C) (3 x 10 mL). 
The suspension was dissolved in ice cold water (40 mL) and ice cold sulfuric acid 
was added until just acidic to litmus. The crude product was extracted into diethyl 
ether (3 x 10 mL) and dried over Na2SO4. The solvent was removed under reduced 
pressure, yielding L1 as a pure yellow oil (0.94 g, 4.31 mmol, 49%). 
1
H NMR (CDCl3, 300.13 MHz, 293.6K) 16.23 (br. 
s, 1H, C-OH), 7.83 (dd, 2H, H6 and H10, 
3
J (
1
H-
1
H) = 
8.7 Hz and 
4
J (
1
H-
1
H) = 4.1 Hz), 7.47 (dd, 2H, H7 
and H9, 
3
J (
1
H-
1
H) = 8.7 Hz and
 4
J (
1
H-
1
H) = 4.0 Hz), 
6.17 (s, 1H, H3), 2.20 (s, 3H, H1), 1.35 (s, 9H, H12-14) 
13
C{
1
H} NMR (CDCl3, 75.5 MHz, 295.4 K) 193.3 (quaternary C-O, C2 or C4), 
183.5 (quaternary C-O, C2 or C4), 156.0 (aromatic quaternary C, C5), 132.0 
(aromatic quaternary C, C8), 126.9 (aromatic CH, C6 and C10), 125.6 (aromatic CH, 
C7 and C9), 96.4 (acac CH, C3), 35.1 (quaternary tert-butyl C, C11), 31.1 (t-butyl 
C(CH3)3, C12-14), 25.8 (aliphatic CH3, C1) Analysis Calculated: C 77.03, H 8.31% 
Analysis Found: C 77.05, H 8.35% ES MS (+): m/z 219.14 [MH
+
] 
OH O
1
2
3
4
5
6
7
8
9
10
11
12
13
14
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9.4.2 Preparation of C12H13FO3 (L2) 
Sodium ethoxide (4.34 g, 64.0 mmol) was added to ethyl acetate (60 mL) and 2,4-
difluoroacetophenone (5.04 g, 25.5 mmol). The mixture was stirred and heated 
under reflux for 3 hours and allowed to cool to room temperature. The suspension 
was dissolved in ice cold water (30 mL) and ice cold sulfuric acid was added until 
just acidic to litmus. The crude product was extracted into diethyl ether (3 x 10 
mL) and dried over MgSO4. The solvent was removed under reduced and 
recrystallised from hot ethanol (20 mL), filtered through glass wool and stored at -
20°C, yielding pale yellow crystals of L2 (4.01g, 17.9 mmol, 56%). The expected 
2,4-difluoro--diketonate ligand was not obtained and instead the ethoxide 
substitutes the para-fluoro substituent. 
1
H NMR (CDCl3, 300.13 MHz, 300.0K) 16.23 (br. s, 
1H, C-OH), 7.94 (dd, 1H, H10, 
3
J (
1
H-
1
H) = 8.7 and 
4
J (
1
H-
19
F) = 7.0 Hz), 6.73 (ddd, 1H, H9, 
3
J (
1
H-
1
H) = 8.9 Hz, 
 3
J 
(
1
H-
19
F) = 7.7 Hz and 
4
J (
1
H-
1
H) = 2.5 Hz), 6.65 (dd, 1H, 
H7, 
3
J (
1
H-
19
F) = 11.0 Hz and 
4
J (
1
H-
1
H) = 2.3 Hz), 6.52 
(br. s, 1H, H3), 4.12 (q, 2H, H11, 
3
J (
1
H-
1
H) = 7.0 Hz), 2.18 (s, 3H, H1), 1.52 (t, 3H, 
H12, 
3
J (
1
H-
1
H) = 7.0 Hz) 
13
C{
1
H} NMR (CDCl3, 125.9 MHz, 300.0 K) 194.2 
(quaternary C-O, C2 or C4), 180.3 (quaternary C-O, C2 or C4), 166.6 (d, aromatic 
quaternary C-F, C8, 
1
J (
13
C-
19
F) = 250.5 Hz), 159.5 (d, aromatic quaternary C, C6, 
3
J (
13
C-
19
F) = 10.3 Hz), 132.1 (d, aromatic CH, C10, 
3
J (
13
C-
19
F) = 11.3 Hz), 120.3 
(d, aromatic quaternary C, C5, 
5
J (
13
C-
19
F) = 3.1 Hz), 107.6 (d, aromatic CH, C9,
 
2
J(
13
C-
19
F) = 21.7 Hz), 101.5 (acac CH, C3), 100.3 (d, aromatic CH, C7, 
2
J(
13
C-
19
F) 
= 103.1 Hz), 64.7 (CH2, C11), 26.0 (CH3, C1), 14.5 (CH3, C12) Analysis 
Calculated: C 64.28, H 5.84% Analysis Found: C 64.30, H 5.90% ES MS (+): 
m/z 247.10 [MNa
+
] 
 
9.4.3 Preparation of C10H8F2O2 (L3) 
Sodium ethoxide (1.09 g, 16.0 mmol) was added to ethyl acetate (40 mL) and 2,5-
difluoroacetophenone (2.02 mL, 16.0 mmol). These were stirred and heated under 
reflux for 3 hours, then allowed to cool to room temperature. The solvent was 
removed under reduced pressure and washed with petrol (60-80˚C) (3 x 10 mL). 
The suspension was dissolved in ice cold water (40 mL) and ice cold sulfuric acid 
was added until just acidic to litmus. The crude product was extracted into diethyl 
OH O
1
2
3
4
5
6
7
8
9
10
11
12
O F
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ether (3 x 10 mL) and dried over MgSO4. Solvent was removed under reduced 
pressure and the residue recrystallised from hot EtOH (10 mL), yielding L3 as pure 
pale yellow crystals (1.90 g, 0.96 mmol, 60%). 
1
H NMR (CDCl3, 500.23 MHz, 299.9 K) 7.64 (ddd, 1H, 
H7 or H8, 
3
J (
1
H-
1
H) = 8.9 Hz 
3
J (
1
H-
19
F) = 5.7 Hz and 
4
J 
(
1
H-
19
F) = 3.2 Hz), 7.18-7.13 (m, 1H, H7 or H8), 7.13-7.08 
(m, 1H, H10), 6.30 (vd, 1H, H3, 
5
J (
1
H-
19
F) = 1.4 Hz), 2.23 
(br. s, 3H, H1 CH3) 
13
C{
1
H} NMR (CDCl3, 125.9 MHz, 
300.0 K) 195.5 (quaternary C-O, C2 or C4), 177.0 (d, quaternary C-O, C5, 
3
J (
13
C-
19
F) = 4.1 Hz), 158.8 (dd, aromatic quaternary C-F, C6 or C9, 
1
J (
13
C-
19
F) = 202.1 
Hz and 
4
J (
13
C-
19
F) = 2.1 Hz), 156.9 (dd, aromatic quaternary C-F, C6 or C9, 
1
J 
(
13
C-
19
F) = 210.3 Hz and 
4
J (
13
C-
19
F) = 2.1 Hz), 124.4 (dd, aromatic quaternary C, 
C5, 
2
J (
13
C-
19
F) = 12.4 Hz and 
3
J (
13
C-
19
F) = 7.2 Hz), 119.9 (dd, aromatic CH, C7 or 
C8, 
2
J (
13
C-
19
F) = 24.7 Hz and 
3
J (
13
C-
19
F) = 9.3 Hz), 117.8 (dd, aromatic CH C7 or 
C8, 
2
J (
13
C-
19
F) = 26.8 Hz and 
3
J (
13
C-
19
F) = 8.3 Hz), 116.2 (dd, aromatic CH, C10,
 
2
J (
13
C-
19
F) = 25.8 Hz and 
3
J (
13
C-
19
F) = 3.1 Hz), 101.5 (d, acac CH, C3, 
4
J (
13
C-
19
F) = 13.4 Hz), 26.1 (CH3, C1) Analysis Calculated: C 60.61, H 4.07% Analysis 
Found: C 60.55, H 4.00% ES MS (+): m/z 221.09 [MNa
+
] 
 
9.4.4 Preparation of C9H9NO2 (L4) 
Sodium ethoxide (1.74 g, 25.5 mmol) was added to ethyl acetate (40 mL) and 4’-
(imidazol-1-yl) acetophenone (5.04 g, 25.5 mmol). These were stirred and heated 
under reflux for 3 hours, then allowed to cool to room temperature. The suspension 
was dissolved in ice cold water (30 mL) and the aqueous layer collected then 
washed with diethyl ether (3 x 20 mL). Ice cold sulfuric acid was added until 
neutral to litmus. The crude product was extracted into diethyl ether (10 mL) and 
solid precipitated out on the first wash. This was filtered under reduced pressure 
and recrystallised by vapour diffusion in dichloromethane/pentane, yielding L4 as 
yellow crystals (3.77 g, 16.5 mmol, 62%). 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 8.02 
(dt, 2H, H7 and H9, 
3
J (
1
H-
1
H) = 8.7 Hz and 
4
J (
1
H-
1
H) = 2.4 Hz), 7.98 (br. s, 1H, H11), 7.50 (dt, 2H, 
H6 and H10, 
3
J (
1
H-
1
H) = 8.7 Hz and 
4
J (
1
H-
1
H) = 
2.4 Hz), 7.36 (br. s, 1H, H12 or H13, 
3
J (
1
H-
1
H) = 
OH O
1
2
3
4
5 6
7
8
9
10
F
F
OH O
1
2
3
4
5 6
7
8
9
N
N
10
11
12
13
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1.6 Hz), 7.26 (br. s, 1H, H12 or H13), 6.20 (s, 1H, H3), 2.24 (s, 3H, H1) 
13
C{
1
H} 
NMR (CDCl3, 125.8 MHz, 300.0 K) (quaternary C-O, C2 or C4), 181.9 
(quaternary C-O, C2 or C4), 140.2 (quaternary aromatic C, C8), 135.4 (imidazole 
CH, C11), 133.9 (quaternary aromatic C, C5), 131.10 (imidazole CH, C12 or C13), 
128.9 (aromatic CH, C6 and C10), 120.9 (aromatic CH, C7 and C9), 117.8 
(imidazole CH, C12 or C13), 96.8 (acac CH, C3), 25.9 (aliphatic CH3, C1) Analysis 
Calculated: C 68.41, H 5.30, N 12.27% Analysis Found: C 68.20, H 5.25, N 
12.15% ES MS (+): m/z 229.10 [MH
+
] 
 
9.4.5 Preparation of C14H11NO2 (L5) 
Sodium ethoxide (1.42 g, 20.8 mmol) was added to diethyl ether (40 mL), ethyl 2-
picolinate (2.81 mL, 20.8 mmol) and acetophenone (4.86 mL, 41.6 mmol). These 
were stirred and heated to reflux for 48 hours, then allowed to cool to room 
temperature. The suspension was stirred whilst adding acetic acid (1.19 mL, 20.8 
mmol) and water (20 mL). The crude product was extracted into diethyl ether (3 x 
20 mL) and dried over Na2SO4. The solvent was removed under reduced pressure 
and the residue recrystallised from hot methanol (20 mL), yielding L5 as colourless 
crystals (2.54 g, 11.3 mmol, 54%) 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 8.66-
8.62 (m, 1H, H1), 8.10 (br. d, 1H, H4, 
3
J (
1
H-
1
H) = 
7.9 Hz), 8.02-7.98 (br. dd, 2H, H10 and H14, 
3
J (
1
H-
1
H) = 7.2 Hz and 
4
J (
1
H-
1
H) = 1.2 Hz), 7.80 (td, 1H, 
H3, 
3
J (
1
H-
1
H) = 7.6 Hz and 
4
J (
1
H-
1
H) = 1.6 Hz), 7.52 (s, 1H, H7), 7.50-7.46 (br. tt, 
1H, H2,
 3
J (
1
H-
1
H) = 7.2 Hz and 
4
J (
1
H-
1
H) = 1.2 Hz), 7.44-7.40 (br. dd, 2H, H11 
and H13, 
3
J (
1
H-
1
H) = 7.6 Hz and 
4
J (
1
H-
1
H) = 1.5 Hz), 7.37 (ddd, 1H, H12, 
3
J (
1
H-
1
H) = 7.6 Hz and 
4
J (
1
H-
1
H) = 4.8 Hz) 
13
C{
1
H} NMR (CDCl3, 125.8 MHz, 300.0 
K) (quaternary C-O, C6 or C8), 183.7 (quaternary C-O, C6 or C8), 152.6 
(pyridine quaternary C, C5), 149.3 (pyridine CH, C1), 137.1 (pyridine CH, C3), 
135.3 (aromatic quaternary C, C9), 132.7 (pyridine CH, C2), 128.7 (aromatic CH, 
C10 and C14), 127.5 (aromatic CH, C11 and C13), 126.4 (pyridine CH, C4), 122.2 
(aromatic CH, C12), 93.6 (acac CH, C7) Analysis Calculated: C 74.65, H 4.92, N 
6.22% Analysis Found: C 74.80, H 4.85, N 6.05% ES MS (+): m/z 226.10 [MH
+
] 
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9.4.6 Preparation of C14H10BrNO2 (L6) 
Sodium ethoxide (1.08 g, 15.9 mmol) was added to diethyl ether (40 mL), ethyl 2-
picolinate (2.15 mL, 15.9 mmol) and 4-bromoacetophenone (6.31 g, 31.8 mmol). 
These were stirred and heated to reflux for 48 hours, then allowed to cool to room 
temperature. The suspension was stirred whilst adding acetic acid (0.91 mL, 15.9 
mmol) and water (40 mL). The crude product was extracted into diethyl ether (10 
mL) and product obtained from the aqueous layer. This was filtered under reduced 
pressure and washed with hexane, yielding L6 as a pure white precipitate (1.97 g, 
7.59 mmol, 48%). 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 8.73-
8.70 (m, 1H, H1), 8.17 (d, 1H, H4, 
3
J (
1
H-
1
H) = 8.0 
Hz), 7.94 (br. d, 2H, H10 and H14, 
3
J (
1
H-
1
H) = 8.8 
Hz), 7.88 (td, 1H, H3, 
3
J (
1
H-
1
H) = 8.0 Hz and 
4
J 
(
1
H-
1
H) = 2.0 Hz), 7.65-7.61 (br. dt, 2H, H11 and H13,
 3
J (
1
H-
1
H) = 8.3 Hz and 
4
J 
(
1
H-
1
H) = 2.4 Hz), 7.55 (s, 1H, H7 [enolate tautomer]), 7.46 (br. dd, 1H, H2, 
3
J (
1
H-
1
H) = 7.6 Hz and 
4
J (
1
H-
1
H) = 1.5 Hz), 4.79 (s, acac CH2, H7 [diketonate tautomer]) 
13
C{
1
H} NMR (CDCl3, 125.8 MHz, 300.2 K) (quaternary C=O [diketonate 
tautomer], C6 or C8), 184.9 (quaternary C-O [enolate tautomer], C6 or C8), 184.0 
(quaternary C-O [enolate tautomer], C6 or C8), 152.4 (pyridine quaternary C [both 
tautomers] C5), 149.3 (pyridine CH [both tautomers], C1), 137.1 (pyridine CH 
[both tautomers], C3), 134.2 (aromatic quaternary C [both tautomers], C9), 132.0 
(aromatic CH [both tautomers], C10 and C14), 129.0 (aromatic CH, [both 
tautomers], C11 and C13), 127.6 (aromatic quaternary C [both tautomers], C12), 
126.5 (pyridine CH [both tautomers], C4), 93.5 (acac CH [enolate tautomer], C7), 
30.9 (acac CH2 [diketonate tautomer], C7) Analysis Calculated: C 55.29, H 3.31, 
N 4.61% Analysis Found: C 55.50, H 3.15, N 4.35% ES MS (+): m/z 304.0 
[MH
+
] 
 
9.4.7 Preparation of C15H13NO3 (L7) 
Sodium ethoxide (1.01 g, 14.8 mmol) was added to diethyl ether (40 mL), ethyl 2-
picolinate (2.0 mL, 14.8 mmol) and 4-methoxy acetophenone (4.45 g, 29.6 mmol). 
These were stirred and heated to reflux for 48 hours, then allowed to cool to room 
temperature. The suspension was stirred whilst adding acetic acid (0.85 mL, 14.8 
mmol) and water (40 mL). The product did not dissolve and was filtered under 
N
OH O
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reduced pressure and washed with methanol (10 mL), yielding L7 as a pure yellow 
precipitate (2.34 g, 9.17 mmol, 62%). 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
8.72-8.69 (m, 1H, H1), 8.15 (d, 1H, H4, 
3
J 
(
1
H-
1
H) = 7.4 Hz), 8.09-8.05 (br. dt, 2H, H10 
and H14, 
3
J (
1
H-
1
H) = 8.7 Hz and 
4
J (
1
H-
1
H) = 
2.7 Hz), 7.86 (td, 1H, H3, 
3
J (
1
H-
1
H) = 7.8 Hz and 
4
J (
1
H-
1
H) = 2.0 Hz), 7.51 (s, 
1H, [enolate tautomer], H7), 7.45-7.41 (m, 1H, H2), 7.00-6.96 (br. dt, 2H, H11 and 
H13, 
3
J (
1
H-
1
H) = 9.1 Hz and 
4
J (
1
H-
1
H) = 2.7 Hz), 4.81 (s, acac CH2 [diketonate 
tautomer], H7), 3.89 (s, 3H, H15) 
13
C{
1
H} NMR (CDCl3, 125.8 MHz, 300.0 K) 
(quaternary C=O [diketonate tautomer], C6 or C8), 187.0 (quaternary C-O 
[enolate tautomer], C6 or C8), 181.6 (quaternary C-O [enolate tautomer], C6 or C8), 
163.5 (pyridine quaternary C [both tautomers], C5), 152.7 (aromatic quaternary C 
[both tautomers], C9), 149.3 (pyridine CH [both tautomers], C1), 137.0 (pyridine 
CH [both tautomers], C3), 129.7 (aromatic CH [both tautomers], C10 and C14), 
128.1 (aromatic quaternary C [both tautomers], C12), 126.1 (pyridine CH [both 
tautomers], C2), 122.0 (pyridine CH [both tautomers], C4), 114.0 (aromatic CH 
[both tautomers], C11 and C13), 92.9 (acac CH [enolate tautomer], C7), 55.5 (acac 
CH2 [diketonate tautomer], C7), 30.9 (methoxy OCH3 [both tautomers], C15) 
Analysis Calculated: C 70.58, H 5.13, N 5.49% Analysis Found: C 70.15, H 
5.10, N 5.35 ES MS (+): m/z 256.10 [MH
+
] 
 
9.4.8 Preparation of C15H13NO2 (L8) 
Sodium ethoxide (0.76 g, 11.2 mmol) was added to diethyl ether (40 mL), ethyl 2-
picolinate (1.51 mL, 11.2 mmol) and 4-methylacetophenone (2.99 mL, 22.4 mmol). 
These were stirred and heated to reflux for 48 hours, then allowed to cool to room 
temperature. The suspension was stirred whilst adding acetic acid (0.64 mL, 11.2 
mmol) and water (40 mL). The product was extracted into diethyl ether (10 mL) 
and product was obtained from the aqueous layer. This was filtered under reduced 
pressure and recrystallised from methanol (10 mL), yielding L8 as a pale yellow 
precipitate (1.72 g, 7.19 mmol, 61%). 
1
H NMR (CDCl3, 500.23 MHz, 300.3 K) 8.71 
(dd, 1H, H1, 
3
J (
1
H-
1
H) = 4.8 Hz and 
4
J (
1
H-
1
H) = 
0.8 Hz), 8.16 (d, 1H, H4, 
3
J (
1
H-
1
H) = 7.5 Hz), 
N
OH O
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7.98 (br. d, 2H, H10 and H14, 
3
J (
1
H-
1
H) = 8.3 Hz), 7.89-7.83 (m, 1H, H\), 7.56 (s, 
1H, H7), 7.46-7.41 (m, 1H, H2), 7.29 (d, 2H, H11 and H13, 
3
J (
1
H-
1
H) = 8.3 Hz), 
2.43 (s, 3H, methyl CH3) 
13
C{
1
H} NMR (CDCl3, 125.8 MHz, 297.4 K) 186.8 
(quaternary C-O, C6 or C8), 183.0 (quaternary C-O, C6 or C8), 152.6 (quaternary 
pyridine C, C5), 149.3 (pyridine CH, C1), 143.6 (quaternary aromatic C, C9), 137.1 
(pyridine CH, C3), 132.7 (quaternary aromatic C, C12), 129.4 (aromatic CH, C11 
and C13), 127.6 (aromatic CH, C10 and C14), 126.4 (pyridine CH, C2), 122.1 
(pyridine CH, C4), 93.3 (acac CH, C7). 21.7 (methyl CH3, C15) Analysis 
Calculated: C 75.30, H 5.48, N 5.85% Analysis Found: C 75.65, H 5.40, N 
5.70% ES MS (+): m/z 240.10 [MH
+
] 
 
9.4.9 Preparation of C18H13NO2 (L9) 
Sodium ethoxide (0.40 g, 5.88 mmol) was added to diethyl ether (40 mL), ethyl 2-
picolinate (0.79 mL, 5.88 mmol) and 2-acetonaphthone (2.01 g, 11.8 mmol). These 
were stirred and heated to reflux for 48 hours, then allowed to cool to room 
temperature. The suspension was stirred whilst adding acetic acid (0.34 mL, 5.88 
mmol) and water (40 mL). The crude product was separated with ether (3 x 20 mL) 
and dried over Na2SO4. The crude product was recrystallised from methanol (10 
mL) and stored at -20°C. This was filtered under reduced pressure and washed with 
diethyl ether, yielding L9 as a yellow precipitate (0.98 g, 3.56 mmol, 61%) 
1
H NMR (CDCl3, 500.23 MHz, 300.3 K) 
8.78-8.75 (m, 1H, H1), 8.65 (s, 1H, H10), 
8.21 (d,1H, H4, 
3
J (
1
H-
1
H) = 7.9 Hz), 8.12 (dd, 
1H, naphthyl CH, 
3
J (
1
H-
1
H) = 8.5 Hz and 
4
J 
(
1
H-
1
H) = 1.8Hz), 8.01 (d, 1H, naphthyl CH, 
3
J (
1
H-
1
H) = 7.9 Hz), 7.94 (d, 1H, H3, 
3
J (
1
H-
1
H) = 8.7 Hz), 7.92-7.88 (m, 2H, naphthyl CH), 7.74 (s, 1H, H7), 7.63-7.55 
(m, 2H, naphthyl CH), 7.47 (ddd, 1H, H2, 
3
J (
1
H-
1
H) = 7.6 Hz, 
3
J (
1
H-
1
H) = 4.8 Hz 
and 
4
J (
1
H-
1
H) = 1.2 Hz) 
13
C{
1
H} NMR (CDCl3, 75.5 MHz, 300.1 K) 186.2 
(quaternary C-O, C6 or C8), 183.55 (quaternary C-O, C6 or C8), 152.6 (quaternary 
pyridine C, C5), 149.3 (pyridine CH, C1), 137.1 (pyridine CH, C3), 135.5 
(quaternary naphthyl C, C9), 132.6 (quaternary naphthyl C, C11 and C16), 129.5 
(naphthyl CH), 128.8 (naphthyl CH), 128.4 (pyridine CH, C2), 128.2 (naphthyl 
CH), 127.8 (naphthyl CH), 126.8 (naphthyl CH), 126.4 (naphthyl CH), 123.47 
(naphthyl CH), 122.2 (pyridine CH, C4), 93.9 (acac CH, C7) Analysis Calculated: 
N
OH O
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C 78.53, H 4.76, N 5.09% Analysis Found: C 78.35, H 4.70, N 4.90% ES MS (+): 
m/z 276.10 [MH
+
] 
 
9.4.10 Preparation of C14H8Cl3NO2 (L10)  
Sodium ethoxide (0.47 g, 6.85 mmol) was added to diethyl ether (40 mL), ethyl 2-
picolinate (0.92 mL, 6.85 mmol) and 2,3,4-trichloro acetophenone (3.06 g, 13.7 
mmol). These were stirred and heated to reflux for 48 hours, then allowed to cool 
to room temperature. The suspension was stirred whilst adding acetic acid (0.39 
mL, 6.85 mmol) and water (40 mL). The crude product was extracted with ether (3 
x 20 mL) and dried over Na2SO4. The solvent was removed under reduced pressure 
and washed with diethyl ether (10 mL), yielding L10 as a cream precipitate (1.06 g, 
3.23 mmol, 47%). 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 8.66 
(d, 1H, H1, 
3
J (
1
H-
1
H) = 4.0 Hz), 8.13 (d, 1H, H4, 
3
J (
1
H-
1
H) = 7.9 Hz), 7.85 (td, 1H, H3, 
3
J (
1
H-
1
H) 
= 7.7 Hz and 
4
J (
1
H-
1
H) = 1.6 Hz), 7.46 (d, 2H, 
H13 and H14, 
3
J (
1
H-
1
H) = 1.6 Hz), 7.45-7.41 (m, 1H, H2), 7.24 (s, 1H, H7) 
13
C{
1
H} 
NMR (CDCl3, 125.8 MHz, 300.2 K) 186.98 (quaternary C-O, C6 or C8), 182.46 
(quaternary C-O, C6 or C8), 151.66 (quaternary pyridine C, C5), 149.54 (pyridine 
CH, C1), 137.13 (pyridine CH, C3), 136.80 (quaternary aromatic C, C9), 136.48 
(aromatic C-Cl, C10-12), 133.23 (aromatic C-Cl, C10-12), 132.13 (aromatic C-Cl, C10-
12), 128.48 (pyridine CH, C2), 127.82 (aromatic CH, C13), 126.70 (aromatic CH, 
C14), 122.40 (pyridine CH, C4), 98.74 (acac CH, C7) Analysis Calculated: C 
51.18, H 2.45, Cl 32.37 N 4.26% Analysis Found: C 51.25, H 2.30, Cl 32.50 N 
4.00% ES MS (+): m/z 327.97 [M
+
] 
 
9.5 Syntheses of Functionalised -Ketoiminate Ligands 
Ligands L11-28 were synthesised using a modified synthetic route based on work 
by Tang et al.
2
 
9.5.1 Preparation of C17H17NO (L11) 
4’-Methyl--diketonate (0.50 g, 2.84 mmol) was dissolved in toluene (10 mL), 
aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the precipitate was 
filtered and the solvent was removed under reduced pressure. The crude product 
N
OH O
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was recrystallised from hot ethanol (20 mL), yielding L11 as a yellow crystals 
(0.42 g, 1.67 mmol, 59%). This ligand has previously been prepared,
12
 although the 
X-ray crystal structure has been reported in Chapter 2, 
1
H NMR has been reported 
here to prove synthesis. 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 13.08 
(br. d, 1H, NH), 7.86-7.86 (m, 2H, aromatic CH, 
H13 and H15), 7.41-7.34 (m, 2H, anline CH, H3 
and H5), 7.26-7.22 (m, 3H, aniline CH, H2, H4 
and H6), 7.21-7.17 (m, 2H, aromatic CH, H13 and 
H15), 5.89 (s, 1H, acnac CH, H9), 2.41 (s, 3H, 
para methyl CH3, H17), 2.15 (s, 3H, aliphatic CH3, H7) 
 
9.5.2 Preparation of C16H14FNO (L12) 
3’-Fluoro--diketonate (0.52 g, 2.89 mmol) was dissolved in toluene (10 mL), 
aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the precipitate was 
filtered and the remove solvent was under reduced pressure. The crude product 
recrystallised was from hot ethanol (10 mL), yielding yellow crystals of L12 (0.61 
g, 2.39 mmol, 83%) 
 
1
H NMR (CDCl3, 300 MHz, 300 K) δ 13.09 (br. s, 
1H, NH), 7.70 (br. d, 1H, aromatic CH, H16, 
3
J(
1
H-
1
H) = 7.9 Hz), 7.65-7.59 (m, 1H, aromatic CH, 
H12), 7.44-7.36 (m, 3H, aniline CH, H3 and H5 and 
aromatic H15), 7.28-7.24 (m, 1H, aniline CH, H4), 
7.23-7.18 (m, 2H, aniline CH, H2 and H6), 7.18-
7.12 (m, 1H, aromatic CH, H14), 5.85 (s, 1H, acnac CH, H9), 2.16 (s, 3H, aliphatic 
CH3, H7) 
13
C{
1
H} NMR (CDCl3, 75 MHz, 300 K) δ 186.9 (quaternary C-O, C10), 
163.9 (quaternary C, C1 or C8), 157.5 (quaternary C, C1 or C8), 137.0 (d, quaternary 
C-F, C13, 
1
J (
13
C-
19
F) = 217.5 Hz), 129.8 (d, quaternary C meta to C-F, C11, 
3
J (
13
C-
19
F) = 7.5 Hz), 129.2 (aniline or aromatic CH, C3, C5 and C15), 126.1( aniline CH, 
C4), 124.9 (aniline CH, C2 and C6), 122.6 (d, aromatic CH, C16, 
4
J (
13
C-
19
F) = 3.0 
Hz), 117.6 (d, aromatic CH, C14, 
2
J (
13
C-
19
F) = 21 Hz), 114.0 (d, aromatic CH, C12, 
2
J (
13
C-
19
F) = 21 Hz), 94.1 (acnac CH, C9), 20.4 (aliphatic CH3, C7) Analysis 
Calculated: C 75.30 H 5.53, N 5.49% Analysis Found: C 74.90, H 5.20, N 5.16% 
ES MS (+): m/z 255.4 [M
+
] 
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9.5.3 Preparation of C16H14FNO (L13) 
4’-Fluoro-diketonate (0.51 g, 2.83 mmol) was dissolved in toluene (10 mL), 
aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the precipitate was 
filtered and the solvent was removed under reduced pressure. The crude product 
was recrystallised from hot ethanol (10 mL), yielding L13 as green crystals (0.63 g, 
2.47 mmol, 87%) 
1
H NMR (CDCl3, 300 MHz, 300 K) δ 13.05 (s, 1H, 
NH), 7.94 (v. dd, 2H, aromatic CH, H12 and H16, 
3
J(
1
H-
1
H) = 9.2 Hz and 
3
J(
1
H-
19
F) = 2.3 Hz), 7.39 
(br. t, 2H, aniline CH, H3 and H5, 
3
J(
1
H-
1
H) = 7.9 
Hz), 7.24 (br. t, 1H, aniline CH, H4, 
3
J(
1
H-
1
H) = 7.6 
Hz), 7.19 (br. d, 2H, aromatic CH, H2 and H6, 
3
J(
1
H-
1
H) = 7.2 Hz), 7.11 (v. t, 2H, aromatic CH, H12 and H16, , 
3
J(
1
H-
1
H) = 8.7 Hz 
and , 
4
J(
1
H-
19
F) = 1.9 Hz), 5.85 (s, 1H, acnac CH, H9), 2.15 (s, 1H, aliphatic CH3, 
H7) 
13
C{
1
H} NMR (CDCl3, 75MHz, 300K) δ 187.2 (quaternary C-O, C10), 164.5 
(d, quaternary C-F, C14, 
1
J(
13
C-
19
F) = 249.7 Hz), 162.4 (quaternary aromatic C, 
C11), 138.5 (quaternary aromatic C, C1 and C8), 129.3 (d, aromatic CH, C13 and 
C15, 
2
J(
13
C-
19
F) = 8.7 Hz), 129.2 (aniline CH, C3 and C5), 125.9 (aniline CH, C4), 
124.8 (aniline CH, C2 and C6), 115.2 (d, aromatic CH, C12 and C16, 
3
J(
13
C-
19
F) = 
21.0 Hz), 93.8 (acnac CH, C9), 20.38 (aliphatic CH3, C7) Analysis Calculated: C 
74.30 H 5.53, N 5.49% Analysis Found: C 74.35, H 5.40, N 5.25% ES MS (+): 
m/z 255.6 [M
+
] 
 
9.5.4 Preparation of C16H13Cl2NO (L14) 
2’,5’-Dichloro--diketonate (0.51 g, 2.21 mmol) was dissolved in toluene (10 mL), 
aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the precipitate 
filtered and solvent was removed under reduced pressure. The crude product was 
recrystallised from hot ethanol (10 mL), yielding L14 as colourless crystals (0.46 g, 
2.20 mmol, 68%) 
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1
H NMR (CDCl3, 300 MHz, 300 K) δ 12.71 (s, 
1H, NH), 7.43 (m, 1H, aniline CH, H4), 7.33 (br. t, 
2H, aniline CH, H3 and H5, 
3
J(
1
H-
1
H) =7.5 Hz), 
7.24 (br. s, 1H, aromatic CH, H16), 7.21-7.16 (m, 
2H, aromatic CH, H13 and H14), 7.13(d, 2H, aniline 
CH, H2 and H6, 
3
J(
1
H-
1
H) = 7.5 Hz), 5.43 (s, 1H, 
acnac CH, H9), 2.03 (s, 3H, aliphatic CH3, H7) 
13
C{
1
H} NMR (CDCl3, 75 MHz, 300 K) δ 187.8 (quaternary C-O, C10), 163.2 
(quaternary C, C11), 142.4 (quaternary C, C1), 138.1 (quaternary C, C8), 132.6 
(quaternary C-Cl, C12 and C15), 131.3 (aromatic CH, C13 or C14), 130.0 (aromatic 
CH, C13 or C14), 129.3 (aniline CH, C3 and C5), 126.4 (aniline CH, C4), 125.1 
(aniline CH, C2 and C6), 97.9 (acnac CH, C9), 20.2 (aliphatic CH3, C7) Analysis 
Calculated: C 62.67, H 4.29, N 4.58, Cl 23.15% Analysis Found: C 62.65, H 
4.20, N 4.45, Cl 23.30 ES MS (+): m/z 306.2 [M
+
] 
 
9.5.5 Preparation of C16H13Cl2NO (L15) 
3’,4’-Dichloro--diketonate (0.62 g, 2.60 mmol) was dissolved in toluene (10 mL), 
aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the precipitate 
filtered and the solvent was removed under reduced pressure. The crude product 
was recrystallised from hot ethanol (10 mL), yielding L15 as yellow crystals (0.54 
g, 1.77 mmol, 68%) 
1
H NMR (CDCl3, 300.13 MHz, 300.1 K) 13.07 
(br. s, 1H, NH), 8.01 (d, 1H, H12, 
4
J (
1
H-
1
H) = 1.9 
Hz), 7.55 (dd, 1H, H16, 
3
J (
1
H-
1
H) = 8.5 Hz, 
4
J 
(
1
H-
1
H) = 2.1 Hz), 7.51 (d, 1H, H15, 
3
J (
1
H-
1
H) = 
8.7 Hz), 7.40 (br. t, 2H, H3 and H5, 
3
J (
1
H-
1
H) = 
7.9 Hz), 7.26 (br. t, 1H,H4, 
3
J (
1
H-
1
H) = 7.6 Hz), 
7.19 (d, 2H, H2 and H6, 
3
J (
1
H-
1
H) = 7.6 Hz), 5.85 (s, 1H, H9), 2.16 (s, 3H, H7) 
13
C{
1
H} NMR (CDCl3, 75.0 MHz, 300.0 K)  185.5 (quaternary C-O, C10), 163.5 
(quaternary aromatic C, C11), 139.9 (quaternary aniline C, C1), 138.3 (quaternary 
C-NH, C8), 135.0 (quaternary aromatic C-Cl, C13 or C14), 132.7 (quaternary 
aromatic C-Cl, C13 or C14), 130.3 (aromatic CH, C15). 129.3 (aniline CH, C3 and 
C5), 129.2 (aromatic CH, C12), 126.3 (aniline/aromatic CH, C4 and C16), 124.9 
(aniline CH, C2 and C6), 93.7 (acnac CH, C9), 20.4 (aliphatic CH3, C7) Analysis 
NH O1
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Calculated: C 62.76, H 4.28, N 4.57, Cl 23.16% Analysis Found: C 62.50, H 
4.30, N 5.00, Cl 23.20% ES MS (+): m/z 306.1 [M
+
] 
 
9.5.6 Preparation of C16H12Cl3NO (L16) 
2’,3’,4’-Trichloro--diketonate (0.14 g, 0.53 mmol) was dissolved in toluene (10 
mL), aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the 
precipitate was filtered and solvent was removed under reduced pressure. The 
crude product was recrystallised from hot ethanol (10 mL), yielding L16 as a gold 
crystalline solid (0.10 g, 0.29 mmol, 55%) 
1
H NMR (CDCl3, 500.23 MHz, 300.1 K) 12.75 
(br. s, 1H, NH), 7.43-7.39 (m, 3H, H3-H5), 7.33 (d, 
1H, H16, 
3
J (
1
H-
1
H) = 8.2 Hz), 7.29 (br. d, 1H, H15, 
3
J (
1
H-
1
H) = 7.3 Hz), 7.22 (br. d, 2H, H2 and H6, 
3
J 
(
1
H-
1
H) = 7.6 Hz), 5.45 (s, 1H, H9), 2.11 (s, 3H, 
H7) 
13
C NMR (CDCl3, 125.9 MHz, 300.0 K)  
187.9 (quaternary C-O, C10), 163.4 (quaternary aromatic C, C``), 141.6 (quaternary 
aniline C, C1), 138.0 (quaternary C-NH, C8), 134.5 (quaternary aromatic C-Cl, C12, 
C13 or C14), 132.4 (quaternary aromatic C-Cl, C12, C13 or C14), 131.0 (quaternary 
aromatic C-Cl, C12, C13 or C14). 129.3 (aniline CH, C3 and C5), 128.4 (aniline CH, 
C4), 126.9 (aromatic CH, C16), 126.4 (aromatic CH, C15), 125.1 (aniline CH, C2 and 
C6), 97.8 (acnac CH, C9), 20.2 (aliphatic CH3, C7) Analysis Calculated: C 56.42, 
H 3.55, Cl 31.22, N 4.11% Analysis Found: C 56.25, H 3.45, Cl 31.05, N 4.05% 
ES MS (+): m/z 340.0 [M
+
] 
 
9.5.7 Preparation of C16H14BrNO (L17) 
3’-Bromo--diketonate (0.52 g, 2.16 mmol) was dissolved in toluene (20 mL), 
aniline (2 mL) and HCl (1 mL). This was stirred for 16 hours, the product was 
filtered and solvent was removed under reduced pressure. The crude product was 
recrystallised from hot ethanol (10 mL), yielding L17 as pale orange crystals (0.42 
g, 1.33 mmol, 62%) 
 
 
 
NH O12
3
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1
H NMR (CDCl3, 300 MHz, 300 K) δ 13.08 (s, 
1H, NH), 8.06 (t, 1H, aromatic CH, H12, 
4
J(
1
H-
1
H) = 1.7 Hz), 7.84 (br. dt, 1H, aromatic 
CH, H14, 
3
J(
1
H-
1
H) = 8.0 Hz and 
3
J(
1
H-
1
H) = 1.5 
Hz), 7.59 (dq, 1H, aromatic CH, H16, 
3
J(
1
H-
1
H) = 
7.9 Hz and 
4
J(
1
H-
1
H) = 0.9(x3) Hz), 7.40 (br. t, 
2H, aniline CH, H3 and H5, 
3
J(
1
H-
1
H) = 8.1 Hz) 7.31 (t, 1H, aromatic CH, H15, 
3
J(
1
H-
1
H) = 7.9 Hz), 7.25 (br. t, 1H, aniline CH, H4, 
3
J(
1
H-
1
H) =  7.2 Hz), 7.20 (br. 
d, 2H, aniline CH, H2 and H6, 
3
J(
1
H-
1
H) = 7.5 Hz), 5.83 (s, 1H, acnac CH, H9), 
2.16 (s, 3H, aliphatic CH3, H7) 
13
C{
1
H} NMR (CDCl3, 75 MHz, 300 K) δ 
186.7(quaternary C-O, C10), 163.0 (quaternary aromatic C, C11), 142.0 (quaternary 
C-NH, C8 and quaternary aniline C, C1), 138.4 (quaternary aromatic C-Br, C13), 
133.6 (aromatic CH, C16), 130.2 (aromatic CH, C15), 129.8 (aromatic CH, C12), 
129.2 (aniline CH, C3 and C5), 126.1 (aniline CH, C4), 125.6 (aromatic CH, C14), 
124.9 (aromatic CH, C2 and C6), 94.0 (acnac CH, C9), 20.4 (aliphatic CH3, C7) 
Analysis Calculated: C 60.76, H 4.47, N 4.43% Analysis Found: C 60.80, H 
4.45, N 4.43% ES MS (+): m/z 316.3 [M
+
] 
 
9.5.8 Preparation of C16H14INO (L18) 
4’-Iodo--diketonate (0.79 g, 2.74 mmol) was dissolved in toluene (20 mL), aniline 
(2 mL) and HCl (1 mL). This was stirred for 16 hours, the precipitate filtered and 
the solvent was removed under reduced pressure. The crude product was 
recrystallised from hot ethanol (10 mL), yielding L18 as a gold crystalline solid 
(0.76 g, 2.09 mmol, 76%) 
1
H NMR (CDCl3, 500.23 MHz, 300.1 K) 13.09 
(br. s, 1H, NH), 7.79 (d, 2H, H12 and H16, 
3
J (
1
H-
1
H) = 8.3 Hz), 7.65 (d, 2H, H13 and H15, 
3
J (
1
H-
1
H) 
= 8.3 Hz), 7.39 (br. t, 2H, H3 and H5, 
3
J (
1
H-
1
H) = 
7.8 Hz), 7.25 (br. t, 1H, H4, 
3
J (
1
H-
1
H) = 7.3 Hz), 
7.19 (br. d, 2H, H2 and H6, 
3
J (
1
H-
1
H) = 7.3 Hz), 
5.84 (s, 1H, H9), 2.15 (s, 3H, H7) 
13
C{
1
H} NMR (CDCl3, 75 MHz, 300 K) δ 187.4 
(quaternary C-O, C10), 162.8 (quaternary aromatic C, C11), 139.4 (quaternary C-
NH, C8 and quaternary aniline C, C1), 138.4 (quaternary C-I, C14), 137.5 (aromatic 
CH, C12 and C16), 129.2 (aniline CH, C3 and C5), 128.7 (aromatic CH, C13 and C15), 
NH O1
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126.0 (aniline CH, C4), 124.9 (aniline CH, C2 and C6), 93.8 (acnac CH, C9), 20.4 
(aliphatic CH3, C7) Analysis Calculated: C 52.91, H 3.89, I 34.94, N 3.86% 
Analysis Found: C 52.95, H 4.10, I 34.65, N 3.75% ES MS (+): m/z 364.0 [MH
+
] 
 
9.5.9 Preparation of C18H19NO (L19) 
4’-Ethyl--diketonate (1.03 g, 0.53 mmol) was dissolved in toluene (20 mL), 
aniline (2 mL) and HCl (1 mL). This was stirred for 16 hours, the precipitate 
filtered and the solvent removed under reduced pressure. The crude product was 
recrystallised from hot ethanol (20 mL), yielding L19 as oily brown crystals (1.05 
g, 3.96 mmol, 73%) 
1
H NMR (CDCl3, 300.13 MHz, 300.0 K) 
13.09 (br. s, 1H, NH), 7.87 (d, 2H, H12 and 
H16, 
3
J (
1
H-
1
H) = 7.9 Hz), 7.38 (br. t, 2H, H3 
and H5, 
3
J (
1
H-
1
H) = 7.9 Hz), 7.29-7.26 (m, 
2H, H2 and H6), 7.25-7.22 (m, 1H, H4), 7.19 
(br. d, 2H, H13 and H15,
 3
J (
1
H-
1
H) = 7.2 Hz ), 
5.90 (s, 1H, H9), 2.71 (q, 2H, H17, 
3
J (
1
H-
1
H) = 8.0 Hz), 2.16 (s, 3H, H7), 1.28 (t, 
3H, H18, 
3
J (
1
H-
1
H) = 7.6 Hz) 
13
C NMR (CDCl3, 75.5 MHz, 300.0 K)  188.6 
(quaternary C-O, C10), 161.8(quaternary aromatic C, C11), 147.5 (quaternary aniline 
C, C1), 138.0 (quaternary C-NH, C8), 137.6(quaternary aromatic C-C, C14), 129.1 
(aniline CH, C3 and C5), 127.8 (aniline CH, C2 and H6), 127.2 (aromatic CH, C12 
and C16), 125.6 (aniline CH, C4), 124.7 (aromatic CH, C13 and C15), 94.2 (acnac 
CH, C9), 28.8 (aliphatic CH2, C17), 20.5 (aliphatic CH3, C7), 15.3 (aliphatic CH3, 
C18) Analysis Calculated: C 80.86, H 7.92, N 5.24% Analysis Found: C 80.85, H 
7.15, N 5.05% ES MS (+): m/z 266.16 [MH
+
] 
 
9.5.10 Preparation of C17H17NO2 (L20) 
4’-Methoxy--diketonate (1.01 g, 5.25 mmol) was dissolved in toluene (20 mL), 
aniline (2 mL) and HCl (1 mL). This was stirred for 16 hours, the precipitate 
filtered and the solvent was removed under reduced pressure. The crude product 
washed with petrol (60-80˚C) (10 mL) and recrystallised from hot ethanol (20 mL), 
yielding L20 as a pale yellow crystalline precipitate (0.76 g, 2.84 mmol, 54%). 
NH O1
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1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
13.04 (br. s, 1H, NH), 7.92 (d, 2H, H12 and 
H16, 
3
J (
1
H-
1
H) = 8.9 Hz), 7.37 (br. t, 2H, H3 
and H5, 
3
J (
1
H-
1
H) = 7.9 Hz), 7.24-7.20 (m, 1H, 
H4), 7.18 (br. d, 2H, H2 and H6, 
3
J (
1
H-
1
H) = 7.3 
Hz), 6.94 (br. d, 2H, H13 and H15, 
3
J (
1
H-
1
H) = 
8.5 Hz), 5.87 (br. s, 1H, H9), 3.87 (s, 3H, H17), 2.15 (s, 3H, H7) 
13
C{
1
H} NMR 
(CDCl3, 125.9 MHz, 300.0 K) 187.9 (quaternary C-O, C10), 162.0 (quaternary 
aromatic C, C11), 161.4 (quaternary aniline C, C1), 138.9 (quaternary C-NH, C8), 
132.7 (quaternary aromatic C, C14), 129.1 (aniline CH, C3 and C5), 129.0 (aromatic 
CH, C12 and C16), 125.5 (aniline CH, C4), 124.7 (anline CH, C2 and C6), 113.5 
(aromatic CH, C13 and C15), 93.8 (acnac CH, C9), 55.3 (methoxy OCH3 C17), 20.5 
(aliphatic CH3, C7) Analysis Calculated: C 76.38, H 6.41, N 5.24% Analysis 
Found: C 75.75, H 6.40, N 5.20% ES MS (+): m/z 268.13 [MH
+
] 
 
9.5.11 Preparation of C18H19NO3 (L21) 
3’,4’-Dimethoxy--diketonate (0.76 g, 3.42 mmol) was dissolved in toluene (15 
mL), aniline (1.5 mL) and HCl (1.2 mL). This was stirred for 16 hours, the 
precipitate filtered and the solvent was removed under reduced pressure. The crude 
product was recrystallised from hot ethanol (20 mL), yielding L21 as a yellow 
crystalline precipitate (0.67 g, 2.26 mmol, 66%). 
1
H NMR (CDCl3, 300.13 MHz, 295.7 K) 
13.05 (br. s, 1H, NH), 7.57 (br. d, 1H, H12, 
4
J 
(
1
H-
1
H) = 1.7 Hz), 7.53 (br. dd, 1H, H15, 
3
J 
(
1
H-
1
H) = 8.3 Hz and 
4
J (
1
H-
1
H) = 2.3 Hz), 
7.41-7.35 (m, 2H, H3 and H5), 7.25-7.22 (m, 
1H, H4), 7.21-7.16 (m, 2H, H2 and H6), 6.90 
(d, 1H16, 
3
J (
1
H-
1
H) = 8.3 Hz), 5.88 (br. s, 1H, H9), 3.98 (s, 3H, H17), 3.95 (s, 3H, 
H18), 2.17 (s, 3H, H7) 
13
C{
1
H} NMR (CDCl3, 75.5 MHz, 296.3 K) 187.7 
(quaternary C-O, C10), 161.5 (quaternary aromatic C, C11), 151.5 (quaternary C, C1 
and C8), 132.9 (quaternary aromatic C, C14 and C15), 129.1 (aniline CH, C3 and C5), 
125.6 (aniline CH, C4), 124.6 (anline CH, C2 and C6), 120.5 (aromatic CH, C15), 
110.1 (aromatic CH, C12), 109.9 (aromatic CH, C16), 93.7 (acnac CH, C9), 56.0 
(2C, methoxy OCH3, C17 and C18), 20.5 (aliphatic CH3, C7) Analysis Calculated: 
NH O12
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C 72.71, H 6.44, N 4.71% Analysis Found: C 72.75, H 6.50, N 4.65% ES MS (+): 
m/z 320.13 [MNa
+
] 
 
9.5.12 Preparation of C18H18FNO2 (L22) 
2’-Ethyl-4-fluoro--diketonate (0.41g, 1.83 mmol) was dissolved in toluene (10 
mL), aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the 
precipitate filtered and the solvent was removed under reduced pressure. The crude 
product was washed with petrol (60-80˚C) (10 mL) and recrystallised from hot 
ethanol (20 mL), yielding L22 as pale yellow crystals (0.25 g, 0.84 mmol, 46%). 
1
H NMR (CDCl3, 500.23 MHz, 294.7 K) 12.98 
(br. s, 1H, NH), 7.78 (dd, 1H, H16, 
3
J (
1
H-
1
H) = 8.5 
Hz and 
4
J (
1
H-
19
F) = 7.3 Hz), 7.40-7.35 (m, 2H, H3 
and H5), 7.23 (br. d, 1H, H4, 
3
J (
1
H-
1
H) = 7.3 Hz), 
7.21-7.18 (m, 2H, H2 and H6), 6.71 (td, 1H, H15, 
3
J 
(
1
H-
1
H) = 8.2 Hz and 
3
J (
1
H-
19
F) = 2.4 Hz), 6.64 
(dd, 1H, H13, 
3
J (
1
H-
19
F) = 11.1 Hz and 
4
J (
1
H-
1
H) 
= 2.3 Hz), 6.02 (br. s, 1H, H9), 4.12 (br. q, 2H, H17 , 
3
J (
1
H-
1
H) = 7.0 Hz), 2.12 (s, 
3H, H7), 1.50 (br. t, 3H, H18, 
3
J (
1
H-
1
H) = 7.0 Hz) 
13
C NMR (CDCl3, 125.9 MHz, 
300.0 K)  187.6 (quaternary C-O, C10), 164.7 (quaternary aromatic C-F, C14, 
1
J 
(
13
C-
19
F) = 248.4 Hz), 163.7 (quaternary aromatic C, C11), 161.1 (quaternary C, C1 
or C8), 158.2 (d, quaternary aromatic C, C12, 
3
J (
13
C-
19
F) = 10.3 Hz), 138.9 
(quaternary C, C1 or C8), 131.9 (d, aromatic CH, C16, 
3
J (
13
C-
19
F) = 10.3 Hz). 129.1 
(aniline CH, C3 and C5), 125.6 (aniline CH, C4), 124.8 (aniline CH, C2 and C6), 
107.2 (aromatic CH, C15, 
2
J (
13
C-
19
F) = 20.6 Hz), 100.3 (aromatic CH, C13, 
2
J (
13
C-
19
F) = 24.7 Hz), 99.2 (acnac CH, C9), 64.5 (ethoxy CH2,  C17), 20.2 (aliphatic CH3, 
C7), 14.6 (ethoxy CH3, C18) Analysis Calculated: C 72.22, H 6.06, N 4.68% 
Analysis Found: C 71.65, H 6.05, N 4.75% ES MS (+): m/z 300.14 [MH
+
] 
 
9.5.13 Preparation of C18H19NO2 (L23) 
4’-Ethoxy--diketonate (0.77 g, 3.73 mmol) was dissolved in toluene (10 mL), 
aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the precipitate 
filtered and the solvent was removed under reduced pressure. The crude product 
was recrystallised from hot ethanol (20 mL), yielding L23 as yellow needle-like 
crystals (0.40 g, 1.42 mmol, 38%). 
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1
H NMR (CDCl3, 500.13 MHz, 319.2 K) 
13.01 (br. s, 1H, NH), 7.91 (br. d, 2H, H12 
and H16, 
3
J (
1
H-
1
H) = 8.8 Hz), 7.39-7.34 (br. 
t, 2H, H3 and H5, 
3
J (
1
H-
1
H) = 7.3 Hz) 7.23-
7.20 (m, 1H, H4), 7.18 (br. d, 2H, H2 and H6, 
3
J (
1
H-
1
H) = 8.8 Hz), 5.86 (s, 1H, H9), 4.11 
(q, 2H, H17, 
3
J (
1
H-
1
H) = 6.7 Hz ), 2.14 (s, 3H, H7), 1.45 (t, 3H, H18, 
3
J (
1
H-
1
H) = 
6.7 Hz) 
13
C{
1
H} NMR (CDCl3, 75.5 MHz, 300.0 K) 187.9 (quaternary C-O, 
C10), 161.4 (quaternary aromatic C, C11), 138.9 (quaternary aniline C, C1 and C8), 
132.5 (quaternary aromatic C14), 129.1 (aniline CH, C3 and C5), 129.0 (aromatic 
CH, C12 and C16), 125.5 (aniline CH, C4), 124.7 (aniline CH, C2 and C6), 114.0 
(aromatic CH, C13 and C15), 93.8 (acnac CH, C9), 63.6 (ethoxy CH2, C17), 20.5 
(aliphatic CH3, C7), 14.8 (ethoxy CH3, C18) Analysis Calculated: C75.23, H 5.65, 
N 13.85 Analysis Found: C 74.75, H 5.70, N 13.80 ES MS (+): m/z 282.15 [MH+] 
 
9.5.14 Preparation of C17H15NO3 (L24) 
3’,4’-Methylene--diketonate (0.51 g, 2.47 mmol) was dissolved in toluene (10 
mL), aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the 
precipitate filtered and the solvent was removed under reduced pressure. The crude 
product was recrystallised from hot ethanol (20 mL), yielding L24 as green crystals 
(0.33 g, 1.17 mmol, 47%). 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
12.99 (br. s, 1H, NH), 7.51 (dd, 1H, H16, 
3
J 
(
1
H-
1
H) = 8.1Hz and 
4
J (
1
H-
1
H) = 1.4 Hz), 7.44 
(d, 1H, H12, 
4
J (
1
H-
1
H) = 1.5 Hz) 7.42-7.37 (m, 
2H, H2 and H6), 7.27-7.23 (m, 1H, H4), 7.20-
7.17 (m, 2H, H3 and H5), 6.85 (d, 1H, H15, 
3
J 
(
1
H-
1
H) = 8.2 Hz), 6.03 (s, 2H, H17), 5.81 (s, 1H, H9), 2.14 (s, 3H, H7) 
13
C{
1
H} 
NMR (CDCl3, 125.8 MHz, 300.0 K) 161.7 (quaternary C-O, C10), 150.0 
(quaternary aromatic C, C13 or C14), 147.9 (quaternary aromatic C, C13 or C14), 
138.7 (quaternary aromatic C, C11), 130.7 (quaternary C, C1 or C8), 129.2 (aniline 
CH, C2 and C6), 129.2 (aniline CH, C3 and C5), 125.7 (aromatic CH, C12), 124.8 
(quaternary C, C1 or C8), 122.2 (aniline CH, C4), 107.8 (aromatic CH, C16), 107.5 
(aromatic CH, C15), 101.5 (methylene CH2, C17), 98.2 (acnac CH, C9), 20.5 
NH O12
3
4
5
6
7
8
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12 13
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(aliphatic CH3, C7) Analysis Calculated: C 72.58, H 5.37, N 4.98% Analysis 
Found: C 72.25, H 5.35, N 4.95% ES MS (+): m/z 282.10 [M
+
] 
 
9.5.15 Preparation of C17H15NO3 (L25) 
4’-Imidazole--diketonate (L4) (0.12 g, 0.644 mmol) was dissolved in toluene (10 
mL), aniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the 
precipitate filtered and the solvent was removed under reduced pressure. The crude 
product was recrystallised from hot ethanol (20 mL) and stored at -20°C, yielding 
L25 as green crystals (0.34 g, 1.12 mmol, 49%).  
1
H NMR (CDCl3, 300.13 MHz, 300.0 K) 
13.13 (br. s, 1H, NH), 8.05 (d, 2H, H12 
and H16, 
3
J (
1
H-
1
H) = 8.5 Hz), 7.47 (d, 2H, 
H13 and H15, 
3
J (
1
H-
1
H) = 8.5 Hz), 7.45-
7.36 (m, 3H, H2, H4 and H6), 7.29-7.26 (m, 
2H, H3 or H5), 7.25-7.17 (m, 3H, H17-19), 
5.90 (s, 1H, H9), 2.18 (s, 3H, H7) 
13
C{
1
H} 
NMR (CDCl3, 75.5 MHz, 299.9 K) 186.7 (quaternary C-O, C10), 162.9 
(quaternary aromatic C, C11), 139.0 (quaternary aromatic C, C14), 138.4 (quaternary 
C, C1 or C8), 137.4 (quaternary C, C1 or C8), 129.2 (aniline CH, C3 and C5), 128.9 
(aromatic CH, C12 and C16), 126.1 (aniline CH, C2, C4 and C6), 124.9 (aromatic 
CH, C13 and C15), 120.8 (imidazole CH, C17-19), 93.9 (acnac CH, C9), 20.4 (aliphatic 
CH3, C7) Analysis Calculated: C75.23, H 5.65, N 13.85% Analysis Found: C 
74.75, H 5.70, N 13.80% ES MS (+): m/z 304.14 [MH
+
] 
 
9.5.16 Preparation of C20H17NO (L26)  
3’-Napthyl--diketonate (0.59 g, 2.78 mmol) was dissolved in toluene (10 mL), 
aniline (1 mL) and HCl (0.5 mL). The suspension was stirred for 16 hours, the 
precipitate filtered and the solvent was removed under reduced pressure. The crude 
product was recrystallised from hot ethanol (20 mL), yielding L26 as pale yellow 
crystals (0.65 g, 2.26 mmol, 81%) 
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1
H NMR (CDCl3, 500 MHz, 300.0 K) 13.13 
(br. s, 1H, NH), 8.51 (d, 2H, aniline CH, H2 
and H6, 
3
J (
1
H-
1
H) = 8.3 Hz), 7.89 (br. t, 2H, 
aniline CH, H3 and C5, 
3
J (
1
H-
1
H) = 8.3 Hz), 
7.70 (br. d, 1H, aromatic CH, H12, 
4
J(
1
H-
1
H) = 
6.9 Hz), 7.57-7.53 (m, 1H, aniline CH, H4), 
7.53-7.48 (m, 2H, aromatic CH, H19 and H20), 7.42 (br, t, 2H, aromatic CH, H14-17, 
3
J(
1
H-
1
H) = 8.3 Hz), 7.28-7.25 (m, 2H, aromatic CH, H14-17), 5.70 (s, 1H, acnac 
CH, H9), 2.16 (s, 3H, aliphatic CH3, H7) 
13
C{
1
H} NMR (CDCl3, 125 MHz, 300 K) 
193.0 (quaternary C-O, C10), 162.0 (quaternary aromatic C, C11), 143.2 
(quaternary C, C13 or C18), 140.1 (quaternary C, C13 or C18), 138.6 (quaternary 
aromatic C, C1 and C8), 130.3 (aniline CH, C3 or C5), 129.9 (aniline CH, C3 or C5), 
129.2 (naphthyl CH), 128.4 (naphthyl CH), 126.6 (naphthyl CH), 126.1 (naphthyl 
CH), 125.4 (naphthyl CH), 124.9 (naphthyl CH), 124.9 (naphthyl CH), 99.0 (acnac 
CH, C9), 20.3 (aliphatic CH3, C7) Analysis Calculated: C 83.59, H 5.96, N 4.87% 
Analysis Found: C 83.70, H 6.00, N 4.80% ES MS (+): m/z 288.14 [MH
+
] 
 
9.5.17 Preparation of C16H11F3NO (27) 
4’-Fluoro--diketonate (0.54 g, 3.00 mmol) was dissolved in toluene (10 mL), 2,5-
difluoroaniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the 
precipitate filtered and the solvent was removed under reduced pressure. The crude 
product was recrystallised from hot ethanol (20 mL), yielding L27 as a pale brown 
crystalline precipitate (0.56 g, 1.92 mmol, 64%) 
1
H NMR (CDCl3, 300.13 MHz, 300.0 K) 12.90 
(br. s, 1H, NH), 7.97-7.92 (m, 2H, H12 and H16), 
7.16-7.09 (m, 3H, H3, H4 and H6), 6.99 (ddd, 1H, 
H13 or H15, 
3
J (
1
H-
1
H) = 9.0 Hz and 
3
J (
1
H-
19
F) = 
3.1 and 2.0 Hz), 6.93–6.87 (m, 1H, H13 or H15), 
5.95 (s, 1H, H9), 2.17 (s, 3H, H7) 
13
C{
1
H} NMR 
(CDCl3, 125.9 MHz, 300.0 K)  188.1 (quaternary C-O, C10), 164.8 (d, quaternary 
C-F, C14, 
1
J(
13
C-
19
F) = 250.5 Hz), 161.5 (quaternary aromatic C, C11), 158.3 (dd, 
quaternary aniline C-F, C2 or C5, 
1
J(
13
C-
19
F) = 242.3 Hz and 
4
J(
13
C-
19
F) = 3.1 Hz), 
152.7 (dd, quaternary aniline C-F, C2 or C5, 
1
J(
13
C-
19
F) = 242.3Hz and 
4
J(
13
C-
19
F) 
= 3.1 Hz), 135.7 (d, quaternary aromatic C, C8, 
4
J(
13
C-
19
F) = 3.1 Hz), 129.6 (d, 2C, 
NH O1
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aromatic CH, C12 and C16, 
3
J(
13
C-
19
F) = 8.3 Hz). 127.9 (dd, quaternary aniline C, 
C1, 
2
J(
13
C-
19
F) = 24.7 Hz and 
3
J(
13
C-
19
F) = 4.1 Hz), 115.3 (d, 3C, C3, C4 and C6, 
3
J(
13
C-
19
F) = 21.7 Hz), 113.1 (d, aromatic CH, C12 and C16, 
3
J(
13
C-
19
F) = 23.7 Hz), 
113.0 (d, aromatic CH, C13 and C15, 
2
J(
13
C-
19
F) = 25.8Hz), 95.3 (acnac CH, C9), 
20.3 (aliphatic CH3, C7) Analysis Calculated: C 65.98, H 4.15, N 4.81% Analysis 
Found: C 65.35, H 4.35, N 4.70% ES MS (+): m/z 292.09 [MH
+
]  
 
9.5.18 Preparation of C16H13F2NO (L28) 
4’-Fluoro--diketonate (0.63g, 2.84 mmol) was dissolved in toluene (10 mL), 2-
fluoroaniline (1 mL) and HCl (0.5 mL). This was stirred for 16 hours, the 
precipitate filtered and the solvent was removed under reduced pressure. The crude 
product was recrystallised from hot ethanol (20 mL), yielding L28 as a yellow 
crystalline precipitate (0.41 g, 1.50 mmol, 53%) 
1
H NMR (CDCl3, 300.13 MHz, 300.1 K) 12.82 
(br. s, 1H, NH), 7.95 (ddd, 2H, H12 and H16,
3
J (
1
H-
1
H) = 9.1 Hz, 
4
J (
1
H-
1
H) = 4.9 Hz, 
4
J (
1
H-
19
F) = 2.3 
Hz), 7.28-7.22 (m, 2H, H3-H6), 7.21-7.15 (m, 2H, 
H3-H6), 7.11 (ddd, 2H, H13 and H15, 
3
J (
1
H-
1
H) = 
9.1 Hz, 
4
J (
1
H-
1
H) = 4.9 Hz, 
3
J (
1
H-
19
F) = 2.6 Hz), 
5.92 (s, 1H, H9), 2.11 (s, 3H, H7) 
13
C{
1
H}  NMR (CDCl3, 75.5 MHz, 300.0 K)  
187.7 (quaternary C-O, C10), 164.6 (d, quaternary C-F, C2 or C14,
1
J(
13
C-
19
F) = 
249.7 Hz), 162.7 (quaternary aromatic C, C11), 156.7 (d, quaternary C-F, C2 or C14, 
1
J(
13
C-
19
F) = 247.2 Hz), 136.0 (d, quaternary aniline C, C8 
4
J(
13
C-
19
F) = 2.5 Hz), 
129.4 (d, aromatic CH, C12 and C16, 
3
J(
13
C-
19
F) = 8.7 Hz), 127.5 (d, aniline CH,
 
C4, 
3
J(
13
C-
19
F) = 7.4 Hz), 127.1 (aniline CH, C6), 126.7 (d, quaternary aromatic C, C1, 
2
J(
13
C-
19
F) = 12.4 Hz). 124.4 (d, aniline CH, C5, 
4
J(
13
C-
19
F) = 3.7 Hz,), 116.4 (d, 
aniline CH, C3, 
2
J(
13
C-
19
F) = 19.8 Hz), 115.2 (d, aromatic CH, C13 and C15, 
2
J(
13
C-
19
F) = 21.0 Hz,), 94.3 (acnac CH, C9), 20.1 (d, aliphatic CH3, C7, 
5
J(
13
C-
19
F) = 2.5 
Hz) Analysis Calculated: C 70.32, H 4.79, N 5.13% Analysis Found: C 69.60, H 
4.80, N 4.90% ES MS (+): m/z 274.1 [M
+
] 
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9.6 Synthesis of Ruthenium Chloride Complexes 
9.6.1 Preparation of C26H27ClFNORu (1) 
3-Fluoro--ketoiminate (L12) (0.10 g, 0.392 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.05 mL, 0.39 mmol) 
and [p-cymRuCl2]2 (0.12 g, 0.200 mmol) were added. The mixture was stirred at 
room temperature for 16 hours and then the solvent was removed under reduced 
pressure. The crude product was recrystallised from methanol (10 mL) and stored 
at 4°C for 2 days, yielding red crystals of 1 (0.12 g, 0.227 mmol, 58%). 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
br. d, 1H, H22, 
3
J (
1
H-
1
H) = 8.5 Hz), 
7.61-7.56 (m, 2H, H25 and H26), 7.43 (br. tt, 2H, 
H13 and H15, 
3
J (
1
H-
1
H) = 6.9 Hz and 
3
J (
1
H-
1
H) 
= 1.6 Hz), 7.31-7.28 (m, 1H, H14), 7.26-7.22 (m, 
1H, H12 or H16), 7.10-7.07 (m, 1H, H12 or H16), 
7.07-7.03 (m, 1H, H24), 5.41 (s, 1H, H19), 5.35 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 
Hz), 5.17 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.4 Hz), 5.07 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.6 Hz), 3.69 (br. d, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 Hz), 2.72-2.66 (br. sept, 1H, H8, 
CH(CH3)2), 2.03 (s, 3H, H1), 1.79 (s, 3H, H17), 1.21 (br. d, 3H, H9 or H10, 
3
J (
1
H-
1
H) = 6.8 Hz), 1.20 (br. d, 3H, H9 or H10, 
3
J (
1
H-
1
H) = 7.3 Hz) 
13
C{
1
H}  NMR 
(CDCl3, 75.5 MHz, 300.0 K) dquaternary C-O, C20, 
4
J (
13
C-
19
F) = 2.1 
Hz), 165.1 (quaternary C, C11 or C18), 162.7 (d, quaternary C-F, C23, 
1
J (
13
C-
19
F) = 
243.3 Hz), 157.2 (quaternary C, C11 or C18), 142.0 (d, quaternary C, C21 ipso, 
3
J 
(
13
C-
19
F) = 6.2 Hz), 129.7 (aniline CH, C13 or C15), 129.2 (d, aromatic CH, C25, 
3
J 
(
13
C-
19
F) = 7.2 Hz), 127.8 (aniline CH, C13 or C15), 126.0 (aniline CH, C14), 125.5 
(aniline CH, C12 or C16), 123.3 (aniline CH, C12 or C16), 122.4 (d, aromatic CH, 
C26, 
4
J (
13
C-
19
F) = 2.1 Hz), 116.1 (d, aromatic CH, C24, 
2
J (
13
C-
19
F) = 20.6 Hz), 
114.0 (d, aromatic CH, C22, 
2
J (
13
C-
19
F) = 22.7 Hz), 101.0 (quaternary C, C2 or C5), 
96.3 (quaternary C, C2 or C5), 94.8 (acnac CH, C19), 87.1 (p-cymene CH, C3,4,6,7), 
84.6 (p-cymene CH, C3,4,6,7), 84.5 (p-cymene CH, C3,4,6,7), 79.6 (p-cymene CH, 
C3,4,6,7), 30.5 (p-cymene CH, C8), 24.7 (aliphatic CH3, C17), 23.4 (p-cymene CH3, 
C9 or C10), 20.9 (p-cymene CH3, C9 or C10), 18.4 (p-cymene CH3, C1) Analysis 
Calculated: C 59.48, H 5.18, N 2.67% Analysis Found: C 59.40, H 5.20, N 
2.60% ES MS (+): m/z 490.11 [M
+
]-Cl 
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9.6.2 Preparation of C26H27ClFNORu (2) 
4-Fluoro--ketoiminate (L13) (0.13 g, 0.490 mmol) was dissolved in 
dichloromethane (30 mL), whilst stirring triethylamine (0.07 mL, 0.490 mmol) and 
[p-cymRuCl2]2 (0.15 g, 0.245 mmol) were added. The mixture was stirred for 16 
hours at room temperature and then the solvent was removed under reduced 
pressure. The crude product was recrystallised from methanol (10 mL), the residue 
was filtered and the solution stored at 4°C for 5 days, yielding red crystals of 2 
which were washed with THF (3 x 10 mL) (0.07 g, 0.133 mmol, 54%). 
1
H NMR (CDCl3, 500.57 MHz, 300.0 K) 
7.84 dd, 2H, H22 and H26, 
3
J (
1
H-
1
H)= 9.0 Hz 
and 
4
J (
1
H-
1
H)= 2.2 Hz), 7.75 (br. d, 1H, H14, 
3
J (
1
H-
1
H)= 9.0 Hz), 7.43 (br. t, 2H, H13 and 
H15, 
3
J (
1
H-
1
H)= 7.7 Hz), 7.26-7.22 (br. dd, 1H, 
H12 or H16, 
3
J (
1
H-
1
H)= 6.2 Hz and 
4
J (
1
H-
1
H) = 
2.1 Hz), 7.09 (br. d, 1H, H12 or H16, 
3
J (
1
H-
1
H)= 6.9 Hz), 7.03-6.99 (a. t (v. dd), 2H, 
H23 and H25, 
3
J (
1
H-
1
H) = 8.6 Hz and 
4
J (
1
H-
1
H) = 3.9 Hz), 5.37 (s, 1H, H19), 5.35 
(br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 Hz), 5.16 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 
Hz), 5.06 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.6 Hz), 3.68 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.6 Hz), 2.67 (br. sept, 1H, H8, 
3
J (
1
H-
1
H) = 6.9 Hz), 2.03 (s, 3H, H1), 1.79 (s, 
3H, H17), 1.20 (a. t (v.dd), 6H, H9 and H10, 
3
J (
1
H-
1
H) = 7.5 Hz) 
13
C{
1
H} NMR 
(CDCl3, 125.9 MHz, 300.0 K) quaternary C-O, C20), 164.8 (quaternary C-
N, C21), 163.6 (quaternary C-F, C24, 
1
J (
13
C-
19
F) = 247.4 Hz), 157.2 (quaternary C, 
C11 or C18), 137.5 (quaternary C, C11 or C18), 129.6 (aniline CH, C12 and C16), 
128.2 (aromatic CH, C22 and C26, 
3
J (
13
C-
19
F) = 7.3 Hz), 126.1 (aniline CH, C14), 
125.4 (aniline CH, C13 or C15), 123.9 (aniline CH, C13 or C15), 114.6 (aromatic CH, 
C23 and C25, 
2
J (
13
C-
19
F) = 21.7 Hz), 100.8 (quaternary C, C2 or C5), 96.2 
(quaternary C, C2 or C5), 94.2 (acnac CH, C19), 87.0 (p-cymene CH, C3,4,6,7), 84.6 
(p-cymene CH, C3,4,6,7), 84.5 (p-cymene CH, C3,4,6,7), 79.4 (p-cymene CH, C3,4,6,7), 
30.5 (p-cymene CH, C8), 24.7 (acnac CH3, C17), 23.6 (p-cymene CH3, C9 or C10), 
20.9 (p-cymene CH3, C9 or C10), 18.3 (p-cymene CH3, C1) Analysis Calculated: C 
59.48, H 5.18, N 2.67% Analysis Found: C 59.25, H 5.20, N 2.75% ES MS (+): 
m/z 490.11 [M
+
]-Cl 
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9.6.3 Preparation of C26H27Cl2NORu (3) 
4’-Chloro--ketoiminate (0.05 g, 0.184 mmol) was dissolved in dichloromethane 
(30 mL) and whilst stirring triethylamine (0.03 mL, 0.184 mmol) and [p-
cymRuCl2]2 (0.06 g, 0.092 mmol) were added. The mixture was stirred overnight at 
room temperature, and then the solvent removed under reduced pressure. The crude 
product was recrystallised from methanol (10 mL), and the residue filtered. The 
dark red solution was stored at 4°C for 2 days, yielding 3 as a red crystalline solid 
(0.06 g.0.114 mmol, 62%). 
1
H NMR (CDCl3, 500.23 MHz, 299.9 K) 
br. dt, 2H, H23 and H25, 
3
J (
1
H-
1
H)= 8.7 Hz and 
4
J (
1
H-
1
H)= 1.8 Hz ), 7.74 
(br. d, 1H, H13 or H15, 
3
J (
1
H-
1
H)= 7.5 Hz), 
7.43 (br. t, 2H, H12 and H16, 
3
J (
1
H-
1
H)= 8.3 
Hz), 7.30 (br. dt, 2H, H22 and H26, 
3
J (
1
H-
1
H)= 
8.7 Hz and 
4
J (
1
H-
1
H)= 2.0 Hz), 7.26-7.22 (br. t, 1H, H13 or H15, 
3
J (
1
H-
1
H)= 7.5 
Hz), 7.09 (br. d, 1H, H14, 
3
J (
1
H-
1
H) = 6.8 Hz), 5.39 (s, 1H, H19), 5.35 (br. d, 
H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 Hz), 5.16 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 Hz), 5.06 (br. 
d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.6 Hz), 3.68 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.6 Hz), 
2.67 (br. sept, 1H, H8, 
3
J (
1
H-
1
H) = 7.0 Hz), 2.03 (s, 3H, H1), 1.79 (s, 3H, H17), 1.21 
(d, 3H, CH3, H9 or H10, 
3
J (
1
H-
1
H) = 9.9 Hz), 1. 91 (d, 3H, CH3, H9 or H10, 
3
J (
1
H-
1
H) = 9.9 Hz) 
13
C{
1
H} NMR (CDCl3, 75.5 MHz, 300.1 K) quaternary C-
O, C20), 164.9 (quaternary C, C21), 157.2 (quaternary C-Cl, C24), 138.0 (quaternary 
C, C11 or C18), 135.2 (quaternary C, C11 or C18), 129.6 (aniline CH, C12 and C16), 
128.2 (aromatic CH, C23 or C25), 128.0 (aromatic CH, C23 or C25), 127.8 (aromatic 
CH, C22 and C26), 126.0 (aniline CH, C13 or C15), 125.5 (aniline CH, C13 or C15), 
123.3 (aniline CH, C14), 104.4 (quaternary C, C2 or C5), 96.3 (quaternary C, C2 or 
C5), 94.5 (acnac CH, C19), 87.1 (p-cymene CH, C3,4,6,7), 84.7 (p-cymene CH, 
C3,4,6,7), 84.6 (p-cymene CH, C3,4,6,7), 79.5 (p-cymene CH, C3,4,6,7), 30.5 (p-cymene 
CH, C8), 24.7 (acnac CH3, C17), 23.6 (p-cymene CH3, C9 or C10), 20.9 (p-cymene 
CH3, C9 or C10), 18.4 (p-cymene CH3, C1) Analysis Calculated: C 57.67, H 5.03, N 
2.59, Cl 13.09% Analysis Found: C 57.40, H 5.00, N 2.40, Cl 13.05% ES MS (+): 
m/z 506.08 [M
+
]-Cl 
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9.6.4 Preparation of C26H26Cl3NORu (4) 
2’,4’-Dichloro--ketoiminate (0.16 g, 0.523 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.07 mL, 0.523 mmol) 
and [p-cymRuCl2]2 (0.16 g, 0.261 mmol) were added. The mixture was stirred for 
16 hours at room temperature, and then the solvent removed under reduced 
pressure. The crude product was recrystallised from methanol (10 mL) and after a 
period of 2 days yielded red crystals of 4, which were further washed with petrol 
(40-60°) (3 x 5 mL) (0.19 g. 0.330 mmol, 63%). 
1
H NMR (CDCl3, 500.13 MHz, 240.2 K) 
br. d, 1H, H14, 
3
J (
1
H-
1
H) = 7.8 Hz ), 
7.45 (br. d, 2H, H13 and H15, 
3
J (
1
H-
1
H)= 6.2 
Hz), 7.35 (br. d, 1H, H25, 
3
J (
1
H-
1
H)= 5.9 Hz), 
7.32 (br. d, 1H, H26, 
3
J (
1
H-
1
H) = 8.2 Hz), 
7.26-7.23 (m, 1H, H12 or H16), 7.20 (br. dd, 
1H, H23, 
3
J (
1
H-
1
H)= 8.2 Hz and 
4
J (
1
H-
1
H)= 1.9 Hz), 5.30 (br. d, 1H, H3,4,6,7), 5.22 
(br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 Hz), 5.01 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.2 
Hz), 4.93 (s, 1H, H19), 3.44 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.1 Hz), 2.74 (br. sept, 
1H, H8, 
3
J (
1
H-
1
H) = 6.6 Hz), 2.05 (s, 3H, H1), 1.74 (s, 3H, H17), 1.27 (br. d, 3H, H9 
or H10, 
3
J (
1
H-
1
H) = 6.7 Hz), 1. 22 (br. d, 3H, H9 or H10, 
3
J (
1
H-
1
H) = 6.7 Hz) 
13
C{
1
H} NMR (CDCl3, 125.8 MHz, 240.2 K) quaternary C-O, C20), 164.3 
(quaternary C, C21), 156.7 (quaternary C, C18), 138.5 (quaternary C, C11), 133.9 
(quaternary C-Cl, C22 or C24), 131.4 (quaternary C-Cl, C22 or C24), 130.9 (aromatic 
CH, C25 or C26), 129.6 (aniline CH, C13 or C15), 129.1 (aromatic CH, C23), 127.8 
(aniline CH, C13 or C15), 126.7 (aromatic CH, C25 or C26), 125.2 (aniline CH, C14), 
99.6 (quaternary C, C2 or C5), 98.1 (acnac CH, C19), 97.2 (quaternary C, C2 or C5), 
87.8 (p-cymene CH, C3,4,6,7), 83.4 (p-cymene CH, C3,4,6,7), 83.2 (p-cymene CH, 
C3,4,6,7), 79.9 (p-cymene CH, C3,4,6,7), 30.1 (p-cymene CH, C8), 24.6 (acnac CH3, 
C17), 23.8 (p-cymene CH3, C9 or C10), 21.1 (p-cymene CH3, C9 or C10), 18.8 (p-
cymene CH3, C1) Analysis Calculated: C 54.22, H 4.55, N 2.43, Cl 18.47% 
Analysis Found: C 54.05, H 4.65, N 2.35, Cl 18.45% ES MS (+): m/z 540.04 
[M
+
]-Cl 
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9.6.5 Preparation of C26H26Cl3NORu (5) 
2’,5’-Dichloro--ketoiminate (L14) (0.28 g, 0.912 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.13 mL, 0.912 mmol) 
and [p-cymRuCl2]2 (0.28 g, 0.457 mmol) were added. The mixture was stirred for 
16 hours at room temperature, and then the solvent removed under reduced 
pressure. The crude product was recrystallised from methanol (10 mL) and after a 
period of 2 days yielded red crystalline precipitate of 5 which was further washed 
with THF (3 x 5 mL) (0.32 g. 0.558 mmol, 61%) 
1
H NMR (CDCl3, 300.13 MHz, 295.5 K) 
m, 1H, H14), 7.47-7.43 (br. d, 2H, 
H13 and H15), 7.42 (m, 1H, H23 or H24), 7.25 (d, 
2H, H12 and H16, 
3
J (
1
H-
1
H)= 7.0 Hz), 7.21-7.16 
(m, 1H, H26), 7.13-7.08 (m, 1H, H23 or H24), 
5.28 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 
5.14 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 5.02 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 
5.5 Hz), 4.94 (s, 1H, H19), 3.64 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.7 Hz), 2.76 (br. 
sept, 1H, H8, 
3
J (
1
H-
1
H) = 7.0 Hz), 2.07 (s, 3H, H1), 1.74 (s, 3H, H17), 1.28 (br. d, 
3H, CH3, H9 or H10, 
3
J (
1
H-
1
H) = 6.8 Hz), 1. 22 (br. d, 3H, CH3, H9 or H10, 
3
J (
1
H-
1
H) = 7.0 Hz) 
13
C{
1
H} NMR (CDCl3, 75.5 MHz, 295.6 K) quaternary C-
O, C20), 164.9 (quaternary C, C21), 156.9 (quaternary C-Cl, C22 and C25), 141.7 
(aromatic quaternary C, C11 or C18), 132.3 (quaternary C, C11 or C18), 130.6 (aniline 
CH, C13 or C15), 130.2 (aromatic CH, C23 or C24), 129.0 (aromatic CH, C26), 127.0 
(aniline CH, C13 or C15), 125.8 (aniline CH, C16 and C16), 125.6 (aniline CH, C14), 
123.2 (aromatic CH, C23 or C24), 100.7 (quaternary C, C2 or C5), 98.5 (acnac CH, 
C19), 97.2 (quaternary C, C2 or C5), 87.0 (p-cymene CH,C3,4,6,7), 83.7 (p-cymene 
CH, C3,4,6,7), 83.5 (p-cymene CH, C3,4,6,7), 80.4 (p-cymene CH, C3,4,6,7), 30.3 (p-
cymene CH, C8), 24.3 (acnac CH3, C17), 23.5 (p-cymene CH3, C9 or C10), 21.4 (p-
cymene CH3, C9 or C10), 18.6 (p-cymene CH3, C1) Analysis Calculated: C 54.22, 
H 4.55, N 2.43, Cl 18.47% Analysis Found: C 53.95, H 4.50, N 2.35, Cl 18.70% 
ES MS (+): m/z 540.05 [M
+
]-Cl 
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9.6.6 Preparation of C26H25Cl4NORu (6) 
2’,3’,4’-Trichloro--ketoiminate (L16) (0.11 g, 0.327 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.05 mL, 0.327 mmol) 
and [p-cymRuCl2]2 (0.10 g, 0.163 mmol) were added. The mixture was stirred for 
16 hours at room temperature, and then the solvent removed under reduced 
pressure. The crude product was recrystallised from methanol (10 mL) and stored 
at 4°C for 1 day, yielding red crystals of 6 (0.06 g. 0.098 mmol, 60%). 
 
1
H NMR (CDCl3, 300.13 MHz, 300.0 K) 
dd, 1H, H26, 
3
J (
1
H-
1
H)= 7.3 Hz, 
4
J (
1
H-
1
H)= 1.6 Hz), 7.45 (br. t, 2H, H13 and H15, 
3
J 
(
1
H-
1
H)= 8.5 Hz), 7.34 (d, 1H, H25, 
3
J (
1
H-
1
H)= 
8.3 Hz), 7.27-7.22 (m, 2H, H12 and H16), 7.14-
7.09 (m, 1H,  H14), 5.27 (br. d, 1H, H3,4,6,7, 
3
J 
(
1
H-
1
H) = 6.2 Hz), 5.12 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 5.03 (br. d, 1H, 
H3,4,6,7, 
3
J (
1
H-
1
H) = 5.7 Hz), 4.88 (s, 1H, H19), 3.63 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 
5.7 Hz), 2.76 (br. sept, 1H, H8, 
3
J (
1
H-
1
H) = 7.0 Hz), 2.07 (s, 3H, H1), 1.74 (s, 3H, 
H17), 1.30 (d, 3H, CH3, H9 or H10, 
3
J (
1
H-
1
H) = 6.8 Hz), 1. 23 (d, 3H, CH3, H9 or 
H10, 
3
J (
1
H-
1
H) = 7.0 Hz) 
13
C{
1
H} NMR (CDCl3, 75.5 MHz, 295.6 K) 
quaternary C-O, C20), 165.0 (quaternary C, C21), 156.9 (quaternary C, 
C18), 141.0 (quaternary C, C11), 133.4 (quaternary C-Cl, C22-24), 131.5 (quaternary 
C-Cl, C22-24), 130.9 (quaternary C-Cl, C22-24), 129.7 (aniline CH, C13 and C15), 
128.5 (aniline CH, C12 or C16), 128.1 (aniline CH, C12 or C16), 127.8 (aromatic CH, 
C25), 125.6 (aromatic CH, C25), 123.2 (aniline CH, C14), 100.8 (quaternary C, C2 or 
C5), 98.5 (acnac CH, C19), 97.2 (quaternary C, C2 or C5), 87.0 (p-cymene 
CH,C3,4,6,7), 83.8 (p-cymene CH, C3,4,6,7), 83.7 (p-cymene CH, C3,4,6,7), 80.4 (p-
cymene CH, C3,4,6,7), 30.3 (p-cymene CH, C8), 24.3 (acnac CH3, C17), 23.6 (p-
cymene CH3, C9 or C10), 21.4 (p-cymene CH3, C9 or C10), 18.6 (p-cymene CH3, C1) 
Analysis Calculated: C 51.16, H 4.13, N 2.29, Cl 23.23 % Analysis Found: C 
51.00, H 4.15, N 2.20, Cl 23.20% ES MS (+): m/z 574.00 [M
+
]-Cl 
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9.6.7 Preparation of C26H27BrClNORu (7) 
3’-Bromo--ketoiminate (L19) (0.24 g, 0.759 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.11 mL, 0.759 mmol) 
and [p-cymRuCl2]2 (0.23 g, 0.380 mmol) were added. The mixture was stirred for 
16 hours at room temperature, and then the solvent removed under reduced 
pressure. The crude product was recrystallised from methanol (10 mL) and stored 
at 4°C for 2 days, yielding a red crystalline solid of 7, which was further washed 
with THF (3 x 5mL) (0.31 g, 0.539 mmol, 71%). 
1
H NMR (CDCl3, 500.23 MHz, 300.0 K) 
br. t, 1H, H22, 
4
J (
1
H-
1
H) = 1.6 Hz), 7.76-
7.73 (br. d, 2H, H12 and H16, 
3
J (
1
H-
1
H) = 8.0 
Hz), 7.48 (br. d, 1H, H24, 
3
J (
1
H-
1
H)= 7.6 Hz), 
7.43 (br. t, 2H, H13 and H15, 
3
J (
1
H-
1
H)= 7.5 Hz), 
7.24 (br. t, 1H,  
3
J (
1
H-
1
H)= 7.6 Hz), 7.20 (t, 1H, 
3
J (
1
H-
1
H) = 7.9 Hz), 7.09 (d, 1H, H25, 
3
J (
1
H-
1
H) = 6.4 Hz), 5.38 (s, 1H, H19), 5.35 
(br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.4 Hz), 5.17 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 
Hz), 5.07 (br. d, 1H, p-cymene CH, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.6 Hz), 3.69 (br. d, 1H, 
H3,4,6,7, 
3
J (
1
H-
1
H) = 5.6 Hz), 2.67 (br. sept, 1H, H8), 2.03 (s, 3H, H1), 1.79 (s, 3H, 
H17), 1.22 (d, 3H, H9 or H10, 
3
J (
1
H-
1
H) = 7.1 Hz), 1.20 (d, 3H, CH3, H9 or H10, 
3
J 
(
1
H-
1
H) = 7.1 Hz) 
13
C{
1
H} NMR (CDCl3, 125.9 MHz, 301.2 K) 
quaternary C-O, C20), 165.1 (quaternary C, C21), 157.1 (quaternary C-Br, 
C23), 141.7 (quaternary  C, C11 or C18), 132.1 (aromatic CH, C24), 130.0 (aromatic 
CH, C22 and C26), 129.7 (aniline CH, C13 or C15), 129.3 (aniline CH, C14), 127.8 
(aniline CH, C13 or C15), 125.4 (aniline CH, C12 or C16), 125.4 (aniline CH, C12 or 
C16), 123.3 (aromatic CH, C25), 122.2 (quaternary C, C2 or C5), 101.0 (quaternary 
C, C2 or C5), 94.8 (acnac CH, C19), 87.1 (p-cymene CH, C3,4,6,7), 84.6 (p-cymene 
CH, C3,4,6,7), 84.4 (p-cymene CH, C3,4,6,7), 79.4 (p-cymene CH, C3,4,6,7), 30.5 (p-
cymene CH, C8), 24.7 (acnac CH3, C17), 23.3 (p-cymene CH3, C9 or C10), 21.0 (p-
cymene CH3, C9 or C10), 18.4 (p-cymene CH3, C1) Analysis Calculated: C 53.30, 
H 4.64, N 2.39% Analysis Found: C 52.90, H 4.60, N 2.35% ES MS (+): m/z 
522.03 [M
+
]-Cl (
79
Br) 
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9.6.8 Preparation of C26H27BrClNORu (8) 
4’-Bromo--ketoiminate (0.15 g, 0.490 mmol) was dissolved in dichloromethane 
(30 mL) and whilst stirring triethylamine (0.07 mL, 0.490 mmol) and [p-
cymRuCl2]2 (0.15 g, 0.245 mmol) were added. The mixture was stirred for 16 
hours at room temperature, and then the solvent removed under reduced pressure. 
The crude product was recrystallised from methanol (10 mL) and stored at 4°C. for 
2 days, yielding a red crystalline solid of 8, which was further washed with THF (3 
x 10 mL) (0.19 g, 0.324 mmol, 66%). 
1
H NMR (CDCl3, 300 MHz, 300 K) 7.76-
7.70m, 3H, H22, H26 and H13 or 15), 7.49-7.44 
(m, 3H, H23, H25 and H13 or 15), 7.42 (br. d, 1H, 
H12 or H16, 
3
J (
1
H-
1
H)= 7.6 Hz), 7.23 (a. br. t, 
1H, H12 or H16, 
3
J (
1
H-
1
H)= 7.4 Hz), 7.09 (br. 
d, 1H, H14, 
3
J (
1
H-
1
H)= 6.4 Hz), 5.39 (s, 1H, 
H19), 5.35 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 5.16 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 5.07 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.3 Hz), 3.68 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.7 Hz), 2.66 (br. sept, 1H, H8, 
3
J (
1
H-
1
H) = 6.9 Hz), 2.02 (s, 3H, H1), 
1.79 (s, 3H, H17), 1.20 (a. t, 6H, H9 and H10, 
3
J (
1
H-
1
H) = 6.3 Hz) 
13
C{
1
H} NMR 
(CDCl3, 75 MHz, 300 K) quaternary C-O, C20), 157.2 (quaternary C, C21), 
138.7(quaternary C-Br, C24), 135.2 (quaternary C, C11 or C18), 130.9 (aromatic CH, 
C23 and C25), 129.6 (aniline CH, C13 or C15), 128.5 (aromatic CH, C22 and C26), 
127.8 (aniline CH, C12 or C16), 126.0 (aniline CH, C13 or C15), 125.5 (aniline CH, 
C12 or C16), 123.3 (aniline CH, C14), 100.9 (quaternary C, C2 or C5), 96.2 
(quaternary C, C2 or C5), 94.4 (acnac CH, C19), 87.1 (p-cymene CH, C3,4,6,7), 84.6 
(p-cymene CH, C3,4,6,7), 84.5 (p-cymene CH, C3,4,6,7), 79.4 (p-cymene CH, C3,4,6,7), 
30.5 (p-cymene CH, C8), 24.7 (acnac CH3, C17), 23.3 (p-cymene CH3, C9 or C10), 
20.9 (p-cymene CH3, C9 or C10), 18.4 (p-cymene CH3, C1) Analysis Calculated: C 
53.30, H 4.64, N 2.39% Analysis Found: C 53.20, H 4.65, N 2.30% ES MS (+): 
m/z 552.03 [M
+
]-Cl (
79
Br) 
 
9.6.9 Preparation of C26H27ClINORu (9) 
4’-Iodo--ketoiminate (L20) (0.13 g, 0.405 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.06 mL, 0.405 mmol) 
and [p-cymRuCl2]2 (0.13 g, 0.205 mmol) were added. The mixture was stirred for 
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16 hours at room temperature, and then the solvent removed under reduced 
pressure. The crude product was washed recrystallised from methanol (10 mL) and 
stored at 4°C for 2 days, yielding red crystals of 9 (0.16 g, 0.2534 mmol, 62%) 
1
H NMR (CDCl3, 300 MHz, 300 K) 7.74 d, 
2H, H26 and H1, 
3
J (
1
H-
1
H)= 8.3 Hz ), 7.49-7.44 
(m, 3H, H23, H25 and H13 or 15), 7.42 (br. d, 1H, 
H12 or H16, 
3
J (
1
H-
1
H)= 7.6 Hz), 7.23 (a. br. t, 
1H, H12 or H16, 
3
J (
1
H-
1
H)= 7.4 Hz), 7.09 (br. d, 
1H, H14, 
3
J (
1
H-
1
H)= 6.4 Hz), 5.39 (s, 1H, H19), 
5.35 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 5.16 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 
6.2 Hz), 5.07 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.3 Hz), 3.68 (br. d, 1H, H3,4,6,7, 
3
J 
(
1
H-
1
H) = 5.7 Hz), 2.66 (br. sept, 1H, H8, 
3
J (
1
H-
1
H) = 6.9 Hz), 2.02 (s, 3H, H1), 
1.79 (s, 3H, H17), 1.20 (a. t, 6H, H9 and H10, 
3
J (
1
H-
1
H) = 6.3 Hz) 
13
C{
1
H} NMR 
(CDCl3, 75 MHz, 300 K) quaternary C-O, C20), 157.2 (quaternary C, C21), 
137.0 (quaternary C-I, C24), 135.2 (quaternary C, C11 or C18), 130.9 (aromatic CH, 
C23 and C25), 129.7 (aniline CH, C13 or C15), 128.7 (aromatic CH, C22 and C26), 
127.8 (aniline CH, C12 or C16), 126.0 (aniline CH, C13 or C15), 125.5 (aniline CH, 
C12 or C16), 123.3 (aniline CH, C14), 100.9 (quaternary C, C2 or C5), 95.7 
(quaternary C, C2 or C5), 94.5 (acnac CH, C19), 87.1 (p-cymene CH, C3,4,6,7), 84.7 
(p-cymene CH, C3,4,6,7), 84.5 (p-cymene CH, C3,4,6,7), 79.5 (p-cymene CH, C3,4,6,7), 
30.5 (p-cymene CH, C8), 24.7 (acnac CH3, C17), 23.4 (p-cymene CH3, C9 or C10), 
21.0 (p-cymene CH3, C9 or C10), 18.4 (p-cymene CH3, C1) Analysis Calculated: C 
49.34, H 4.30, N 2.21% Analysis Found: C 48.80, H 4.30, N 2.20% ES MS (+): 
m/z 632.85 [M
+
] 
 
9.6.10 Preparation of C28H32ClNO2Ru (10) 
4-Ethoxy--ketoiminate (L25) (0.14 g, 0.490 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.07 mL, 0.490 mmol) 
and [p-cymRuCl2]2 (0.15 g, 0.245 mmol) were added. The mixture was stirred for 
16 hours at room temperature, and then the solvent removed under reduced 
pressure. The crude product was washed with petrol (40-60°) (3 x 5 mL) and 
recrystallised from methanol (10 mL) and stored at 4°C for 2 days, yielding red 
crystals of 9, which were further washed with petrol (40-60°) (3 x 5 mL) (0.16 g, 
0.294 mmol, 60%). 
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1
H NMR (CDCl3, 500.57 MHz, 300.7 K) 
br. d, 2H, H22 and H26, 
3
J (
1
H-
1
H)= 8.7 Hz), 7.76 (br. d, 1H, H14, 
3
J (
1
H-
1
H)= 8.2 Hz), 7.42 (br. t, 2H, H13 and 
H15, 
3
J (
1
H-
1
H)= 7.6 Hz), 7.25-7.20 (m, 
1H, H12 or H16), 7.10 (br. d, 1H, H12 or 
H16, 
3
J (
1
H-
1
H)= 7.4 Hz), 6.84 (br. d, 2H, H23 and H25, 
3
J (
1
H-
1
H)= 8.7 Hz), 5.39 (s, 
1H, H19), 5.34 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.0 Hz), 5.16 (br. d, 1H, H3,4,6,7, 
3
J 
(
1
H-
1
H) = 6.0 Hz), 5.05 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.0 Hz), 4.07 (q, 2H, H27, 
3
J (
1
H-
1
H) = 6.9 Hz), 3.69 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.0 Hz), 2.68 (br. sept, 
1H, H8, 
3
J (
1
H-
1
H)= 7.4 Hz), 2.03 (s, 3H, H1), 1.78 (s, 3H, H17), 1.43 (t, 3H, H28, 
3
J 
(
1
H-
1
H) = 6.9 Hz), 1.24-1.16 (br. t, 6H, H9 and H10, 
3
J (
1
H-
1
H) = 6.9 Hz) 
13
C{
1
H} 
NMR (CDCl3, 125.5 MHz, 300.7 K) quaternary C-O, C20), 164.3 
(quaternary C, C21), 160.2 (quaternary C-O, C24), 157.4 (quaternary C, C11 or C18), 
131.(quaternary C, C11 or C18), 128.5 (aromatic CH, C22 and C26), 127.7 (aniline 
CH, C13 and C15), 126.3 (aniline CH, C14), 125.3 (aniline CH, C12 or C16), 123.7 
(aniline CH, C12 or C16), 113.6 (aromatic CH, C23 and C25), 100.7 (quaternary C, C2 
or C5), 96.1 (quaternary C, C2 or C5), 93.5 (acnac CH, C19), 87.1 (p-cymene CH, 
C3,4,6,7), 84.6 (p-cymene CH, C3,4,6,7), 84.4 (p-cymene CH, C3,4,6,7), 79.4 (p-cymene 
CH, C3,4,6,7), 63.4 (ethoxy CH2, C27), 30.5 (p-cymene CH, C8), 24.7 (acnac CH3, 
C17), 23.4 (p-cymene CH3, C9 or C10), 21.0 (p-cymene CH3, C9 or C10), 18.4 (p-
cymene CH3, C1), 14.8 (ethoxy CH3, C28) Analysis Calculated: C 61.03, H 5.85, N 
2.54, Cl 6.43% Analysis Found: C 59.65, H 5.85, N 2.55, Cl I/m% ES MS (+): 
m/z 516.15 [M
+
]-Cl 
 
2.1.1 Preparation of C27H30ClNORu (11)  
4’-Methyl--ketoiminate (L11) (0.05 g, 0.187 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.03 mL, 0.187 mmol) 
and [p-cymRuCl2]2 (0.06 g, 0.094 mmol) were added. The mixture was stirred for 
16 hours at room temperature, and then the solvent removed under reduced 
pressure. The crude product was recrystallised from methanol (10 mL) and stored 
at 4°C for 2 days, yielding red crystals of 11 (0.06 g, 0.115 mmol, 62%) 
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1
H NMR (CDCl3, 300 MHz, 300 K) 
br. d, 2H, H22 and H26, 
3
J (
1
H-
1
H)= 8.3 
Hz), 7.42 (br. t, 2H, H13 and H15, 
3
J (
1
H-
1
H)= 
7.7 Hz), 7.25-7.20 (m, 2H, H12 or H16), 7.14 
(br. d, 2H, H23 or H25, 
3
J (
1
H-
1
H)= 7.9 Hz), 
7.09 (br. d, 1H, H24, 
3
J (
1
H-
1
H)= 7.2 Hz), 5.42 
(s, 1H, H19), 5.35 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 Hz), 5.17 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.0 Hz), 5.06 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.7 Hz), 3.69 (br. d, 1H, 
H3,4,6,7, 
3
J (
1
H-
1
H) = 5.7 Hz), 2.68 (br. sept, 1H, H8, 
3
J (
1
H-
1
H)= 6.9 Hz), 2.37 (s, 
3H, methyl H27), 2.03 (s, 3H, H1), 1.79 (s, 3H, H17), 1.24-1.16 (m, 6H, H9 and H10) 
13
C{
1
H} NMR (CDCl3, 75 MHz, 300 K) quaternary C-O, C20), 164.5 
(quaternary C, C21), 157.4 (quaternary C, C18), 139.4 (quaternary C, C11), 
136.8.(quaternary C, C24), 128.5 (aromatic CH, C23 and C25), 127.6 (aniline CH, 
C13 and C15), 126.9 (aromatic CH, C22 and C26), 125.3 (aniline CH, C12 or C16), 
123.5 (aniline CH, C14), 100.7 (quaternary C, C2 or C5), 96.2 (quaternary C, C2 or 
C5), 94.0 (acnac CH, C19), 87.2 (p-cymene CH, C3,4,6,7), 84.6 (p-cymene CH, 
C3,4,6,7), 84.4 (p-cymene CH, C3,4,6,7), 79.4 (p-cymene CH, C3,4,6,7), 30.4 (p-cymene 
CH, C8), 24.7 (acnac CH3, C17), 23.4 (p-cymene CH3, C9 or C10), 21.4 (methyl CH3, 
C27), 20.9 (p-cymene CH3, C9 or C10), 18.4 (p-cymene CH3, C1) Analysis 
Calculated: C 62.24, H 5.80, N 2.69, Cl 6.80% Analysis Found: C 62.10, H 5.85, 
N 2.65, Cl 6.85% ES MS (+): m/z 486.14 [M
+
]-Cl 
 
9.6.11 Preparation of C30H30ClNORu (12) 
3’-Nathyl--ketoiminate (L28) (0.08 g, 0.281 mmol) was dissolved in 
dichloromethane (30 mL) and whilst stirring triethylamine (0.04 mL, 0.281 mmol) 
and [p-cymRuCl2]2 (0.09 g, 0.141 mmol) were added. The mixture was stirred for 
16 hours at room temperature, and then the solvent removed under reduced 
pressure. The crude product was recrystallised from methanol (10 mL) and stored 
at 4°C for 2 days, yielding red crystals of 12 (0.10 g, 0.172 mmol, 61%) 
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1
H NMR (CDCl3, 300 MHz, 300 K) 
m, 3H, aromatic CH), 7.53-7.36 
(m, 9H, aromatic CH), 5.60 (s, 1H, H19), 5.56 
(br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 5.49 
(br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.5 Hz), 5.27 
(br. d, 2H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.7 Hz), 3.00-
2.90 (m, 1H, H8), 2.13 (s, 3H, H1), 1.57 (s, 3H, H17), 1.35 (dd, 6H, H9 and H10, 
3
J 
(
1
H-
1
H) = 6.9 Hz and 
3
J (
1
H-
1
H) = 3.9Hz) 
13
C{
1
H} NMR (CDCl3, 75 MHz, 300 K) 
quaternary C-O, C20), 154.3 (quaternary C, C21), 148.3 (quaternary C, C11 
or C18), 133.7.(quaternary C, C11 or C18), 126.7 (quaternary C, C22 or C27), 125.4 
(quaternary C, C22 or C27), 129.8 (aromatic CH), 127.8 (aromatic CH), 126.4 
(aromatic CH), 126.0 (aromatic CH), 125.0 (aromatic CH), 124.6 (aromatic CH), 
100.8 (quaternary C, C2 or C5), 99.8 (acnac CH, C19), 97.5 (quaternary C, C2 or 
C5), 84.3 (p-cymene CH, C3,4,6,7), 82.5 (p-cymene CH, C3,4,6,7), 79.1 (p-cymene CH, 
C3,4,6,7), 79.0 (p-cymene CH, C3,4,6,7), 30.7 (p-cymene CH, C8), 27.9 (acnac CH3, 
C17), 22.4 (p-cymene CH3, C9 or C10), 22.3 (p-cymene CH3, C9 or C10), 17.9 (p-
cymene CH3, C1) Analysis Calculated: C 64.68, H 5.43, N 2.51, Cl 6.36% 
Analysis Found: C 61.70, H 5.35, N 1.55, Cl 7.30% ES MS (+): m/z 522.1 [M
+
]-
Cl  
 
9.6.12 Preparation of C30H30ClNORu (13) 
4’-Fluoro-2,4-difluoroaniline--ketoiminate (L29) (0.14 g, 0.512 mmol) was 
dissolved in dichloromethane (30 mL) and whilst stirring triethylamine (0.07 mL, 
0.512 mmol) and [p-cymRuCl2]2 (0.16 g, 0.256 mmol) were added. The mixture 
was stirred for 16 hours at room temperature, and then the solvent removed under 
reduced pressure. The crude product was recrystallised from methanol (10 mL) and 
stored at 4°C for 2 days, yielding red crystals of 13, which were further washed 
with petrol (40-60°) (3 x 5 mL) (0.18 g, 0.317 mmol, 62%). 
1
H NMR (CDCl3, 300.13 MHz, 300.0 K) 
7.88-7.81 m, 2H, H22 and H26), 7.65 (ddd, 
1H, H16, 
3
J (
1
H-
19
F)= 9.3 Hz, 
4
J (
1
H-
19
F)= 6.2 
Hz and 
4
J (
1
H-
1
H)= 3.2 Hz), 7.18 (td, 1H, H13, 
3
J (
1
H-
19
F)= 9.1 Hz and 
3
J (
1
H-
1
H)= 4.8 Hz), 
7.06-6.97 (m, 2H, H23 and H25), 6.93 (ddt, 1H, 
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H14, 
3
J (
1
H-
19
F) = 9.1 Hz, 
3
J (
1
H-
1
H)= 7.2 Hz and 
4
J (
1
H-
19
F)= 3.5 Hz), 5.43 (s, 1H, 
H19), 5.41 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.7 Hz), 5.24 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.7 Hz), 5.18 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 3.86 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 5.5 Hz), 2.65 (br. sept, 1H, H8, 
3
J (
1
H-
1
H)= 7.0 Hz), 2.05 (s, 3H, H1), 
1.82 (br. d, 3H, H17, 
5
J (
1
H-
19
F) = 0.8 Hz), 1.18 (dd (vt), 6H, H9 and H10, 
3
J (
1
H-
1
H) 
= 7.3 Hz) 
13
C{
1
H} NMR (CDCl3, 75.5 MHz, 300.1 K) 166.1 quaternary C-O, 
C20), 163.8 (d, quaternary aromatic C-F, C24, 
1
J (
13
C-
19
F) = 247.2 Hz), 161.4 
(quaternary C, C21), 155.0 (d, quaternary aniline C-F, C12 or C15, 
1
J (
13
C-
19
F) = 
213.9 Hz), 152.6 (d, quaternary aniline C-F, C12 or C15, 
1
J (
13
C-
19
F) = 225.0 Hz), 
135.4 (quaternary C, C18), 131.3 (d, quaternary aromatic C, C11, 
2
J (
13
C-
19
F) = 
119.9 Hz) 128.9 (aromatic CH, C22 and C26, 
3
J (
13
C-
19
F) = 8.7 Hz), 115.8 (d, 
aniline CH, C13, C14 or C16, 
2
J (
13
C-
19
F) = 23.5 Hz), 115.6 (d, aniline CH, C13, C14 
or C16, 
2
J (
13
C-
19
F) = 23.5 Hz), 114.7 (aromatic CH, C23 and C25, 
2
J (
13
C-
19
F) = 
22.3 Hz), 113.3 (d, aniline CH, C13, C14 or C16, 
2
J (
13
C-
19
F) = 16.1 Hz), 101.1 
(quaternary C, C2 or C5), 96.1 (quaternary C, C2 or C5), 94.2 (acnac CH, C19), 86.9 
(p-cymene CH, C3,4,6,7), 84.9 (p-cymene CH, C3,4,6,7), 84.3 (p-cymene CH, C3,4,6,7), 
78.5 (p-cymene CH, C3,4,6,7), 30.6 (p-cymene CH, C8), 23.9 (p-cymene CH3, C9 or 
C10), 23.2 (p-cymene CH3, C9 or C10), 20.7 (acnac CH3, C17), 18.3 (p-cymene CH3, 
C1) Analysis Calculated: C 55.66, H 4.49, N 2.50% Analysis Found: C 55.45, H 
4.50, N 2.45% ES MS (+): m/z 526.09 [M
+
]-Cl 
 
9.7 Ruthenium and Iridium Adaptations 
9.7.1 Preparation of RuC16H21Cl2NO (14) 
Aniline (0.03 mL, 0.355 mmol) was added to dichloromethane (30 mL) and whilst 
stirring Et3N (0.05 mL, 0.356 mmol) and [p-cymRuCl2]2 (0.11g, 0.180 mmol) were 
added. The mixture was stirred for 16 hours and then the solvent removed under 
reduced pressure. The crude product was recrystallised from methanol (10 mL) and 
stored at 4°C for 3 days, yielding red crystals of 14. These were filtered and excess 
precipitate washed with benzene (10 mL) (0.08 g, 0.210 mmol, 59%). This 
complex has previously been prepared,
11
 although the X-ray crystal structure has 
been reported in Chapter 5, 
1
H NMR and microanalyis have been reported here to 
prove synthesis. 
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1
H NMR (CDCl3, 500 MHz, 300.0 K) 7.41 br. t, 2H, 
H13 and H15, 
3
J (
1
H-
1
H)= 7.3 Hz), 7.31 (br. d, 2H, H12 
and H16, 
3
J (
1
H-
1
H)= 7.6 Hz), 7.26-7.23 (m, 1H, H4), 
5.03 (br. d, 2H, H3 and H7, 
3
J (
1
H-
1
H) = 5.8 Hz), 4.89 
(br. d, 2H, H4 and H6, 
3
J (
1
H-
1
H) = 6.1 Hz), 4.75 (br. s, 
2H, NH2), 2.90 (br. sept, 1H, H8, 
3
J (
1
H-
1
H)= 6.7 Hz), 
2.16 (s, 3H, H1), 1.26 (br. d, 6H, H9 and H10, 
3
J (
1
H-
1
H) = 7.0 Hz) Analysis 
Calculated: C 55.35, H 5.70, N 2.93, Cl 14.37% Analysis Found: C 54.85, H 
5.50, N 3.10, Cl 13.00%  
 
9.7.2 Preparation of RuC25H25ClNO (15) 
Diphenyl--ketoiminate (0.08 g, 0.360 mmol) was added to dichloromethane (30 
mL), and whilst stirring Et3N (0.05 mL, 0.360 mmol) and [p-cymRuCl2]2 (0.11g, 
0.180 mmol) were added. The mixture was stirred for 16 hours and then the solvent 
removed until reduced pressure. The crude product was recrystallised from 
methanol (10 mL) and stored at 4°C and after a period of several days yielded red 
crystals of 15 (0.08g, 0.211 mmol). 
1
H NMR (CDCl3, 300 MHz, 300.0 K) 7.90-7.85 
m, 2H, H12-16 or H21-25), 7.61-7.56 (m, 2H, H12-16 or 
H21-25), 7.45-7.30 (m, 2H, H12-16 or H21-25), 5.72 (d, 
1H, NH, 
4
J (
1
H-
1
H) = 2.3 Hz), 5.45 (br. s, 2H, 
H3,4,6,7), 5.21 (m, 2H, H3,4,6,7), 2.85 (br. sept, 1H, H8, 
3
J (
1
H-
1
H)= 7.0 Hz), 2.30 (s, 3H, H1), 1.32 (br. d, 
6H, H9 and H10, 
3
J (
1
H-
1
H) = 6.8 Hz) 
13
C{
1
H} NMR 
(CDCl3, 75 MHz, 300.0 K) quaternary C-O, C19), 206.4 (quaternary C-O, 
C20), 174.5 (quaternary C, C17), 159.3 (quaternary C, C11), 129.7 (aromatic CH, 
C12-16 or C21-25), 128.7 (aromatic CH, C12-16 or C21-25), 127.8 (aromatic CH, C12-16 or 
C21-25), 126.9 (aromatic CH, C12-16 or C21-25), 126.2 (aromatic CH, C12-16 or C21-25), 
100.9 (quaternary p-cymene C, C2 or C5), 99.8 (quaternary p-cymene C, C2 or C5), 
99.3 (acnac CH, C18), 91.8 (p-cymene CH, C3,4,6,7), 84.9 (p-cymene CH, C3,4,6,7), 
30.7 (p-cymene CH, C8), 25.2 (p-cymene CH3, C9 or C10), 18.3 (p-cymene CH3, C1) 
Analysis Calculated: C 60.91, H 5.32, N 2.84, Cl 7.19% Analysis Found: C 
60.90, H 5.30, N 3.10, Cl 7.40% ES MS (+): m/z 456.33 [M
+
]-Cl 
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9.7.3 Preparation of RuC20H22ClFO2 (16) 
3’-Fluoro--diketonate (0.09 g, 0.49 mmol) dissolved in dichloromethane (30 mL) 
and whilst stirring triethylamine (0.07 mL, 0.49 mmol) and [p-cymRuCl2]2 (0.15 g, 
0.245 mmol) were added. The mixture was stirred at room temperature for 16 
hours, and then the solvent removed under reduced pressure. The crude product 
was recrystallised from methanol at 4°C for 2 days, yielded red crystals of 16 (0.18 
g, 0.401 mmol, 82%). 
1
H NMR (CDCl3, 500.13 MHz, 299.2 K) br. 
d, 1H, H20, 
3
J (
1
H-
1
H) = 7.8 Hz), 7.54 (br. dt, 1H, 
H16, 
3
J (
1
H-
19
F) = 9.3 Hz and 
4
J (
1
H-
1
H) = 2.6 Hz), 
7.30 (dt, 1H, H19, 
3
J (
1
H-
1
H) = 7.8 Hz and 
3
J (
1
H-
1
H) = 5.7 Hz), 7.11 (td, 1H, H18, 
3
J (
1
H-
1
H) = 8.3 
Hz, 
3
J (
1
H-
19
F) = 2.6 Hz and 
4
J (
1
H-
1
H) = 1.0 Hz), 
5.75 (s, 1H, H13), 5.55 (br. d, 1H, H3,4,6,7, 
3
J (
1
H-
1
H) = 6.4 Hz), 5.52 (br. d, 1H, 
H3,4,6,7, 
3
J (
1
H-
1
H) = 6.2 Hz), 5.26 (m, 2H, H3,4,6,7), 2.97 (m, 1H, H8), 2.30 (br. s, 
3H, H1), 2.14 (br. s, 3H, H11), 1.37 (br. d, 6H, H9 and H10, 
3
J (
1
H-
1
H) = 6.7 Hz) 
13
C{
1
H} NMR (CDCl3, 125.8 MHz, 299.2 K) quaternary C-O, C12 or C14), 
177.9 (quaternary C-O, C12 or C14), 162.6 (d, quaternary C-F, C17, 
1
J (
13
C-
19
F) = 
246.1 Hz), 140.8 (quaternary C, C15), 129.5 (d, aromatic CH, C19, 
4
J (
13
C-
19
F) = 8.6 
Hz), 122.4 (d, aromatic CH, C20, 
5
J (
13
C-
19
F) = 3.2 Hz), 117.6 (d, aromatic CH, C18, 
3
J (
13
C-
19
F) = 21.5 Hz), 114.3 (d, aromatic CH, C16, 
3
J (
13
C-
19
F) = 23.6 Hz), 99.8 
(quaternary p-cymene C, C2 or C5), 97.5 (quaternary p-cymene C, C2 or C5), 96.1 
(acac CH, C13), 83.0 (p-cymene CH, C3,4,6,7), 82.6 (p-cymene CH, C3,4,6,7), 79.2 (p-
cymene CH, C3,4,6,7), 30.8 (p-cymene CH, C8), 28.2 (acac CH3, C11), 22.4 (p-
cymene CH3, C9 or C10), 22.31 (p-cymene CH3, C9 or C10), 18.03 (p-cymene CH3, 
C1) Analysis Calculated: C 53.39, H 4.93% Analysis Found: C 53.40, H, 4.90% 
ES MS (+): m/z 415.07 [M
+
]-Cl 
 
9.7.4 Preparation of C16H14ClFO2Ru (17) 
3’-Fluoro--diketonate (0.07 g, 0.383 mmol) dissolved in dichloromethane (30 
mL) and whilst stirring triethylamine (0.05 mL, 0.383 mmol) and [benzeneRuCl2]2 
(0.10 g, 0.191 mmol) were added. The mixture was stirred at room temperature for 
16 hours, and then the solvent removed under reduced pressure. The crude product 
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was recrystallised from methanol (10 mL) and strored at 4°C for 2 days, yielding 
red crystals of 17 (0.12 g, 0.288 mmol, 67%). 
1
H NMR (CDCl3, 500 MHz, 300.0 K) br. d, 
1H, H16, 
3
J (
1
H-
1
H) = 7.9 Hz), 7.56 (m, 1H, H12), 7.30 
(br. d, 1H, H15, 
3
J (
1
H-
1
H) = 7.8), 7.11 (m, 1H, H14), 
5.81 (s, 6H, C6H6), 5.77 (s, 1H, H9), 2.15 (br. s, 3H, H7) 
13
C{
1
H} NMR (CDCl3, 75 MHz, 299.2 K) 
quaternary C-O, C8 or C10), 180.1 (quaternary 
C-O, C8 or C10), 163.0 (d, quaternary C-F, C13, 
1
J (
13
C-
19
F) = 245.1 Hz), 142.2 
(quaternary C, C11), 129.6 (aromatic CH, C15), 122.5 (d, aromatic CH, C16), 117.8 
(d, aromatic CH, C14, 
3
J (
13
C-
19
F) = 21.0 Hz), 114.5 (d, aromatic CH, C12, 
3
J(
13
C-
19
F) = 23.9 Hz), 98.5 (aromatic CH, C6H6), 96.5 (acac CH, C9), 28.3 (acac CH3, C7) 
micro-analysis pending, MS (+): m/z 359.0 [M
+
]-Cl 
 
9.7.5 Preparation of C20H23ClFO2Ir (19) 
3’-Fluoro--diketonate (0.04 g, 0.222 mmol) dissolved in dichloromethane (30 mL 
and whilst stirring triethylamine (0.03 mL, 0.200 mmol) and [Cp*IrCl2]2 (0.08 g, 
0.100 mmol) were added. The mixture was stirred at room temperature for 16 
hours, and then the solvent removed under reduced pressure. The crude product 
was recrystallised from methanol (10 mL) and strored at 4°C for several days 
yielded yellow crystals of 19 (0.07 g, 0.129 mmol, 58%). 
1
H NMR (CDCl3, 300 MHz, 299.2 K) 
m, 1H, H19), 7.61-7.54 (m, 1H, H20), 
7.35-7.28 (m, 1H, H18), 7.19-7.10 (m, 1H, H16), 5.85 
(s, 1H, H13), 2.08 (s, 3H, H11), 1.66 (br. s, 15H, H6-10) 
13
C{
1
H} NMR (CDCl3, 75 MHz, 300 K) 
quaternary C-O, C12 or C14), 175.5 
(quaternary C-O, C12 or C14), 162.7 (d, quaternary C-F, C17, 
1
J (
13
C-
19
F) = 243.5 
Hz), 141.1 (quaternary C, C15), 129.6 (d, aromatic CH, C19, 
3
J (
13
C-
19
F) = 8.7 Hz), 
122.6 (d, aromatic CH, C20, 
4
J (
13
C-
19
F) = 2.5 Hz), 117.5 (d, aromatic CH, C18, 
2
J 
(
13
C-
19
F) = 21.0 Hz), 113.9 (d, aromatic CH, C16, 
2
J (
13
C-
19
F) = 23.5 Hz), 97.3 
(acac CH, C13), 83.7 (quaternary C, Cp* CCH3, C1-5), 28.2 (acac CH3, C11), 8.7 
(Cp* CCH3, C6-10) Analysis Calculated: C 44.31, H 4.28, Cl 6.54% Analysis 
Found: C 44.55, H, 4.20, Cl I/m (re-send)% ES MS (+): m/z 507.0 [MH
+
]-Cl 
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9.8 Syntheses of Titanium(IV) -Diketonate Complexes 
The following complexes were synthesised following a modification of previously 
established synthetic route from within the McGowan group.
12
 
9.8.1 Preparation of Ti2(C28H20N2O4)(OCH3)6 (20) 
L5 (0.30 g, 1.33 mmol) dissolved with stirring in dry THF (20 mL) and added to a 
stirred solution of Ti(O
i
Pr)4 (0.20 mL, 0.67 mmol) in dry THF (20 mL). The yellow 
solution was stirred for 4 hours and then the solvent removed in vacuo. The crude 
yellow product was washed with dry MeOH (20 mL) and filtered; the solution was 
stored at -20°C and yielded yellow crystals of 20 after a period of several days. 
X-ray crystallographic analysis was obtained for complex 20, but the crystals 
disintegrated after exposure to air and no further analytical data was obtained. 
Further synthesis has proven unsuccessful to date. 
 
9.8.2 Preparation of Ti(C32H26F2N2O2)Cl2 (21) 
3’-Fluoro--ketoiminate (L12) (0.66 g, 2.59 mmol) and KH (0.11 g, 2.74  mmol) 
were dissolved with stirring in dry dichloromethane (20 mL) and added to a stirred 
solution of TiCl4 (0.14 mL, 1.29 mmol) in dry dichloromethane (20 mL). The dark 
red solution was stirred for approximately 16 hours and then the solvent filtered in 
vacuo. The solution was stored at -20°C, yielding yellow crystals of 21 after a 
period of several days. 
X-ray crystallographic analysis was obtained for complex 21, but the crystals 
disintegrated after exposure to air and no further analytical data was obtained. 
Further synthesis has proven unsuccessful to date. 
 
9.8.3 Preparation of Ti(C32H26Cl2N2O2)Cl2 (22) 
4’-Chloro--ketoiminate (0.13 g, 0.478 mmol) and KH (0.025 g, 0.623 mmol) were 
dissolved with stirring in dry dichloromethane (20 mL) and added to a stirred 
solution of TiCl4 (0.03 mL, 0.239 mmol) in dry dichloromethane (20 mL). The 
dark red solution was stirred for approximately 16 hours and then the solvent 
removed in vacuo. The suspension was filtered and the solution was stored at -
20°C, yielding yellow crystals of 22 after a period of several days. 
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X-ray crystallographic analysis was obtained for complex 22, but the crystals 
disintegrated after exposure to air and no further analytical data was obtained. 
Further synthesis has proven unsuccessful to date. 
 
9.8.4 Preparation of Ti(C32H26F2N2O2)Cl2 (23) 
4-Fluoro--ketoiminate (L13) (0.39 g, 1.61 mmol) and KH (0.06 g, 1.61 mmol) 
were dissolved with stirring in dry dichloromethane (20 mL) and added to a stirred 
solution of TiCl4 (0.03 mL, 0.239 mmol) in dry dichloromethane (20 mL). The 
dark red solution was stirred for approximately 16 hours the solution, turning green 
overnight. The solution was stored at 
-
20°C and had returned to the dark red colour 
first seen. After a period of several weeks orange crystals of 23 were obtained. 
X-ray crystallographic analysis was obtained for complex 23, but the crystals 
disintegrated after exposure to air and no further analytical data was obtained. 
Further synthesis has since proven to be unsuccessful to date. 
 
9.8.5 Preparation of Ti(C34H32N2O2)Cl2 (24) 
4-Methyl--ketoiminate (L11) (0.50 g, 1.99 mmol) in dry diethyl ether (20 mL) 
was stirred and cooled to 
-
78°C, 
n
BuLi 1.6M in hexane (1.24 mL, 1.99 mmol) was 
added and the suspension allowed to warm to room temperature. This was then 
filtered onto a stirred solution of TiCl4 (0.11 mL, 0.995 mmol) in dry diethyl ether 
(20 mL) at -78°C. Once added the dark red solution was allowed to warm to room 
temperature and stirred for approximately 16 hours. The solvent was filtered in 
vacuo and the crude product recrystallised from acetonitrile (20 mL) and stored at -
20°C, yielding yellow crystals of 24 after a period of several days. 
X-ray crystallographic analysis was obtained for complex 24, but the crystals 
disintegrated after exposure to air and no further analytical data was obtained. 
Further synthesis has proven unsuccessful to date 
 
9.8.6 Preparation of Ti(C36H36N2O2)Cl2 (25) 
4-Methyl--ketoiminate (L19) (0.54 g, 2.04 mmol) in dry diethyl ether (20 mL) 
was stirred and cooled to -78°C, 
n
BuLi 1.6M in hexane (1.27 mL, 2.04 mmol) was 
added and the suspension allowed to warm to room temperature. This was then 
filtered onto a stirred solution of TiCl4 (0.11 mL, 1.02 mmol) in dry diethyl ether 
(20 mL) at 
-
78°C. Once added the dark red solution was allowed to warm to room 
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temperature and stirred for approximately 16 hours. The solvent was filtered in 
vacuo and the crude product recrystallised from acetonitrile (20 mL) and stored at 
-
20°C, yielding yellow crystals of 25 after a period of several days (0.71 g, 1.10 
mmol, 54%). 
1
H NMR (CDCl3, 500 MHz, 300 K) d, 
4H, H12 and H16, 
3
J (
1
H-
1
H) = 8.3 Hz), 7.37-
7.34 (m, 2H, H2 or H6), 7.09 (d, 4H, H13 and 
H15, 
3
J (
1
H-
1
H) = 8.3 Hz), 7.05 (dtd, 4H, H3 
and H5, 
3
J (
1
H-
1
H) = 7.7 Hz, 
4
J (
1
H-
1
H) = 3.95 
(x 2) Hz and 
4
J (
1
H-
1
H) = 2.3 Hz), 6.78 (br. t, 
2H, H4, 
3
J (
1
H-
1
H) = 7.6 Hz), 6.69-6.66 (m, 
2H, H2 or H6), 6.08 (s, 2H, H9), 2.66 (q, 4H, H17, 
3
J (
1
H-
1
H) = 7.5 Hz), 1.83 (br. s, 
6H, H7), 1.24 (t, 6H, H18, 
3
J (
1
H-
1
H) = 7.6 Hz) 
13
C NMR (CDCl3, 75 MHz, 300 K) 
quaternary C-O, C10), 169.9 (quaternary aromatic C, C11), 151.1 
(quaternary aniline C, C1), 148.1 (quaternary C-N, C8), 130.9 (quaternary aromatic 
C, C14), 128.9 (aromatic CH, C3 or C5), 128.0 (aromatic CH, C3 or C5), 127.5 
(aromatic CH, C12,13,15 and 16), 125.6 (aromatic or aniline CH, C2,4 or 6), 125.4 
(aromatic or aniline CH, C2,4 or 6), 121.8 (aniline CH, C2 or 6), 105.6 (acnac CH, C9), 
28.9 (ethyl CH2CH3, C17), 25.1 (aliphatic CH3, C7), 15.3 (ethyl CH2CH3, C18)  
 
9.8.7 Preparation of Ti(C32H24Cl4N2O2)Cl2 (26) 
2’,5’-Dichloro--ketoiminate (L14) (0.30 g, 0.979 mmol) in dry diethyl ether (20 
mL) was stirred and cooled to 
-
78°C, 
n
BuLi (0.61 mL, 0.979 mmol) was added and 
the suspension allowed to warm to room temperature. This was then filtered onto a 
stirred solution of TiCl4 (0.05 mL, 0.490 mmol) in dry diethyl ether (20 mL) at -
78°C. Once added the red solution was allowed to warm to room temperature and 
stirred for approximately 16 hours. The solvent was filtered in vacuo and the crude 
product recrystallised from acetonitrile (20 mL) and stored at -20°C, yielding an 
orange precipitate of 26 (0.40g, 0.548 mmol, 56%). 
1
H NMR (CDCl3, 500 MHz, 300 K) d, 2H, 
H16, 
4
J (
1
H-
1
H) = 1.8 Hz), 7.32 (d, 2H, H H2 or H6, 
3
J 
(
1
H-
1
H) = 8.3 Hz), 7.28-7.26 (m, 2H, H4), 7.25-7.22 
(m, 2H, H13), 7.18 (dd, 2H, H14, 
3
J (
1
H-
1
H) = 8.3 Hz 
and 
4
J (
1
H-
1
H) = 1.8 Hz), 7.09 (td, 2H, H3 or H5, 
3
J 
N O
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O
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(
1
H-
1
H) = 7.7 Hz and 
4
J (
1
H-
1
H) = 1.2 Hz), 7.00 (br. t, 2H, H3 or H5, 
3
J (
1
H-
1
H) = 
7.8 Hz), 6.70 (d, 2H, H2 or H6, 
4
J (
1
H-
1
H) = 7.8 Hz), 6.38 (s, 2H, H9), 1.86 (s, 6H, 
H7) 
13
C NMR (CDCl3, 75 MHz, 300K) quaternary C-O, C10), 165.4 
(quaternary aromatic C, C11), 150.7 (quaternary aniline C, C1), 136.5 (quaternary 
C-N, C8), 132.6 (aniline CH, C2 or C6), 132.6 (quaternary C-Cl, C12 or C15), 131.3 
(quaternary C-Cl, C12 or C15), 130.3 (aromatic CH, C16), 129.0 (aniline CH, C3 or 
C5), 128.5 (aromatic CH, C13), 127.0 (aromatic CH, C14), 125.9 (aniline CH, C3 or 
C5), 125.4 (aniline CH, C4), 121.6 (aniline CH, C2 or C6), 111.4 (acnac CH, C9), 
25.4 (aliphatic CH3, C7) 
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9.9 Normoxic Cytotoxic Evaluation 
9.9.1  General 
Sterile techniques were used throughout this work. Chemicals were purchased from 
Sigma Aldrich and used as supplied. MCF-7 cells (human breast adenocarcinoma), 
HT-29 cells (human colon adenocarcinoma), A2780 cells (human ovarian 
carcinoma) and A2780cis cells (cisplatin resistant human ovarian carcinoma) were 
obtained from Dr. Roger Phillips (Reader in Cancer Pharmacology, University of 
Bradford UK). The stock cultures were grown in either T-25 or T-75 flasks 
containing RPMI-1640 complete medium (20 mL) and incubated at 37°C with 
5.0% CO2. The complete medium was prepared from RPMI-1640 incomplete 
medium (500 mL), sodium pyruvate (5 mL, 0.5 mmol), L-glutamine (5 mL, 1.0 
mmol) and foetal bovine serum (50 mL). HANKS Balanced Salt Solution (HBSS) 
was used to wash cells before use, and 0.25% trypsin-EDTA solution was used to 
detach the cells from the flask. MTT stock solutions (5 mg/ mL) were prepared by 
dissolving MTT (250 g) in distilled water (50 mL), then passing through a 0.2 m 
sterile filter. RPMI-1640 incomplete medium, RPMI-1640 complete medium, 
sodium pyruvate, MTT and MTT stock solutions were all stored at 4°C. L-
glutamine, foetal bovine serum and 0.25% trypsin-EDTA solution were all stored 
at -20°C. All chemicals except the MTT stock solution were incubated at 37°C 
prior to use. 
 
9.9.2  Passaging Cells 
Cell monolayer was washed with HANKS Balanced Salt Solution (3 x 10 mL), and 
then all HBSS was carefully removed. 0.25% trypsin-EDTA solution (5 mL) was 
added to the flasks and incubated at 37°C for 5 minutes. When the cells became 
detached from the flask wall, cell medium (10 mL) was added. Cells were split into 
new flasks and diluted with cell medium; the lids were loosened and placed into the 
incubator for future use. 
 
9.9.3  Cell Counting 
The cells were passaged to the point of suspension, as previously described. 10 L 
of the cell suspension was transferred to each side of the glass haemocytometer and 
cells were counted under the microscope and an average was taken, with units of 
10
4
 cells/ mL. 
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9.9.4 Conducting the 5-Day MTT Assay 
After counting the cells, the cell suspension was diluted with RPMI-1640 complete 
medium to give a concentration of 2 x 10
4
 cells/ mL. 96-well plates were used and 
100 L of cell medium was added to lane one, to serve as a blank. 100 L of the 
diluted cell suspension was then added to lanes two to twelve, and the plates 
incubated overnight at 37°C with 5.0% CO2. 
The drugs to be tested were dissolved in DMSO to give concentrations of 25 mM. 
40 L of this solution was added to 1960 L of RPMI-1640 complete media to 
give a total of 2 mL. This was mixed well and 1 mL taken and added to another 1 
mL of RPMI-1640 complete media, further dilutions were carried out to give 10 
different concentrations of the drug. 100 L of RPMI-1640 cell media was added 
to lanes 1 and 2 to serve a control and 100% cell respectively. 100 L of the least 
concentrated drug solution was added to lane 3, and subsequent concentrations 
were added until 100 L of the most concentrated drug solution was added to lane 
12. The plates were incubated for 5 days at 37°C with 5.0% CO2. 
After 5 days incubation, MTT stock solution was prepared (5 mg/ mL) and 20 L 
added to each 96-well plate and incubated at 37°C in 5.0% CO2 for a further 3 
hours. The medium/MTT was removed via pipette and 150 L of DMSO added to 
each well. Solutions were mixed well and the absorbance measured at 540 nm, 
using a Thermo Scientific Multiskan EX microplate photometer. 
 
9.9.5  Data Analysis 
Averages were taken from the eight cells in each lane, and the % cell survival for 
each concentration was calculated using the following formula: 
  
     
     
     
Where C is the % cell survival for lane n and Ln is the mean absorbance at 540 nm 
for lane n. IC50 values and standard deviations were calculated from a minimum of 
three repeats for each drug used. 
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9.10 Hypoxic Cytotoxic Evaluation 
This assay was conducted according to the protocol stated previously for normoxic 
conditions. However, all the incubations periods, the addition of the drug dilutions 
and the addition of the MTT solution were carried out inside a Don Whitley 
Scientific H35 Hypoxystation which was set at 1.0 or 0.1% O2. 
 
9.11 Hydrophobicity 
Firstly, equal volumes of octanol and NaCl saturated water were stirred overnight 
at room temperature then separated to give octanol-saturated water and water-
saturated octanol. Accurate amounts of the complexes were dissolved in water-
saturated octanol (25 mL). 2 mL of octanol-saturated water was placed in a 
centrifuge tube and 2 mL of water-saturated octanol complex samples layered on 
top. The samples were shaken for 4 hours using a vibrax machine at 1000 gmin
-1
; a 
minimum of six repeats were analysed. The layers were separated and the water-
saturated octanol layer retained for analysis by UV/vis spectroscopy. Using the 
maximum absorbance of each complex, the average of the six runs was calculated 
and rearrangement of individual calibration graphs gave the [C]org final. The 
following equations were used to determine the partition coefficient and hence 
determining if the compound is predominantly hydrophilic or hydrophobic.  
       
      
     
      
       
            
                              
 
 
9.12 DSB Comet Assay 
9.12.1 Preparation of Comet assay slides: 
1% normal melting point agarose (500 mg) in PBS (50 mL) was prepared and 
placed in the microwave for approximately 20 seconds until it had fully dissolved. 
This was poured into a 50 mL centrifuge tube and the glass slides were dipped into 
the agrarose. The underside of the slide was wiped clean and these were left on the 
bench overnight to dry. 
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9.12.2 Reagents 
 Neutral Lysing Solution (2% sarkosyl, 0.5 M Na2EDTA, 0.5 mg/ mL 
proteinase K (pH 8.0)) 
Sarkosyl (2 g) and Na2EDTA (18.61 g) were added to distilled water (80 mL) and 
the pH adjusted to 8.0 with 10M NaOH. Proteinase K (50 mg) was then added and 
made up to a final volume of 100 mL. 
 Electrophoresis Buffer (90 mM Tris buffer, 90 mM boric acid, 2 mM 
Na2EDTA (pH 8.0)) 
Tris base (32.707 g), boric acid (16.694 g) and Na2EDTA (2.233 g) were added to 
distilled water (2.5 L). The pH was adjusted to 8.0 and the volume made up to 3 L 
with distilled water. 
 
 Staining Solution: 
SYBR™Gold solution (molecular probes inc, S-11494) (1 L) was added to PBS 
1(10 mL); this was made on the day of imaging. 
 Imaging and Analysis 
Staining solution (150 mL) was added to each slide and a cover slip placed on top. 
Excess solution was blotted away and the comets analysed using Comet assay III 
software. A minimum of 50 different comets were scored and the computer outputs 
an average on head and tail intensities and tail moments. Images were taken of the 
comets and the tail moments plotted against concentration of drug sample used. 
 
9.12.3 Sample Preparation: 
The cells were washed with PBS, trypsinised and counted (see previous, same as 
cytotoxicity assay). The cells were diluted with complete medium to a 
concentration of 1 x 10
6
 cells/ mL, 2 mL of the cell suspension was placed in each 
well of a 6-well plate. The cells were incubated for 24 hours at 37˚C in a 5.0% CO2 
atmosphere. Drug samples were prepared in the range 20-1.25 M, the medium 
was removed from the wells, and 2 mL of drug sample added to each well. The 
plate was then incubated again for 24 hours in the drug solutions, at 37˚C in a 5.0% 
CO2 atmosphere. The drug samples were removed and added to centrifuge tubes, 
the wells each washed with PBS (1 mL), which was also placed into the centrifuge 
tube. The wells were then trypsinised (1 mL) for 5 minutes and then neutralised 
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with complete medium (1 mL), these were all added to the centrifuge tube and 
centrifuged at 1500 rpm for 3 minutes. The supernatant was removed and the pellet 
re-suspended in complete medium containing 10% DMSO. The tubes were 
wrapped in several sheets of tissue and stored at -80˚C until required for the assay. 
 
9.12.4 Conducting the Assay: 
 Preparation of sample slides (conducted under low light conditions): 
0.5% low melting agarose (LMPA) was prepared (250 mg/ 50 mL PBS) and placed 
in the microwave for approximately 20 seconds, until fully dissolved. This was 
placed into a water bath set at 37°C and the temperature allowed to equilibrate. The 
sample eppendorfs from Section 9.12.3 were defrosted and centrifuged at 16.1 rcf 
for 20 seconds. The supernatant was removed and the pellet re-suspended in LMPA 
(150-1000 L, depending on pellet size). The cell suspension (150 L) was added 
to a previously coated glass slide and a cover slip placed over, these were placed on 
a cool tray and allowed to set (3-5 minutes). Once set the slip was removed and 
LMPA (150 L) added to the slide and another slip placed on top. These were 
again transferred to a cool tray to set. The slip was again removed and all slides 
placed into a tray where freshly prepared neutral lysing solution was added and the 
slides incubate for 1 hour at 37˚C in dark conditions. 
 Electrophoresis Conditions 
The lysing solution was gently poured off and the slides submerged in 
electrophoresis buffer for 30 minutes. The buffer was gently poured off and this 
step repeated two more times. The slides were then placed close together in a 
electrophoresis chamber and reservoirs were carefully filled with freshly prepared 
buffer (pH 8.0) and filled until the buffer just covered the slides. The chamber was 
adjusted to 24 V and the electrophoresis was run for 25 minutes. The slides were 
transferred to a clean tray and rinsed three times with distilled water and finally 
with 100% ice cold ethanol. They were then transferred to a slide rack and left to 
dry overnight before imaging could commence. 
 Imaging and Analysis 
Staining solution (150 mL) was added to each slide and a cover slip placed on top, 
excess solution was blotted away and the comets analysed using Comet assay III 
software. A minimum of 50 different comets were scored and the computer outputs 
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an average on head and tail intensities and tail moments. Images were taken of the 
comets and the tail moments plotted against concentration of drug sample used. 
 
9.13 SSB and Cross-Linking Comet Assay 
9.13.1 Preparation of Comet assay slides: 
1% normal melting point agarose (500 mg) in PBS (50 mL) was prepared and 
placed in the microwave for approximately 20 seconds until it had fully dissolved. 
This was poured into a 50 mL centrifuge tube and the glass slides were dipped into 
the agrarose. The underside of the slide was wiped clean and these were left on the 
bench overnight to dry. 
 
9.13.2 Reagents 
 Alkaline Lysing Solution: 
2.5 M NaCl (146.1 g), 100 mM EDTA (37.2 g) and 10 mM Trizma base (1.2 g) 
were added to distilled water (700 mL). NaOH (8 g) was added and stirred until 
fully dissolved, once dissolved the pH was adjusted to pH 10.0 and made up to a 
final volume of 890 mL and stored at 4°C. 
 Final Lysing Solution:  
The previously made lysing solution (178 mL) was added to Triton-X-100 (2 mL) 
and DMSO (20 ml) 
 
 Electrophoresis Buffer (300 mM NaOH/ 1mM EDTA) 
10 M NaOH - 200 g/ 500 mL distilled water 
200 mM EDTA - 14.89 g/ 200 mL distilled water at pH 10.0 
10 M NaOH (90 mL) was added to 200 mM EDTA (15 mL) and made up to a total 
volume of 3 L using distilled water and adjusted to a pH > 13.0 
 Neutralisation Buffer: 
Tris base (48.5 g) was dissolved in distilled water (800 mL) and adjusted to pH 7.5 
using concentrated HCl. This was then made up to 1 L using distilled water and 
stored at room temperature. 
 Staining Solution: 
The staining was carried out according to that stated previously in Section 9.12.1 
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9.13.3 Sample Preparation: 
The samples were prepared following the same steps as the DBS assay, with 
elimination of the 10% DMSO in the final step. 
 
9.13.4 Conducting the Assay: 
 Preparation of sample slides (conducted under low light conditions): 
0.5% low melting agarose (LMPA) was prepared (250 mg/ 50 mL PBS) and placed 
in the microwave for approximately 20 seconds, until fully dissolved. This was 
placed into a water bath set at 37°C and the temperature allowed to equilibrate. The 
sample eppendorfs were defrosted and centrifuged at 16.1 rcf for 20 seconds. The 
supernatant was removed and the pellet re-suspended in LMPA (150-1000 L, 
depending on pellet size). The cell suspension (150 L) was added to a previously 
coated glass slide and a cover slip placed over, these were placed on a cool tray and 
allowed to set (3-5 minutes). Once set the slip was removed and LMPA (150 L) 
added to the slide and another slip placed on top. These were again transferred to a 
cool tray to set. The slip was again removed and all slides placed into a tray where 
freshly prepared ice cold lysing solution was added, these were left to incubate for 
1 hour at 4°C. 
 Electrophoresis Conditions 
After the 1 hour incubation, the lysing solution was gently poured off and the slides 
placed close together in an electrophoresis chamber. The reservoirs were carefully 
filled with freshly prepared buffer (pH > 13.0) and filled until the buffer just 
covered the slides. The slides were incubated for 30 minutes and then the chamber 
adjusted to 24 V, the electrophoresis was run for 25 minutes and then the slides 
were removed. The slides were transferred to a clean tray and drop-wise 
neutralisation with the neutralisation buffer. The buffer was added to coat the slides 
and then these were incubated for 5 minutes. The buffer was removed and this step 
repeated twice more. Then slides were then rinsed three times with distilled water 
and finally with 100% ice cold ethanol. They were then transferred to a slide rack 
and left to dry overnight before imaging could commence. 
 Imaging and Analysis 
The imaging for the SSB and cross-linking assay was carried out according to that 
stated in the DSB assay. 
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9.14 Apoptosis 
9.14.1 Cell counting 
This assay was conducting using both HT-29 and A2780 cells, where the cells were 
counted using a haemocytometer and an average taken from the 10 quadrants. The 
cells were diluted with complete media to give concentrations of 2.5 x 10
4
 
cells/flask (0.5 x 10
4 
cells/ mL). The flasks were incubated for 24 hours at 37°C 
and an atmosphere of 5.0% CO2. Initial stock solutions of the drugs were made at 1 
mM, these were further diluted with complete media to give dilutions of 20 M 
and 10 M. The flasks were incubated in 5 mL of these drug solutions or media 
only (control), for a period of 48 hours at 37°C and an atmosphere of 5.0% CO2. 
 
9.14.2 Harvesting 
The media/drug solution was removed from the flasks and placed into a 25 mL 
centrifuge tube, the flask is then washed with PBS (5 mL), which was also added to 
the centrifuge tube. Trypsin (1 mL/flask) was added and then incubated for 5 
minutes are until a single cell suspension was obtained. The trypsin was then 
neutralised with media (5 mL) and the whole contents of the flask is transferred to 
the same centrifuge tube. The tube was spun at 1000 rcf for 3-5 minutes, the 
supernatant was removed and the pellet re-suspended in PBS (1 mL). The 1 mL 
was transferred to an eppendorf and spun again at 1500 rpm for 5 minutes, the 
supernatant is removed and the pellet re-suspended in 16 L PI, 16 L AmV and 
800 L buffer solution (100 L). The eppendorfs were incubated at room 
temperature for 10 minutes and kept in suspension; and then transferred to FACS 
tubes for analysis. 
 
9.15 Data Analysis 
Samples were run using flow cytometry and parameters adjusted depending on the 
sample tested. A cell count of 10,000 was necessary to conduct this experiment and 
gave results of PI versus AnV, each quadrant was analysed manually and a 
percentage taken from each quadrant of the plot. 
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9.16 Thioredoxin Reductase 
Thioredoxin reductase was obtained from Sigma Aldrich and is sourced from rat 
liver. It is a buffered aqueous glycerol solution, ≥ 100 units/ mg protein. Solution in 
50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 1 mM EDTA, and 10% glycerol. 
Stock solutions: 
1 M K2HPO4 - 17.42 g in 100 mL distilled water 
1 M KH2PO4 – 13.6 g in 100 mL distilled water 
100 mM EDTA – 3.72 g in 100 mL distilled water at pH 7.0 
 
9.16.1 Reaction Reagents: 
 Potassium phosphate buffer (0.1 M at pH 7.0)  
K2HPO4 (61.5 mL), KH2PO4 (38.5 mL), EDTA (10 mL) all made up to 1 L using 
distilled water and the pH was adjusted to 7.0. 
 Reaction Buffer A 
Potassium phosphate buffer (50 mL), NADPH (8.3 mg) and BSA (5.0 mg) 
 Reaction Buffer B 
Phosphate buffer (50 mL), NADPH (8.3 mg), BSA (5.0 mg) and DTNB (1.98 mg) 
 
9.16.2 Conducting the assay 
Buffer A (0.5 mL) was added to a 1 mL cuvette and to this TrxR (2 L) was added. 
The test compound or DMSO control (1 L) was added and the reaction left for 
approximately 30 seconds. Buffer B (0.5 mL) was added to the cuvette and using a 
pipette mixed well. The UV-vis absorbance was measure at 412 nm and the 
experiment was carried out using just the enzyme to get the initial absorbance; 
different dilutions of the test compound were tested using a maximum of 10 M. 
 
9.16.3 Analysis of Results 
The UV-vis was obtained for just the enzyme, hence giving the maximum 
absorbance. Using the maximum absorbance obtained from each run, a value was 
obtained for A and once plotted against [I], giving the % inhibition. The IC50 value 
is obtained at 50% enzyme inhibition. 
Experimental  Chapter 9 
248 
9.17 References 
1. R. Levine and J. K. Sneed, J. Am. Chem. Soc., 1951, 73, 5614-5616. 
2. L.-M. Tang, Y.-Q. Duan, X.-F. Li and Y.-S. Li, J. Organomet. Chem., 
2006, 691, 2023. 
3. J. Cosier and A. M. Glazer, J. Appl. Crystallogr., 1986, 19, 105-107. 
4. Z. Otwinowski and W. Minor, in 'DENZO and SCALEPACK programs', 
1995. 
5. G. Sheldrick, in 'SHELXS86, Program for Crystal Structure Solution', 
1986. 
6. A. Altomare, G. Cascarano, C. Giacovazzo and A. Guagliardi, J. Appl. 
Crystallogr., 1993, 26, 343-350. 
7. A. Altomare, M. C. Burla, M. Camalli, G. L. Cascarano, C. Giacovazzo, A. 
Guagliardi, A. G. G. Moliterni, G. Polidori and R. Spagna, J. Appl. 
Crystallogr., 1999, 32, 115-119. 
8. L. J. Barbour, in 'XSeed', 1999. 
9. M. Thornton-Pett, in 'WC-A Windows CIF Processor', 2000. 
10. A. L. Spek, J. Appl. Crystallogr., 2003, 36, 7-13. 
11 P. Govindaswamy and M. R. Kollipara, J. Coord. Chem., 2006, 59, 131-
136 
12. J. J. Mannion, Ph. D Thesis, University of Leeds, 2008. 
13. A. J. Hebden, Ph. D Thesis, University of Leeds, 2010. 
 
 
 243 
Appendix 
  
Appendix 
244 
Crystal data and structure refinement for ligand L11 
 
Formula C17H17NO 
Formula weight 251.32 
Size 0.27 x 0.24 x 0.21 mm 
Crystal morphology Colourless Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 7.3817(3) Å  = 90° 
 b = 12.0369(4) Å  = 90.0110(10)° 
 c = 29.9551(11) Å  = 90° 
Volume 2661.59(17) Å
3
 
Z 8 
Density (calculated) 1.254 Mg/m
3
 
Absorption coefficient 0.078 mm
-1
 
F(000) 1072 
Data collection range 2.17  33.92° 
Index ranges -9  h 11,  -14  k  18,  -42  l  46 
Reflections collected 40768 
Independent reflections 10589 [R(int) = 0.0513] 
Observed reflections 6833 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9841 and 0.9797 
Refinement method Full 
Data / restraints / parameters 10589 / 0 / 349 
Goodness of fit 1.016 
Final R indices  [I >2(I)] R1 = 0.0517, wR2 = 0.1322 
R indices (all data) R1 = 0.0889, wR2 = 0.1532 
Largest diff. peak and hole 0.419 and -0.257e.Å
-3 
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Crystal data and structure refinement for ligand L12 
 
Formula C16H14FNO 
Formula weight 255.28 
Size 0.54 x 0.28 x 0.11 mm 
Crystal morphology Yellow Plate 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 14.6120(14) Å  = 90° 
 b = 7.0373(6) Å  = 106.929(3)° 
 c = 12.8634(10) Å  = 90° 
Volume 1265.41(19) Å
3
 
Z 4 
Density (calculated) 1.34 Mg/m
3
 
Absorption coefficient 0.094 mm
-1
 
F(000) 536 
Data collection range 2.91  27.41° 
Index ranges -18  h 18,  -9  k  8,  -16  l  16 
Reflections collected 9617 
Independent reflections 2860 [R(int) = 0.0488] 
Observed reflections 2598 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9898 and 0.9512 
Refinement method Full 
Data / restraints / parameters 2860 / 0 / 174 
Goodness of fit 1.055 
Final R indices  [I >2(I)] R1 = 0.0426, wR2 = 0.1139 
R indices (all data) R1 = 0.046, wR2 = 0.1175 
Largest diff. peak and hole 0.37 and -0.266e.Å
-3 
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Crystal data and structure refinement for ligand L14 
 
Formula C16H13Cl2NO 
Formula weight 306.17 
Size 0.22 x 0.18 x 0.05 mm 
Crystal morphology Yellow plate 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 12.3180(4) Å  = 90° 
 b = 7.4714(2) Å  = 108.3020(10)° 
 c = 16.4245(5) Å  = 90° 
Volume 1435.13(7) Å
3
 
Z 4 
Density (calculated) 1.417 Mg/m
3
 
Absorption coefficient 0.446 mm
-1
 
F(000) 632 
Data collection range 2.48  27.49° 
Index ranges -16  h 14,  -6  k  9,  -21  l  21 
Reflections collected 12165 
Independent reflections 3264 [R(int) = 0.0572] 
Observed reflections 2944 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.978 and 0.9083 
Refinement method Full 
Data / restraints / parameters 3264 / 0 / 183 
Goodness of fit 1.025 
Final R indices  [I >2(I)] R1 = 0.0344, wR2 = 0.0938 
R indices (all data) R1 = 0.0381, wR2 = 0.0986 
Largest diff. peak and hole 0.337 and -0.415e.Å
-3 
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Crystal data and structure refinement for ligand L15 
 
Formula C16H13Cl2NO 
Formula weight 306.17 
Size 0.3655 x 0.1575 x 0.0861 mm 
Crystal morphology Yellow Plate 
Temperature 100.00(10) K 
Wavelength 0.7107 Å  [Mo -K] 
Crystal system  
Space group  
Unit cell dimensions a = 12.6921(14) Å  = 90° 
 b = 8.4056(6) Å  = 90° 
 c = 26.694(2) Å  = 90° 
Volume 2847.9(4) Å
3
 
Z 8 
Density (calculated) 1.428 Mg/m
3
 
Absorption coefficient 0.45 mm
-1
 
F(000) 1264 
Data collection range 2.21  29.9° 
Index ranges -10  h 15,  -8  k  10,  -37  l  23 
Reflections collected 8100 
Independent reflections 3301 [R(int) = 0.0533] 
Observed reflections 2423 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.82463 
Refinement method Full 
Data / restraints / parameters 3301 / 0 / 182 
Goodness of fit 1.078 
Final R indices  [I >2(I)] R1 = 0.0575, wR2 = 0.1011 
R indices (all data) R1 = 0.0872, wR2 = 0.1132 
Largest diff. peak and hole 0.339 and -0.331e.Å
-3 
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Crystal data and structure refinement for ligand L16 
 
Formula C16H12Cl3NO 
Formula weight 340.62 
Size 0.29 x 0.25 x 0.21 mm 
Crystal morphology Yellow Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 11.4886(4) Å  = 90° 
 b = 9.5459(3) Å  = 98.829(3)° 
 c = 13.6456(4) Å  = 90° 
Volume 1478.77(8) Å
3
 
Z 4 
Density (calculated) 1.53 Mg/m
3
 
Absorption coefficient 0.616 mm
-1
 
F(000) 696 
Data collection range 1.79  29.72° 
Index ranges -15  h 15,  -12  k  13,  -18  l  11 
Reflections collected 6404 
Independent reflections 3469 [R(int) = 0.0285] 
Observed reflections 2956 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.8524 
Refinement method Full 
Data / restraints / parameters 3469 / 0 / 191 
Goodness of fit 1.054 
Final R indices  [I >2(I)] R1 = 0.0358, wR2 = 0.0765 
R indices (all data) R1 = 0.0446, wR2 = 0.0831 
Largest diff. peak and hole 0.372 and -0.334e.Å
-3
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Crystal data and structure refinement for ligand L19 
 
Formula C36H38N2O2 
Formula weight 530.68 
Size 0.4296 x 0.3789 x 0.1417 mm 
Crystal morphology Brown Fragment 
Temperature 293(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 7.7796(5) Å  = 90° 
 b = 11.6210(7) Å  = 91.400(5)° 
 c = 31.457(2) Å  = 90° 
Volume 2843.1(3) Å
3
 
Z 4 
Density (calculated) 1.24 Mg/m
3
 
Absorption coefficient 0.076 mm
-1
 
F(000) 1136 
Data collection range 2.59  29.8° 
Index ranges -9  h 10,  -15  k  15,  -26  l  43 
Reflections collected 12204 
Independent reflections 6563 [R(int) = 0.0343] 
Observed reflections 4869 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.65501 
Refinement method Full 
Data / restraints / parameters 6563 / 0 / 365 
Goodness of fit 1.087 
Final R indices  [I >2(I)] R1 = 0.0623, wR2 = 0.1231 
R indices (all data) R1 = 0.0888, wR2 = 0.1371 
Largest diff. peak and hole 0.277 and -0.262e.Å
-3
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Crystal data and structure refinement for ligand L21 
 
Formula C18H19NO3 
Formula weight 297.34 
Size 0.35 x 0.35 x 0.21 mm 
Crystal morphology Yellow Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 6.6562(7) Å  = 89.870(5)° 
 b = 8.6335(9) Å  = 89.960(5)° 
 c = 14.6783(14) Å  = 72.170(5)° 
Volume 802.99(14) Å
3
 
Z 2 
Density (calculated) 1.23 Mg/m
3
 
Absorption coefficient 0.084 mm
-1
 
F(000) 316 
Data collection range 1.39  33.75° 
Index ranges -10  h 9,  -12  k  11,  -22  l  19 
Reflections collected 9291 
Independent reflections 7369 [R(int) = 0.0524] 
Observed reflections 6256 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9829 and 0.971 
Refinement method Full 
Data / restraints / parameters 7369 / 3 / 403 
Goodness of fit 1.031 
Final R indices  [I >2(I)] R1 = 0.0747, wR2 = 0.2011 
R indices (all data) R1 = 0.0834, wR2 = 0.214 
Largest diff. peak and hole 0.671 and -0.646e.Å
-3
 
Absolute structure parameter -0.5(11) 
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Crystal data and structure refinement for ligand L22 
 
Formula C18H17FNO2 
Formula weight 298.33 
Size 0.41 x 0.23 x 0.12 mm 
Crystal morphology Yellow Plate 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 10.5457(16) Å  = 66.443(5)° 
 b = 12.754(2) Å  = 74.668(6)° 
 c = 13.716(2) Å  = 70.382(5)° 
Volume 1574.6(4) Å
3
 
Z 4 
Density (calculated) 1.258 Mg/m
3
 
Absorption coefficient 0.09 mm
-1
 
F(000) 628 
Data collection range 1.64  30.33° 
Index ranges -13  h 14,  -17  k  18,  -19  l  16 
Reflections collected 22286 
Independent reflections 8869 [R(int) = 0.0865] 
Observed reflections 5069 [I >2(I)] 
Absorption correction none 
Max. and min. transmission 0.9893 and 0.9641 
Refinement method Full 
Data / restraints / parameters 8869 / 0 / 401 
Goodness of fit 1.126 
Final R indices  [I >2(I)] R1 = 0.1147, wR2 = 0.3088 
R indices (all data) R1 = 0.1664, wR2 = 0.3501 
Largest diff. peak and hole 0.71 and -0.861e.Å
-3 
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Crystal data and structure refinement for ligand L24 
 
Formula C17H15NO3 
Formula weight 281.3 
Size 0.9 x 0.71 x 0.4 mm 
Crystal morphology Green Plate 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21 
Unit cell dimensions a = 3.9619(6) Å  = 90° 
 b = 18.622(3) Å  = 91.075(7)° 
 c = 9.1110(15) Å  = 90° 
Volume 672.07(19) Å
3
 
Z 2 
Density (calculated) 1.39 Mg/m
3
 
Absorption coefficient 0.096 mm
-1
 
F(000) 296 
Data collection range 2.19  33.72° 
Index ranges -4  h 4,  -29  k  29,  -14  l  14 
Reflections collected 15456 
Independent reflections 4004 [R(int) = 0.0853] 
Observed reflections 3065 [I >2(I)] 
Absorption correction none 
Max. and min. transmission 0.9627 and 0.9187 
Refinement method Full 
Data / restraints / parameters 4004 / 1 / 192 
Goodness of fit 0.992 
Final R indices  [I >2(I)] R1 = 0.0581, wR2 = 0.1391 
R indices (all data) R1 = 0.0814, wR2 = 0.1553 
Largest diff. peak and hole 0.392 and -0.407e.Å
-3
 
Absolute structure parameter -0.8(12)  
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Crystal data and structure refinement for ligand L25 
 
Formula C19H17N3O 
Formula weight 303.36 
Size 0.43 x 0.32 x 0.19 mm 
Crystal morphology Green Plate 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Orthorhombic 
Space group Pbca 
Unit cell dimensions a = 7.7635(8) Å  = 90° 
 b = 11.0134(11) Å  = 90° 
 c = 36.431(4) Å  = 90° 
Volume 3114.9(6) Å
3
 
Z 8 
Density (calculated) 1.294 Mg/m
3
 
Absorption coefficient 0.082 mm
-1
 
F(000) 1280 
Data collection range 2.24  30.17° 
Index ranges -10  h 9,  -15  k  15,  -50  l  51 
Reflections collected 64849 
Independent reflections 4572 [R(int) = 0.0759] 
Observed reflections 3782 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9845 and 0.9655 
Refinement method Full 
Data / restraints / parameters 4572 / 0 / 209 
Goodness of fit 1.036 
Final R indices  [I >2(I)] R1 = 0.0478, wR2 = 0.1265 
R indices (all data) R1 = 0.0588, wR2 = 0.1371 
Largest diff. peak and hole 0.408 and -0.249e.Å
-3 
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Crystal data and structure refinement for complex 1 
 
Formula C26H27ClFNORu 
Formula weight 525.01 
Size 0.18 x 0.15 x 0.12 mm 
Crystal morphology Red Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 9.8410(5) Å  = 100.643(2)° 
 b = 10.4805(6) Å  = 102.502(2)° 
 c = 12.3289(7) Å  = 104.424(2)° 
Volume 1163.39(11) Å
3
 
Z 2 
Density (calculated) 1.499 Mg/m
3
 
Absorption coefficient 0.814 mm
-1
 
F(000) 536 
Data collection range 3.14  30.55° 
Index ranges -14  h 12,  -14  k  13,  -17  l  17 
Reflections collected 19946 
Independent reflections 6817 [R(int) = 0.0326] 
Observed reflections 6190 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.91 and 0.8693 
Refinement method Full 
Data / restraints / parameters 6817 / 0 / 284 
Goodness of fit 1.036 
Final R indices  [I >2(I)] R1 = 0.0286, wR2 = 0.0793 
R indices (all data) R1 = 0.0326, wR2 = 0.0819 
Largest diff. peak and hole 2.243 and -0.636e.Å
-3 
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Crystal data and structure refinement for complex 2 
 
Formula C26H27ClFNORu 
Formula weight 525.01 
Size 0.2678 x 0.161 x 0.0985 mm 
Crystal morphology Red Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 7.5924(8) Å  = 101.176(8)° 
 b = 10.2922(11) Å  = 94.516(8)° 
 c = 15.9991(15) Å  = 106.506(9)° 
Volume 1164.0(2) Å
3
 
Z 2 
Density (calculated) 1.498 Mg/m
3
 
Absorption coefficient 0.814 mm
-1
 
F(000) 536 
Data collection range 2.62  29.76° 
Index ranges -9  h 9,  -12  k  10,  -15  l  21 
Reflections collected 8512 
Independent reflections 5315 [R(int) = 0.0583] 
Observed reflections 4083 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.2399 
Refinement method Full 
Data / restraints / parameters 5315 / 0 / 284 
Goodness of fit 1.037 
Final R indices  [I >2(I)] R1 = 0.0555, wR2 = 0.1024 
R indices (all data) R1 = 0.0767, wR2 = 0.1208 
Largest diff. peak and hole 1.222 and -1.296e.Å
-3
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Crystal data and structure refinement for complex 3 
 
Formula C26H27Cl2NORu 
Formula weight 541.46 
Size 0.49 x 0.26 x 0.11 mm 
Crystal morphology Red Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 7.7826(7) Å  = 68.270(3)° 
 b = 11.3982(10) Å  = 83.106(4)° 
 c = 15.2492(14) Å  = 70.938(4)° 
Volume 1187.69(18) Å
3
 
Z 2 
Density (calculated) 1.514 Mg/m
3
 
Absorption coefficient 0.903 mm
-1
 
F(000) 552 
Data collection range 1.44  30.38° 
Index ranges -11  h 11,  -16  k  16,  -21  l  18 
Reflections collected 9731 
Independent reflections 4330 [R(int) = 0.0475] 
Observed reflections 4113 [I >2(I)] 
Absorption correction none 
Max. and min. transmission 0.9072 and 0.6659 
Refinement method Full 
Data / restraints / parameters 4330 / 0 / 284 
Goodness of fit 1.231 
Final R indices  [I >2(I)] R1 = 0.0575, wR2 = 0.178 
R indices (all data) R1 = 0.0593, wR2 = 0.1821 
Largest diff. peak and hole 1.515 and -1.469e.Å
-3
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Crystal data and structure refinement for complex 4 
 
Formula C17.33H17.33Cl2N0.67O0.67Ru0.67 
Formula weight 383.94 
Size 0.47 x 0.33 x 0.24 mm 
Crystal morphology Red Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 11.3992(12) Å  = 88.692(4)° 
 b = 11.6491(11) Å  = 87.058(4)° 
 c = 19.5678(19) Å  = 80.287(4)° 
Volume 2557.5(4) Å
3
 
Z 6 
Density (calculated) 1.496 Mg/m
3
 
Absorption coefficient 0.945 mm
-1
 
F(000) 1168 
Data collection range 2.96  28.17° 
Index ranges -15  h 15,  -15  k  15,  -25  l  25 
Reflections collected 47038 
Independent reflections 12361 [R(int) = 0.0504] 
Observed reflections 11047 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.8078 and 0.6651 
Refinement method Full 
Data / restraints / parameters 12361 / 0 / 585 
Goodness of fit 1.043 
Final R indices  [I >2(I)] R1 = 0.0254, wR2 = 0.0658 
R indices (all data) R1 = 0.0298, wR2 = 0.069 
Largest diff. peak and hole 0.799 and -0.605e.Å
-3 
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Crystal data and structure refinement for complex 5 
 
Formula C26H26Cl3NORu 
Formula weight 575.9 
Size 0.1363 x 0.1102 x 0.0754 mm 
Crystal morphology Red Plate 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group Cc 
Unit cell dimensions a = 14.2172(6) Å  = 90° 
 b = 14.3632(6) Å  = 90.373(4)° 
 c = 11.7497(4) Å  = 90° 
Volume 2399.29(16) Å
3
 
Z 4 
Density (calculated) 1.594 Mg/m
3
 
Absorption coefficient 1.007 mm
-1
 
F(000) 1168 
Data collection range 2.02  29.66° 
Index ranges -19  h 18,  -18  k  19,  -16  l  12 
Reflections collected 6519 
Independent reflections 4231 [R(int) = 0.0417] 
Observed reflections 3907 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.8823 
Refinement method Full 
Data / restraints / parameters 4231 / 2 / 293 
Goodness of fit 1.05 
Final R indices  [I >2(I)] R1 = 0.0411, wR2 = 0.0726 
R indices (all data) R1 = 0.0462, wR2 = 0.0764 
Largest diff. peak and hole 0.784 and -0.609e.Å
-3
 
Absolute structure parameter -0.06(4) 
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Crystal data and structure refinement for complex 6 
 
Formula C4.16H4Cl0.64N0.16O0.16Ru0.16 
Formula weight 97.65 
Size 0.47 x 0.41 x 0.41 mm 
Crystal morphology Red Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 11.4864(13) Å  = 76.377(6)° 
 b = 13.9138(16) Å  = 86.339(6)° 
 c = 18.324(2) Å  = 75.571(6)° 
Volume 2756.4(5) Å
3
 
Z 25 
Density (calculated) 1.471 Mg/m
3
 
Absorption coefficient 0.975 mm
-1
 
F(000) 1232 
Data collection range 2.15  30.13° 
Index ranges -16  h 16,  -19  k  19,  -25  l  25 
Reflections collected 135555 
Independent reflections 16199 [R(int) = 0.0753] 
Observed reflections 12965 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.6889 and 0.6561 
Refinement method Full 
Data / restraints / parameters 16199 / 0 / 598 
Goodness of fit 1.045 
Final R indices  [I >2(I)] R1 = 0.0534, wR2 = 0.1572 
R indices (all data) R1 = 0.068, wR2 = 0.1746 
Largest diff. peak and hole 3.802 and -1.463e.Å
-3
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Crystal data and structure refinement for complex 7 
 
Formula C26H27BrClNORu 
Formula weight 585.92 
Size 0.22 x 0.17 x 0.13 mm 
Crystal morphology Red Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group Cc 
Unit cell dimensions a = 14.8418(5) Å  = 90° 
 b = 13.6395(5) Å  = 90.581(3)° 
 c = 11.7988(4) Å  = 90° 
Volume 2388.36(14) Å
3
 
Z 4 
Density (calculated) 1.629 Mg/m
3
 
Absorption coefficient 2.46 mm
-1
 
F(000) 1176 
Data collection range 2.03  29.83° 
Index ranges -20  h 19,  -18  k  19,  -16  l  16 
Reflections collected 17435 
Independent reflections 5760 [R(int) = 0.0451] 
Observed reflections 5536 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.7324 and 0.6088 
Refinement method Full 
Data / restraints / parameters 5760 / 2 / 284 
Goodness of fit 1.034 
Final R indices  [I >2(I)] R1 = 0.0281, wR2 = 0.0524 
R indices (all data) R1 = 0.0303, wR2 = 0.0537 
Largest diff. peak and hole 0.351 and -0.643e.Å
-3
 
Absolute structure parameter 0.004(5) 
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Crystal data and structure refinement for complex 8 
 
Formula C26H27BrClNORu 
Formula weight 585.92 
Size 0.1486 x 0.1419 x 0.113 mm 
Crystal morphology Red Plate 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 7.7084(3) Å  = 68.311(4)° 
 b = 11.3524(5) Å  = 82.804(4)° 
 c = 15.1513(7) Å  = 70.580(4)° 
Volume 1161.91(9) Å
3
 
Z 2 
Density (calculated) 1.675 Mg/m
3
 
Absorption coefficient 2.528 mm
-1
 
F(000) 588 
Data collection range 2.03  29.76° 
Index ranges -9  h 8,  -15  k  12,  -18  l  17 
Reflections collected 11871 
Independent reflections 5475 [R(int) = 0.041] 
Observed reflections 4847 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.90679 
Refinement method Full 
Data / restraints / parameters 5475 / 0 / 284 
Goodness of fit 1.053 
Final R indices  [I >2(I)] R1 = 0.0328, wR2 = 0.0628 
R indices (all data) R1 = 0.0392, wR2 = 0.0674 
Largest diff. peak and hole 0.537 and -0.597e.Å
-3
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Crystal data and structure refinement for complex 9 
 
Formula C26H27ClINORu 
Formula weight 632.91 
Size 0.2195 x 0.1161 x 0.0959 mm 
Crystal morphology Orange Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 7.7700(7) Å  = 106.660(9)° 
 b = 11.5552(10) Å  = 97.552(8)° 
 c = 15.2078(15) Å  = 109.544(8)° 
Volume 1193.01(19) Å
3
 
Z 2 
Density (calculated) 1.762 Mg/m
3
 
Absorption coefficient 2.081 mm
-1
 
F(000) 624 
Data collection range 2  29.82° 
Index ranges -10  h 9,  -11  k  15,  -19  l  17 
Reflections collected 10248 
Independent reflections 5583 [R(int) = 0.038] 
Observed reflections 4481 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.72236 
Refinement method Full 
Data / restraints / parameters 5583 / 0 / 284 
Goodness of fit 1.02 
Final R indices  [I >2(I)] R1 = 0.0429, wR2 = 0.0841 
R indices (all data) R1 = 0.057, wR2 = 0.0929 
Largest diff. peak and hole 1.48 and -1.045e.Å
-3
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Crystal data and structure refinement for complex 10 
 
Formula C28H32ClNO2Ru 
Formula weight 551.07 
Size 0.21 x 0.1511 x 0.1103 mm 
Crystal morphology Red Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 9.5863(5) Å  = 106.161(4)° 
 b = 11.5806(5) Å  = 102.739(4)° 
 c = 13.3596(6) Å  = 110.123(4)° 
Volume 1252.61(10) Å
3
 
Z 2 
Density (calculated) 1.461 Mg/m
3
 
Absorption coefficient 0.758 mm
-1
 
F(000) 568 
Data collection range 1.69  29.77° 
Index ranges -13  h 13,  -16  k  15,  -16  l  18 
Reflections collected 23922 
Independent reflections 6323 [R(int) = 0.0443] 
Observed reflections 5807 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.85957 
Refinement method Full 
Data / restraints / parameters 6323 / 0 / 303 
Goodness of fit 1.067 
Final R indices  [I >2(I)] R1 = 0.03, wR2 = 0.0654 
R indices (all data) R1 = 0.0344, wR2 = 0.0678 
Largest diff. peak and hole 0.65 and -0.615e.Å
-3 
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Crystal data and structure refinement for complex 11 
 
Formula C27H30ClNORu 
Formula weight 521.04 
Size 0.35 x 0.29 x 0.24 mm 
Crystal morphology Red Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 7.7691(10) Å  = 68.399(6)° 
 b = 11.4508(14) Å  = 83.185(6)° 
 c = 15.4307(18) Å  = 71.461(6)° 
Volume 1210.1(3) Å
3
 
Z 2 
Density (calculated) 1.43 Mg/m
3
 
Absorption coefficient 0.777 mm
-1
 
F(000) 536 
Data collection range 2.01  32.23° 
Index ranges -11  h 11,  -17  k  17,  -22  l  22 
Reflections collected 76647 
Independent reflections 8293 [R(int) = 0.0556] 
Observed reflections 7744 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.8379 and 0.7706 
Refinement method Full 
Data / restraints / parameters 8293 / 0 / 285 
Goodness of fit 1.079 
Final R indices  [I >2(I)] R1 = 0.0322, wR2 = 0.0848 
R indices (all data) R1 = 0.0344, wR2 = 0.0862 
Largest diff. peak and hole 1.191 and -1.848e.Å
-3
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Crystal data and structure refinement for complex 12 
 
Formula C59.72H58.85Cl2N2O2Ru2 
Formula weight 1109.56 
Size 0.258 x 0.2103 x 0.1547 mm 
Crystal morphology Red Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 13.7807(7) Å  = 90.868(4)° 
 b = 14.3381(6) Å  = 114.234(5)° 
 c = 14.7586(6) Å  = 104.725(4)° 
Volume 2548.1(2) Å
3
 
Z 2 
Density (calculated) 1.446 Mg/m
3
 
Absorption coefficient 0.743 mm
-1
 
F(000) 1138 
Data collection range 1.69  25.03° 
Index ranges -14  h 16,  -17  k  15,  -17  l  16 
Reflections collected 19216 
Independent reflections 9023 [R(int) = 0.0589] 
Observed reflections 7512 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.8536 and 0.819 
Refinement method Full 
Data / restraints / parameters 9023 / 0 / 632 
Goodness of fit 1.154 
Final R indices  [I >2(I)] R1 = 0.0702, wR2 = 0.1566 
R indices (all data) R1 = 0.0847, wR2 = 0.1648 
Largest diff. peak and hole 2.006 and -0.813e.Å
-3
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Crystal data and structure refinement for complex 13 
 
Formula C26H25ClF3NORu 
Formula weight 560.99 
Size 0.59 x 0.29 x 0.21 mm 
Crystal morphology Red Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group Cc 
Unit cell dimensions a = 14.0726(14) Å  = 90° 
 b = 14.2648(14) Å  = 90.643(5)° 
 c = 12.2405(14) Å  = 90° 
Volume 2457.0(4) Å
3
 
Z 4 
Density (calculated) 1.517 Mg/m
3
 
Absorption coefficient 0.788 mm
-1
 
F(000) 1136 
Data collection range 2.03  30.55° 
Index ranges -19  h 19,  -20  k  20,  -17  l  17 
Reflections collected 39809 
Independent reflections 7151 [R(int) = 0.0606] 
Observed reflections 6998 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.8539 and 0.6536 
Refinement method Full 
Data / restraints / parameters 7151 / 2 / 302 
Goodness of fit 1.085 
Final R indices  [I >2(I)] R1 = 0.0272, wR2 = 0.0826 
R indices (all data) R1 = 0.0285, wR2 = 0.084 
Largest diff. peak and hole 0.96 and -1.525e.Å
-3
 
Absolute structure parameter -0.01(2) 
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Crystal data and structure refinement for complex 14 
 
Formula C16H21Cl2NRu 
Formula weight 399.31 
Size 0.26 x 0.22 x 0.19 mm 
Crystal morphology Red Fragment 
Temperature 296(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Triclinic 
Space group P1 
Unit cell dimensions a = 7.9068(7) Å  = 87.914(3)° 
 b = 9.0739(7) Å  = 85.084(3)° 
 c = 12.5987(10) Å  = 69.616(3)° 
Volume 844.16(12) Å
3
 
Z 2 
Density (calculated) 1.571 Mg/m
3
 
Absorption coefficient 1.235 mm
-1
 
F(000) 404 
Data collection range 2.76  26.29° 
Index ranges -9  h 9,  -11  k  11,  -14  l  15 
Reflections collected 10049 
Independent reflections 3358 [R(int) = 0.0174] 
Observed reflections 3267 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.745 and 0.65 
Refinement method Full 
Data / restraints / parameters 3358 / 0 / 192 
Goodness of fit 1.121 
Final R indices  [I >2(I)] R1 = 0.0163, wR2 = 0.0405 
R indices (all data) R1 = 0.017, wR2 = 0.0408 
Largest diff. peak and hole 0.271 and -0.539e.Å
-3
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Crystal data and structure refinement for complex 15 
 
Formula C25H26ClNORu 
Formula weight 492.99 
Size 0.2645 x 0.2443 x 0.1851 mm 
Crystal morphology Red Plate 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 9.4634(9) Å  = 90° 
 b = 25.1678(17) Å  = 113.405(10)° 
 c = 9.9602(9) Å  = 90° 
Volume 2177.1(3) Å
3
 
Z 4 
Density (calculated) 1.504 Mg/m
3
 
Absorption coefficient 0.859 mm
-1
 
F(000) 1008 
Data collection range 2.35  29.74° 
Index ranges -13  h 9,  -34  k  33,  -11  l  13 
Reflections collected 11633 
Independent reflections 5210 [R(int) = 0.0692] 
Observed reflections 4097 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.78519 
Refinement method Full 
Data / restraints / parameters 5210 / 0 / 265 
Goodness of fit 1.036 
Final R indices  [I >2(I)] R1 = 0.0536, wR2 = 0.1058 
R indices (all data) R1 = 0.0722, wR2 = 0.1157 
Largest diff. peak and hole 1.869 and -1.321e.Å
-3
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Crystal data and structure refinement for complex 16 
 
Formula C20H22ClFO2Ru 
Formula weight 449.9 
Size 0.77 x 0.71 x 0.68 mm 
Crystal morphology Red Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 8.0542(10) Å  = 90° 
 b = 12.4910(16) Å  = 100.154(6)° 
 c = 20.288(2) Å  = 90° 
Volume 2009.1(4) Å
3
 
Z 4 
Density (calculated) 1.487 Mg/m
3
 
Absorption coefficient 0.931 mm
-1
 
F(000) 912 
Data collection range 2.57  36.8° 
Index ranges -11  h 11,  -17  k  17,  -27  l  28 
Reflections collected 67057 
Independent reflections 6061 [R(int) = 0.0638] 
Observed reflections 5671 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.57 and 0.5341 
Refinement method Full 
Data / restraints / parameters 6061 / 0 / 230 
Goodness of fit 1.186 
Final R indices  [I >2(I)] R1 = 0.0449, wR2 = 0.1204 
R indices (all data) R1 = 0.0482, wR2 = 0.1233 
Largest diff. peak and hole 2.532 and -1.139e.Å
-3
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Crystal data and structure refinement for complex 17 
 
Formula C64H56Cl4F4O8Ru4 
Formula weight 1575.17 
Size 0.2384 x 0.1015 x 0.0463 mm 
Crystal morphology Fragment Red 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 9.7211(3) Å  = 90° 
 b = 15.3371(5) Å  = 104.656(3)° 
 c = 10.0487(4) Å  = 90° 
Volume 1449.45(9) Å
3
 
Z 1 
Density (calculated) 1.805 Mg/m
3
 
Absorption coefficient 1.277 mm
-1
 
F(000) 784 
Data collection range 2.66  29.8° 
Index ranges -13  h 10,  -13  k  20,  -10  l  12 
Reflections collected 8123 
Independent reflections 3467 [R(int) = 0.0364] 
Observed reflections 3019 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.46536 
Refinement method Full 
Data / restraints / parameters 3467 / 0 / 191 
Goodness of fit 1.049 
Final R indices  [I >2(I)] R1 = 0.0322, wR2 = 0.0722 
R indices (all data) R1 = 0.0396, wR2 = 0.076 
Largest diff. peak and hole 0.753 and -0.73e.Å
-3
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Crystal data and structure refinement for complex 19 
 
Formula C20H23ClFIrO2 
Formula weight 542.03 
Size 0.21 x 0.18 x 0.12 mm 
Crystal morphology Yellow Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Orthorhombic 
Space group P212121 
Unit cell dimensions a = 8.3447(9) Å  = 90° 
 b = 15.2720(18) Å  = 90° 
 c = 15.4729(18) Å  = 90° 
Volume 1971.9(4) Å
3
 
Z 4 
Density (calculated) 1.826 Mg/m
3
 
Absorption coefficient 6.925 mm
-1
 
F(000) 1048 
Data collection range 2.63  31.9° 
Index ranges -10  h 12,  -22  k  22,  -22  l  22 
Reflections collected 109495 
Independent reflections 6682 [R(int) = 0.0492] 
Observed reflections 6515 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.4954 and 0.3282 
Refinement method Full 
Data / restraints / parameters 6682 / 0 / 232 
Goodness of fit 1.038 
Final R indices  [I >2(I)] R1 = 0.0144, wR2 = 0.0323 
R indices (all data) R1 = 0.0154, wR2 = 0.0327 
Largest diff. peak and hole 0.84 and -1e.Å
-3
 
Absolute structure parameter 0.010(4) 
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Crystal data and structure refinement for complex 20 
 
Formula C3.09H3.45N0.18O0.91Ti0.18 
Formula weight 66.4 
Size 0.33 x 0.29 x 0.28 mm 
Crystal morphology Yellow Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/c 
Unit cell dimensions a = 8.6093(17) Å  = 90° 
 b = 16.186(3) Å  = 102.517(9)° 
 c = 12.669(2) Å  = 90° 
Volume 1723.5(6) Å
3
 
Z 22 
Density (calculated) 1.408 Mg/m
3
 
Absorption coefficient 0.522 mm
-1
 
F(000) 760 
Data collection range 2.07  33.11° 
Index ranges -13  h 8,  -24  k  24,  -16  l  19 
Reflections collected 56323 
Independent reflections 6532 [R(int) = 0.0599] 
Observed reflections 5062 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.8663 and 0.8487 
Refinement method Full 
Data / restraints / parameters 6532 / 0 / 220 
Goodness of fit 1.047 
Final R indices  [I >2(I)] R1 = 0.0504, wR2 = 0.1367 
R indices (all data) R1 = 0.0671, wR2 = 0.1506 
Largest diff. peak and hole 0.814 and -0.317e.Å
-3
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Crystal data and structure refinement for complex 21 
 
Formula C16H13ClFNOTi0.50 
Formula weight 313.67 
Size 0.29 x 0.17 x 0.11 mm 
Crystal morphology Yellow Fragment 
Temperature 150(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group C2/c 
Unit cell dimensions a = 25.614(3) Å  = 90° 
 b = 8.3638(9) Å  = 126.138(4)° 
 c = 16.6382(19) Å  = 90° 
Volume 2878.6(6) Å
3
 
Z 8 
Density (calculated) 1.448 Mg/m
3
 
Absorption coefficient 0.529 mm
-1
 
F(000) 1288 
Data collection range 1.97  34.46° 
Index ranges -39  h 40,  -12  k  12,  -25  l  26 
Reflections collected 39322 
Independent reflections 5866 [R(int) = 0.0528] 
Observed reflections 4505 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.9431 and 0.8595 
Refinement method Full 
Data / restraints / parameters 5866 / 0 / 187 
Goodness of fit 1.03 
Final R indices  [I >2(I)] R1 = 0.0378, wR2 = 0.0943 
R indices (all data) R1 = 0.0568, wR2 = 0.1042 
Largest diff. peak and hole 0.58 and -0.263e.Å
-3
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Crystal data and structure refinement for complex 22 
 
Formula C36H32Cl4N4O2Ti 
Formula weight 742.36 
Size 0.47 x 0.18 x 0.09 mm 
Crystal morphology Yellow Fragment 
Temperature 293(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 15.1938(5) Å  = 90° 
 b = 15.4956(5) Å  = 113.222(2)° 
 c = 16.0930(7) Å  = 90° 
Volume 3481.9(2) Å
3
 
Z 4 
Density (calculated) 1.416 Mg/m
3
 
Absorption coefficient 0.592 mm
-1
 
F(000) 1528 
Data collection range 2.63  26.4° 
Index ranges -18  h 18,  -16  k  19,  -20  l  17 
Reflections collected 18609 
Independent reflections 6914 [R(int) = 0.0405] 
Observed reflections 5178 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.7454 and 0.6607 
Refinement method Full 
Data / restraints / parameters 6914 / 0 / 428 
Goodness of fit 1.029 
Final R indices  [I >2(I)] R1 = 0.0414, wR2 = 0.0863 
R indices (all data) R1 = 0.065, wR2 = 0.0959 
Largest diff. peak and hole 0.502 and -0.488e.Å
-3
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Crystal data and structure refinement for complex 23 
 
Formula C32H26F2N2O4Ti 
Formula weight 588.45 
Size 0.31 x 0.27 x 0.17 mm 
Crystal morphology Orange prism 
Temperature 120(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system  
Space group  
Unit cell dimensions a = 13.9627(13) Å  = 90° 
 b = 13.9627(13) Å  = 90° 
 c = 77.719(7) Å  = 120° 
Volume 13122(2) Å
3
 
Z 18 
Density (calculated) 1.34 Mg/m
3
 
Absorption coefficient 0.345 mm
-1
 
F(000) 5472 
Data collection range 2.13  25.02° 
Index ranges -16  h 16,  -16  k  16,  -92  l  91 
Reflections collected 33971 
Independent reflections 5166 [R(int) = 0.0487] 
Observed reflections 4423 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.7457 and 0.7016 
Refinement method Full 
Data / restraints / parameters 5166 / 0 / 372 
Goodness of fit 1.144 
Final R indices  [I >2(I)] R1 = 0.057, wR2 = 0.1229 
R indices (all data) R1 = 0.0676, wR2 = 0.1267 
Largest diff. peak and hole 0.332 and -0.464e.Å
-3
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Crystal data and structure refinement for complex 24 
 
Formula C38H38Cl2N4O2Ti 
Formula weight 701.52 
Size 0.31 x 0.27 x 0.09 mm 
Crystal morphology Orange Fragment 
Temperature 293(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 15.3737(12) Å  = 90° 
 b = 15.4790(14) Å  = 113.003(2)° 
 c = 16.1154(12) Å  = 90° 
Volume 3530.0(5) Å
3
 
Z 4 
Density (calculated) 1.32 Mg/m
3
 
Absorption coefficient 0.433 mm
-1
 
F(000) 1464 
Data collection range 2.63  29.24° 
Index ranges -18  h 21,  -21  k  21,  -21  l  22 
Reflections collected 36183 
Independent reflections 9529 [R(int) = 0.0837] 
Observed reflections 5244 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 0.7459 and 0.6847 
Refinement method Full 
Data / restraints / parameters 9529 / 0 / 430 
Goodness of fit 0.851 
Final R indices  [I >2(I)] R1 = 0.0436, wR2 = 0.0702 
R indices (all data) R1 = 0.101, wR2 = 0.0818 
Largest diff. peak and hole 0.286 and -0.528e.Å
-3
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Crystal data and structure refinement for complex 25 
 
Formula C36H36Cl2N2O2Ti 
Formula weight 647.47 
Size 0.33 x 0.29 x 0.11 mm 
Crystal morphology Orange Fragment 
Temperature 173(2) K 
Wavelength 0.71073 Å  [Mo-K] 
Crystal system Monoclinic 
Space group C2/c 
Unit cell dimensions a = 30.836(5) Å  = 90° 
 b = 8.2511(6) Å  = 126.83(3)° 
 c = 15.442(2) Å  = 90° 
Volume 3145.0(7) Å
3
 
Z 4 
Density (calculated) 1.367 Mg/m
3
 
Absorption coefficient 0.478 mm
-1
 
F(000) 1352 
Data collection range 3.17  29.78° 
Index ranges -41  h 42,  -10  k  9,  -20  l  15 
Reflections collected 12084 
Independent reflections 3817 [R(int) = 0.0322] 
Observed reflections 3080 [I >2(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.86393 
Refinement method Full 
Data / restraints / parameters 3817 / 0 / 197 
Goodness of fit 1.039 
Final R indices  [I >2(I)] R1 = 0.0388, wR2 = 0.0804 
R indices (all data) R1 = 0.0555, wR2 = 0.0872 
Largest diff. peak and hole 0.406 and -0.367e.Å
-3
 
 
